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Abstract 
 
High intensity intermittent exercise may provide an alternative means of exercise 
training with greater health benefits than the lower exercise doses used in current 
practice, yet definitive guidelines for intermittent exercise are lacking.  This thesis 
examines the methodology for intermittent exercise prescription, and assesses the 
efficacy of an intermittent exercise training intervention for chronic heart failure 
patients (CHF), thus providing a novel application in UK cardiac rehabilitation 
programmes.  
Study one was methodological.  Ten chronic heart failure (CHF) patients of mixed 
aetiology (NYHA class II/III; age 75 ± 8 years; LVEF 36 ± 9 %) and 7 healthy controls 
(age 67 ± 7 years; LVEF 69 ± 7 %) performed two exercise tests: a standard test (10 
W.min-1) and a steep test (25 W.10-s) to determine intermittent training workloads.  The 
tests were repeated one week later. In the standard test, a learning effect on maximal 
values was demonstrated (VO2peak: test 1: 16.6 ± 1.7 ml.kg-1.min-1 vs test 2: 17.9 ± 1.7 
ml.kg-1.min-1: P < 0.01; limits of agreement (LOA) bias ± random error 1.57 ± 1.88 
ml.kg-1.min-1). Sub-maximal exercise measures were more reproducible than peak 
measures, but still prone to variability between tests (ventilatory threshold: test 1: 10.8 
± 0.9 ml.kg-1.min-1 vs test 2: 10.8 ± 0.9 ml.kg-1.min-1: P > 0.05; LOA bias ± random 
error 0.00 ± 1.02 ml.kg-1.min-1; respiratory compensation point: test 1: 15.6 ± 1.5 ml.kg-
1.min-1 vs test 2: 15.6 ± 1.6 ml.kg-1.min-1: P > 0.05; LOA bias ± random error 0.27 ± 
1.33 ml.kg-1.min-1
Study two compared the cardiovascular, respiratory, and metabolic responses to, and 
perception of effort during, 20 minutes of moderate intensity continuous or intermittent 
exercise of matched total workload in the same group of CHF and controls as Study 1.  
There were no differences in oxygen uptake, respiratory exchange ratio, heart rate, 
).  In CHF this variability, combined with the narrow range of work 
rates between the gas exchange thresholds (27 ± 20 W), makes it difficult to accurately 
define exercise intensity domains from these thresholds.  In controls, intermittent 
training work rates set by Meyer et al’s (1997) protocol (50% steep test peak work rate: 
118 ± 13 W), were significantly lower than those set by the traditional method (100% 
standard test peak work rate: 141 ± 16 W), whereas in CHF there was no difference in 
work rate between the two methods (96 ± 9 vs 88 ± 10 W).   
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blood pressure, blood lactate concentration (Lac) or rating of perceived exertion 
between the two modes of exercise.  
Study three investigated the effect of adjusting the volatility (the amplitude above and 
below the mean work rate) of intermittent exercise.  Nine CHF (NYHA class II/III; age 
75 ± 9 years; LVEF 36 ± 9 %) and 5 healthy controls (63 ± 2 years; LVEF 70 ± 7 %) 
performed three 20 min exercise bouts of matched total workload:  1) moderate 
intensity continuous, 2) low volatility (half-way between VT and RCP work rate) and 
3) high volatility (110% standard test peak work rate) intermittent exercise. There was 
no discernable difference in respiratory and cardiovascular variables or in perception of 
effort between the three modes of exercise. However, Lac was greater when the 
volatility was high (2.4 ± 0.2 vs 1.9 ± 0.2 and 1.8 ± 0.2 mmol.L-1 in low volatility and 
continuous exercise).    
In the fourth and final study 26 CHF (NYHA class II/III; age 73 ± 7 years; LVEF 32 ± 
13 %) of mixed aetiology, including patients with implantable devices, were randomly 
assigned to either traditional circuit training or  high intensity intermittent training in a 
twice-weekly 6 week cardiac rehabilitation programme.  After training there was a 
significant improvement in ventilatory threshold (circuit 11 ± 6%; intermittent 18 ± 
5%) and disease-specific quality of life (circuit -8 ± 3 points; intermittent -8 ± 3 points), 
but there was no difference between the two training methods.  Neither intervention 
resulted in improvements in VO2peak, ventilatory efficiency or B-type natriuretic 
peptide (BNP).  Longer-term and/or more frequent training may be required to achieve 
improvements in these parameters.   
The results of these studies suggest that high intensity intermittent exercise offers an 
alternative, although no more effective, training method for the management of elderly 
CHF in UK cardiac rehabilitation programmes.   
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HR
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HRR  
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IL-6 Interleukin-6 
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Limits of agreement 
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LVEF Left ventricular ejection fraction (%) 
LVESV Left ventricular end systolic volume (ml) 
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NYHA New York Heart Association  
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NYHA Class I:   No limitation: ordinary physical exercise does not cause undue 
fatigue, dyspnoea, or palpitations 
NYHA Class II:   Slight limitation of physical activity: comfortable at rest but 
ordinary activity results in fatigue, palpitations, or dyspnoea 
NYHA Class III:  Marked limitation of physical activity: comfortable at rest but less 
than ordinary activity results in symptoms 
NYHA Class IV:   Unable to carry out any physical activity without discomfort: 
symptoms of heart failure are present even at rest with increased 
discomfort with any physical activity 
xxi 
 
 
 
  
PETCO End tidal gas tension for carbon dioxide (kPa or mmHg) 2 
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work rate relationship, RER ≥ 1.15, final heart rate within ± 10 
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Chronic heart failure is a complex syndrome that can result from any structural or 
functional cardiac disorder that impairs the heart’s ability to support the physiological 
circulation (NICE Guideline No. 5) (National Collaborating Centre for Chronic 
Conditions, 2003). The main causes are myocardial infarction, hypertension and 
degenerative valve disease, or idiopathic dilated cardiomyopathy (McMurray and 
Pfeffer, 2005).  The disease is characterised by symptoms of breathlessness, fatigue and 
exercise intolerance.  The pathophysiology underlying the reduced exercise tolerance is 
not yet fully understood, but cannot be explained solely by limitations in central 
haemodynamics. In response to left ventricular (LV) dysfunction, impairments to 
peripheral mechanisms, including abnormalities in muscle structure and function, and 
overactivation of neurohormonal and inflammatory systems, develop in CHF (Lunde et 
al., 2001; Pina et al., 2003; Clark, 2006).  The severity of symptoms may fluctuate, and 
as they are non-specific to heart failure, diagnosis is made via objective evidence of 
cardiac dysfunction at rest in addition to symptoms of heart failure at rest or during 
exercise (Swedberg et al., 2005).   
 
The European Society of Cardiology (ESC) estimates that there are more than 10 
million individuals with known CHF, 800,000 of whom are in the UK, for whom the 
prognosis is poor (Metra et al., 2007).   The prevalence of CHF increases with age, and 
is often exacerbated by the presence of co-morbidies (Braunstein et al., 2003).  Six to 
ten % of  people over 65 years old have CHF (McMurray and Pfeffer, 2005), and 
hospital admission rates for the disorder are increasing, particularly in the elderly 
(McMurray, 2000). The five-year survival rate is 30-40% (Swedberg et al., 2005), 
although this may have improved with advances in medical therapy.  
 
Introduction 
Cardiovascular diseases result in substantial disability and a loss of productivity, and 
contribute considerably to the escalating costs of health care, especially in regard to an 
ageing population.  CHF in particular puts a considerable burden on health services, 
with an estimated annual cost to the NHS of £625 million, with 70% of that cost being 
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due to hospitalisation (Health Care Commission 2007). However, there is evidence that 
physical activity interventions are cost-effective for older people and CHF patients 
(Georgiou et al., 2001; Hagberg and Lindholm, 2006).  The major challenge in 
preventive cardiology is to prevent subsequent cardiac events, while maintaining 
adequate physical functioning and  independence, and a good quality of life (QoL) 
(Giannuzzi et al., 2003a).  CHF reduces QoL more than other chronic illnesses (Hobbs 
et al., 2002), therefore therapies that improve functional capacity and QoL are of 
particular importance in the management of this disease.   
 
There is accumulating evidence that exercise training benefits CHF by reducing 
mortality and morbidity, and improving functional capacity and QoL (Piepoli et al., 
2004; Rees et al., 2004; van Tol et al., 2006). Results recently published from the HF-
ACTION trial, the largest randomised controlled, long-term, multi-centre trial, confirm 
that exercise training is safe and is associated with moderate improvements in mortality 
and hospitalisation, and in exercise capacity and self-reported health status,  in patients 
receiving contemporary medical management for CHF (Flynn et al., 2009; O'Connor et 
al., 2009).  It is not yet clear if there is an optimal exercise dose, and few studies have 
compared different methods of exercise training. Traditionally, exercise prescription for 
CHF has followed the methods used in healthy individuals, where the intensity is based 
on a percentage of maximal capacity, including maximum oxygen uptake (VO2max), 
maximum heart rate (HRmax), oxygen uptake reserve (VO2R) or heart rate reserve 
(HRR). There are various exercise intensity guidelines and prescription methods for 
cardiac patients (Balady et al., 2000; Fletcher et al., 2001; American College of Sports 
Medicine, 2006), including suggestions that the exercise intensity for CHF should be at 
the lower level of these guidelines.  However, these methods have been questioned, 
since percentages of  VO2max and HRmax correspond to a wide range of intensities and 
are likely to elicit variable metabolic responses in individuals (Meyer et al., 1999; 
Wasserman et al., 2005).  Consideration of the exercise intensity “domains”, based on 
the characteristic responses of acid-base status and respiratory gas exchange, are 
important for accurately predicting the physiological responses to exercise, and provide 
a better model for prescribing and regulating exercise intensity (Jones et al., 2007) . 
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Determining the appropriate exercise intensity for CHF is particularly difficult due to a 
low heart rate (HR) response (Witte et al., 2006), and to the variability in the 
relationship between VO2
The National Institute for Health and Clinical Excellence (NICE) Guidelines advise 
that patients with CHF should be encouraged to adopt regular aerobic exercise, and that 
this may be more effective when part of a rehabilitation programme (National 
Collaborating Centre for Chronic Conditions, 2003) (p. 32). Although cardiac 
rehabilitation (CR) should be an integral step in the management of cardiac patients, 
only a minority of patients join these programmes.  In particular, CHF patients are less 
likely to be offered CR even though they may gain even greater benefits than other 
cardiac patients, through improvements in prognosis as well as QoL  (Bethell et al., 
R and HRR, on which the prescription of exercise intensity is 
traditionally based (Mezzani et al., 2007).  It is therefore recommended that 
cardiopulmonary exercise testing (CPET) should be used to objectively evaluate 
functional capacity and prescribe subsequent exercise training (Pina et al., 2003).  Gas 
exchange measurements enable the identification of the submaximal “thresholds” that 
demarcate the exercise intensity domains, thus providing a framework for exercise 
intensity prescription.  In this way, training intensities are aligned to robust 
physiological parameters (Meyer et al., 2005b).  An intensity below the ventilatory 
threshold (VT),  i.e.  moderate intensity exercise, has been  proposed for CHF (Meyer 
et al., 2005a).    
 
 
Intermittent exercise, where short intervals of high intensity work are interspersed with 
recovery phases, induces a greater training adaptation than continuous exercise of an 
equal total workload in healthy individuals and cardiac patients (Meyer et al., 1990; 
Gorostiaga et al., 1991; Daussin et al., 2008).  It has been reported that short-term 
intermittent exercise training can achieve improvements in functional capacity 
comparable to lower intensity, longer duration training in CHF (Meyer et al., 1997b).  
Intermittent exercise may therefore offer an alternative and time-efficient means of 
training for populations who find it difficult to perform continuous exercise, and  may 
permit a higher training stimulus.   
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2004).  There is a lack of evidence to demonstrate the effectiveness of  exercise training  
in a real-life setting for CHF patients  in the UK.  
 
Current exercise training guidelines for CHF recommend intermittent exercise as a 
training mode (British Association for Cardiac Rehabilitation, 2006; Association of 
Chartered Physiotherapists in Cardiac Rehabilitation, 2009), but it is not clear if it can 
be effectively included in current CR practice. The aim of this thesis is to examine the 
methodology for intermittent exercise prescription, to assess the acute and chronic 
responses to intermittent exercise and to evaluate its effectiveness for CHF patients in a 
UK CR programme. 
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2.1 Chronic heart failure 
2.1.1 Definition of chronic heart failure 
CHF is a complex syndrome, involving the development of  pathopysiological changes 
in response to LV dysfunction, including over-activation of the neurohormonal (Packer, 
1992) and inflammatory systems (Seta et al., 1996), and skeletal muscle myopathy 
(Williams et al., 2004; Witte and Clark, 2007).  Patients experience symptoms of 
breathlessness and fatigue, and their functional capacity and quality of life are 
impaired.  The ESC definition of heart failure is shown in Table 2.1 (Swedberg et al., 
2005). 
Table 2.1: Definition of heart failure 
 
I Symptoms of heart failure at rest or during exercise 
and 
II Objective evidence (preferably by echocardiography) of cardiac dysfunction 
 (systolic and/or diastolic) at rest  
and (in cases where the diagnosis is in doubt) 
III Response to treatment directed towards heart failure 
 Criteria I and II should be fulfilled in all cases 
 
2.1.2 Diagnosis and classification of chronic heart failure 
As indicated in Table 2.1, diagnosis is based on symptoms and objective measures of 
cardiac dysfunction at rest, including echocardiography, electrocardiography (ECG), 
haematology and biochemistry  (Swedberg et al., 2005).  The severity of heart failure is 
commonly classified by the New York Heart Association (NYHA) Classification, 
based on subjective assessment of symptoms and functional capacity (Table 2.2).  
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Table 2.2: New York Heart Association classification of heart failure 
 
Class I:   No limitation: ordinary physical exercise does not cause undue fatigue, 
dyspnoea, or palpitations 
Class II:   Slight limitation of physical activity: comfortable at rest but ordinary 
activity results in fatigue, palpitations, or dyspnoea 
Class III:  Marked limitation of physical activity: comfortable at rest but less than 
ordinary activity results in symptoms 
Class IV:   Unable to carry out any physical activity without discomfort: symptoms of 
heart failure are present even at rest with increased discomfort with any 
physical activity 
 
The Weber Classification, developed in order to  better stratify hemodynamic 
severity using VO2peak
 
 and the anaerobic threshold, may also be used as an objective 
method of characterising functional status from CPET (Table 2.3) (Weber et al., 1982).   
Table 2.3: Weber classification  
 
Weber 
Classification 
VO2 peak 
(ml. kg.-1.min-1) 
Anaerobic threshold 
(ml. kg.-1.min-1) 
A > 20 >14 
B 16 – 20 11-14 
C 10.1 – 15.9 8-11 
D ≤ 10 < 8 
 
CHF is usually associated with evidence of LV systolic dysfunction, although diastolic 
impairment at rest commonly accompanies this.  An LV ejection fraction (LVEF) ≥ 
50% indicates good LV function,  40-49% indicates moderate LV function and < 40% 
indicates poor LV function.  Diastolic heart failure is often diagnosed when symptoms 
and signs of heart failure occur in the presence of a normal LVEF at rest (Swedberg et 
al., 2005). This thesis will focus on CHF with reduced systolic function, which 
accounts for approximately half of the cases of symptomatic heart failure in the 
community (McMurray and Pfeffer, 2005).   
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2.2 Pathophysiology of chronic heart failure 
Chronic heart failure is a multifaceted disease involving impairment of central and 
peripheral mechanisms and increased neurohormonal and inflammatory activity.   The 
pathophysiology has been described in several review papers (Lunde et al., 2001; 
Tavazzi et al., 2001; Pina et al., 2003; Swedberg et al., 2005; Clark, 2006), and will be 
summarised below.  It is now accepted that CHF is not only a haemodynamic disorder; 
the “neurohormonal hypothesis” (Packer, 1992), “muscle hypothesis” (Coats et al., 
1994) and “cytokine hypothesis” (Seta et al., 1996) combine to explain its progression 
and symptoms. 
2.2.1 Cardiovascular function 
A characteristic of CHF is the progressive dilation of the heart chambers and 
deterioration in cardiac function, termed “left ventricular remodelling” (Haykowsky et 
al., 2007). Reduced cardiac output, reduced perfusion and decreased oxygen delivery 
results in the inability of the heart to meet the demands of the tissues. CHF with 
impaired LV systolic function appear able to use the Frank-Starling mechanism to 
compensate to some extent for their decreased contractile reserve.  However, 
pericardial constraint may limit diastolic filling and contribute to reduced exercise 
tolerance (Warburton et al., 2007).  The primary symptoms are fatigue and/or 
breathlessness on exertion, although exercise intolerance is only weakly correlated to 
resting ventricular function (Pina et al., 2003).   
2.2.2 Neurohormonal hypothesis 
In order to compensate for reduced cardiac output and organ perfusion, neurohumoral 
abnormalities occur.  The sympathetic nervous system and renin-angiotensin 
aldosterone systems are activated in order to increase myocardial contractility, HR and 
vasoconstriction, and to expand extracellular fluid volume.  The persistant 
overactivation of these systems then leads to further myocardial damage, an increased 
inflammatory response, and skeletal muscle abnormalities (Packer, 1992; Crimi et al., 
2009). 
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2.2.3 Muscle hypothesis 
Coats et al’s “muscle hypothesis” (1994), described in Figure 2.1, proposes that 
abnormal skeletal muscle is a central abnormality in CHF that accounts for much of the 
pathophysiology and symptoms.  
 
 
Figure 2.1: The muscle hypothesis of chronic heart failure 
A reduction in left ventricular function activates catabolic and reduces anabolic factors that cause 
skeletal myopathy.  This in turn leads to exercise intolerance and sympathoexcitation that, through the 
combined effects of a persistent catabolic state and of inactivity, further worsen skeletal muscle and 
function, and may eventually lead to a progressive effect on remodelling of the left ventricle (Coats et al., 
1994). 
Ultrastructural abnormalities of skeletal muscle in CHF include decreased 
vascularisation, decreased volume and density of mitochondria, lower oxidative 
enzyme activity, and increased ratio of type II to type I fibres, resulting in decreased 
oxidative capacity which is significantly correlated with exercise performance (Drexler 
et al., 1992).  Energy transfer and utilisation is impaired in both cardiac and skeletal 
muscle, with increased anaerobic metabolism in exercising muscles, delayed recovery 
of PCr/ATP ratio and a slowing of intracellular calcium cycling  (Lunde et al., 2001). 
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In addition, mechanical efficiency is reduced, thus increasing the energy cost of 
contraction (Ventura-Clapier et al., 2007).  The derangement of energy metabolism and 
the “energy-depletion hypothesis” accounts for further disease progression (Neubauer, 
2007).   
Disuse may exacerbate the muscle abnormalities, leading to further muscle atrophy, 
decreased resistance to fatigue and reduced muscle strength. These are similar to the 
characteristics of physical deconditioning and the ageing process, and thus many 
elderly CHF will suffer the additive effect of all three conditions,  partially explaining 
the greater impairment in these elderly patients, and the accelerated progression of the 
disease process (Gielen et al., 2005).  Cycle ergometer exercise performance is directly 
related to quadriceps muscle area and upper leg muscle function (Senden et al., 2004). 
2.2.4 Ergoreflex activation 
The ergoreflex is the stimulation of the muscle receptors sensitive to work, leading to 
increased ventilation and sympathetic activation. These include metaboreceptors which 
are sensitive to metabolic stimulation, and mechanoreceptors which are sensitive to 
mechanical changes (Scott et al., 2000).  Due to structural muscle abnormalities, during 
exercise CHF are effectively performing more work per unit of muscle volume than 
normal muscle, and producing more metabolic products, which in turn stimulate the 
ergoreceptors to increase ventilation relative to carbon dioxide (CO2
The role of skeletal muscle ergoreceptors in increasing ventilatory drive, and thus 
contributing to the symptom of breathlessness in CHF, has been the subject of 
considerable debate. It is proposed that the impaired skeletal muscle function results in 
ergoreflex stimulation, causing increased ventilation, thus linking the symptoms of 
breathlessness and fatigue (Piepoli et al., 1996). The severity of CHF symptoms is 
related to the ergoreflex activation, thus supporting the theory that this reflex is the 
neural link between peripheral muscle abnormalities and exercise limitation (Piepoli et 
al., 2001).  Scott et al (2000) demonstrated that symptoms of breathlessness during 
exercise are mainly due to metabolic stimulation of the muscle metaboreceptors in 
CHF, a response that was absent in healthy controls.  Mechanoreceptors appear to have 
a limited effect on the ergoreflex response.  
) production (Witte 
and Clark, 2007). 
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2.2.5 Inflammatory cytokine hypothesis 
Myocardial damage causes an overexpression of both vasoconstrictor cytokines, such 
as endothelin, and pro-inflammatory cytokines, such as tumor necrosis factor-alpha 
(TNF-α) and interleukin-6 (IL-6).  These exacerbate haemodynamic abnormalities 
and/or exert direct toxic effects on the heart (Seta et al., 1996).  Increased free radical 
production alters the production of nitric oxide, by triggering apoptosis through 
oxidative stress, and by attenuating mitochondrial energy transfer through increased 
gene expression of iNOS in skeletal muscle  (Adamopoulos et al., 2002).  Reduced 
nitric oxide (NO) bioavailability is linked to abnormal endothelial function  (Walther et 
al., 2004).  The adverse effects of the inflammatory cytokine cascade in CHF on 
cardiac, vascular and skeletal muscle function, and the potential of exercise as an 
immunomodulatory treatment, is explained in detail by Adamaopoulos (2003). 
 2.2.6 Excessive ventilatory response 
Excessive ventilatory effort and breathlessness are associated with CHF, due to a 
ventilation-perfusion mismatch arising from haemodynamic dysfunction, augmentation 
of chemoreflex due to sympathetic overactivity and neurohormonal imbalance, as well 
as inactivity.  The increase in chemosensitivity may serve as a compensatory 
mechanism to increase ventilatory response during exercise and preserve blood gas 
homeostasis and maintain arterial oxygen concentration (Chua et al., 1996).  As 
discussed in section 2.2.4, it has been proposed that ergoreflex activation, due to  
earlier acidosis and the subsequent abnormal muscle signalling in peripheral muscles, 
including those used for respiration, is the main stimulus for the excessive ventilatory 
response in CHF (Clark, 2006; Witte and Clark, 2007).   
2.3 Determinants of exercise capacity in CHF 
In healthy individuals, VO2max is primarily limited by the ability of the 
cardiorespiratory system to deliver oxygen to the exercising muscle rather than by 
skeletal muscle oxygen extraction (Bassett and Howley, 2000). Submaximal exercise 
performance is determined by mitochondrial enzyme activity and capillary density, 
which influence metabolic factors (fat oxidation and lactic acid accumulation).  In 
CHF, the impairment of central and peripheral mechanisms and the increased 
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neurohormonal and inflammatory activity described above all contribute to reduced 
exercise tolerance in CHF.  Table 2.4 summarises the determinants of exercise capacity 
in CHF (Tavazzi et al., 2001).  
Patients with a lower functional capacity, in contrast with healthy individuals and CHF 
patients with a higher functional capacity,  do not exhaust their cardiopulmonary 
reserve during maximal cycle ergometer testing (Jondeau et al., 1992).  CHF patients 
with a VO2peak > 15.ml.kg-1.min-1 and age-matched healthy controls reached the same 
VO2max in cycling alone or cycling plus upper body ergometry combined, whereas 
patients whose VO2peak was < 15 ml.kg-1.min-1 during cycle ergometry  increased this 
value, and their peak heart rate (HRpeak), during combined exercise.  The authors 
hypothesised that in healthy individuals and patients with a VO2peak > 15 ml.kg-1.min-1, 
classified in this study as “moderate” CHF, when 50% or more of the total skeletal 
muscle mass is activated in exercise VO2max is limited by cardiac output, and is not 
affected by increasing the active muscle mass.  In more severe CHF (classified in this 
study as VO2peak < 15.ml.kg-1.min-1) VO2peak
  
 is also limited by muscle atrophy and/or 
reduced vasodilatory responses and impaired muscle metabolism.   
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Table 2.4: Main determinants of exercise capacity in chronic heart failure  
 
Central 
haemodynamics 
Heart rate response to exercise 
Stroke volume response to exercise 
Left and right ventricular ejection fraction 
Neurohormones Sympathetic drive during exercise 
Beta-adrenergic sensitisation 
Balance between vasoconstrictor and antinatriuretic systems 
 versus vasodilatory and natriuretic systems 
Peripheral response Skeletal muscle perfusion and vasodilatory capacity 
Muscle vasculature resistance 
Vascular endothelial function 
Cytokines, local growth factors and sodium content in the vessel   
wall 
Skeletal muscle mass 
Skeletal muscle function 
Pulmonary function Breathing pattern 
Bronchial reactivity 
Gas diffusion 
Ventilation/perfusion ratio 
Ventilatory response 
 
2.4 Current medical therapy for CHF 
Treatment for CHF is aimed at relieving symptoms, avoiding hospital admission and 
prolonging life.  Drugs form the mainstay therapy for CHF patients with reduced LV 
systolic function, although modern treatments now include surgery and implantable 
devices for some patients (McMurray and Pfeffer, 2005)  
The NHS NICE guideline algorithm for treatment in illustrated in Figure 2.2. Table 2.5 
shows current recommended medications for CHF, their actions, and, where 
appropriate, the side effects that need to be considered during exercise (National 
Collaborating Centre for Chronic Conditions, 2003; McMurray and Pfeffer, 2005; 
British Association for Cardiac Rehabilitation, 2006).  Even optimally treated patients 
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have many unrelieved symptoms which reduce their functional capacity and QoL. 
Exercise training to improve muscle structure and function may add to the 
improvements from medical therapy aimed at improving haemodynamic function 
(Coats et al., 1994).  
Figure 2.2: Algorithm for the pharmacological treatment of symptomatic heart 
failure due to LV systolic dysfunction 
NICE Guideline (National Collaborating Centre for Chronic Conditions, 2003) 
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Table 2.5: Guide to medication used in CHF  
Drug Group/Name Action Side effects: exercise considerations 
Angiotensin Converting 
Enzyme  inhibitor 
Reduces production of angiotensin II, thus reducing vasoconstriction, 
preventing fluid retention and reducing afterload and circulating volume  
Hypotension: avoid rapid changes in 
posture or abrupt cessation of exercise 
Angiotensin II receptor 
blockers  
Prevents binding of angiotensin II to its receptor, thus preventing 
vasoconstrictor action 
Fatigue, Hypotension: avoid rapid changes 
in posture or abrupt cessation of exercise 
Anti-arrhythmics 
Amiodarone  
Digoxin 
Prolongs the refractory period of the heart (i.e. when there is no electrical 
activity), thus suppressing arrhythmias 
Increases myocardial contraction and reduces conductivity within the AV node, 
thereby preventing rapid atrial rates from being transmitted to the ventricles, 
thus increasing myocardial efficiency 
 
Possible slower heart rate response to 
exercise, and reduced exercise capacity 
Anti-coagulants Interferes with synthesis of blood clotting proteins in the liver  Haemorrhage: care to avoid injury 
Anti-platelets 
 
Decreases platelet aggregation to stop clots forming in the arterial circulation  
β-blocker Blocks β-receptors to decrease sympathetic activity, resulting in reduced 
myocardial oxygen demand, reduced heart rate and suppression of arrhythmias   
Selective β-blockers (e.g. bisoprolol) reduce the effect of noradrenaline and 
adrenaline on β1 receptors. Non-selective β-blockers (e.g. carvedilol) block β1, 
β2 and α1
Hypotension: avoid rapid changes in 
posture or abrupt cessation of exercise. 
Reduced heart rate at rest, and during 
submaximal and maximal exercise: 
exercise training heart rates should be 
adjusted and interpreted with caution 
 receptors, as well as having vasodilatory and anti-oxidant properties 
Calcium Channel 
Blocker 
Type 2 (Amlodipine) 
Reduces calcium influx into smooth muscle in walls of systemic arteries, thus 
reducing blood pressure 
Hypotension: avoid rapid changes in 
posture or abrupt cessation of exercise 
Diuretic (Loop)  
 
 
(Potassium sparing/ 
aldosterone antagonist)  
Interferes with transport of sodium and water across loop of Henle cells in the 
kidneys, thus increasing the volume of urine excretion, reducing circulating 
fluid and blood pressure 
Inhibits the action of aldosterone thereby causing the kidneys to excrete salt 
and fluid in the urine while retaining potassium.  
Dehydration and hypotension: encourage 
fluid intake during exercise 
Aching legs and/or fatigue: may affect 
exercise capacity 
Nitrate (Isosorbide 
dinitrate/ hydralazine) 
Vasodilates veins and arteries, thus improving coronary blood flow, and 
reducing preload and afterload 
Hypotension: avoid rapid changes in 
posture or abrupt cessation of exercise 
Statin Inhibit enzymes involved in cholesterol synthesis, reducing levels of 
cholesterol and triglycerides in the blood 
Possible aching legs: may affect exercise 
capacity 
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Pacemakers, cardiac resynchronisation therapy and implantable cardioverter 
defibrillators are current treatments for the management of CHF (National 
Collaborating Centre for Chronic Conditions, 2003; Swedberg et al., 2005).  There is 
emerging evidence that exercise training offers additional improvements in functional 
capacity in patients with these devices, and should be recommended in clinical practice 
for this population (Conraads et al., 2007; Patwala et al., 2009).   
2.5 Exercise training as therapy for CHF 
Historically, it was feared that exercise could worsen LV function.  In the 1970s and 
1980s, studies reported an increase in exercise capacity following exercise training in 
patients with poor LV function, without any deleterious effect on LV function (Lee et 
al., 1979; Conn et al., 1982).  It was subsequently demonstrated, in a randomised cross-
over trial on a small sample of CHF patients with ischaemic aetiology, that 8 weeks of 
exercise training increased exercise tolerance and peak oxygen uptake (VO2peak) 
compared with the normal treatment of activity restriction (Coats et al., 1990b).  Since 
this landmark study, numerous studies have confirmed the benefits of exercise training, 
and investigated the mechanisms for these benefits.  Tables A1 (aerobic training) and 
A2 (combined aerobic and resistance training) (Appendix 1) provide a summary of 
exercise training studies in CHF, including details of the study design, participants, 
exercise interventions (including available details of exercise type, frequency, intensity 
and duration), outcome measures and main results, and their findings are discussed in 
subsequent paragraphs. The studies were identified by a combined electronic database 
search of the following databases: Cochrane Library, PubMed, Web of Science and 
Science Direct.  The search terms used were “exercise training” and “heart failure”, and 
restrictions to humans and English language papers only were applied. All studies 
dating from 1990 to 2010, for which the full paper could be accessed, and which 
included a predominantly aerobic exercise training intervention exclusively for CHF 
patients, were included. The design and methodological quality of these studies was 
diverse, and includes observational studies and randomised controlled trials (RCTs), 
studies of short duration and those with long-term follow-up, studies with sample sizes 
of 8 to ≥ 80 participants, and those assessing clinical outcomes, exercise performance, 
mechanistic effects, or a combination of these.  Analysis of the methodological quality 
of exercise training studies in CHF has been provided by several authors  (Lloyd-
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Williams et al., 2002; Rees et al., 2004; van Tol et al., 2006; Davies et al., 2010).  The 
variability in findings from exercise training studies is likely to be due to a combination 
of the differences in heart failure aetiology and severity, medical therapy and exercise 
intervention, in addition to different methodological approaches.  
2.5.1 Exercise training review papers and meta-analyses 
In 1998, data from 134 CHF patients from RCTs was reviewed, and it was concluded 
that moderate exercise training was safe and beneficial (European Heart Failure 
Training Group, 1998). In 2002, a systematic review of 22 RCTs and 9 non-RCTs 
concluded that exercise training had both physiological and psychological benefits for 
selected sub-groups of CHF patients, but emphasised that the patients enrolled in these 
studies were not representative of the CHF population as a whole (Lloyd-Williams et 
al., 2002).  In 2004, a meta-analysis by the ExTraMATCH Collaboration reported that 
there was no evidence that exercise training was dangerous for CHF patients, and that it 
significantly reduced mortality (hazard ratio 0.65, 95% confidence interval, 0.46 to 
0.92).  The authors emphasised the need for research examining the optimal exercise 
therapy and identifying appropriate groups of CHF patients to target (Piepoli et al., 
2004).  The first Cochrane Review of exercise based rehabilitation for heart failure 
evaluated 29 randomised controlled trials, including 1126 patients, of exercise-based 
interventions compared with usual medical care to determine the effect on mortality, 
morbidity, exercise capacity and health related QoL (Rees et al., 2004). Short-term 
exercise training was reported to significantly increase VO2peak by 2.16 ml.kg-1.min-1 
(95% CI 2.82 – 1.49) and work capacity by 15 W (95% CI 18 – 13), with greater 
improvements in programmes of greater intensity and duration.  Health related QoL 
improved in 7 of the 9 trials that measured this outcome.  Further long-term trials were 
needed to examine the effect on mortality and morbidity.  The authors noted that the 
results were based on patients who were not representative of the total population of 
CHF, which includes more severe patients, the elderly and females.  They 
recommended that large-scale pragmatic trials of exercise training of longer duration, 
recruiting a wider spectrum of patients are needed to address these issues.  The recent 
updated Cochrane Review added that exercise does not increase the risk of all-cause 
mortality, may reduce heart failure-related hospital admissions and offer important 
improvements in  health-related quality of life (Davies et al., 2010).   This review 
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included data from the HF-ACTION trial, the largest RCT of exercise training in CHF, 
which is discussed below in section 2.5.3. 
 
The effects of exercise training have been reviewed by other authors (Meyer et al., 
2004a). Van Tol et al. (2006) were the first to conduct a quantitative analysis on the 
effects of exercise training compared to usual care on cardiac performance, exercise 
capacity and QoL in CHF patients (van Tol et al., 2006).   They concluded that exercise 
training has clinically important effects on exercise capacity and health-related QoL, 
and may have small positive effects on cardiac performance during exercise.   
2.5.2 Proposed mechanisms for benefits following exercise training 
The improvement in exercise capacity following training is due to a combination of 
mechanisms, including peripheral vascular, muscular and metabolic function, and 
possible improvements in cardiac function, or attenuation of the progression of LV 
dysfunction.  A summary of each of these is provided below, and comprehensive 
reviews are provided by several authors (Piepoli et al., 2001; Adamopoulos et al., 2003; 
Gademan et al., 2007; Whellan et al., 2007; Crimi et al., 2009).  The pathobiological 
pathways that are favourably influenced by exercise training are illustrated in Figure 
2.3 (Crimi et al , 2009).  
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.  
Figure 2.3: Pathobiological pathways induced by exercise training in CHF patients  
 
2.5.3 Reduction in all cause mortality and hospitalisation: HF-ACTION trial 
The HF-ACTION trial is the largest randomised controlled trial to measure the effects 
of exercise training on clinical outcomes of mortality, hospitalisation and QoL 
(Whellan et al., 2007).  The multi-centre trial took place at 82 centres within the United 
States, Canada and France and recruited 2,331 medically stable outpatients with heart 
failure and ejection fraction ≤ 35 %.  Patients were randomised to usual care plus 
aerobic training, consisting of 36 supervised sessions followed by home-based training, 
or usual care alone.  The median follow-up duration was 30 months. There were non-
significant reductions in the primary endpoint of all-cause mortality or hospitalisation. 
Exercise 
training in 
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↑ insulin-like growth 
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Inflamatory response
↓ inducible nitric oxide 
synthase
↓ tumor necrosis factor
↓ interleukin-6
Nervous system
↓ reactive oxygen 
species
↓ sympthetic activity
↑ nitric oxide
↑ vagal activity
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Non-significant reductions were also found in secondary end points (cardiovascular 
mortality or hospitalisation, and cardiovascular mortality and heart failure 
hospitalisation).  However, after adjustment for highly prognostic predictors of the 
primary end point, including LVEF and VO2peak, exercise training was associated with 
modest significant reductions for both all-cause mortality (11%) or hospitalisation, and 
cardiovascular mortality or heart failure hospitalisation (15%) (O'Connor et al., 2009).  
Exercise training also resulted in modest but statistically significant improvements in 
VO2peak (4%), and in self-reported health status, assessed by the Kansas City 
Cardiomyopathy Questionnaire (KCCQ) (which measures physical limitation, social 
limitation, symptoms and QoL), an improvement that was sustained at 3 month 
intervals during a median follow-up of 2.5 years (Flynn et al., 2009).   
 
The HF-ACTION trial, due to its design, provides the strongest evidence to date on the 
effects of exercise training on CHF. It is the only single study with an adequate sample 
size and of a sufficient duration to properly evaluate clinical outcomes (Whellan et al., 
2007).  The risk of bias is reduced by its multicentre design and blinding of outcome 
assessors, and complete outcome data was reported non-selectively.  Nevertheless, 
several limitations were identified, including issues of site variation, adherence to 
exercise, and crossover of patients in the usual care group to exercise training 
(O'Connor et al., 2009).  
 
Keteyian presented further data from the trial at the 58th Annual Scientific Session of 
the American College of Cardiology (2009) demonstrating a dose-response effect of 
exercise training on the 959 patients in the exercise group who were event-free at 90 
days. VO2peak, 6-minute walk distance and KCCQ score improved after every 1MET-
hour/week increment achieved in exercise intensity.  This suggests that patients who 
comply with an exercise training programme achieve a better outcome, although the 
ability of patients with a good prognosis to exercise for longer may confound the issue. 
Furthermore, those who adhered to exercise may have also been more likely to adhere 
to their medical therapy, thus confounding the issue further. 
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2.5.4 Effect on exercise capacity 
2.5.4.1 Peak oxygen uptake (VO2peak) 
The reduced exercise capacity in CHF, due to a decline in cardiac function and 
peripheral abnormalities, is exhibited by a VO2peak in the region of 40-55% of the age-
predicted value (Cohen-Solal et al., 1990).  A VO2peak < 14 ml.kg-1.min-1 was formerly 
used as the cut-off point for heart transplant evaluation, but improved medical 
treatment suggests that values < 10 ml.kg-1.min-1 is a more appropriate cut-off point. 
VO2peak values below 11 ml.kg-1.min-1 have been associated with a poor prognosis 
(Myers et al., 1998). 
The majority of studies report an increase in VO2peak of 10-30% following exercise 
training of 1 - 6 months’ duration. A systematic quantitative review reports a 13% 
significant increase in VO2peak, with a pooled effect size of 0.60 and 95% confidence 
intervals of 0.42 – 0.79 ml.kg-1.min-1  (van Tol et al., 2006).  Improvements in cardiac 
output and oxygen extraction may both contribute to the improvement, as discussed in 
subsequent paragraphs. Not all studies report an increase in VO2peak (Jonsdottir et al., 
2006).  There is some evidence to suggest that exercise training may be less effective at 
increasing VO2peak in older CHF patients, with reported average improvements of 1.2 
ml.kg-1.min-1 in patients under 65 year compared with 0.5 ml.kg-1.min-1 in patients over 
65 years (Wielenga et al., 1998).  As the majority of research to date has focussed on 
patients < 65 years, this warrants further investigation. The 4% improvement in VO2peak 
reported in the HF-ACTION trial, where the median age of patients was 59 years, is 
also lower than improvements previously reported.  Possible reasons include the lower 
volume of exercise performed compared with the prescribed exercise goals, and the 
reduced additional benefits conferred by exercise on patients treated with contemporary 
medical therapy. 
  
The shortest duration studies show that improvements can be gained after only 3 weeks 
(Meyer et al., 1996c), but greater effects appear to be gained from longer duration 
programmes, with a plateau in improvements at 16-26 weeks (Kavanagh et al., 1996).   
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2.5.4.2 Sub-maximal exercise capacity 
Day-to-day limitations are more likely to be related to sub-maximal exercise tolerance, 
such as the ventilatory threshold (VT) (Larsen et al., 2001). VT is used alongside 
VO2peak to characterise functional status in CHF (Weber et al., 1982). It is considerably 
lower in CHF patients compared with healthy individuals, and decreases according to 
the severity of the disease. However, the % VO2peak at VT may be high (~72% VO2peak 
in CHF vs ~60% in healthy individuals), due to an attenuated rise in VO2 above the VT, 
and/or the fact that exercise tolerance is very low (Meyer et al., 2005a).  van Tol et al’s 
(2006) systematic quantitative review reports a 17.4% significant increase in VT, with 
a pooled effect size of 0.84 and 95% confidence intervals of 0.48 –1.20 ml.kg-1.min-1
2.5.5 Improvements in cardiovascular function 
. 
Improvements in exercise capacity are associated with numerous improvements in 
central and peripheral function, as discussed below. 
2.5.5.1 Left ventricular function 
Numerous studies confirm that there is no adverse effect on LV function (assessed by 
echocardiography) (Sullivan et al., 1988; Belardinelli et al., 1999; Conraads et al., 
2004) which appears to remain largely unchanged by exercise training, although some 
studies have reported modest improvements.  A meta-analysis of the effect of exercise 
training on LV remodelling reported 14 trials with ejection fraction (LVEF) data and 7 
with end diastolic volume (EDV) and end systolic volume (ESV) data.  Aerobic 
training, but not combined aerobic and strength training, significantly improved LVEF 
(weighted mean difference 2.59%) and reduced EDV (-11.49 ml) and ESV (-12.87 ml) 
(Haykowsky et al., 2007).  Van Tol et al’s meta analysis (2006) shows a small 
significant decrease in resting EDV and increase in HR and cardiac output during 
maximal exercise (van Tol et al., 2006). Small increases in stroke volume (Coats et al., 
1990b; Hambrecht et al., 2000) and HRpeak (Keteyian et al., 1996; Keteyian et al., 1999) 
contribute to the increase in cardiac output. Parnell et al (2002) reported a 35% increase 
in systemic arterial compliance following exercise training, which would be expected 
to reduce afterload and myocardial oxygen demand and increase coronary perfusion. In 
Hambrecht et al’s study (2000), improvements in stroke volume and LV end diastolic 
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diameter  were significantly correlated with reduced peripheral resistance (Hambrecht 
et al., 2000).   
LV remodelling appears to be a slower process than other improvements achieved in 
the shorter-term. Exercise performance was significantly improved and abnormal LV 
remodelling diminished following 6 months’ moderate intensity training (Hambrecht et 
al., 2000; Giannuzzi et al., 2003b).  Training programmes of shorter duration have not 
demonstrated such changes. This is confirmed in a more recent study (Beer et al., 2008) 
evaluating LV function using MRI, which is a more precise, reproducible and accurate 
technique  than echocardiography for LV assessment (Rajappan et al., 2000). Although 
unchanged after 2 months of exercise training, significant improvements were 
measured in LVESV and LVEF at 8 months’ follow up.  Another study using MRI on 
CHF of ischaemic origin also reported improvements in LVEF, LVEDV and wall 
motion score index after 6 months’ training.  In the non-trained control group LV 
function deteriorated (Klecha et al., 2007). 
2.5.6 Peripheral blood flow and endothelial function 
Regular exercise training increases nitric oxide generation and responsiveness, thus 
improving endothelial function and reducing peripheral vascular resistance (Hornig et 
al., 1996; Walther et al., 2004; Parnell et al., 2005). Skeletal muscle blood flow is 
therefore increased (Sullivan et al., 1988; Hambrecht et al., 1998).  It is not clear if the 
improved peripheral blood flow is specific to the exercised musculature (Demopoulos 
et al., 1997a; Kobayashi et al., 2003), or if  the improvements are systemic (Linke et al., 
2001; Roveda et al., 2003).  Increases in systemic endothelium-dependent dilation are 
correlated with improvements in exercise capacity, suggesting a causal relationship 
(Hambrecht et al., 2000; Linke et al., 2001).   
2.5.7 Anti-inflammatory effect 
Exercise training modulates the inflammatory and skeletal muscle apoptotic process 
associated with CHF.  The reductions in peripheral inflammatory markers correlate 
well with improvements in functional capacity (Adamopoulos et al., 2001; 
Adamopoulos et al., 2002).  Interestingly, another study reported no change in plasma 
inflammatory markers, although muscle biopsy analysis did reveal a significant 
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reduction in local TNF-α, IL-1 and IL-6, and in inducible nitric oxide synthase (iNOS) 
(Gielen et al., 2003).   
2.5.8 Skeletal muscle function 
The delay in anaerobic metabolism and improvement in dynamic muscle strength 
following exercise training (McKelvie et al., 2002) are partly mediated by increased 
skeletal muscle blood flow (Sullivan et al., 1988) and improved endothelial and 
neurohormonal function. In addition there is evidence for training-induced 
improvements in histology, mitochondrial structure, and oxidative capacity.  Exercise 
training is associated with increases in muscle fibre size and mitochondrial density, a 
histochemical shift from type II to type I fibres and improvements in oxidative capacity 
(Belardinelli et al., 1995b; Gordon et al., 1996; Hambrecht et al., 1997). Shorter periods 
(≤ 3 months) of lower intensity training did not result in increases in type I fibre 
expression or oxidative enzymes (Kiilavuori et al., 2000; Larsen et al., 2002).  
However, where the training was focussed on knee extensor exercises, improvements in 
oxidative vs glycolytic capacity were achieved after only 8 weeks’ training (Gordon et 
al., 1996; Tyni-Lenné et al., 1997).  A recent study reported that 6 weeks’ knee 
extensor training improved skeletal muscle calcium handling in healthy controls, but 
not in CHF patients (Munkvik et al., 2010). Thus, reduced calcium release does not 
appear to be related to skeletal muscle fatigue in CHF. It appears that exercise training 
has beneficial effects on skeletal muscle both directly, on muscle function, histological 
and biochemical features) and indirectly, by attenuating muscle ergoreflex activation, 
as discussed in section 2.5.9 (Piepoli et al., 2001).  Table 2.6 summarises the benefits of 
exercise training to skeletal muscle. 
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Table 2.6: Skeletal muscle benefit of exercise training  
 
Morphology ↑ cross-sectional area 
Function ↑ peak work rate 
↑ strength 
↑ endurance 
↓ fatigability 
Blood Function ↑ oxygen delivery 
↓ vascular resistance 
↑ arterio-venous oxygen difference 
Metabolism ↑ oxidative metabolism 
↑ adenosine triphosphate re-synthesis 
↓ or ↔ anaerobic metabolism 
↓ lacate accumulation & acidosis 
↓ phosphocreatine depletion 
Ultrastructural ↑ mitochondria content 
↑ oxidative enzyme activity 
↑ fibre size 
↑ capillary density 
↑ endothelial function 
↑ nitric oxide release 
  
2.5.9 Ventilatory function  
Exercise training appears to reduce the contribution of the ergoreflex to ventilation  due 
to the improvements in muscle function described above. It has been argued that an 
improvement in symptoms following exercise training, or indeed following other 
therapy, is dependent on the resolution of skeletal muscle abnormalities and the 
associated exaggerated ergoreflex response (Piepoli, 1996).  An attenutation in 
ergoreflex response and an improved ventilatory response to exercise were 
demonstrated after 6 weeks’ training of the forearm (Piepoli et al., 1996). 
Improvements in ventilatory efficiency have been reported following  8 weeks’ cycle 
ergometer training (Coats et al., 1992a) and 3 weeks’ cycle ergometer and treadmill 
exercise (Meyer et al., 1996c).   Similar improvements have also been reported in CHF 
on optimal medical therapy participating in a 6 month training programme (Klecha et 
al., 2007). These studies suggest that an appropriate exercise programme mediates the 
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exaggerated ergoreflex activity that contributes to breathlessness in CHF, presumably 
due to improved peripheral muscle function.  
2.5.10 Neuroendocrine and autonomic nervous system activity 
Exercise training has direct and reflex sympatho-inhibitory effects on autonomic 
derangement and neurohumoral activation (Gademan et al., 2007).  The mechanisms 
include improved baroreflex control of sympathetic activity due to reduction in 
circulating angiotensin II and/or improved cardiac output leading to augmented renal 
perfusion and thus reduced stimulation of the renin-angiotensin aldosterone system.  
 
Decreases in plasma catecholamines and in muscle sympathetic nerve activity have 
been reported (Coats et al., 1992a; Hambrecht et al., 1995a; Passino et al., 2006b).  
Assessment of time domain HR variability has shown enhanced vagal activity (Coats et 
al., 1992a). ECG analysis of frequency rather than time domain showed increases in the 
parasympathetic component of HR variability during the day, probably via an increase 
in vagal tone (Kiilavuori et al., 1995).  A similar analysis of patients on β-blocker 
therapy also demonstrated restored autonomic tone and reactivity to vagal and 
sympathetic stimuli following a 3 month low intensity rehabilitation programme. 
Further improvements were noted after 6 months’ home-based training (Malfatto et al., 
2002). Significant reductions in muscle sympathetic nerve activity recorded directly 
using microneurography to levels similar to those in healthy individuals (Roveda et al., 
2003), and in resting, but not peak, levels of the plasma neurohormones angiotensin II, 
aldosterone, vasopressin and atrial natriuretic peptide (Braith et al., 1999) have also 
been reported following 4 months’ training.   
 
2.5.11 Cardiac energy metabolism  
As discussed in section 2.5.8, exercise training improves skeletal muscle function and 
metabolism. It is less clear if these benefits occur in cardiac muscle. Direct assessment 
of mitochondrial function and energy transfer in CHF patients is lacking (Ventura-
Clapier, 2009).  The aforementioned improvements in cardiac function and 
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inflammatory markers following exercise training would, in theory, decrease oxidative 
stress and therefore improve energy transfer and utilisation (Ventura-Clapier et al., 
2007).  A small study of mild CHF with idiopathic dilated cardiomyopathy  reported 
reduced biventricular oxidative metabolism and improved myocardial work efficiency, 
measured by positron emission tomography and echocardiography, alongside 
improvements in ejection fraction and end systolic diameter, after 5 months’ training 
(Stolen et al., 2003). However, further evidence to support an improvement in 
myocardial energetics is lacking. Beer et al (2008) reported that PCr/ATP ratio, 
assessed by phosphorous-31 magnetic resonance spectroscopy, was unchanged 
following 8 months’ training, suggesting that exercise training appears neither to 
improve or worsen cardiac metabolism (Beer et al., 2008).  
2.5.12 Improvements in health-related quality of life 
CHF reduces QoL therefore improving well-being in CHF and should be an important 
target for health care interventions  (Hobbs et al., 2002). In an elderly CHF population, 
maintenance or improvement in QoL may be more valuable than prolonging survival 
(Swedberg et al., 2005). While some studies have reported no change in QoL following 
exercise training (Keteyian et al., 1999; Owen and Croucher, 2000; van den Berg-
Emons et al., 2004), others have reported significant improvements (Belardinelli et al., 
1999; Parnell et al., 2002; Passino et al., 2006b). 
2.5.13 Cost-effectiveness 
The estimated annual cost of heart failure to the NHS is £625 million, with 70% of that 
cost being due to hospitalisation (Commission for Healthcare Audit and Inspection, 
2007). A cost-analysis based on the largest randomised trial at the time, involving 94 
CHF patients in NYHA class II-III, aged 55-64 years, assigned to  a 14-month training 
programme or a non-exercising control group (Belardinelli et al., 1999) concluded that 
exercise training is cost effective and prolongs survival by an additional 1.82 years at a 
cost of $1,773 per life-year saved  (Georgiou et al., 2001).  More recently, patients who 
participated in a short-term 8 week training programme had significantly fewer 
hospitalisation events and days spent in hospital due to cardiac problems at a 5 year 
follow-up than patients who did not participate in the training programme (Hagerman 
et al., 2005). 
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2.6 Current guidelines for exercise training 
Current physical activity guidelines recommend that all healthy adults aged 10-65 years 
should aim to take part in at least 150 min of moderate-intensity aerobic activity or 75 
min of vigorous intensity activity for health benefits (Haskell et al., 2007; O'Donovan 
et al., 2010).  Depending on body weight, this amount of activity expends about 800-
1200 kcal per week.  These recommendations have been adapted for older individuals 
and/or those with chronic conditions or functional limitations that affect physical 
activity, but the guidelines for aerobic activity are maintained (Nelson et al., 2007). 
Exercise training for CHF is recommended by the American Heart Association (AHA) 
(Hunt et al., 2005), the European Society of Cardiology (ESC) (Swedberg et al., 2005) 
and the National Institute of Clinical Excellence (NICE, 2003) in their guidelines for 
the management of chronic heart failure.  Standardised recommendations for exercise 
have been published, with the aim of applying aerobic and strength training with 
sufficient stimuli to skeletal muscles without overloading the cardiovascular system  
(Giannuzzi et al., 2001).  These recommendations are based on the evidence 
accumulated from the various research studies on exercise training in CHF (as detailed 
in Tables A1 and A2 (Appendix 1).  There is no agreement on a universal exercise 
prescription, partly due to the large variations in exercise trial interventions, in terms of 
frequency, duration, intensity and type of training, and thus an individualised approach 
is recommended  (Pina et al., 2003).  Exercise training guidelines specific to CHF are 
discussed in more details in section 2.6.3.   
2.6.1 Safety of exercise training 
Although regular physical activity reduces the risk of coronary heart disease events, 
vigorous physical activity can transiently increase the acute risk of acute myocardial 
infarction and sudden cardiac death (Thompson et al., 2007).   In an apparently health 
population, based on the available evidence, the maximal risk estimates for an acute 
cardiovascular event during physical activity is 0.3-2.7 in men and 0.6-6.0 in women 
for 10,000 person hours.  A summary of medically-supervised, contempary CR 
programmes showed 1 cardiac arrest per 116,906 patient hours, and 1 fatality per 
752,365 patient hours (Thompson et al., 2007).  For those at risk of, or with, CHD the 
benefits of regular physical activity appear to outweigh the risks.  The risk is related to 
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the relative intensity of the exercise, with vigorous unaccustomed exercise (defined as 
≥ 60% VO2R) increasing the risk. The risk is reduced by observing guidelines on 
contraindications to exercise, and performing exercise testing in individuals with or at 
risk of known cardiovascular disease, before recommending vigorous exercise training  
(Gibbons et al., 1997; Fletcher et al., 2001). 
 
The latest Cochrane Review concludes that there is no evidence that exercise training 
increases the risk of death in CHF  (Davies et al., 2010).  Smart and  Marwick’s (2004) 
sytematic review  reported  no exercise-related deaths in > 60,000 patient hours of 
training.  The HF-ACTION trial reported that only 3% of patients in the exercise group 
were hospitalised for an event that occured during or within 3 hours after exercise, 
similar to the 2% of patients in the usual care group who were hospitalised during or 
within 3 hours after activity (Keteyian, 2010). These findings are likely to be 
influenced by the eligibility criteria in research studies; high risk patients, for example 
those with documented myocardial ischaemia, abnormal blood pressure responses or 
rhythm disorder, are usually excluded (Giannuzzi et al., 2001).  Supervised hospital-
based exercise programmes with appropriate risk stratification and pre-exercise 
screening, are recommended, at least in the initial stages of training (Giannuzzi et al., 
2001; Association of Chartered Physiotherapists in Cardiac Rehabilitation, 2009).  
Optimal screening includes a maximal CPET, and data from the HF-ACTION trial 
reported that the major event rate was 0.45 per 1,000 tests and the minor event rate was 
6.1 per 1,000 tests (Keteyian, 2010). 
2.6.2 The exercise dose 
The exercise dose is dependent on the interrelationship of frequency, intensity, duration 
(American College of Sports Medicine, 2006).  There is evidence of a graded dose-
response between the total volume of physical activity performed and cardiorespiratory 
fitness, but only weak evidence for a dose response for activity volume and health 
measures.  The intensity of the the activity appears to be more important than the total 
volume for increasing cardiorespiratory fitness (Oja, 2001).  There is compelling 
evidence that vigorous intensity activity is associated with a lower risk of 
cardiovascular disease, and of other chronic diseases (O'Donovan et al., 2010).   
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2.6.2.1 Exercise intensity  
Exercise intensity has been defined and characterised in several ways. From a public 
health perspective, The British Association of Sport and Exercise Sciences (BASES) 
(O'Donovan et al., 2010) expresses intensity of physical activity in metabolic 
equivalents (METS) or rating of perceived exertion (RPE).  In METS, where  1 MET is 
equivalent to the energy expended at rest, moderate intensity exercise is typically 
defined as 3-6 METS, and vigorous intensity exercise as > 6 METS.  Using the 6-20 
RPE scale (Borg, 1998), an RPE of 12-13 represents moderate intensity and 14-16 
represents vigorous intensity. The ACSM guidelines recommend exercise intensity in 
the range of 50-85% VO2R, which includes moderate intensity at the lower end and 
vigorous intensity at the higher end (Nelson et al., 2007).   
In simple physiological terms, exercise is defined as being low or moderate intensity 
when there is no increase in oxygen uptake (VO2) or blood lactate concentration (Lac) 
(beyond the initial adjustment to a new steady-state) with increasing time, or high 
intensity when it results in an elevation of oxygen uptake and Lac, and is non-
sustainable (Brickley et al., 2007).  More sophisticated  physiological definitions 
include models based on Lac (Billat et al., 2003; Faude et al., 2009) and gas exchange 
measurements (Meyer et al., 2005b). Indicators of exercise intensity derived from gas 
exchange thresholds measured during CPET are attractive as they are non-invasive, and 
valid for athletes, healthy individuals and those with chronic diasease (Meyer et al., 
2005b).  
2.6.2.2 Exercise intensity domains  
Meyer et al (2005b) propose a conceptual framework for the evaluation of endurance 
capacity and for the derivation of exercise intensity by the use of two gas exchange 
thresholds, each representing important landmarks within the spectrum of workloads. 
During incremental exercise, the level of exercise above which aerobic energy 
production is supplemented by anaerobic mechanisms leads to lactic acidosis. The 
subsequent bicarbonate buffering increases carbon dioxide (CO2) partial pressure, 
which stimulates the ventilatory drive via the carotid bodies (Wasserman et al., 2005). 
The workload corresponding to these events is termed  the aerobic gas exchange 
threshold (Meyer et al., 2005b), although it is primarily a metabolic phenomenon. It is 
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determined graphically by the V-slope method (Beaver et al., 1986).  It has also been 
called the metabolic threshold (Cooper and Storer, 2001), the anaerobic threshold 
(Wasserman et al., 2005), the ventilatory threshold or first ventilatory threshold. In this 
thesis the threshold will be termed the ventilatory threshold (VT).  After VT, 
circulating bicarbonate compensates for lactic acidosis to begin with.  This is termed 
the isocapnic buffering stage.  Once lactic acid production becomes so great that it 
cannot be compensated by circulating bicarbonate, ventilation is uncoupled from CO2 
production, and hyperventilation begins.  Meyer et al (2005) call this point the 
anaerobic gas exchange threshold.   It is detected graphically from the plot VE against 
VCO2 as the point where VE increases disproportionately above VCO2, confirmed by 
the point at which VE/VCO2 inflects upward and PET CO2 decreases simultaneously. It 
has also been called the second ventilatory threshold and the respiratory compensation 
threshold (Jones et al., 2007), or respiratory compensation point (RCP) (Tanehata et al., 
1999; Cooper and Storer, 2001), as it will now be termed in this thesis .   
Figure 2.4 illustrates Meyer’s model for the delineation of exercise training intensity 
zones by use of the gas exchange thresholds, and includes typical values for trained and 
untrained individuals and for patients with chronic disease.   
 
Figure 2.4: Model for the delineation of exercise intensity domains by use of gas 
exchange thresholds  
(adapted from Meyer et al., 2005a)  
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These delineations of exercise intensity have more recently been termed “exercise 
intensity domains”  (Jones and Poole, 2005; Jones et al., 2007).  Figure 2.5 provides 
schematic representation of the VO2 response to moderate, heavy and severe intensity 
constant load exercise.   
 
Figure 2.5: Schematic representation of the VO2 response to moderate, heavy and 
severe intensity exercise 
 (adapted from  Jones et al, 2007).  The shaded areas represent the increase in VO2 
above the expected steady-state level.  
 
The upper boundary for “moderate” intensity exercise is VT, or the lactate threshold 
(the intensity at which Lac begins to rise above baseline levels during incremental 
exercise).  The upper boundary for “heavy” intensity exercise is the maximal lactate 
steady state (MLSS) (the highest intensity at which lactate production and elimination 
are in equilibrium), which corresponds broadly to RCP,  although RCP may be 
approximately 10% higher (Dekerle et al., 2003).  “Severe” intensity is exercise above 
MLSS/RCP, with the upper boundary being VO2max. VO2max is the demarcation 
between submaximal and supramaximal exercise, and intensities above VO2max are 
defined as being “extreme” intensity (Jones and Poole, 2005; Jones et al., 2007).   This 
thesis will follow the terminology of Jones et al for  the exercise intensity domains, 
which will be called “moderate”, “heavy”, “severe” and “extreme”.  In the moderate 
intensity domain VO2 reaches an early steady-state, and Lac remains close to resting 
levels. In the heavy intensity domain VO2 and Lac reach a delayed but elevated steady-
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state. In the severe intensity domain, both VO2 and Lac will increase over time until 
VO2max is reached and the exercise is terminated.  In the extreme intensity domain, 
exercise tolerance is very limited and VO2 remains lower than VO2max when exhaustion 
is reached. 
2.6.3 Exercise guidelines for chronic heart failure 
Determining the appropriate exercise dose in CHF is important for reasons of safety 
and efficacy, but is not straightforward.  Methodological issues, including variation in 
exercise testing protocols and different methods for measuring and defining intensity 
have confounded the exercise prescription guidelines to date. There is no consensus as 
to the optimal exercise intensity, nor indeed the best parameter for measuring exercise 
intensity.  Exercise training studies, and recommendations arising from these, have 
used basic exercise prescription methods adapted from healthy populations, or the 
wider cardiac population.  The exercise is generally described as “aerobic” and 
“moderate”, and the recommended intensity is based on a percentage of maximal 
capacity, defined by VO2max, VO2R, HRmax or HRR.  Current exercise guidelines from 
various organisations, including the, AHA, ESC, and American College of Sports 
Medicine (ACSM) recommend aerobic or endurance activities at intensities ranging 
from 25% to 80% VO2max (Balady et al., 2000; Fletcher et al., 2001; Giannuzzi et al., 
2001; American College of Sports Medicine, 2006). This variation in recommended 
intensity highlights that the principles of exercise training in terms of overload and 
progression should take into account the initial clinical status and functional capacity of 
the individual. However, there is a danger that these broad guidelines may lead 
practitioners setting exercise programmes that are either too low or too high for 
patients.  The Association of Chartered Physiotherapists in Cardiac Reahabilitation 
(ACPICR) and British Association for Cardiac Rehabilitation (BACR) recommend 
target HR ranges of 60-75% predicted HRmax or 40-60% HRR in Phase III 
rehabilitation exercise classes, increasing to 60-80% and 40-70% respectively in Phase 
IV if appropriate, combined with an RPE of 12-15 (British Association for Cardiac 
Rehabilitation, 2006; Association of Chartered Physiotherapists in Cardiac 
Rehabilitation, 2009).  For very deconditioned or compromised patients, the initial 
intensity might need to be lower than this.  The exercise dose is usually progressed by 
increasing the duration and/or frequency of the exercise before the intensity.  
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The most detailed recommendations are provided by the ESC, who specify that 
exercise training should comprise an initial stage, an improvement stage, and a 
maintenance stage (Giannuzzi et al., 2001)  During the initial stage, intensity should be 
kept at a low level (40-50% VO2peak) until an exercise duration of 10-15 min is 
achieved. The primary aim of the improvement stage is to gradually increase the 
intensity (from 50% to 60% to ≥ 70% VO2peak), with a secondary aim of prolonging the 
session to 15-20 min, and up 30 min if tolerated.  After approximately 6 months, 
patients will be in the “maintenance” stage of their exercise programme.  Training 
intensity should be readjusted on the basis of repeated exercise testing.  
Details of the exercise interventions applied in training studies for CHF are provided in 
Appendix 1 (Tables 1A and 1B). The majority of  these studies use aerobic training at a 
continuous or “steady-state” intensity, although the more recent studies have included 
different interventions. A meta-analysis of randomised controlled trials reported that 
exercise training was mainly aerobic (including walking, cycling, stepping), with a few 
studies including interval training and resistance training, and the intensity varied from 
50-80% VO2peak or 60-80% HRmax or HRR (van Tol et al., 2006).  The average training 
period was 13 ± 8 weeks, with a session duration of 50 ± 22 min at a frequency of 3.7 ± 
1.7 times a week.   
It is difficult to assess how these exercise interventions agree with the recommended 
guidelines, partly due to the variation in what is recommended, and to the differences in 
age, severity of CHF and initial functional capacity in the study populations.  
Furthermore, many of the exercise interventions in these studies have actually 
contributed to the subsequent published recommendations for exercise, thus agreement 
between the two is to be expected.  Some studies have applied shorter, more frequent 
exercise sessions (e.g. 4-6 10-20 min sessions per day) (Coats et al., 1990a; Hambrecht 
et al., 1995b; Linke et al., 2001), in line with the ESC guidelines for the “initial” and 
“improvement” stages.  In other studies, the exercise volume was high, due to high 
frequency and duration of exercise sessions (e.g. 60 min walking twice daily, plus 45 
min cycling @ 70-80% HRmax 4 times per week), although the training period was short 
(4-8 weeks) (Jette et al., 1991; Dubach et al., 1997; Myers et al., 2007).  In the majority 
of studies, limited details are provided about exercise progression, repeated exercise 
testing to re-adjust exercise intensity, or the measurement of unsupervised exercise.  
However,  some studies do demonstrate systematic training progression, for examples  
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an increase in  frequency from 3 to 5, then to 7 days per week, and in duration from 30 
to 60 min per session (Parnell et al., 2002). In the HF-ACTION trial, the aim was for 
exercise duration to be increased from 15-30 to 40 min, intensity to be increased from 
60% to 70%  HRR.  Unsupervised exercise was monitored by activity logs and heart 
rate monitoring.  However, the exercise actually performed by patients fell short of the 
goal of 90 min per week in the first 3 months, and 120 min per week thereafter, and 
only 30% of patients were exercising at or above the target exercise minutes at all time 
points (O'Connor et al., 2009).  Such issues make it even harder to assess the real 
exercise dose experienced by patients in these studies. 
It is clear from the paragraphs above that setting appropriate guidelines for exercise, 
and exercise intensity in particular, is challenging.  There is considerable variability 
among methods of expressing exercise intensity in elderly individuals and cardiac 
patients, including CHF (Panton et al., 1996; Brawner et al., 2002; Mezzani et al., 
2007). The thresholds that determine the exercise intensity domains occur at a different 
percentage of maximal capacity in individuals (Wasserman et al., 2005), hence 
intensities based solely on a percentage of maximal capacity are likely to elicit variable 
metabolic responses in individuals (Dwyer, 1994) including CHF (Coplan et al., 1986). 
Furthermore, chronotropic incompetence, defined as < 80% age-predicted maximum 
HR or HRR, is common in CHF, and current day medication is also likely to affect HR 
response, adding to the problems when using HR as a guide to exercise intensity (Witte 
et al., 2006; Whellan et al., 2007).  The authors of a recent exercise training study 
explain that they had initially set training intensity at 70-80% HRmax, but had to 
abandon this method because of narrow HRR in most patients, atrial fibrillation and 
“other problems” (Prescott et al., 2009).  For these reasons, it is likely that the exercise 
dose varies widely in training studies for CHF, and this has contributed to fact that 
there is no agreement on a universally recommended exercise prescription for CHF.   
The American Heart Association recommend that CPET should be used to objectively 
evaluate functional capacity and prescribe exercise (Pina et al., 2003).  In this way, 
training intensities can be aligned to robust physiological parameters using the gas 
exchange thesholds and exercise intensity domains. For example, an intensity within 
10% of VT, has been  proposed as safe, effective and able to be maintained over a 
prolonged exercise period for CHF (Meyer et al., 2005a).  
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Nevertheless, CPET is not feasible on many CR programmes, and although individual 
clinical history and symptoms are taken into account, exercise is still commonly 
prescribed from generic HR guidelines. ESC guidelines caution that RPE should be 
used only as an adjunct to determination of intensity by other methods as some patients 
are unable to reliably use the scale, and as ratings of fatigue and dyspnoea are often 
differently perceived, the recommendation is that the two symptoms should be 
monitored separately.  
An additional issue is the effect of the mode of exercise on the subsequent calculation 
of exercise intensities.  For example, some studies have  used maximal treadmill 
exercise tests, then prescribed exercise at a percentage of VO2peak, or a workload 
corresponding to a percentage of VO2peak for a different mode of exercise such as cycle 
ergometry (Ennezat et al., 2001).  However, it is not clear if workload on a treadmill, 
which is notoriously difficult to calculate, transfers to a cycle ergometer, and as VO2peak 
is generally lower during cycling exercise, the relative percentage of peak is likely to be 
higher if the original value is from treadmill exercise. In order to maintain homogeneity 
of exercise intensity, the HF-ACTION trial used only moderate continuous training at 
60-70% HRR.  However, both walking and cycling were permitted. Hence there might 
have been some variation in relative exercise intensity as weight bearing and non-
weight bearing exercise may elicit a different metabolic response and HR response in 
relation to percentage of maximum.  It has been suggested that HR correlates with VO2 
during cyling, but not during circuit training exercise (Green et al., 2001).  
In theory, patients with low baseline clinical and functional status respond well to low 
intensity exercise.  The interrelationship of duration and intensity allows low intensity 
exercise to be partly compensated for by increasing the duration and/or frequency of 
the training sessions (Giannuzzi et al., 2001).  In reality, the frequency of supervised 
sessions is low (Taylor et al., 2007), therefore it might be more appropriate to question 
whether this low frequency can be compensated for by higher intensity. 
2.6.4 Intermittent exercise training 
Although CR guidelines recommend moderate intensity exercise, which is often 
continuous in nature, they also acknowledge intermittent exercise as a potential training 
modality. Intermittent exercise (also known as interval training) consists of short bouts 
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of high intensity exercise interspersed with recovery periods, and is recommended for 
both healthy and clinical populations.  Regardless of the population, the workload for 
short high intensity work phases, applied for between 20s and 2 min, is usually ≥ 100% 
VO2peak work rate achieved in a maximum incremental test (Poole and Gaesser, 1985; 
Meyer et al., 1990; Gorostiaga et al., 1991; Dimopoulos et al., 2006).   
In healthy individuals, intermittent training produces a similar or greater increase in 
exercise capacity than continuous (or steady-state) exercise of an equal total workload 
(Poole and Gaesser, 1985; Gorostiaga et al., 1991; Tabata et al., 1996).   In healthy 
sedentary participants, intermittent training improved muscle oxidative capacity to a 
greater extent than continuous training of a similar duration and total mechanical 
workload (Daussin et al., 2008).  In a short term (< 4 weeks) programme, high intensity 
intermittent training was more effective than continuous training at improving maximal 
and sub-maximal exercise performance in cardiac patients, even though the total 
amount of work done was lower (Meyer et al., 1990).  Meyer and colleagues 
subsequently demonstrated that short-term intermittent exercise training was effective 
for CHF patients with low functional capacity, who achieved improvements 
comparable to those reported in longer-duration training programmes of continuous 
exercise (Meyer et al., 1996b; Meyer et al., 1997b).  In a 3 week randomised controlled 
trial, both intermittent and continuous training improved VO2peak and VT (14% and 8-
9% respectively) to a similar extent. Only the intermittent training group showed 
improvements in central haemodynamics, although the continuous group showed 
greater improvements in psychological well-being (Nechwatal et al., 2002).   
Despite concerns that high intensity exercise may increase LV wall stress and induce 
deterioration in function in CHF patients (Demopoulos et al., 1997b) (Koike et al., 
1989), LV function is reported to be equally stable during 16 min of either continuous 
or intermittent exercise (Meyer et al., 1998a).  A few recent studies have confirmed that 
CHF can safely undertake high intensity intermittent training, and that some, although 
not all, beneficial training adaptations may be greater than those resulting from 
continuous moderate intensity training (Dimopoulos et al., 2006; Roditis et al., 2007; 
Wisloff et al., 2007).    
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 2.6.4.1 Physiology of intermittent training 
In healthy individuals, there is no substantial difference in haemodynamic responses, 
including HR, blood pressure (BP), cardiac output and ejection fraction, during 
intermittent and continuous exercise of matched average workload (Foster et al., 1999). 
Similarly, short work bouts alternated with rest or recovery intervals allow a relative 
balance to be achieved between the energy requirements of exercise and the level of 
aerobic energy transfer within the muscle. This was first demonstrated by Astrand & 
Christensen’s group in the 1960s. For the same total workload, intermittent running 
results in lower HR, VO2, VE and Lac compared with continuous exercise (Astrand et 
al., 1960b).  For the same reason, a greater amount of total work can be achieved 
during high intensity intermittent exercise compared to the same intensity of exercise 
performed continuously.  Healthy males achieved 30 minutes’ exercise, consisting of 
work-rest intervals of 10s:5s, 10s:10s or 15s:30s at work rates close to VO2max, with a 
much lower Lac and distance run compared to continuous exercise, where exhaustion 
occurred after only 4 minutes (Christensen et al., 1960).  In trained runners, high 
intensity intermittent running (30s at VO2max velocity, alternated with 30s recovery @ 
50% VO2max) enables maximal work to be achieved without high Lac (Billat et al., 
2000).  During cycling exercise, the metabolic response to intermittent exercise was 
found to be similar to that found in continuous exercise with the same average power 
output when measured by blood-borne metabolites and muscle biopsies (Essen et al., 
1977; Essen and Kaijser, 1978; Brickley et al., 2007).  This response may be explained  
by a) the recovery of metabolites during the recovery phase, b) a dampening of 
metabolic responses due to the prior exercise (work and  recovery phases) the reloading 
of myoglobin stores in the rest periods increasing the availability of oxygen and 
therefore a higher aerobic energy output, and higher ATP production per unit of 
glucose compared with lactate formation.  
However, another study on sedentary adults reports that the fluctuating workload of 
high intensity intermittent training induces fluctuations in VO2, whereas VO2 remains 
steady in continuous training of the same duration and mechanical workload (Daussin 
et al., 2007).  Further investigation by the same group demonstrates that the repeated 
fluctuations of VO2 during intermittent training improve muscle oxidative capacity to a 
greater extent than continuous training, and this contributes to a greater improvement in 
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VO2max (Daussin et al., 2008).  It was proposed that the repeated variations in intensity 
imposed by intermittent training induced repeated disturbances of cellular homeostasis, 
inducing variations in VO2, and contributing to adaptations in skeletal muscle 
mitochondrial function . 
There have been few studies into the acute response of CHF to high intensity 
intermittent exercise.  Meyer and colleagues’ work suggests that CHF show similar 
responses to those described above; although Lac increases to a greater extent during 
short phases of high intensity cycling interspersed with recovery phases, the levels are 
low. Furthermore,  rate-pressure product is similar to that during continuous exercise 
(Meyer et al., 1996b).   
2.6.4.2 Rationale for high intensity intermittent exercise for CHF 
In CHF, increased exercise capability following training is primarily due to peripheral 
rather than central adaptations (McConnell, 2005) and patients with a very low exercise 
capacity may not be able to achieve continuous endurance training workloads high 
enough to have an optimal training effect on the peripheral muscles without 
experiencing cardiac symptoms or local muscular fatigue.  ESC and AHA guidelines 
suggest that intermittent exercise, based on Meyer et al’s protocols, may be appropriate 
for CHF (Giannuzzi et al., 2001; Pina et al., 2003).  It may provide an alternative and 
time-efficient means of exercise training with greater health benefits than the lower 
exercise doses used in are current practice.  A similar hypothesis has been applied to 
other clinical populations, including individuals with pre-diabetes (Earnest, 2008) and  
chronic obstructive pulmonary disease (Puhan et al., 2006) and cancer (De Backer et 
al., 2007) .  
2.6.4.3 Methods for intermittent exercise prescription 
In intermittent exercise training research in healthy and cardiac populations the 
duration of the high intensity work phases is between 20s and 2 min at an intensity of ≥ 
100% VO2peak work rate achieved in a maximal incremental test (Poole and Gaesser, 
1985; Meyer et al., 1990; Gorostiaga et al., 1991).  In CHF, some studies follow the 
traditional method of applying workloads of 100% VO2peak work rate (Dimopoulos et 
al., 2006; Roditis et al., 2007).  However, Meyer et al (1997) recommend that the 
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intermittent work phases are determined from a specific steep test that has increments 
of 25W every 10s and lasts only 30-120s (Meyer et al., 1997b; Meyer, 2001).  The 
intermittent work phases of 30s duration are set at 50% peak work rate achieved in the 
steep test, interspersed with 60s recovery of unloaded cycling. The rationale behind this 
is that the steep test tests muscle strength and anaerobic capacity, both important in 
short bouts of high intensity exercise, whereas a standard maximal exercise test does 
not measure these, and may underestimate the training load. Despite limited scientific 
verification for this protocol, it is included in the European Society of Cardiology 
recommendations for exercise training (Giannuzzi et al., 2001), and has been used in 
studies in CHF (Sabelis et al., 2004; Kemps et al., 2008) and other clinical populations 
(Vogiatzis et al., 2002; Puhan et al., 2006; De Backer et al., 2007).  It is not clear how 
the intermittent exercise intensity calculated from this test compares with the more 
traditional method of setting the intensity at the workload achieved at VO2max, a robust 
physiological parameter of exercise intensity, calculated from a standard incremental 
exercise test.    
2.6.4.4 A novel application of intermittent exercise prescription 
The intermittent exercise dose, both in a single training session and over time, consists 
of the interrelating variables of intensity, volatility (the amplitude of the work phases 
above and below the mean), duration and frequency.  Manipulating the intensity and 
volatility of intermittent exercise may alter the the amount of work achievable in a 
single session, and may  affect the duration and frequency of activity required to 
achieve a training response, yet the research in this area is very limited.  One study has 
examined the effect of manipulating the intensity and duration of the intermittent work 
phases in CHF (Meyer et al., 1996b). By decreasing the duration of the work phase to 
compensate for an increase in intensity, the exercise was tolerable, and did not induce 
an increase in VO2 or Lac. In this study, the intensity of the work phases was 
determined by Meyer’s steep test.    
A novel and more robust physiological approach would be to alter the volatility of the 
work and rest intervals within the framework of the exercise intensity domains, as 
shown in figure 2.5.  The example illustrated shows that the total work done is equal in 
all exercise protocols, but the intensity of the work and rest phases is manipulated.  It 
includes a protocol where the volatility is zero, ie. constant-rate or continuous exercise, 
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set below VT in the moderate intensity domain. An investigation of this nature could 
assess whether moving the intensity of the work and rest phases across exercise 
intensity domain borders influences the physiological and perceptual responses to 
exercise.  
 
Figure 2.6: Diagram of 4 different exercise protocols. 
Total work done is equal but amplitude above and below the mean is adjusted.  When the 
volatility is zero, the work is maintained at constant rate The work:rest ratio of the low, 
medium and high volatility protocols is 1:2.  The work phases are in different exercise intensity 
domains, depending on the volatility of the exercise.   
VT: ventilatory threshold.  RCP: respiratory compensation point 
 
In order to determine the optimal exercise training dose for CHF, there is need for 
further investigation into robust methods for determining accurate exercise intensity 
prescription, particularly for intermittent exercise.  In addition, further information 
about the acute and chronic responses to different intermittent exercise training 
protocols is required.  
2.6.5 Circuit training 
Numerous UK-based CR exercise classes comprise circuit-training where patients 
move around a series of different work stations to perform aerobic and/or muscular 
strength and endurance exercises for a pre-determined period (usually 1-2 min) (British 
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Association for Cardiac Rehabilitation, 2006; Association of Chartered 
Physiotherapists in Cardiac Rehabilitation, 2009).  The recommended intensity for 
aerobic exercise is 60-80% HRmax or 40-70% HRR and/or an RPE of 12-15. One small 
study of 6 patients suggests that circuit-training is appropriate for CHF, and that it 
induces a similar oxygen and haemodynamic demand to continuous cycle ergometer 
exercise at 70-80% HRmax (Green et al., 2001).  Circuit training is, arguably, a form of 
intermittent training in that there are periods of aerobic exercise interspersed with 
active recovery and/or muscular strength and endurance exercises.  However, this 
differs from high intensity intermittent exercise because  the intensity of the work 
phases is intended to be moderate.   
2.7 Ecological validity: application to current practice 
Despite the growing body of evidence in favour of exercise training for CHF, there is 
less evidence that the results of reported studies are transferable to clinical practice. 
Firstly, it has been reported that the exercise dose in randomised controlled trials of CR 
is more than four times greater than usual practice in the UK (Taylor et al., 2007).  
Secondly, the majority of studies are not representative of the total population of CHF 
patients, and tend to exclude older patients, females, individuals with implantable 
devices, and those with more severe heart failure and/or co-morbidities (Rees et al., 
2004).  The Medicare Beneficiaries study indicated that only 4% of CHF patients will 
be free from one or more co-morbidities (Braunstein et al., 2003). Therefore, as well as 
being important to study the effects of training in the “real life” CHF population, it is 
also important to consider the potential effect of the intervention on patients’ co-
morbidities.  
 
More recent studies have demonstrated the safety and effectiveness of supervised 
exercise training on different sub-populations of CHF patients. These include: elderly 
patients, some with chronic atrial fibrillation (Owen and Croucher, 2000); those in 
NYHA class III (Freimark et al., 2007); those who have undergone cardiac 
resynchronisation therapy (Patwala et al., 2009); and those with implantable cardiac 
defibrillators (Fan et al., 2009).  However, it is not clear how the aetiology or severity 
of heart failure or other characteristics of the patients affect the response to exercise 
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training. For example, some studies report greater improvements in patients with lower 
initial functional capacity and/or more severe LV dysfunction  (Hambrecht et al., 
1995a; Meyer et al., 1997a).  By contrast, other studies report no, or lesser, 
improvements in these patients (Wilson et al., 1996; Belardinelli et al., 1999; Wielenga 
et al., 1999).   Some studies demonstrate that patients with ischaemic aetiology are 
more responsive to exercise training (Willenheimer et al., 1998), whereas others 
suggest that patients with non-ischaemic aetiology are more likely to show a positive 
training response (Forissier et al., 2001). 
Standard pharmacological treatment for CHF patients has developed since the initial 
exercise training studies in this population.  β-blocker therapy is now standard for the 
majority of patients, but it is only the more recent studies that report the effect of 
exercise training in patients on this medication (Demopoulos et al., 1997a; Forissier et 
al., 2001; Fraga et al., 2007). VO2peak improved to a similar extent after exercise 
training in CHF taking selective (14%), non-selective (17%) or no β-blockers (19%) 
(Forissier et al., 2001). β-blockers do not change maximal exercise performance, but 
they do appear to improve the ventilatory response to exercise (Witte et al., 2005), and 
to reduce symptoms of breathlessness (Wolk et al., 2005).    Optimising medical 
therapy may increase functional capacity and measures of exercise tolerance by 
decreasing symptoms and thus allowing a spontaneous increase in activity (Fraga et al., 
2007).  Alternatively, as current medical therapy becomes increasingly effective at 
attenuating symptoms, the additional potential benefit from exercise training might be 
limited.  
2.7.1 Cardiac rehabilitation 
It is important to note the distinction between cardiac and exercise rehabilitation. CR is 
not a programme that consists solely of exercise training.  It is a multi-faceted, long-
term process, comprising comprehensive lifestyle intervention programmes that include 
psychological support and education.  Advice on risk factors and lifestyle changes for 
secondary prevention, are offered in addition to structured exercise programmes 
(British Association for Cardiac Rehabilitation, 2006).   CR is effective and 
economically justified for secondary prevention in numerous sub-populations of 
cardiac patients, including CHF (Giannuzzi et al., 2003a). Comprehensive CR is 
provided by a multi-disciplinary health care team, usually including a consultant 
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cardiologist, cardiac specialist nurses, an exercise professional, physiotherapist, 
psychologist and dietician.  Ecologically valid research studies should include exercise 
training as part of a comprehensive CR programme.   
2.7.2 UK based cardiac rehabilitation programmes 
In the UK, CR is traditionally described in terms of phases of recovery (Table 2.7). 
Table 2.7  UK Cardiac rehabilitation phases 
 
  Number of UK centres providing each phase of rehabilitation (total n = 382) 
Phase I Inpatient stage 250 
Phase II Early discharge period 199 
Phase III Clinically supervised outpatient programme 361 
Phase IV Long term maintenance of physical activity and lifestyle change 114 
 
There are approximately 382 UK cardiac rehabilitation centres (British Heart 
Foundation, 2009).  The majority of referrals to CR are patients who have had an MI, 
percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG). 
Uptake of CR is 30-34% for MI and PCI patients, and 68% for CABG patients.  
Despite the evidence that CR can benefit several other diagnostic groups (e.g. chronic 
stable angina, implantable devices and CHF), referral is still limited among these 
patients. The majority of individuals attending CR are white males aged 65-69 years.   
There is evidence that UK hospital and community-based CR programmes improve 
functional status and QoL in CHF > 60 years (Austin et al., 2005b).   One study 
demonstrated that CHF with a mean age of 82 years, including those with chronic atrial 
fibrillation, could safely participate in a once weekly CR class, and that 6-minute walk 
distance improved significantly (20%) after 12 weeks (Owen and Croucher, 2000).  
Exercise training may be particularly beneficial to these patients, who tend to have 
greater symptoms due to the overlapping effect of both ageing and CHF (Gielen et al., 
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2005), yet they are often excluded from exercise-based rehabilitation because of their 
age and symptoms.   
2.7.3 Current provision of cardiac rehabilitation for CHF patients 
The ESC Position Paper sets out the core components of CR in CHF, and one of its 
objectives was to broaden the indication for CR in this population (Corra  et al., 2005).  
Despite this, and the examples of CR schemes for CHF patients within the published 
literature, only 25% of CR programmes in England accept CHF (Brodie et al., 2006).  
The 2009 National Audit of CR reported that 25% of CR centres had a specific policy 
of not accepting CHF, and only 1% of referrals were in patients whose main referral 
reason was CHF (British Heart Foundation, 2009).  This is partly due to lack of 
resources, since CHF patients are considered high risk and require a staff to patient 
ratio of 1:4.  The low level of exercise tolerance of the majority of CHF patients also 
makes it difficult for them to be integrated into general CR classes. It is therefore not 
surprising that UK studies to date have typically included small subject numbers and 
had methodological limitations (Coats et al., 1992b; Taylor, 1999; Owen and Croucher, 
2000; Austin et al., 2005b; Witham et al., 2007; Patwala et al., 2009).  In Norway, 
exercise training was modified for CHF patients who were unable to participate in 
mainstream classes for individuals with coronary artery disease due to dyspnea, 
inability to keep up to pace, and inadequate counselling (Nilsson et al., 2008a).  In 
Eastbourne, East Sussex, a separate class is run once a week for high risk patients 
and/or those with orthopaedic problems or co-morbidities that limit their ability to 
exercise (personal communication, Hilda Healy, Cardiac Rehabilitation Sister, 2008).  
Ideally, these patients should have access to twice-weekly sessions, in line with the 
provision for low-moderate risk cardiac patients.  
2.8 Methodological considerations in the study of responses to exercise training 
in CHF 
There are numerous methodological issues to consider in the study of acute and chronic 
exercise responses in CHF, and these have been discussed in several key papers  (Fleg 
et al., 2000; Agostoni, 2006; Ingle, 2007).  The following paragraphs will discuss those 
that are pertinent to this study.  Appendix 2 includes discussion of methods commonly 
used by other authors, and a rationale for not including them in this study.  
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2.8.1 Cardiopulmonary exercise testing (CPET) 
Maximal CPET using an incremental protocol to exhaustion is a valid and reproducible 
method of assessing functional capacity in CHF in clinical and research applications.  It 
provides good prognostic information, assesses sub-maximal and maximal exercise 
capacity, and ventilatory efficiency (Fleg et al., 2000).   
2.8.1.1 Exercise mode 
In both healthy and clinical populations, one of the general recommendations for the 
assessment of VO2max or VO2peak is that the exercise should be rhythmic, and should 
engage a large muscle mass (Cooke, 2001). The influence of exercise mode on 
physiological responses is well-recognised. In athletes, the mode of exercise should be 
specific to the individual.  In untrained individuals, treadmill exercise generally elicits 
VO2peak values approximately 10% higher than  cycle ergometer exercise, due to the 
larger exercising muscle mass, and this holds true for CHF  (Page et al., 1994).  A 16% 
higher VO2peak in treadmill compared with cycle ergometer exercise, associated with an 
7% higher cardiac output and an 8% higher a-vO2 difference, has been reported in 
CHF, suggesting that central and peripheral factors contribute equally to the increased 
VO2peak  (Kim et al., 1999). Ventilatory response and VE/VCO2 slope are also higher in 
treadmill protocols due to their weight-bearing nature, which may increase the 
ergoreflex activation to a greater extent than weight-supported exercise, thus 
stimulating ventilation (Witte and Clark, 2005). Cycle-based exercise led to CHF and 
healthy controls stopping exercise more frequently because of fatigue rather than 
breathlessness, whereas breathlessness was the more frequent cause in treadmill 
exercise.  Interestingly, for a given oxygen uptake, RPE was the same on the cycle 
ergometer as on the treadmill (Witte and Clark, 2005).   Treadmill exercise might be 
more familiar than the cycle ergometer, and permits the use of handrails, although this 
will influence the energy cost.  In older CHF with systolic dysfunction and co-
morbidities (e.g. COPD, osteoarthritis, diabetes) cycle ergometer protocols with small 
and regular increases in work rate (e.g. 10 W.min-1) are more appropriate (Ingle, 2008).  
Cycle ergometry is easier for patients with orthopaedic limitations, and allows other 
measurements, e.g. blood sampling and exercise echocardiography, to be performed.   
Subsequent exercise training on a cycle ergometer allows exercise at low workloads, 
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accurate reproduction of the prescribed workload, particularly in the application of 
intermittent training, and monitoring of HR, rhythm and BP.  A cycle ergometer may 
be upright or semi-recumbent, and the exercise responses are likely to be influenced by 
differences in haemodynamics and the muscle mass engaged. Semi-recumbent cycling, 
which allows echocardiography to be performed  more easily than upright cycling, 
appears to elicit lower HR, BP and VO2 responses to submaximal and maximal 
exercise in healthy and mildly hypertensive adults (Walsh-Riddle and Blumenthal, 
1989; Scott et al., 2006).   
2.8.1.2 Effect of test protocol duration 
The general consensus has long been held that the optimal duration for a maximal 
cardiopulmonary exercise test is 8-12 min, as shorter or longer tests tend to 
underestimateVO2max.(Cooper and Storer, 2001).  However, this premise has recently 
been challenged. Current evidence suggests that cycle ergometer tests should last 
between 7 and 26 min, and treadmill tests 5 and 26 min, in order to elicit valid VO2max 
values, provided that short tests are preceded by an adequate warm-up (Midgley et al., 
2008).  In CHF,  exercise protocols designed to elicit maximal exertion in either 5, 10 
or 15 minutes appear to have a small effect on VO2peak and the ratio of change in 
oxygen consumption to change in work rate (ΔVO2/Δ work), but do not affect VO2 at 
VT, or VE/VCO2 slope.  A short (5 min) test with steeper increments induced a 
significantly lower  HRpeak, VO2peak, and ventilation than tests of 10 or 15 min duration 
(Agostoni et al., 2005).  Although VO2 at VT was the same for all 3 protocols, the 
workload at which it was identified was influenced, varying from 58 to 74W, which has 
implications when using CPET to set training workloads below this threshold.   
2.8.2 Reproducibility 
Although maximal CPET is still considered the “gold standard” for assessing functional 
capacity, this method is still subject to variability, particularly in CHF.  Measurements 
will be affected by individual patient motivation and variation in day-to-day health, as 
well as biological and technical variability, which is more likely at higher intensities 
(Meyer et al., 2004a).  Serial assessment of exercise capacity presents greater 
challenges than the single determination used to characterise baseline function.  There 
are no universal criteria for reproducibility, but guidelines for clinical populations 
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suggest that VO2peak should vary < 10%  and exercise duration < 60s (i.e. 10% of a 10 
min test), on separate days for it to be considered reproducible (Fleg et al., 2000).  
There is comprehensive evidence that circadian rhythms influence measures of exercise 
performance, and serial exercise tests should therefore be conducted at the same time of 
day (Reilly, 2007).  Tests should be performed > 2 hours after eating to avoid the 
effects of food on myocardial oxygen demand (Fleg et al., 2000).  The issue of 
reproducibility of CPET parameters in CHF has been investigated by several authors.  
Some report good reproducibility in repeated exercise tests  (Cohen-Solal et al., 1991; 
Meyer et al., 1997c; Marburger et al., 1998); others report an apparent learning effect, 
demonstrated by a lower exercise duration (-17%) and VO2peak (-6%) between the first 
and second test compared with similar values between the second and third test (Elborn 
et al., 1990). The HF-ACTION trial showed substantial within-subject variability, but 
no apparent learning effect (Bensimhon et al., 2008).   Further investigation is required 
to clarify the effects of familiarisation, within-subject variability, mode of exercise and 
the characteristics of individuals tested.   
2.8.3 Outcome measures in CPET 
2.8.3.1 VO2peak 
As discussed in section 2.5.4.1, VO2peak is reduced in CHF, and the extent of the 
reduction is a prognostic indicator.  In healthy adults, the accepted criteria for 
establishing VO2max are: a plateau in the VO2-intensity relationship (< 2 ml.kg-1.min-1 
or 3% with an increase in exercise intensity), a respiratory exchange ratio (RER) value 
≥ 1.15, a final HR within 5 beats.min-1 of predicted age-related maximum, a post-
exercise Lac ≥ 8 mmol.L-1
CHF patients are often unable to exercise long enough for a plateau in VO2 to be 
observed, therefore the term VO2peak is used (Ingle, 2008).  VO2peak values in CHF 
patients may occur in the immediate post exercise period, due to slowed VO2 kinetics in 
this population (Cohen-Solal et al., 1997), therefore it is good practice to measure 
VO2peak as the highest average value over 20-30s in the final stage of the exercise test or 
in the immediate post-exercise period (up to 45s post exercise).  The sampling interval 
of gas exchange data influences the reported VO2 value (Johnson et al., 1998).  In the 
, subjective fatigue and volitional exhaustion, and an RPE of 
19 or 20 on the Borg scale (Cooke, 2001).   
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absence of standardisation in methodology across studies, the use of rolling averages, 
and the reporting of the specific sampling intervals chosen is the minimum 
recommendation (Myers, 2001).   According to ESC guidelines, an RER > 1.0 suggests 
adequate patient effort (Tavazzi et al., 2001). However, VO2peak  is a better prognostic 
indicator in patients who achieve an RER ≥ 1.15 (Mezzani et al., 2003).  Due to the 
effects of medication and chrontropic incompetence, the heart rate criteria are not 
appropriate for establishing VO2max in CHF, nor are the standard Lac and RPE criteria 
likely to be applicable. Peak RPE in cardiac patients is lower than in healthy 
individuals (16 vs 18) (Whaley et al., 1997), and Lac of approximately 2 mmol.L-1 has 
been reported after maximal exercise testing (Meyer et al., 1997b). 
VO2peak may be expressed in absolute (ml.min-1 or L.min-1) or relative to body mass 
(ml.kg-1.min-1
2.8.3.2 Ventilatory threshold (VT) 
) terms.  In non-weight bearing exercise such as cycling in healthy 
individuals, values are often expressed in absolute terms. Relative values are more 
commonly reported in clinical trials and are useful for reflecting cardio-respiratory 
fitness in terms of health or disease, for example, in the Weber classification of the 
severity of CHF (Weber et al., 1982).  As relative values are affected by weight 
fluctuations, it is useful to report change in absolute and relative values following an 
exercise training intervention.  Some studies reporting larger improvements in VO2peak 
have not reported familiarisation procedures, or have acknowledged that the 
improvements may be attributed in part to a learning effect (Arad et al., 2008).  Studies 
that have specifically included a familiarisation maximal exercise test tend to report 
smaller improvements in VO2peak. 
VT reflects the disproportional increase in CO2 above O2 due to bicarbonate buffering 
in response to a rise in Lac (Beaver et al., 1986; Cooper and Storer, 2001; Wasserman 
et al., 2005).  The exercise intensity at VT is a measure of endurance performance, or 
sub-maximal exercise capability, as it defines the highest work rate that can be 
sustained for a prolonged period of exercise.   A rightward shift in VT is characteristic 
of a successful endurance training intervention, as it allows a higher absolute work rate 
and relative (%VO2max) exercise intensity to be sustained without the accumulation of 
Lac (Jones et al., 2007).  For this reason, efficacy of training in CHF is arguably better 
assessed by VT rather than VO2peak, and exercise at this intensity more closely reflects 
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daily activities (Larsen et al., 2001). VT is increasingly used in addition to VO2peak as 
an outcome measure in exercise training studies in CHF (Willenheimer et al., 1998; 
Keteyian et al., 1999; Dimopoulos et al., 2006; Van Laethem et al., 2007). VT is 
considerably lower in CHF than in healthy individuals, and decreases according to the 
severity of the disease.  However, the % VO2peak at VT may be high (around 70% in 
CHF compared to 40-60% VO2peak in a healthy population), due to an attenuated rise in 
VO2 above VT, and/or the fact that VO2peak is very low (Meyer et al., 2005a).  VT is a 
valid indicator of functional capacity, if procedural recommendations are followed 
(Meyer et al., 1996a), and is responsive to training in CHF (Simonton et al., 1988; 
Meyer et al., 2005b).  However, VT cannot be detected in approximately 16% of tests 
in CHF, due to insufficient or noisy gas exchange data, or oscillatory breathing (Myers 
et al., 2010).  Automatic determination of VT via regression-based computer 
algorithms is available on modern metabolic systems, but these may not be accurate, 
and Myers et al (2010) recommended that experimenters ultimately determine VT via 
visual methods. 
2.8.3.3 Ventilatory efficiency 
The ventilatory response to exercise is increased in many CHF and may be 
characterized by the regression slope of minute ventilation to carbon dioxide output 
during exercise (VE/VCO2 slope).  It is significantly correlated with aerobic capacity, 
cardiac function, and pulmonary perfusion, and there is evidence that it may be superior 
to VO2peak in predicting outcome in CHF (Chua et al., 1997; Arena et al., 2007; Ingle, 
2008).   The normal range in healthy individuals is 20-29.  In CHF a slope >34 defines 
a high ventilatory response to exercise, and indicates  more severe heart failure and a 
poorer prognosis.  The ventilatory response to cycle ergometer exercise is lower than in 
treadmill exercise, perhaps due to lower ergoreflex stimulation during weight-
supported exercise (Witte and Clark, 2005). 
There is some debate about whether the VE/VCO2 slope should be calculated from 
exercise data prior to RCP, i.e the linear part of the slope, or from all data points from 
the onset of exercise to peak exercise.  Whilst the sampling interval (breath-by-breath, 
or average over 10s, 30s or 60s) has little impact on the value obtained or its prognostic 
utility (Arena et al., 2003), using data from rest to peak exercise has the greatest 
prognostic value (Tabet, 2003).  The relation between VE and VCO2 becomes nonlinear 
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near the end of an incremental maximal CPET, this will influence the value of the 
slope.   At this point (RCP), ventilation is driven both by CO2 output and by a decrease 
in plasma pH, and increases disproportionately to VCO2. Patients whose symptoms 
contribute to them stopping the exercise test prematurely are likely to have a linear 
slope, with a lower value than those who manage to exercise for longer.    In Tabet’s 
study, 64% of the patients showed two distinct slopes: an initial linear slope (31.8+/-
7.5, 18-62) and a final steeper slope (48.6+/-15.7, 24-101). Patients in whom no 
second, steeper slope was observed had more severe CHF, presumably because they 
were unable to exercise beyond RCP.  Nevertheless, the VE/VCO2 slope computed 
from all the data points had the highest prognostic value (Tabet, 2003). However, other 
authors calculate the VE/VCO2 slope by its linear part (Passino et al., 2006a). 
Standardising the measurement in this way is more valid, particularly when 
investigating the effect of an exercise training intervention on ventilatory efficiency.   
A further consideration is the effect of β-blockers which inhibit the sympathetic activity 
that contributes to increased ventilation (Wolk et al., 2005), and thus reduces the 
VE/VCO2 slope (Witte et al., 2005). For this reason, values reported in studies of 
patients on current medical therapy may be lower than in older studies.   
2.8.3.4 Oxygen uptake-work rate relationship (ΔVO2/ΔWR) 
Work “efficiency” is a measure of the metabolic cost of performing external work and 
for incremental exercise is often expressed as the change in slope of the relationship 
between VO2 and work rate (∆VO2/∆WR).  The slope reflects the adequacy of oxygen 
flow and utilisation in the periphery and indicates whether oxygen supply can keep 
pace with demand.  The predicted normal slope is 10.3 ml.min-1.W-1, with 95% of 
normal values lying between 8.3 and 12.3 ml.min-1.W-1
2.8.4 Heart rate response to exercise in CHF  
.  Conditions such as heart 
disease, including CHF, where oxygen delivery is impaired, can lower the slope 
(Cooper and Storer, 2001; Wasserman et al., 2005).  
A lowered resting HR is often used as an indicator of improved cardio-respiratory 
fitness, but may not be relevant in clinical populations where medical therapy, β-
blockade in particular, exerts a greater effect at reducing HR.  CHF show an attenuated 
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HR response to exercise, limiting their ability to increase cardiac output.  Chronotropic 
incompetence, defined as the inability of a patient to achieve a peak HR > 80% of age-
predicted maximum, is common in CHF, and is correlated with poor functional 
capacity (Vallebona et al., 2005; Witte et al., 2006).  However, a reduced HR response 
to exercise does not determine exercise capacity.  Although chronotropic incompetence 
is associated with higher mortality in patients not taking β-blockers, in patients on β-
blockers it is not associated with higher mortality (Witte et al., 2006).  The effect of 
chronotropic incompetence and/or β-blockers preclude the use of a HR within ± 10 
beats.min-1
2.8.5 Rating of perceived exertion (RPE) 
 age-predicted HRmax as a criteria (Cooke, 2001) to determine the attainment 
of VO2max in CHF.  
HR recovery has been proposed as a simple marker of autonomic function that can be 
used to assess outcomes during CR (Myers et al., 2007).  To some extent, it reflects the 
extent of vagal reactivation, i.e. the inhibition of sympathetic activity and 
predominance of vagal activity, and poor HR recovery is associated with poorer 
prognosis in cardiac patients (Arena et al., 2006). HR recovery in the first minute after 
exercise has been used to estimate parasympathetic activity in CHF (Dimopoulos et al., 
2006).  HR variability is a more sophisticated tool for assessing autonomic balance, and  
improvements in HR variability have been reported after exercise training in CHF 
(Malfatto et al., 2002).  
Borg’s Perceived Exertion Scale (Borg, 1998) is commonly used for quantifying an 
individual’s subjective feelings of exertion during exercise as a means of determining 
or regulating the exercise intensity.  RPE ratings increase linearly with exercise 
intensity, HR, VO2 and Lac, and are highly correlated with these physiological markers 
of relative exercise intensity (Eston et al., 2009).  The strongest stimuli influencing an 
individual’s RPE are ventilatory work and sensations of muscle and joint strain 
(Buckley and Eston, 2007).  Table 2.8 summarises the relationship between RPE and 
related physiological markers.  
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Table 2.8: Relationship between percentages of maximal oxygen uptake (% 
VO2max), heart rate reserve (%HRR), maximal heart rate (%HRmax) and Borg’s 
rating of perceived exertion (RPE) 
(adapted from Buckley and Eston, 2007) 
% VO2max < 20 20-39 40-59 60-84 ≥ 85 100 
%HRR < 20 20-39 40-59 60-84 ≥ 85 100 
%HRmax < 35 35-54 55-69 70-89 ≥ 90 100 
RPE < 10 10-11 12-13 14-16 17-19 19-20 
 
RPE is conventionally used for an “estimation-production” procedure  to regulate exercise 
intensity.  In this procedure, the RPE at a given heart rate, VO2 or blood lactate value 
during a prior incremental exercise test is used to prescribe exercise at a chosen intensity.  
This is considered to be a physiologically valid method of regulating exercise intensity in 
individuals of varying age, gender, fitness and health (Eston et al., 2009).  However, inter-
individual variablity has been reported at 60% and 80% HRR during a maximal 
incremental exercise test in healthy individuals and cardiac patients (Whaley et al., 1997).  
In this study, 32% cardiac patients and 39% healthy controls had an RPE value either < or 
> 11-14 at 60% HRR, while 52% patients and 32% controls had an RPE value either < or > 
14-17 at 80% HRR.  It has previously been reported that RPE at VT is 11.0 ± 2.1, and does 
not differ between cardiac patients taking β-blockers, those not taking β-blockers or 
younger healthy individuals (McConnell et al., 1993).  If there is a consistent relationship 
between RPE and VT, it is not surprising that there is individual variability between RPE 
and HRmax or HRR, because VT occurs at different percentages of these in individuals, as 
discussed previously.   
RPE is useful in CR to prescribe and monitor exercise intensity. For example, exercise 
guidelines recommend that patients work at an intensity of 12-15 during the “aerobic” 
component of an exercise session (British Association for Cardiac Rehabilitation, 
2006). The use of the 6-20 scale is recommended for whole body exercise, rather than 
the CR-10 which was developed to focus on localised muscle pain, fatigue or 
breathlessness (Borg, 1998).  The accuracy of matching exercise intensity to RPE is 
dependent of familiarity and practice for both the production and estimation 
procedures, and may  be influenced by medication, mental well-being and motivation 
to exercise (Buckley, 2006). The accuracy can be improved by ensuring that adequate 
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explanation and instruction is provided to the exerciser (Maresh and Noble, 1984) 
including the  sensation of the “whole body” exercise responses, anchoring the 
perceptual strain, and identifying  the verbal descriptor before relating to the numerical 
value (Noble and Robertson, 1996).   Nevertheless, cardiac patients may “inflate” their 
RPE if they have low-self-efficacy, or are nervous of the exercise testing or training 
environment (Buckley and Eston, 2007). 
It is not clear how RPE links to physiological responses during intemittent exercise 
training.  However, Meyer and colleagues demonstrated that average ratings for leg 
fatigue and dyspnoea (assessed by the Borg 6-20 scale) were both 11 (light) during 
intermittent exercise, the same value as at VT during an incremental exercise test.  Leg 
fatigue was rated at 13 (somewhat hard) during the work phases and 10 in recovery, 
whereas dysnoea was rated at 10 during both work and  recovery (Meyer et al., 1997b).  
It is not clear why the authors used the 6-20 scale rather than the CR-10 scale which is 
arguably more appropriate for assessing leg fatigue and breathlessness. 
2.8.6 B-type natriuretic peptide (BNP) 
Plasma BNP, and its inactive N-terminal fragment NT-pro BNP, is released primarily 
from the left ventricle in response to increased filling pressure, and correlates with LV 
dysfunction.  It is used in the diagnosis and prognosis of heart failure, is an important 
predictor of morbidity and mortality, and changes over time are associated with 
corresponding changes in morbidity and mortality. There has been considerable debate 
in recent years about the role of BNP monitoring in the diagnosis and management of 
CHF patients (Bhatia et al., 2003; Cowie et al., 2010).  Plasma BNP appears to be a 
useful objective biomarker for monitoring CHF  (Lee et al., 2002), and may be a less 
time-consuming and more cost-effective means of risk-stratification than CPET (de 
Groote et al., 2004). There is support for its  role as a surrogate marker in interventional 
CHF trials (Anand et al., 2003). 
BNP is associated with exercise capacity and correlates with VO2peak and VT (Kruger et 
al., 2002).  When combined with measurement of VO2peak, BNP improves risk 
stratification in CHF (de Groote et al., 2004).  Patients with plasma BNP < 109 pg/ml 
have an excellent prognosis, while those with BNP > 109 pg/ml benefit from a 
subsequent prognostic evaluation, including CPET and echocardiography. BNP > 109 
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pg/ml and % predicted VO2peak ≤ 50% are indicative of a poorer prognosis (de Groote 
et al., 2004).  A more recent study confirms that the persistence of a high BNP level, 
combined with a poor ventilatory efficiency (VE/VCO2 slope > 35), identifies patients 
on optimal medical therapy, including β-blockers, with a poor prognosis (Pascual-Figal 
et al., 2008). 
Although BNP levels show a significant correlation with the impairment of VO2 at 
peak exercise and anaerobic threshold (Kruger et al., 2002), it is less clear whether 
BNP reflects improvements in exercise capacity following exercise training. Studies 
measuring the response of NT-proBNP levels following exercise training have reported 
no changes (Jonsdottir et al., 2006; Arad et al., 2008; Beckers et al., 2008) or a decrease 
(Conraads et al., 2004; Passino et al., 2006b; Berent et al., 2009) that correlates with 
increased exercise capacity, but not with LV dimensions or ejection fraction.  The 
authors suggest that peripheral adaptations such as a decrease in afterload, as well as 
reduced diastolic wall stress, could have contributed to the observed decrease in NT-
proBNP.  
NT-proBNP is reportedly more stable than BNP under laboratory conditions, and is 
reproducible in a stable CHF population after a 4 month period (Conraads et al., 2004). 
the BNP is also considered to be a valid and reproducible tool for monitoring CHF (Lee 
et al., 2002; McNairy et al., 2002). Passino et al (2006) found similar reductions in both 
NT-BNP and BNP following exercise training, and a recent systematic review 
concluded that exercise training has a favourable effect on BNP (Smart and Steele, 
2009). Nevertheless, there is some doubt over its reliability or usefulness in the serial 
monitoring and evaluation of CHF therapy (Packer, 2003; Wu and Smith, 2004). Until 
recently, the assay for BNP has been difficult and time-consuming to perform. A rapid 
point-of-care immunoassay for the quantitative analysis of B-type Natriuretic Peptide 
(BNP) has recently been developed: The Triage® BNP Test (Biosite Ltd, Belfast, or 
Biosite Diagnostice Inc, San Diego, California).  This test is reported to be a sensitive 
(with a 98% negative predictive value at a blood concentration < 80 pg/ml and specific 
test used to diagnose CHF (Dao et al., 2001).  However, there is little research into its 
use as a marker to evaluate therapies, including exercise rehabilitation. A small study 
examining its utility to evaluate the effect of exercise training in an outpatient setting 
reported a trend for BNP to decrease in the exercise group, mirroring improvements in 
functional capacity, whereas BNP increased in the control group (Butterfield et al., 
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2008). This test was also used by Malfatto et al (2009), who reported reductions in 
BNP following exercise training that correlated with improvements in LV compliance..  
2.8.7 Daily physical activity 
When evaluating the effectiveness of a supervised exercise training intervention, it is 
important to monitor changes in physical activity levels outside the supervised 
programme which could contribute to changes in outcome measures.  There are various 
methods, including objective measures such as HR, accelerometry and pedometry, and 
subjective recall questionnaires (Macfarlane et al., 2006).  For the purpose of recording 
physical activity during daily life during an exercise training study in CHF, a physical 
activity log book is arguably the most appropriate tool.  HR monitors are limited by the 
interference of environmental conditions and emotional stress while accelerometers do 
not measure non-ambulatory or upper body movements, and cannot determine exercise 
intensity. Physical activity questionnaires rely on subjective recall, and are generally 
designed for healthy young to middle age populations, rather than cardiac patients. 
Daily physical activity records also rely on subjective recall, but only for up to 24 
hours.  They are time-consuming to process, but are feasible for shorter studies with a 
limited number of participants.    
2.8.8 Quality of life 
The goal of health care for individuals with chronic disease is to improve function and 
well-being. An individual’s perception of his or her QoL is a good indicator of this 
goal, and may be assessed by generic and disease-specific questionnaires. The 
effectiveness of a therapeutic intervention cannot be judged solely on improvements in 
functional capacity or disease progression.  It is important to integrate laboratory and 
physical examination results with measurement of health status in order to assess the 
true “value” of the intervention to the patient (Jette and Downing, 1994).  UK statistics 
suggest that 24-42% of CHF patients suffer from depression (British Heart 
Foundation), and interventions that improve QoL may be particularly beneficial to this 
population. There are a variety of instruments available to assess QoL, including those 
that assess generic health status, and those that focus on the problems associated with 
single disease-states or patients groups.  Disease-specific measures are aimed to focus 
on the important aspects of health-related QoL in the patients being studied, and are 
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therefore often more likely to be senstive to clinical change (Guyatt et al., 1993).   The 
majority of exercise training studies in CHF have used the disease-specific Minnesota 
Living with Heart Failure Questionnaire (MLHFQ) (Davies et al., 2010), and the 
Medical Outcomes Short Form 36 (SF-36), as illustrated in Table 1A  (Appendix 1).   
2.8.8.1 Disease-specific quality of life: Minnesota Living with Heart Failure 
Questionnaire (MLHFQ) 
Disease-specific QoL is clinically relevant, and can be measured using the MLHFQ 
developed by Rector et al (1987) (Rector et al., 1987a; Rector et al., 1987b).  This tool 
consists of 21 items recording patients’ perceptions of how CHF affects their physical, 
psychological and socioeconomic lives, using a 6-point zero to five Likert scale, with a 
maximum possible score of 105 points.    A higher score indicates a poorer perceived 
QoL. The reproducibility (r and Chronbach’s alpha coefficient) is reported at 0.87-0.95, 
with estimates of the standard error of measurement between 5.8-8.6 points (Rector, 
2005).  The MLHFQ incorporates relevant aspects of the key dimensions of QoL, but 
was not designed to measure any particular dimension separately; hence it is 
recommended that the total score is the best measure of how heart failure and 
treatments affects the patient’s QoL.  However, a factor analysis of responses has 
demonstrated that a subgroup of 8 questions related to physical symptoms and a 
subgroup of 5 questions related to psychological symptoms are highly inter-related, and 
can be used to characterise the physical and emotional domains  (Rector and Cohn, 
1992). 
Authors who have not found any improvement in MLHFQ following exercise training 
have suggested that, although this instrument has been used effectively in drugs trials, a 
more generalised tool such as the SF-36 might be more applicable in exercise training 
studies (Keteyian et al., 1999).  The SF-36 is discussed in section 2.8.8.2 below.  It has 
also been suggested that MLHFQ may not be appropriate for use on elderly CHF, as it 
was validated on a population aged 59 ± 11 years  
The Kansas City Cardiomyopathy Questionnaire is a recently developed questionnaire 
for measuring health status in CHF, and there is evidence that it has greater sensitivity 
to clinical change than MLHFQ or SF-36  (Green et al., 2000).  It measures physical 
limitations, and independently quantifies symptoms, social limitations, self-efficacy 
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and knowledge, and QoL.  However, at the current time, it has only been used in one 
exercise training study in CHF (Whellan et al., 2007).  This study, the HF-ACTION 
trial, demonstrated  small but statistically significant improvements in self-reported 
health status assessed by the Kansas City Cardiomyopathy Questionnaire (Flynn et al., 
2009). 
2.8.8.2 Generic health status: Medical Outcomes Short Form 36 (SF-36) 
The SF-36 is a validated generic health status measure (Davies et al., 2010) that 
assesses eight health concepts: 1) limitations in physical activities because of health 
problems; 2) limitations in social activities because of physical or emotional problems; 
3) limitations in usual role activities because of physical health problems; 4) bodily 
pain; 5) general mental health (psychological distress and well-being); 6) limitations in 
usual role activities because of emotional problems; 7) vitality (energy and fatigue); 
and 8) general health perceptions (Ware and Sherbourne, 1992).  It has been used in 
several CR studies (Jette and Downing, 1994; Cohen et al., 1999), as well as in 
numerous exercise training studies in CHF (see Table 1A, Appendix 1).  In CHF–
specific studies, an exercise intervention is associated with improvements in physical 
and social functioning, physical role fulfilment and vitality (Quittan et al., 1999), and 
comprehensive CR, including exercise and education, improves mental health as well 
as physical functioning (Meyer and Laederach-Hofmann, 2003).  
2.8.8.3 Clinical significance 
The difficulty of ensuring that outcome measures in clinical trials accurately reflect 
changes in clinical status is widely acknowledged, and understanding the sensitivity of 
different assessment techniques to reflect clinically relevant changes is important 
(Spertus et al., 2005). Statistical analysis of group means, particularly on studies with 
small sample sizes, may not reflect clinical or practical meaningfulness, or changes in 
individual patient status. Equally, trials with sufficiently large sample sizes may detect 
changes that are statistically significant but not clinically meaningful. Recent exercise 
training studies that include a more heterogeneous CHF population tend to report 
smaller changes in physiological parameters than previous studies, and this may lead to 
a mistaken conclusion that exercise is of no benefit to many patients.  However, it is 
important to integrate clinical results and prognostic markers with measurement of 
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health status in order to assess the true “value” of the intervention to the patient (Jette 
and Downing, 1994). This is complicated by the fact that there is no agreed criterion 
standard by which to define a change in patient disease status (Spertus et al., 2005).   
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2.9 Proposed aims of the thesis 
The exercise intensity domains, delineated by VO2peak and gas exchange thresholds (VT 
and RCP) may enable precise exercise training guidelines to be applied in CHF (Jones 
and Poole, 2005; Meyer et al., 2005a). Several authors have used a steep test (Meyer et 
al., 1997b) for setting intermittent exercise intensity work rates, yet this test has not 
been validated in CHF or in non-clinical populations.   The two methods for prescribing 
intermittent exercise have not been compared.   
The acute and chronic responses to intermittent exercise in CHF remain unclear.  It 
may provide an alternative and time-efficient means of exercise training with greater 
health benefits than the lower exercise doses used in current practice, which might be 
more easily achievable or more enjoyable for some.  The potential benefits of 
intermittent training are recognised by the ESC (Giannuzzi et al., 2001), but definitive 
guidelines on how it should be implemented are lacking.  This thesis will examine the 
methodology for intermittent exercise prescription in order to find a reproducible and 
valid protocol, and to assess the effect of an intermittent exercise intervention 
compared with a training regimen in current practice. 
Therefore, the aims of the current thesis are:- 
1. (a) To examine the reproducibility of physiological parameters measured during a 
standard and a steep incremental cycle ergometer test, and (b) to compare the 
exercise training workloads derived from a standard and steep test in CHF patients 
and age-matched control participants. 
2. To compare the acute respiratory, cardiovascular and metabolic responses to 
matched workloads of moderate continuous and intermittent exercise in CHF and 
control participants.  
3. To examine the effect of volatility on acute cardiovascular, respiratory and 
metabolic responses to exercise by comparing an exercise bout where the amplitude 
of the work phases above the mean was increased (i.e. high volatility) with an 
exercise bout where the amplitude of the work phases was decreased (i.e. low 
volatility), whilst maintaining the same total work by adjusting the workload of the 
recovery phase.  
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4. To investigate whether there is a difference between the effect of high intensity 
intermittent exercise training and traditional circuit-based training on functional 
capacity, ventilatory efficiency, BNP and QoL in CHF patients in a short-term 
twice-weekly CR programme.   
Hypotheses:- 
1. a)  Physiological parameters measured in duplicate standard and steep incremental 
cycle ergometer tests performed one week apart by CHF and control participants 
will show acceptable reproducibility in terms of statistical significance, re-test 
correlation and limits of agreement (LOA),  and  a  difference < 10% between tests.  
b) Intermittent exercise training workloads derived from a steep test will differ to 
those derived from a standard test in CHF and control participants. 
 
2. Intermittent exercise will elicit similar cardiovascular and respiratory responses, but 
higher metabolic and RPE responses, than continuous exercise, in CHF.   In control 
participants there will be no difference in cardiovascular, respiratory, metabolic or 
RPE responses to intermittent or continuous exercise. 
 
3. High volatility (i.e. a large amplitude between the work and recovery phases) 
intermittent exercise will elicit higher cardiovascular, respiratory, metabolic and 
RPE responses than low volatility (i.e. a small amplitude between the work and 
recovery phases) intermittent exercise or continuous exercise of matched total 
workload in CHF and control participants.   
 
4. There will be no difference between the effect of traditional circuit-based training 
and high intensity intermittent training on functional capacity, ventilatory 
efficiency, BNP and quality of life in CHF on a 6 week CR programme. 
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CHAPTER 3: GENERAL METHODS 
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3.0 Introduction 
The following section provides details of the methods common to more than one study 
of this thesis.  Additional techniques and methods used in separate studies are described 
in the relevant chapters. 
3.1 Study location 
The study was carried out at Eastbourne District General Hospital, Eastbourne, BN21 
2UD. Studies 1-3 were conducted on the Coronary Care Unit, in a dedicated testing 
area, curtained off to allow full privacy. Study 4 was conducted in the Cardiology 
Multifunction Room, and in the Physiotherapy gym. All testing sessions were 
conducted under the direct supervision of a cardiologist and an exercise physiologist. 
Studies 1-3: Patients attended 6 separate testing sessions one week apart.  Testing 
sessions were scheduled for the same time of day to minimise the effect of diurnal 
variability in exercise capacity (Fleg et al., 2000; Reilly, 2007).  Patients were 
instructed not to perform exhaustive exercise during the 48 hours prior to testing, and 
not to consume alcohol or caffeine for 24 hours before testing. Patients continued to 
take routine medication before exercise testing. Exercise was performed at least 2 hours 
postprandially.   All tests were performed on an electrically-braked upright Lode cycle 
ergometer (Lode Corival, Groningen, The Netherlands) (Figure 2.1).  The seat and 
handlebar positions were measured and remained constant throughout all tests for each 
individual.  None of the participants had any prior experience of either maximal or sub-
maximal exercise testing on a cycle ergometer. 
  
A      B           C 
Figure 3.1: (A) Lode Corival cycle ergometer  (B) Jaeger Oxycon Pro (C) Patient 
prior to cardipulmonary exercise test (Studies 1-3) 
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Study 4: All tests were performed on a semi-recumbent cycle ergometer (911 BP/LS, 
Schiller, Baar, Switzerland) (Figure 3.2). 
 
A B 
Figure 3.2: (A) Schiller semi-couch cycle ergometer and (B) patient prior to 
exercise test (Study 4) 
3.2 Participants and ethics 
CHF patients were recruited from the Heart Failure clinic at Eastbourne District 
General Hospital, under the inclusion and exclusion criteria detailed in Table 3.1.  
Patients meeting the criteria were initially identified by the Specialist Heart Function 
Nurse, and their medical details were then checked by a cardiologist to confirm that 
they met the criteria. All patients were receiving evidence-based care according to 
current guidelines (National Collaborating Centre for Chronic Conditions, 2003).  
Patients with pacemaker or ICD devices were excluded from Studies 1-3 to eliminate 
variability in heart rate response to exercise due to these devices.  Furthermore, specific 
recommendations that patients with ICDs should be offered comprehensive CR 
(Corra  et al., 2005) were not published until after the start of these studies.  By Study 
4, the published literature demonstrated that these patients were being included in 
exercise training studies (Whellan et al., 2007), and that exercise could safely be 
undertaken by those undergoing cardiac resynchronisation therapy (Conraads et al., 
2007; Patwala et al., 2009) and those with ICDs (Vanhees et al., 2004).  Provided they 
did not meet any exclusion criteria, these patients were therefore included in Study 4. 
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Table 3.1: Study inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
Systolic heart failure Acute coronary syndrome or surgery 
within previous 6 months 
Resting left ventricular ejection fraction  
< 40% (measured by echocardiography) 
 
Decompensated heart failure 
 
Clinically stable for 4 weeks with no  
changes in medication 
 
New York Heart Association Class II – III 
 
Severe valvular heart disease 
 
Hypertrophic obstructive cardiomyopathy 
 
 
 
Unstable angina 
 
 Complex/sustained ventricular arrhythmia 
 
 Severe systemic/pulmonary hypertension 
  
 Aortic stenosis 
 
Presence of non-cardiac exercise limiting 
disorders or comorbidities (e.g. severe 
osteoarthritis or chronic obstructive 
pulmonary disease) 
  
 Presence of any other absolute 
contraindications for exercise testing and 
training in CHF (Fletcher et al., 2001; 
Giannuzzi et al., 2001) 
 
 
Age-matched asymptomatic control participants were recruited via poster 
advertisement, and 12-lead ECG analysis was performed to confirm that they were free 
from cardiac abnormalities.  
3.2.1 Research ethics 
The study protocol conformed to the guidelines of the 1975 Declaration of Helsinki, 
and was approved by University of Brighton Ethics Committee and  East Sussex Local 
Ethics Research Committee (Appendix 3).  Participants’ GPs were informed in writing 
of their enrollment in the study.  
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3.2.2 Informed consent 
Participants were provided with written and verbal explanations of the aims, 
procedures, benefits and risks relating to the study, and of their right to withdraw from 
the study at any stage, before providing written informed consent (Appendix 4).  They 
were given a minimum of 7 days from the date of receiving full information of the 
study to decide whether or not to participate. All data was stored on password-protected 
computers, and participant anonymity was maintained. 
3.3 Procedures for maximal exercise testing  
3.3.1 Maximal cardiopulmonary exercise test (standard test) and maximum 
short time exercise capacity test (steep test)  
All patients performed two exercise tests: a standard incremental exercise test (Cohen-
Solal et al., 1991) (standard test) and a maximum short time exercise capacity test  
(steep test), as described by (Meyer et al., 1997b) (Figure 3.3).  These two tests were 
performed on the same day, in a fixed order, with patients resting for 1 hour between 
the first and second test. 
Standard test: patients rested on the cycle ergometer for 3 minutes, then pedalled for 3 
minutes without load as a warming-up period. The incremental exercise test then 
commenced, with CHF starting at a workload of 20 W, increasing by 10 W every 
minute.  The starting workload (20 or 50 W) and ramp rate (10, 15 or 20 W.min-1) for 
the control participants was adjusted according to age and fitness in order to maintain a 
test duration of ~ 10 minutes (Buchfuhrer et al., 1983; Wasserman et al., 2005).  All 
participants pedalled at a self-selected constant cadence between 60 and 80 rpm and 
were verbally encouraged to exercise to exhaustion, as defined by intolerable leg 
fatigue or dyspnoea.     
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Figure 3.3: Protocol for steep and standard incremental exercise tests 
 
3.3.2 Measurements 
Height and body mass were recorded on the first visit, and body mass was recorded on 
each subsequent visit.  Heart rate and rhythm were monitored continually via 3-lead 
ECG.  BP was measured manually with a sphygmomanometer (Accosan, UK) at rest 
and every 2 minutes during exercise and the recovery period. RPE on the Borg 6-20 
Scale (Borg, 1970) (Figure 3.4) was measured at the end of each stage, provided that 
this did not distract the patient from maintaining a regular pedal cadence or breathing 
pattern.   Explanation and instruction on the use of the scale was provided according to 
the recommended guidelines (Noble and Robertson, 1996). 
Ventilatory expired gases were obtained at rest, during exercise, and 5 minutes post 
exercise via a face mask using a breath-by-breath respiratory gas analysis system 
(Jaeger Oxycon Pro, Hoechberg, Germany).  Calibration was performed before each 
test with known volumes of air and known concentrations of oxygen and carbon 
dioxide. 
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Steep ramp: after 1 hour of rest, a second maximal incremental exercise test was 
performed. After 2 minutes of unloaded pedalling, the workload was set at 25W for 10 
seconds, and increased by 25W every 10 seconds until the pedal cadence could not be 
maintained above 60 revolutions per minute. Ventilatory expired gases were obtained 
at rest and during exercise, heart rate and rhythm were monitored continually by ECG , 
and BP was monitored with a sphygmomanometer (Accoson, UK) at rest and during 
the recovery period.  Provided that no ECG abnormalities were present, patients were 
permitted to leave the hospital 15 min after completion of exercise, and/or when HR 
and BP had returned to resting values. 
Both exercise tests were repeated one week later, using the same procedures as before, 
in order to determine reproducibility. 
 
Figure 3.4: Borg 6-20 scale  
3.4 Procedures for continuous and intermittent exercise tests 
The exercise intensity domains, delineated by VT, RCP and VO2peak, determined in the 
standard ramp test were used to determine the exercise workloads for four subsequent 
20 min exercise bouts, to be performed in experiments 2 and 3. Exercise training 
sessions of this duration have been demonstrated to be achievable by and beneficial for 
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CHF patients (Coats et al., 1992a; Meyer et al., 1996b; O'Connor et al., 2009), and 
correspond with the guidelines for exercise duration in CHF starting an exercise 
training programme (Giannuzzi et al., 2001; Pina et al., 2003). 
Firstly, a continuous protocol (CON) was set at a constant workload corresponding to 
90% VT.   In addition, there were three intermittent protocols with 30s work phases 
interspersed with 60s recovery phases at a low workload.  The intermittent exercise 
protocols were defined as low (LOW), medium (MED) or high (HIGH) volatility, 
depending on the amplitude of the work and rest phases above and below the mean 
workload (i.e. the workload during CON).  The workload for the work phases were set 
as follows:- 
LOW: half way between VT and RCP (Δ50% = VT + ((RCP-VT) 0.5)) 
MED:  110% RCP 
HIGH: 110% VO2peak 
CON and MED  were performed in Study 2, and CON, LOW and HIGH were 
performed in Study 3. 
Figure 3.5 illustrates the protocol for calculating these workloads.  The duration for all 
4 exercise bouts was 20 min, and 13 work phases were completed in each intermittent 
bout. The recovery phase workload was 15-30 W for CHF and 15-60 W for controls, 
adjusted so that the average workload was equal for all four exercise bouts.  CHF 
patients with very low exercise capacities (peak work rate (WRpeak) < 70W) rested 
without pedalling during the HIGH recovery phases.  The exercise bout commenced 
with a rest phase, and the intensity during the first 2 work phases of MED and HIGH 
was progressively increased to reach the final intensity by the third work phase.  In 
LOW the intensity was constant throughout all 13 work phases.  In all tests, after 10 
minutes of exercise participants rested for 2 minutes before completing the final 10 
minutes of exercise.  The purpose of this 2 minute break was primarily to facilitate 
blood sampling. The four exercise protocols were performed in random order one week 
apart, starting one week after the incremental exercise test. 
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Figure 3.5:  Continuous and intermittent exercise intensities based on exercise 
domain framework. The exercise domains are delineated by ventilatory threshold 
(VT), respiratory compensation point (RCP) and VO2peak 
 
3.4.1 Experimental procedures 
HR was measured continuously by a 3-lead ECG.  Average values were recorded for 
minute 4-5, 9-10, 14-15 and 19-20 during the continuous exercise bout. In the 
intermittent exercise bouts, HR was recorded at the end of the work phase at 4 min 30s, 
9 min, 15 min and 19 min 30s, and at the end of the recovery phase at 5 min 30s, 10 
min, 14 min 30s and 19 min. RPE on the Borg 6-20 Scale (as described in Section 
3.3.2) was measured every 5 minutes during the continuous exercise bout, and every 5 
minutes in both the work and recovery phases (at the same time points specified above 
for HR) during the intermittent exercise bouts.  BP was recorded with a 
sphygmomanometer at rest, during minutes 10 and 20 of exercise, and at 2 minute 
intervals post exercise until it returned to resting level.  Venous blood samples (5 ml) 
were taken from an intravenous cannula in the ante-cubital vein at rest, after 10 minutes 
of exercise, and 2 minutes post exercise.   
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3.5 Statistical analysis 
Statistical analysis was performed using SPSS for Windows (version 15). The mean ± 
standard deviation of the mean (SD) was calculated for descriptive statistics of 
participant characteristics in order to illustrate the distribution of individual scores 
around the mean.  The mean ± standard error of the mean (SEM) were calculated for 
variables on which statistical significance testing was performed, in order to indicate 
the accuracy of the sample mean. This method is conventional in the discipline of 
exercise science, and allows for easy comparison with the results of previous studies.  
Statistical analyses specific to individual studies are described in each experimental 
chapter. For all statistical analyses an α level of P ≤ 0.05 was accepted as significant.   
73 
 
 
 
EXPERIMENTAL CHAPTERS 
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CHAPTER 4: REPRODUCIBILITY OF 
VARIABLES DERIVED FROM MAXIMAL 
INCREMENTAL CYCLING TESTS IN CHF AND 
HEALTHY CONTROLS 
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4.0 Introduction 
CPET is an objective means for assessing functional capacity and for prescribing 
exercise training in CHF patients.  Repeated tests of exercise performance are used to 
evaluate changes in functional capacity attributable to exercise interventions as well as 
medical treatment and progression of the disease process.  It is important that the 
results do not fluctuate between trials to an unacceptable degree, particularly in CHF 
patients who have a low functional capacity, and for whom small changes in 
cardiopulmonary parameters may be important (Fleg et al., 2000; Fletcher et al., 2001; 
Bard, 2005).   The effect of familiarisation is widely acknowledged, and it is therefore 
recommended that individuals complete a “practice” test in advance of the real test.  
Improvements in performance between the first and second test of 1.2% (likely range 
0.5-1.9%) have been reported in healthy populations (Hopkins et al., 2001). This effect 
is greater in a clinical population, particularly in a maximal test, as few patients 
habitually undertake exercise at this intensity, and they may be less familiar with the 
ergometer used.  A study in which CHF performed three maximal cardiopulmonary 
exercise tests on a treadmill demonstrated that at least two tests should be performed, as 
the first test underestimated exercise capacity  by 20% (Elborn et al., 1990).   
Nevertheless, in clinical practice a familiarisation trial is often omitted due to time and 
financial constraints.  There are no universal criteria for reproducibility, but the 
American Heart Association recommend that VO2peak should vary by less than 10% on 
separate days for it to be considered reproducible, while exercise duration should vary 
by less than 60s (i.e. 10% of a 10 minute test) (Fleg et al., 2000).  Good reproducibility 
(differences of 2-7% between 2 tests) of VT and VO2peak in cycle ergometry has been 
reported in elderly patients with both mild-moderate and  severe CHF (Simonton et al., 
1988; Cohen-Solal et al., 1991; Meyer et al., 1997c; Marburger et al., 1998).  However, 
in all of these studies patients had already performed the exercise tests before, either 
during a separate study, or as a practice test on a separate day.  Up-to-date studies 
report a greater variability in repeated exercise tests.  The HF-ACTION trial reported a 
9% difference, with approximately half of patients increasing and half decreasing their 
VO2peak in a second test (Bensimhon et al., 2008).   Results from the PEERLES-HF trial 
demonstrate that patients who do not achieve a peak RER ≥ 1.05 are more likely to 
increase their VO2peak in a repeat test (Keteyian et al., 2010).  The authors suggest that 
the variability between tests should be assumed to be approximately 6%.  
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Exercise test results are also used to prescribe subsequent exercise training. 
Determining the appropriate intensity in this population is important for safety reasons 
as well as for achieving optimal adaptations, but is not straightforward.  Exercise 
training workload is often determined from the identification of VO2peak, although 
several authors now recommend using VT to guide exercise intensity.  VT reflects the 
buffering of bicarbonate in response to a rise in Lac, and represents the highest work 
rate that can be sustained for a prolonged period of exercise.  It is suggested that an 
intensity within 10% of VT is safe, effective and able to be maintained over a 
prolonged exercise period (Gordon and Scott, 1995; Strzelczyk et al., 2001; Meyer et 
al., 2005a).   
In the 1990s Meyer demonstrated that high intensity intermittent exercise was an 
alternative method of training for CHF (Meyer et al., 1996b; Meyer et al., 1997b), and 
recent studies have reinforced this finding (Dimopoulos et al., 2006; Roditis et al., 
2007).  These studies have used different methods for defining intermittent intensities, 
resulting in variations in the exercise dose.  There is no universally accepted set work 
rate for interval training, but CPET provides an objective measure from which to set 
training intensities aligned to robust physiological parameters (Meyer et al., 2005b).  In 
this model, interval training intensities at or close to VO2max work rate are applied, as 
demonstrated in studies comparing acute physiological responses to interval and 
continuous exercise (Astrand et al., 1960a; Poole and Gaesser, 1985; Gorostiaga et al., 
1991; Billat, 2001). Some studies follow a traditional method of applying workloads of 
100% VO2peak work rate (Dimopoulos et al., 2006) (Roditis et al., 2007). However,  
Meyer et al. (1997) introduced a novel method, setting the intermittent training 
intensity at 50% WRpeak achieved on a “maximum short time exercise capacity” test 
(steep test). This protocol is included in ESC recommendations for exercise training in 
CHF, despite limited scientific verification, and has been used in exercise training 
studies for CHF (Sabelis et al., 2004; Kemps et al., 2008) and other clinical populations 
(Vogiatzis et al., 2002; Puhan et al., 2006; De Backer et al., 2007).    Meyer proposed 
that this test, which has increments of 25W every 10s, and lasts only 30-120s, is 
appropriate as it tests “muscle strength” and “anaerobic capacity”, both of which are 
relevant for short high intensity exercise bouts, whereas a standard incremental exercise 
test does not measure these, and may underestimate the training load.  In fact neither 
“muscle strength” nor “anaerobic capacity” is either defined or measured during this 
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test and there is no information on its reproducibility.  It is not clear if the rationale for 
the steep ramp test is justifiable, or how workloads compare with those derived from a 
standard test. Furthermore, since the test has not been used in non-clinical populations, 
there is no information about whether the test would prescribe different relative 
exercise intensities in healthy individuals compared with CHF patients.   
It is proposed that the exercise intensity domains, delineated by the gas exchange 
thresholds (VT and RCP)  and VO2peak (see section 2.6.4), may enable more precise 
exercise training guidelines to be applied.  Although maximal CPET is becoming more 
routinely used both for diagnosis and exercise prescription, this method of exercise 
prescription has not yet been established in CHF.  The reproducibility of these 
thresholds is important for accurate exercise prescription, as well as for assessing 
changes in functional capacity following an intervention.  Analytical goals are more 
useful than the significance of hypothesis tests to determine the acceptable level of 
measurement error in repeated tests (Atkinson and Nevill, 1998).  In the context of this 
thesis, that means deciding on a value that would indicate unacceptable test-retest 
reproducibility in order to accurately prescribe exercise intensity, and to measure 
changes following an exercise training intervention.   
VO2peak values for NYHA class II and III CHF patients are generally between 12 and 
19 ml.kg-1.min-1  (Cohen-Solal et al., 1990).  The Weber classification includes VT 
values in addition to VO2peak values (Class B: VO2peak 10.1-15.9, VT 8-11 ml.kg-1.min-1; 
class C: VO2peak 16-20, VT 11-14 ml.kg-1.min-1) (Weber et al., 1982).  The Cochrane 
Review evaluated 29 randomised controlled trials, with 1126 patients in NYHA class II 
and III.  Exercise training significantly increased VO2peak by 2.16 ml.kg-1.min-1 (95% CI 
2.82 to 1.49 ml.kg-1.min-1) and WRpeak by 15 W (95% CI 18 – 13 W).  A systematic 
quantitative review reports a 13% (+2.6 ml.kg-1.min-1) increase in VO2peak and a 17% 
(+1.9 ml.kg-1.min-1) increase in VO2 at VT following exercise training (van Tol et al., 
2006). Given these values, this thesis accepts the American Heart Association 
guidelines that a repeat measurement for VO2 at peak exercise, and at VT and RCP, > 
10% would indicate unacceptable test-retest reproducibility a) in terms of evaluating 
the effectiveness of a training intervention and b) for calculating accurate exercise 
training intensities.   
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A few studies have previously reported reproducibility of cardiopulmonary variables in 
CHF, but these have used different exercise protocols, different methods for 
determining the variables, and some have included familiarisation trials. In addition, 
the statistical methods used to assess reproducibility have been limited. Furthermore, 
no studies have reported the reproducibility of RCP, oxygen uptake-work rate 
relationship (ΔVO2/ΔWR) or VE/VCO2 slope. This study specifically examines the 
protocols to be used in subsequent studies in this thesis, and its purpose is (a) to 
examine the reproducibility of physiological parameters measured during a standard 
and a steep incremental cycle ergometer test, and (b) to compare the exercise training 
workloads derived from a standard and steep test in CHF patients and healthy controls. 
The statistical tests have been chosen to allow:- 
1)  comparisons of the mean to detect systematic bias 
2) description of “relative reliability” using the intraclass correlation coefficients 
(degree to which individuals maintain their position in a sample with repeated 
measurements) 
3) detection of heteroscedasticity, if present, using Bland and Altman’s 95% LOA 
(existing relationship between the error and the size of the measured value) and 
description of “absolute reliability” (degree to which repeated measurements vary for 
individuals) (Bland and Altman, 1986; Atkinson and Nevill, 1998; Hopkins, 2000a; 
Hopkins, 2000b). 
In addition a practical analytical goal of > 10% difference between tests has been 
chosen to indicate unacceptable reproducibility. 
Hypotheses 
a) Physiological parameters measured in duplicate standard and steep incremental 
cycle ergometer tests performed one week apart by CHF and control participants 
will show acceptable reproducibility in terms of statistical significance, re-test 
correlation and LOA,  and  a  difference < 10% between tests.  
 
b) Intermittent exercise training workloads derived from a steep test will differ to 
those derived from a standard test in CHF and control participants. 
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4.1 Methods 
4.1.1 Participants 
Ethical procedures and patient inclusion and exclusion criteria were adhered to as 
detailed in the General Methods.  Ten chronic heart failure (CHF) patients (8 men and 
2 women) in NYHA class II (n=8) or III (n=2) (mean age 75 ± 8 years) and 7 healthy 
controls (4 men and 3 women; mean age 67 ± 7 years) were studied.  The aetiology of 
the CHF patients was ischaemic cardiomyopathy (n=5), idiopathic dilated 
cardiomyopathy (n=5).   All patients had been in a stable condition for the preceding 4 
weeks, with unchanged medication doses: beta-blocker (9), diuretic (8), ace inhibitor 
(4) angiotensin receptor antagonist (4), anti-arrhythmic (3), calcium-channel blocker 
(2). Control participants were not on any medication.   
4.1.2 Experimental design 
General methods were followed as described in Chapter 3.   
4.1.3 Data analysis  
Following the removal of outlying breaths (value ± 500 ml different from the previous 
and following breaths), breath-by–breath respiratory gas exchange variables (VO2, 
VCO2, VE) were interpolated to give second-by-second values.  VO2peak in the standard 
test protocol was expressed as the highest value from a 30s moving average during the 
final stage of, or within 30s of completion of the exercise test.  VO2peak in the steep test 
protocol was expressed as the highest value from a 10s moving average.  The highest 
value from a 10s moving average was also recorded in the standard test, in order to 
compare the two peak values.  From the standard test data, VT was identified by the V-
slope method (Beaver et al., 1986). RCP was determined as the point when ventilation 
increased disproportionately to carbon dioxide output. Both VT and RCP were 
confirmed by plots of the ventilatory equivalents and end tidal pressure for oxygen and 
carbon dioxide (Cooper and Storer, 2001; Wasserman et al., 2005).  Figure 4.1 
illustrates the determination of VT & RCP from the data of one CHF.  
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Figure 4.1: Determination of ventilatory threshold in one CHF patient from plots 
of VCO2 and VO2, ventilatory equivalents (VE/ VO2 and VE/ VCO2) and end tidal 
gas (PETO2 and PETCO2) 
0
200
400
600
800
1000
1200
1400
1600
0 200 400 600 800 1000 1200 1400 1600
V
C
O
2 
(m
l·m
in
-1
)
VO2 (ml.min-1)
Ventilatory Threshold
10
20
30
40
50
0 200 400 600 800 1000 1200 1400 1600
Ve
nt
ila
to
ry
 E
qu
iv
al
en
ts
VO2 (ml.min-1)
VE/VO2
VE/VCO2
Ventilatory Threshold
20
40
60
80
100
120
140
0 200 400 600 800 1000 1200 1400 1600
E
nd
 ti
da
l g
as
 (m
m
H
g)
VO2 (ml.min-1)
PETO2
PETCO2
Ventilatory Threshold
81 
 
 
 
  
 
 
Figure 4.2: Determination of respiratory compensation point in one CHF patient 
from plots of VE and VCO2, ventilatory equivalents (VE/ VO2 and VE/ VCO2), and 
end tidal gas (PETO2 and PETCO2) 
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VT and RCP were identified by two independent observers.  If there was no consensus, 
a third independent observer decided on the values to be used.  This occurred in 4 of 
the 34 tests.  The oxygen uptake-work rate relationship (ΔVO2/ΔWR) and VE/VCO2 
slope were calculated by linear regression from the data from 2 minutes from the start 
of exercise until RCP, i.e. the linear part of the slope. HRpeak was the highest heart rate 
recorded in the final stage of the standard test. WRpeak was the highest workload 
measured during a completed stage in each of the tests.   
4.1.3.1 Calculation of continuous and intermittent exercise workloads 
The workloads for CON and for LOW, MED and HIGH were calculated as described 
in section 2.4.  Work rate at VT, RCP and peak 2OV were calculated via 2 different 
methods: (a) via linear regression from the ΔVO2/ΔWR equation and (b) from the work 
rate corresponding to the test stage at which VT, RCP and peak 2OV were identified.  The 
value of 2/3 of the ramp rate was deducted in both (a) and (b) to allow for the lag in 
ventilatory response to each workload (Whipp et al., 1981; Davis et al., 1982). The 
method that showed the greatest reproducibility was to be used subsequently. 
Workloads for intermittent exercise training according to the protocol described by 
(Meyer et al., 1997b) were calculated as 50% of the steep test WRpeak (STEEP), with 
rest phases of 15W, and these were compared with those derived from the standard test 
data (LOW, MED, HIGH).   
4.1.4 Statistical analysis   
Data from CHF and controls were analysed together (n=17) to examine the 
reproducibility of the steep and the standard tests.  Data from CHF only (n=10) was 
then used to examine the reproducibility in this patient population.  There was 
insufficient data from the control participants to perform a separate analysis on this 
group (n=7). The distribution of individual mean values and absolute differences 
between the 2 tests were examined for normality using the Kolmogorov-Smirnov test 
and Q-Q plots.   Student’s t-test for paired data were carried to determine the difference 
(change in the mean) in VO2peak, VT, RCP, ΔVO2/ΔWR, VE/VCO2 slope, HRpeak and 
WRpeak between test 1 and test 2.  Intraclass correlation coefficients (ICC) were 
calculated and used to assess the significance of relationships between test 1 and 2, and 
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the corresponding 95% confidence intervals of the mean for each ICC were calculated 
(Hopkins, 2000b). LOA (Bland and Altman, 1986) were used to assess the agreement 
between variables from the first and second test of both the standard and the steep test.  
In addition, LOA were used to assess the agreement in VO2peak in the 2nd
4.2  Results 
 standard and 
steep tests.  No heteroscedasticity was detected, and the 95% LOA are reported as 
mean ± 2SD.  All other data are reported as mean and SEM unless stated otherwise.   
Participant characteristics are shown in Table 4.1.  
Table 4.1: Characteristics (mean ± SD) of CHF patients and healthy controls 
 
Characteristic CHF (n=10) Controls (n=7) 
Age (years)         75 ± 8 67 ± 7  
Male/ Female 8/2 4/3 
Height (cm) 172 ± 11 173 ± 10 
Body Mass (kg) 86 ± 18 79 ± 13 
NYHA Class II/III 8/2 - 
Ejection Fraction (%) 36 ± 9 69 ± 7 
Aetiology (ischaemic/dilated cardiomyopathy) 7/3 - 
Co-morbidities   
COPD 1 - 
Diabetes 1 - 
Hypertension 1 - 
Medication   
ACE inhibitor 4 - 
Angiotensin II receptor blocker 4 - 
Anti-arrhythmic 3 - 
β blocker 9 - 
Calcium channel blocker 2 - 
Diuretic 8 - 
 
The data were normally distributed.  VO2peak and VT were identified in both standard 
tests in 9 CHF, VE/VCO2 slope, ΔVO2/ΔWR and HRpeak in 8 CHF, and RCP in 7 CHF.  
Complete data from both standard tests was collected for 5 controls.  In the steep test, 
VO2peak was identified in 9 CHF and 7 controls.  WRpeak was identified in all 
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participants in all tests. The distribution of individual mean values and absolute 
differences between the 2 tests were normally distributed for all variables. 
When asked to give their subjective RPE by pointing to the Borg 6-20 scale during the 
exercise test, the majority of patients were unable to do this without slowing their 
pedalling rate or stopping completely, and/or talking, thus compromising the exercise 
test results.  It was therefore decided not to take this measurement. 
An example of the VO2 response to the standard and steep tests in one CHF and one 
control participant is illustrated in Figure 4.3. Figure 4.4 shows the VE/VCO2slope in the 
same CHF patient and control participant.  
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A 
B  
Figure 4.3: Oxygen uptake response to standard & steep Test in (A) CHF (male, 
66 years, body mass 81 kg) and (B) Control (male, 62 years, body mass 86 kg). 
VO2peak, RCP and VT are shown. 
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Figure 4.4: VE/VCO2 slope in a CHF (male, 66 years, body mass 81 kg) and 
Control (male, 62 years, body mass 86 kg). 
 
4.2.1 Reproducibility of standard test 
Paired t-tests revealed no significant differences in VO2 at VT or RCP, or in 
ΔVO2/ΔWR or VE/VCO2 slope between test 1 and test 2 (P > 0.05), but VO2peak (P = 
0.008), WRpeak (P = 0.047) and HRpeak (P = 0.048) were all significantly higher in test 
2. Mean RER values at peak exercise for CHF and controls were 1.13 ± 0.05 and 1.22 ± 
0.10 for test 1 and 1.10 ± 0.07 and 1.26 ± 0.18 respectively.   All participants reached a 
peak RER > 1.0, with 2/10 CHF and 5/7 controls reaching values > 1.15 in both tests, 
indicating that near-maximal, if not maximal, effort was achieved.   Table 4.2 displays 
the data for the two standard tests for all participants (n=16).  Using the simple goal 
that test 2 should differ by no more than 10% to test 1, table 4.1 shows that all variables 
met this criteria. However, in test 2 VO2peak increased in 79% participants (increase > 
10% in half of these), whereas it remained the same, or decreased slightly, in 21% 
participants. 
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Table 4.2: Mean ± SEM data for CHF and Controls for standard test 1 and test 2.  Mean values ± 10% different to test 1 are also 
shown. 
 
 VO2 peak (ml.kg-1.min-1) 
VT 
(ml.kg-1.min-1) 
RCP 
(ml.kg-1.min-1) 
ΔVO2/ΔWR 
(ml.min-1.W-1) 
VE/VCO2slope 
 
WRpeak 
(W) 
HRpeak 
(beats.min-1) 
Test 1 16.6  ± 1.7 10.8 ± 0.9 15.6 ± 1.5 9.2 ± 0.6 29.9 ± 1.3 106 ± 12 117 ± 8 
Test 2 17.9  ± 1.7* 10.8 ± 0.8 15.6 ± 1.6 9.4 ± 0.5 30.3 ± 1.4 112 ± 13* 120 ± 8* 
Test 1 ± 10% 15.3 – 18.7 9.59 – 11.72 14.4 – 17.54 8.3 – 10.2 26.9 – 32.8 93 - 114 105 - 128 
* Test 1 and Test 2 significantly different (P < 0.05) 
 
Table 4.3: Reproducibility data and confidence intervals (CI) for CHF and Controls for standard tests 1 and 2. 
 
 
 
VO2peak  
(ml.kg-1.min-1) 
VT 
(ml.kg-1.min-1) 
RCP 
(ml.kg-1.min-1) 
ΔVO2/ΔWR 
 (ml.min-1.W-1)        
VE/VCO2  
slope 
WRpeak 
(W) 
HRpeak 
beats. min-1 
ICC values 0.97 0.96 0.98 0.58 0.80 0.99 0.99 
(CI) (0.93-0.99)  (0.89-0.98) (0.95-0.99) (0.12-0.84) (0.53-0.93) (0.97-0.99) (0.96-0.99) 
LOA bias 1.57  0.00 0.27  0.18 0.44 6  3  
random error 1.88  1.02  1.33  1.64  2.99 8  5  
(CI) (-2.12-5.26) (-2.00-1.99) (-2.34-2.88) (-3.04-3.39) (-5.4-6.3) (9-21) (-7-13) 
88 
 
 
 
The relationships between cardiopulmonary variables in standard tests 1 and 2 are 
illustrated in Figures 4.5 – 4.7.   
 
Figure 4.5: Reproducibility of VO2peak in standard tests 1 and 2 
 
 
Figure 4.6: Reproducibility of VO2 at VT in standard tests 1 and 2 
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Figure 4.7: Reproducibility of VO2 at RCP in standard tests 1 and 2 
There was no relation between the error (difference) and the size of the measured value 
(mean), (i.e. the data was homoscedastic), and thus the reliability was assessed using 
the 95% absolute LOA (Figure 4.8).  The results of the tests for reproducibility are 
shown in Table 4.3, and indicate high reproducibility for VO2 at VT and RCP, and for 
WRpeak and HRpeak, with ICC values ≥ 0.96, and low systematic bias (change in the 
mean) and random error (standard deviation of the mean difference). Nine participants 
reached the same WRpeak in test 2, while 7 participants increased WRpeak by 10-20W. 
Although the ICC for VO2peak was high (0.97), there was a 9% increase in the mean (CI 
3 – 15%) in test 2 and the systematic bias and random error were higher than for VO2 at 
VT and RCP, indicating lower reproducibility.  ICC was low (0.58) for ΔVO2/ΔWR, 
theefore it was decided that method b should be used to calculate work rate at the 
different thresholds.  The systematic bias and random error for work rate at VT and 
RCP were - 1 ± 6W and 2 ± 12W, giving 95% absolute LOA of between -13 and 11W 
for VT and between -21 and 25W for RCP. 
  
y = 1.0683x - 1.0535
R2 = 0.982
y = 0.7273x + 6.3009
R2 = 0.8275
5.0
10.0
15.0
20.0
25.0
30.0
5.0 10.0 15.0 20.0 25.0 30.0
Te
st
 2
 V
O
2
at
 R
C
P 
(m
l.k
g-
1 .m
in
-1
)
Test 1 VO2 at RCP (ml.kg-1.min-1)
CHF
Control
line of identity
90 
 
 
 
A  
 
B 
Figure 4.8: Bland and Altman plots of the absolute differences (test 2–test 1) in 
VO2peak (A) and WRpeak (B) versus mean differences in the standard tests  
(CHF closed circles, Control open circles). 
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D 
Figure 4.9: Bland and Altman plots of the absolute differences (test 2–test 1) in 
VO2 at VT (C) and VO2 at RCP (D) versus mean differences in the standard tests  
(CHF closed circles, Control open circles). 
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4.2.1.1 Reproducibility of standard test for CHF patients 
Paired t-tests revealed no significant differences in VO2 at VT o r RCP,  ΔVO2/ΔWR, 
VE/VCO2 slope, WRpeak or HRpeak between test 1 and test 2 (P > 0.05), but VO2peak was 
significantly higher in test 2 (P = 0.026).  Table 4.4 displays the data for the two 
standard tests for CHF patients.  Using the simple goal that test 2 should differ by no 
more than 10% to test 1, table 4.4 shows that all variables met this criteria in CHF. 
The differences between test 1 and 2 were normally distributed for all variables, and 
thus the reproducibility was assessed using the 95% absolute LOA (Figure 4.9). The 
results are displayed in Table 4.5.   As with the combined CHF and control data, VO2 at 
VT and RCP, WRpeak and HRpeak showed high reproducibility, but VO2peak was less 
reproducible, and increased between the 1st and 2nd
  
 tests.  Similarly, ΔVO2/ΔWR and 
VE/VCO2 slope also showed poor reproducibility. Work rate at VT and RCP varied 
between tests to a similar extent as in the whole group data. The systematic bias and 
random error for work rate at VT and RCP were 3 ± 5W and 4 ± 11W, giving 95% 
absolute LOA of between -13 and 7W for VT and between -18 and 27W for RCP.  
 
93 
 
 
 
Table 4.4: Mean (± SEM) data for CHF for standard test 1 and test 2.  Mean values ± 10% different to test 1 are also shown. 
 
 VO2 peak (ml.kg-1.min-1) 
VT 
(ml.kg-1.min-1) 
RCP 
(ml.kg-1.min-1) 
ΔVO2/ΔWR 
(ml.min-1.W-1) 
VE/VCO2slope 
 
WRpeak 
(W) 
HRpeak 
(beats.min-1) 
Test 1 13.6 ± 1.5 9.2 ± 0.9 13.2 ± 1.7 9.2 ± 0.8 31.2 ± 1.1 82 ± 8  100 ± 6 
Test 2 14.8 ± 1.5 * 9.0 ± 0.8 13.1 ± 1.9 9.1 ± 0.7 32.7 ±1.3  88 ± 10 104 ± 5 
Test 1 ± 10% 12.2 – 15.0 8.3 – 10.1 11.9 – 14.5 8.3 –  10.1 28.0 – 34.3 74 – 90 90 –  110 
* Test 1 and Test 2 significantly different (P ≤ 0.05) 
       
Table 4.5: Reproducibility data and confidence intervals (CI) for CHF for standard test 1 and test 2. 
 
 
 
VO2peak  
(ml.kg-1.min-1) 
VT 
(ml.kg-1.min-1) 
RCP 
(ml.kg-1.min-1) 
ΔVO2/ΔWR 
 (ml.min-1.W-1)        
VE/VCO2  
slope 
WRpeak 
(W) 
HRpeak 
beats. min-1 
ICC values 0.96 0.93 0.99 0.59 0.67 0.96 0.96 
(CI) (0.87-0.99)  (0.75-0.98) (0.94-0.99) (0.05-0.88) (0.08-0.91) (0.87-0.99) (0.84-0.99) 
LOA bias 1.13 0.19 0.16 -0.15 1.56 6 4  
random error 1.25 1.05 0.74 1.82      2.79 9 5  
(CI) (-1.32-3.59) (-2.24-1.86) (-1.60-1.28) (-3.72-3.42) (-3.92-7.03) (11-23) (-6-13) 
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4.2.2 Reproducibility of steep test 
Table 4.6 displays the steep test data for CHF and controls together, and CHF alone. 
No significant differences were found (P > 0.05).  Mean peak RER was  0.98 ± 0.02 in 
CHF and 1.08 ± 0.08 in controls. 
Table 4.6: Mean ± SEM data for CHF and controls for steep test 1 and test 2. 
Mean values ± 10% different to test 1 are also shown. 
  
 
CHF and controls CHF  
VO2 peak  
(ml.kg-1.min-1) WRpeak (W) 
VO2 peak  
(ml.kg-1.min-1) WRpeak (W) 
Test 1 18.6 ± 1.7 207 ± 15 14.2 ± 1.6 188 ± 17 
Test 2 18.7 ± 1.5 210 ± 16 15.2 ± 1.0 193 ± 18 
Test 1 ± 10% 16.7 – 20.5 186 - 228 12.8 – 15.6 169 - 207 
 
The relationships between peak values in steep tests 1 and 2 are illustrated in Figures 
4.9 - 4.10. The differences between test 1 and 2 were normally distributed for all 
variables and therefore the reproducibility was assessed using the 95% absolute LOA 
(Figure 4.11).  Reproducibility data for CHF and controls together, and CHF alone, are 
displayed in Table 4.7.  VO2peak was less reproducible than in the standard test, in the 
whole group and in CHF patients in particular.  Although the systematic bias was 
smaller, the random error, and thus the 95 % absolute LOA, was greater (All: -4.07 – 
5.37 ml.kg-1.min-1; CHF: -4.77 – 6.88 ml.kg-1.min-1
Table 4.7: Reproducibility data and confidence intervals (CI) for CHF and 
controls for steep test 1 and test 2. 
).  The 95% absolute LOA of 
WRpeak in the steep test were similar in CHF and controls together, and CHF alone. 
These values are higher than in the standard test, reflecting the greater increments in 
work rate in the steep test.   
 CHF and Controls CHF  
 VO2peak  
(ml.kg-1.min-1) WRpeak (W) 
VO2peak  
(ml.kg-1.min-1) WRpeak (W) 
ICC values 0.92 0.93 0.74 0.93 
(CI) (0.82-0.97) (0.84-0.97) (0.27-0.92) (0.84-0.98) 
LOA bias 0.65 - 0.96 3 5 
random error 2.41 23 2.92 20 
(CI) (-4.07-5.37) (-43 – 48) (-4.77-6.88) (-34-44) 
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Figure 4.9: Reproducibility of VO2peak in steep tests 1 and 2 
 
 
Figure 4.10: Reproducibility of peak work rate in steep tests 1 and 2 
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A 
 B 
Figure 4.11: Bland and Altman plots of the absolute differences (test 2 – test 1) in 
VO2peak (A) and WRpeak (B) versus mean differences in the steep test  
(CHF closed circles, Control open circles).  
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4.2.3 Comparison of intermittent exercise intensity derived from standard and 
steep tests 
Mean intermittent exercise workload derived from the steep test (WRpeak/2) was 105 ± 
32 W (STEEP).  This was significantly higher than the workload for MED derived 
from the standard test (90 ± 38 W, P = 0.009), but not significantly different from the 
intensity for HIGH (111 ± 45 W, P = 0.891).  However, when the workloads for the 
CHF and control groups were calculated separately, there were differences between the 
2 groups. The data are displayed in Table 4.8, and show that there was no significant 
difference between STEEP and MED in Controls, or STEEP and HIGH in CHF.  In 
70% CHF patients STEEP work rate was higher than HIGH work rate, whereas in all 
controls STEEP work rate was lower than HIGH work rate by 10-40 W.   
 
Table 4.8: Intermittent exercise workloads derived from the standard test (LOW, 
MED, HIGH) and the steep test (STEEP) (mean ± SEM).   
 
Intermittent  
Protocol 
CHF  
Work Rate (W) 
Control 
Work Rate (W) 
LOW  54 ± 8 * 81 ± 10 * 
MED  72 ± 10 * 116 ± 13  
HIGH  88 ± 10   141 ± 16 * 
STEEP 96 ± 9 118 ± 13 
*significantly different to STEEP  
 
In controls the steep test WRpeak was 156 ± 6% of the standard test WRpeak.  In CHF the 
steep test WRpeak was 227 ± 12% of the standard test WRpeak (Figure 4.12)  The 
difference between the steep and standard tests was significantly greater in CHF than in 
controls (P < 0.01).   
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Figure 4.12: Percentage of standard rampVO2peak and WRpeak reached in the steep 
test in CHF and controls.   
** P < 0.01: CHF significantly different to control 
 
4.2.4 Comparison of VO2peak in standard and steep tests  
VO2peak in the steep test reached 100 ± 4 % of the standard test value in CHF, and 91 ± 
5 % in controls, and there was no significant difference between tests (P > 0.05) (Figure 
4.12). Correlation between VO2peak in the standard and steep tests was high for CHF (r 
= 0.90), and slightly lower for controls (r = 0.84) (Figure 4.13).  However, the bias and 
random error for VO2peak in all participants was 1.17 ± 2.64 ml.kg-1.min-1, giving 95% 
absolute LOA of -4.00 to 6.34 ml.kg-1.min-1.  The bias and random error for CHF was 
0.45 ± 2.30 ml.kg-1.min-1, thus the steep test may overestimate the standard test by 4.96 
ml.kg.min-1 and underestimate by 4.06 ml.kg.min-1 (Figure 4.14).  However, in 7 of the 
10 CHF, the difference in VO2peak was ≤ 1.4 ml.kg-1.min-1
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Figure 4.13: Correlation between VO2peak in the standard and steep tests, with line 
of identity 
 
Figure 4.14: Bland and Altman plots of the absolute differences in VO2peak versus 
the mean differences in the standard and steep tests   
(CHF closed circles, Control open circles).  
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4.3 Discussion 
The primary aim of this study was to examine the reproducibility of cardiopulmonary 
variables and derived exercise workloads from (a) a standard test and (b) a steep test in 
CHF patients and age-matched controls.   
4.3.1 Reproducibility of standard test 
There were no significant differences in VO2 at VT or RCP, or in ∆VO2/∆WR or 
VE/VCO2 slope between test 1 and test 2, whereas VO2peak, WRpeak and HRpeak were all 
significantly higher in test 2.  These results suggest that there is a learning effect on 
peak values, whereas sub-maximal measures are not affected.  However, although the  
t-test detects statistically significant bias between the tests, it is not useful on its own as 
large amounts of random error mean that systematic bias is less likely to be detected 
(Atkinson and Nevill, 1998).  The ICC is sensitive to the presence of systematic bias, 
and values, including CI, for VO2peak, VO2 at VT and RCP, WRpeak and HRpeak were all 
> .9, indicating reproducibility in the repeat measurements.  Nevertheless, ICC is still 
affected by heterogeneity (range of values in the sample), and thus a high ICC might 
still mean an unacceptable measurement error.  Bland and Altman’s LOA assume a 
population of individual test-retest differences, and are therefore a better measure of 
absolute reliability.  The 95% LOA indicate that, in a population of CHF and age-
matched controls, a repeat measurement of VO2peak  could be lower by 2.12 ml.kg-1.min-
1 or higher by 5.26 ml.kg-1.min-1.  The LOA for CHF patients alone were smaller; for 
an initial VO2peak value of 14.0 ml.kg-1.min-1, a repeat measurement might lie between 
12.7 and 17.6 ml.kg-1.min-1
VO2 at VT and RCP were less variable than VO2peak between the 2 tests, with a 
systematic bias of 0% and +2% respectively, and a random error of 9% for both 
variables.  In CHF for an initial VT value of 9.0 ml.kg
.  WRpeak is likely to be higher by 9-21W in the whole 
group, or 11-23W in CHF alone. This has implications for the usefulness of using 
VO2peak and WRpeak to accurately assess improvements in exercise capacity following a 
therapeutic intervention.   
-1.min-1, a repeat measurement 
will lie between 6.8 and 10.9 ml.kg-1.min-1 in 95% of cases, and for an initial RCP 
value of 13.0 ml.kg-1.min-1, a repeat measurement will lie between 11.4 and 14.3  
ml.kg-1.min-1.  These values might show greater reproducibility than peak values, but 
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still represent substantial alterations in exercise intensity between repeat tests in this 
population.  However, LOA present the “worst scenario” individual difference 
(Atkinson and Nevill, 2007) and  may be too large as a reference range for making a 
decision about a change in a subject's measurements (Hopkins, 2000b).  The results 
from test 2 were < 10% different to test 1, thus fulfilling the American Heart 
Association recommendation that values should vary by less than 10% on separate days 
to be considered reproducible  (Fleg et al., 2000).   
Comparison with previous studies is limited by different methodologies and statistical 
analyses.  Table 4.9 shows the results of this study in comparison to those of previous 
authors, who concluded that reproducibility of VO2 at VT and at peak exercise was 
high.  Apart from the values from Cohen-Solal et al (1991), the results of the current 
study are similar to previous studies, although the standard deviation from the mean 
value is higher.  No studies have reported the reproducibility of RCP or ΔVO2/ΔWR. 
 
Table 4.9: Reported values for VO2 at ventilatory threshold and at peak exercise 
during repeated cycle ergometer tests in CHF patients (mean ± SD). 
 
Authors VO2 at VT (ml.kg-1.min-1) VO2peak (ml.kg-1.min-1) 
 Test 1 Test 2 Test 1 Test 2 
Cohen-Solal et al (1991) n=25/29 14.3 ± 4.6 15.3 ± 5.1 20.9 ± 6.3 20.9 ± 6.9 
Simonton et al (1988) n=15 8 ± 2 9 ± 2 13 ± 3 14 ± 2 
Marburger et al (1998) n=9 10.7 ± 1.7 11.3 ± 2.1 16.2 ± 3.4 16.7 ± 3.5 
Meyer et al (1997b) n=11 10.8 ± 1.5 10.4 ± 1.5 14.1 ± 3.1 13.8 ± 3.0 
Current study n=9 9.1 ± 2.8 8.9 ± 2.3 13.7 ± 4.4 14.8 ± 4.5 
 
Cohen-Solal et al (1991) reported that variations in VT and VO2peak values between two 
consecutive exercise tests < 8 days apart were low enough to allow repeated evaluation 
of functional capacity in CHF (Cohen-Solal et al., 1991).  The 29 patients in their study 
were younger (30-76 years), had greater functional capacity (mean VO2peak 21 ml.kg-
1.min-1) than the patients in this study, and were already familiar with cycle ergometer 
exercise testing. Using the same 10 W.min-1 incremental protocol, they reported no 
systematic bias in VO2peak, and a random error of 2.6 ml.kg-1.min-1.  Based on this data, 
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and assuming that the values are homoscedastic, the 95% absolute LOA for VO2peak  
would be -5 and 5 ml.kg-1.min-1, i.e an upper confidence limit > 1 ml.kg-1.min-1 greater 
and a lower confidence limit > 3 ml.kg-1.min-1 greater than in this study. VT was 
determined using the point at which VE increases disproportionately to VO2 and the 
first crossing of the VO2 and VCO2 curves, when RER = 1.  These methods are less 
reproducible than the V-slope method because ventilation is influenced by numerous 
factors, and VT is difficult to detect from RER (Meyer et al., 2005b). Systematic bias 
and random error were 1 ± 2.4 and 0.8 ± 2.3 ml.kg-1.min-1 respectively, giving absolute 
LOA of -3.7 and 5.7, and -3.7 and 5.3 ml.kg-1.min-1. Once again, the results indicate 
that VT, as determined by their methods, showed lower reproducibility than in CHF 
patients in this study.   
In the same way, the raw data have been taken from a small study (n=9) which 
examined the reproducibility of CPET in CHF patients > 65 years who had previously 
undertaken a familiarisation test.  (Marburger et al., 1998). The resulting bias and 
random error for VO2peak and VT have been calculated as 0.52 ± 1.39 and 0.62 ± 1.32 
ml.kg-1.min-1 respectively, giving 95% absolute LOA of -2.21 and 3.24, and -1.97 and 
3.20 ml.kg-1.min-1, similar to the values in this study.   
Meyer et al (1997) reported high short-term reproducibility of sub-maximal and 
maximal cycle ergometry exercise data in 11 patients with severe CHF, using the error 
of the standard deviation (SD) [√(∑d 2/2n)].  The error of SD was 0.2 ml.kg-1.min-1 for 
VO2 at VT, and 0.6 ml.kg-1.min-1 for VO2peak (Meyer et al., 1997c). Using the same 
calculation, the data from this study show a higher error of SD for VO2peak (4.16 ml.kg-
1.min-1 for the whole group, and 2.4 ml.kg-1.min-1 for the CHF group alone), but similar 
values for VO2 at VT (0.01 ml.kg-1.min-1 for the whole group, and 0.4 ml.kg-1.min-1 for 
the CHF group alone).  HRpeak and WRpeak in the current study were also higher (8 
beats.min-1 and 13 W) than the values in Meyer et al's study (2 beats. min-1 and work 
rate 3 W).  This could be explained by the more homogenous patient sample in Meyer 
et al’s study, or by the fact that patients were familiar with the exercise testing 
procedure and equipment from two previous exercise tests, whereas patients in the 
current study showed a learning effect by achieving higher maximal values in the 2nd 
test.  Sub-maximal values were similar, possibly because moderate intensity exercise 
values are less affected by familiarisation.  
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Simonton et al (1988) studied the reproducibility of VT and VO2peak in 18 men with 
CHF (mean age 60 ± 5 years). VT was determined using two of the same methods as in 
this study, i.e. ventilatory equivalents and end tidal partial pressures, in addition to a 
non-linear increase in VE and in RER. The ventilatory equivalent method was reported 
to be the most reproducible, and identified VT in 15 of the 18 patients. The authors 
reported that day to day reproducibility of VT (r = 0.91, SEE 1.74 ml.kg-1.min-1) was 
higher than that of VO2peak (r = 0.95, SEE 3.31 ml.kg-1.min-1), but acknowledged that a 
day-to-day variation of 3.48 ml.kg-1.min-1 in VO2 at VT represents a significant 
alteration, and this degree of variability may prevent assessment of small changes in 
individuals (Simonton et al., 1988). Equally, the variations of 6.62 ml.kg-1.min-
1 reported 
The values for ΔVO2/ΔWR, a measure of exercise economy, were in the normal range 
(8.3 – 12.3 ml. min
in VO2peak would preclude its usefulness in assessing changes in functional 
capacity following an intervention.    
An additional issue is the intra-observer variability in the measurement of VT, which 
has been reported as 5-10% (Myers et al., 2010).  This means that a given VT might 
vary by this magnitude if the same exercise test data are evaluated by the same 
reviewer on a different day.  The variability increases to 20-27% when different 
reviewers are involved in VT measurement.     
-1.W-1
peak 2OV
), but showed poor retest reproducibility.  This might be 
explained by fluctuations in exercise economy due to poor technique or fatigue, by the 
biological variability in respiratory variables or irregular breathing due to discomfort 
from the face mask, or the oscillatory ventilation reported in some CHF patients (Corra 
et al., 2002). Although none of the patients met the criteria for exercise oscillatory 
breathing (cyclic fluctuations in VE persisting for ≥ 60% of  ex ercise duration with an 
amplitude ≥ 15% cyclic fluctuations at rest) defined by Corra et al (2002), smaller 
fluctuations could still affect the ventilatory measurements. Consequently, when linear 
regression of VO2 versus work rate (method a) is used to calculate WRpeak at VT, RCP 
and VO2peak, errors may be magnified.  Although reproducibility is higher in method b 
(the work rate corresponding to the stage at which VT, RCP and were 
identified, minus 2/3 of the ramp rate), it may not be appropriate to use 2/3 ramp rate to 
compensate for the lag in VO2 uptake in a CHF population, in whom VO2 kinetics are 
reportedly slowed (Meyer et al., 1998b). Other studies have reported that VO2 kinetics 
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during incremental exercise are normal, but slower during recovery (Picozzi et al., 
1999), and are influenced by training (Roditis et al., 2007), indicating the difficulty of 
controlling for the time lag in this population.   
VE/VCO2 slope, a measure of ventilatory efficiency, and a prognostic marker in CHF, 
reportedly has a high reproducibility (CV 6.2%, r = 0.93) (Chua et al., 1997).  
However, the measure showed poor retest reproducibility in this study, although the 
values were within the normal range for the CHF population.  The difference in 
VE/VCO2 slope between repeat tests was > 2 in all but one control participant and in 5 
out of 8 CHF.  As with the ΔVO2/ΔWR measurement, this could be due to irregularity 
in breathing patterns.  As the VE/VCO2 slope is recognised as a valuable prognostic 
marker in CHF (Ingle, 2007), the issue of its reproducibility merits further 
investigation.   
Recently published data from the HF-ACTION trial suggests that there is substantial 
within-subject variability in repeated tests in VO2peak, VO2 at VT and VE/VCO2 slope 
(Bensimhon et al., 2008).  Approximately half of the patients increased and half 
decreased their VO2peak and VT on the second test, suggesting that the variation was 
more likely to be due to daily haemodynamic and volume status fluctuations, rather 
than a learning effect.  By contrast, in the current study VO2peak increased in 79% 
participants in the second test, whereas it did not change, or decreased slightly in 21%, 
indicating that there does appear to be a learning effect on maximal values.  The HF-
ACTION trial conducted tests at 83 different clinical sites, therefore variations in 
testing conditions are likely to have influenced the results.  In addition, only 12% of the 
398 participants performed cycle ergometer rather than treadmill tests, hence the 
findings may not apply to cycle ergometry.  Additional methodological differences to 
the current study, including determination of the VE/VCO2 slope from the whole of the 
exercise test data, rather than from the linear part of the slope, add to the difficulty of 
relating the results of the two studies to one another.   
Consideration should also be given to the effect of β-blockers which are currently 
standard medical therapy in CHF (National Collaborating Centre for Chronic 
Conditions, 2003).  The timing of the β-blocker  dose will influence it’s effect on HR, 
and although patients were instructed to take their medication at the same time on both 
testing days, variations in timing could have affected the results (Whellan et al., 2007).  
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Although β-blockade in CHF reduces HR, reflected by the reduced HRpeak in patients 
compared with age-predicted HRmax and HRpeak in controls, it does not appear to reduce 
VO2peak (Witte et al., 2005).  Chronotropic incompetence also occurs in patients not 
taking β-blockers (Witte et al., 2006), although this was not seen in the one patient in 
this study who did not tolerate  β-blockers.  Anti-arrhythmic medication may also 
reduce HR, but there is little information about the extent of this effect (British 
Association for Cardiac Rehabilitation, 2006).   
4.3.2 Reproducibility of steep test 
There was a smaller bias in VO2peak in the steep test but a larger random error than in 
the standard test, both in the whole group and in CHF patients alone.  The 95% LOA 
showed that a repeat measurement might vary from -4.77 to 6.88 ml.kg-1.min-1 in CHF. 
This lack of reproducibility is not surprising, given the large and rapid increases in 
workload in this protocol, whose aim is to measure the work rate achievable rather than 
VO2.  It is the reproducibility of WRpeak, from which intermittent exercise workloads 
are calculated, which is more important.    The 95% LOA were high (-43 to 48 W for 
the whole group, or -34 to 44 W for CHF), but this is partly due to the large increments 
in workload between stages. Figure 6 shows that 7 out of 10 CHF but only 2 of the 7 
controls reached the same WRpeak in test 2 as in test 1. The remainder had a difference 
in WRpeak of one or two test stages, i.e. 25 or 50 W, which translates to an increase in 
intermittent training workload of 12.5 or 25 W, potentially a substantial increase for 
CHF patients with a low initial WRpeak.  This would add an extra 4875 - 9750 J to the 
total workload of a 20 min intermittent training session with 13 x 30s work bouts.  
However, studies using the steep test to set exercise workloads generally repeat the test 
weekly in order to readjust the intermittent work rates, and to allow training 
progression, which would resolve this issue (Meyer et al., 1997b; Vogiatzis et al., 2002; 
Puhan et al., 2004). Nevertheless, it does perhaps illustrate the difficulty of determining 
precise training workloads in this population.  The advantages of the steep test are that 
it requires less equipment, time and effort, both from the exercise professional and the 
patient, and it can be performed weekly to adjust the training load in line with patient 
progress.  
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4.3.3 Comparison of intermittent exercise intensity derived from standard and 
steep tests 
A secondary aim of the current study was to compare the exercise training workloads 
derived from a standard and steep test in CHF patients and healthy control participants. 
The work rates for the continuous and intermittent exercise bouts were set according to 
exercise intensity domain framework  (Section 2.6.4.4).    VT and RCP occurred at 62 ± 
9% and 84 ± 6 % of VO2peak in CHF, and 54 ± 6% and 82 ± 6 % in controls.  In a small 
study of healthy younger individuals, VT and RCP occurred at 62% and 90% VO2max 
respectively (Lonsdorfer-Wolf et al., 2003). Normative values for the percentage of 
VO2peak at which the VT will occur for men and women aged 70 years are 58% and 
65% respectively, but it is well known that there is considerable variability in both 
healthy and diseased populations (Wasserman et al., 2005).  As discussed previously, 
mean VT in CHF has been reported to occur at 64-75% of VO2peak (Simonton et al., 
1988; Cohen-Solal et al., 1990; Meyer et al., 1997c; Marburger et al., 1998).  In this 
study, in CHF there was a mean (± SD) difference of 27 ± 20 W between the moderate 
and heavy, and 24 ± 9 W between the heavy and severe domains, whereas in controls 
the mean differences were 42 ± 20 and 40 ± 22 W respectively. The work rates 
delineating the exercise intensity domains for CHF and controls are shown in Figure 
4.15 (RCP could not be clearly identified in 3 CHF and 1 control).  This highlights the 
difficulty of accurately prescribing exercise work rates in individual intensity domains 
in CHF, where the range in work rate in each domain is very narrow, and the test-retest 
variability is relatively high (95% absolute LOA for work rates at VT:  -13W to 7W; 
RCP: -18W to 27W; VO2peak 11W to 23 W).   
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Figure 4.15: Exercise intensity domains for CHF (n=7) and Controls (n=6) 
 
The intermittent work rates, determined from the results of the 2nd standard test, were 
compared to those derived according to the protocol of Meyer et al. (1997), i.e. 50% of 
WRpeak achieved in the 2nd
It is surprising that similar mean VO2peak values were achieved in the standard and steep 
tests. Meyer (1997) reported that VO2peak in the steep test reached only 87% of the 
value attained in the standard test.  In the current study, there was no statistically 
significant difference between VO2peak in the two tests in either the whole group or in 
 steep test.  For CHF and controls combined, work rate was 
similar in STEEP (105 ± 8W) and HIGH (111 ± 11W), but there were interesting 
differences between the 2 groups.  In controls, STEEP (118 ± 13W) was closest to 
MED (116 ± 13W), whereas in CHF, STEEP (96 ± 9W) was closest to HIGH (90 ± 
11W).   This was because the WRpeak reached by the majority (7/10) of CHF in the 
steep test was more than double that in the standard test, whereas in controls it was only 
35 - 80% higher.  This suggests that CHF are less limited by their symptoms in short 
duration high intensity exercise.  In a standard maximal exercise test a reduced exercise 
capacity in CHF is associated with an increased ratio of type II to type I fibres and 
decreased oxidative capacity (Drexler et al., 1992), but these factors are less likely to 
influence performance in the shorter steep test.  The results in controls were similar to 
those reported in younger cancer patients, where steep test WRpeak was 61% higher than 
standard test WRpeak (De Backer et al., 2007).   
MODERATE 
HEAVY                       42 ± 13 W     59 ± 17 W 
SEVERE                      69 ± 29 W    101 ± 32 W    
EXTREME                  93 ± 28 W     141 ± 48 W  
VT 
RCP 
VO2peak 
Exercise Intensity            CHF            Controls 
Domain (mean ± SD)   
 
108 
 
 
 
CHF patients, although controls reached only 91% of standard test VO2peak, compared 
to 100% in CHF.  This suggests that it may be possible to measure VO2peak using a 
steep test rather than a standard test.  However, the 95% LOA were unacceptably large 
(All: -4 to 6.34 ml.kg-1.min-1; CHF -4.96 to 4.06 ml.kg-1.min-1), showing that the steep 
test cannot reliably be used to assess VO2peak in either population. Interestingly, 
controls and less severe CHF tended to reach higher values in the standard ramp, 
whereas de-conditioned, or more severe CHF attained similar or higher peak values in 
the steep test (difference ≤ ± 1.4 ml.kg -1.min-1 in 70% patients). With increasing 
severity of heart failure, cardiac output response and oxygen delivery to the exercising 
muscles are increasingly reduced, and peripheral abnormalities reduce aerobic capacity 
further (Wilson et al., 1996; Tavazzi et al., 2001). Thus it is perhaps not surprising that 
these patients show greater limitations during the longer test which imposes a more 
prolonged stress on the aerobic energy system than the shorter test.   
The steep test has previously been evaluated as a substitute for maximal CPET to 
prescribe intermittent training and to monitor the effects of this training in cancer 
patients (De Backer et al., 2007).  The authors reported a high correlation between 
standard and steep test WRpeak, and similar improvements in both tests following a 
training intervention.  Although LOA between tests was not reported, the prediction 
error from regression analysis to predict standard test WRpeak and VO2peak from the 
steep test was 53 W and 616 ml.min-1 (~ 8 ml.kg.-1min-1
The standardised test order, in which the steep test was performed 1 hour after the 
standard test, may have influenced the results.  In younger healthy individuals prior 
heavy exercise appears to have a “priming effect” on VO2 kinetics during subsequent 
heavy exercise, although this effect is no longer apparent after 1 hour of recovery 
(Burnley et al., 2006).  Hence a 1 hour recovery period has previously been used in our 
laboratories for healthy individuals because Lac and gas exchange parameters to return 
to resting levels in this time.  In CHF, repeated testing with a fixed test order and a 
recovery period of 90 minutes has been used with no apparent influence on maximal 
exercise performance (Kim et al., 1999).  Furthermore, elderly individuals who 
performed 2 exercise tests per day for 3 consecutive days, also in a standardised order, 
) respectively.  These findings 
agree with the current study in suggesting that although the steep test might be a useful 
practical tool to guide interval training intensity, it is no substitute for the standard test 
for assessment of VO2peak.   
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achieved their best 6 min walk test score on their final test, despite having performed a 
maximal cardiopulmonary exercise test earlier that same day (Kervio et al., 2003).   
4.4 Conclusion 
This chapter investigated the reproducibility of physiological parameters measured in 
duplicate standard and steep incremental cycle ergometer tests in terms of statistical 
significance, re-test correlation and LOA,  and  a 10% difference between tests.  Peak 
measures showed poor reproducibility in terms of statistical significance and LOA, and 
the positive bias of 1.57 ml.kg-1.min-1
The results of this study reinforce the recommendation that a practice test should be 
performed in advance of a maximal CPET in CHF and in older individuals.  Sub-
maximal measures, which are less dependent on subject motivation, are more 
reproducible than peak measures, but are still prone to within-subject variation between 
tests.  Consequently, it is difficult to accurately define exercise intensity domains via 
this method.  Derived variables such as ΔVO2/ΔWR and VE/VCO2 slope are less 
reproducible, and changes in these measurements following exercise or medical 
interventions should be interpreted with caution.  However, some of this variability 
may be eliminated when patients are more familiar with the equipment and testing 
procedure.   It remains difficult to judge to what extent the within-subject variability 
will limit the usefulness of cardiopulmonary exercise test results in assessing the 
effectiveness of an intervention.    A limitation of this study is the inability to control 
patients’ symptom status between tests. Equally, defining a change in patient disease or 
symptom status is difficult, and there is no agreed criterion standard (Spertus et al., 
 in VO2peak between the first and second test 
suggests that there is a learning effect.  Although the re-test correlation was high, and 
the difference between tests was < 10%, the finding that ~80% participants increased 
their VO2peak in the second test reinforces the likelihood of a learning effect.  Sub-
maximal measures showed good reproducibility in terms of statistical significance, re-
test correlation and a < 10% difference between the first and second test, but poor 
reproducibility in terms of LOA.  However, the bias was smaller, and participants were 
as likely to show a decrease as an increase in values, suggesting that variations were 
not due to a learning effect.  
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2005).  Day-to-day variation in fatigue, breathlessness or general well-being is 
inevitable, and this may have influenced the results.    
This chapter also compared methods for setting intermittent exercise intensity. The 
hypothesis that workloads derived from the two methods would differ is supported in 
controls, but not in CHF. In controls, workloads set at 50% steep test WRpeak were 
significantly lower than those set by the traditional method (100% standard test 
WRpeak), whereas in  CHF there was no difference in workload between the two 
methods.   
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CHAPTER 5: ACUTE RESPONSES TO 
CONTINUOUS AND INTERMITTENT EXERCISE 
IN CHF AND HEALTHY CONTROLS 
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5.0 Introduction 
Exercise training is beneficial for CHF, but the optimal type of training is less clear. 
Numerous studies have demonstrated the benefits of continuous moderate exercise 
training for patients in New York Heart Association (NYHA) Class II and III 
(Giannuzzi et al., 2001; Piepoli et al., 2004; Rees et al., 2004), and some studies have 
reported that intermittent exercise is also an effective mode of training in this 
population (Meyer et al., 1997b; Dimopoulos et al., 2006; Roditis et al., 2007).   
However, many CHF experience fatigue and dyspnoea on exertion, and find it difficult 
to sustain exercise beyond a short duration.  In healthy individuals, exercising 
intermittently rather than continuously significantly prolongs the amount of work 
achieved before exhaustion (Astrand et al, 2003; Christensen et al, 1960).  In non-
clinical populations, intermittent exercise achieves a similar (Eddy et al, 1977; Poole 
and Gaesser, 1985; Cunningham et al, 1979), or greater (Gorostiaga et al., 1991; Tabata 
et al., 1996; Daussin et al., 2008)  training adaptation than continuous exercise of an 
equal total workload.  Intermittent exercise may therefore be an appropriate exercise 
mode for populations who find it difficult to perform continuous exercise, and may 
allow for a higher training stimulus.  In healthy individuals, exercise capacity is 
ultimately limited by oxygen delivery (Bassett and Howley, 2000), whereas peripheral 
limitations appear to be the main determinant of exercise capacity in CHF (Clark et al, 
1996; Foster al at, 2004). The increased exercise capacity following training is 
primarily due to peripheral rather than central adaptations in this population.  CHF with 
a very low exercise capacity may not be able to achieve continuous endurance training 
workloads high enough to have an optimal training effect on the peripheral muscles, 
and compensating for low exercise intensities by increasing the duration of exercise is 
likely to be limited by premature fatigue (Meyer et al, 1997).  By alternating short 
intervals of exercise with recovery periods, CHF can theoretically work at a higher 
intensity and/or achieve a greater total workload than from continuous exercise, while 
minimizing cardiac stress but optimising the peripheral training effect.    
Intermittent exercise may also allow patients to achieve greater benefits than 
continuous exercise for a smaller amount of exercise training.  In coronary bypass 
surgery rehabilitation, intermittent exercise training resulted in a greater increase in 
aerobic capacity, and decrease in HR, rate pressure product (RPP) and lactate at sub-
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maximal work rates than continuous exercise despite the fact that the total amount of 
work performed was significantly lower (Meyer et al., 1990).  CHF patients with a very 
low baseline capacity achieved significant improvements in aerobic and ventilatory 
capacity, and reduction in dyspnoea and leg fatigue, after short-term intermittent 
exercise training.  Improvements after only 3 weeks were similar to the improvements 
reported in longer-duration training programmes of continuous rather than intermittent 
exercise bouts (Meyer et al 1996b; Meyer et al, 1997).   
Studies on healthy individuals report that LV function during high intensity intermittent 
exercise is not different to that during continuous moderate intensity training of the 
same total work load (Foster et al., 1999), and that pulmonary haemodynamics adapt 
well to intermittent work bouts of near maximal intensity (Lonsdorfer-Wolf et al., 
2003).  There is some concern that  high intensity exercise may induce deterioration in 
LV function (Koike et al., 1989), and over stress the LV wall in CHF (Demopoulos et 
al., 1997b).    However, Meyer et al (1998) reported that LV function was equally 
stable during a 16 min bout of both continuous and intermittent exercise  in CHF, 
although HR, systolic BP, Lac and rating of leg fatigue and dyspnoea were all 
significantly higher at the end of the intermittent exercise (Meyer et al., 1998a). The 
authors concluded that intermittent exercise is more strenuous than continuous exercise 
despite the same average power output, but that it does not create any higher short-term 
cardiac stress.  The same authors also reported that intermittent training at 50% of the 
work rate achieved on a specific steep test was markedly higher, but elicited a mean 
HR 13 beats.min-1
In low or moderate intensity exercise, VO2 reaches an early steady-state, and Lac 
remains close to resting levels (Jones et al., 2007). In heavy intensity exercise VO2 and 
Lac reach a delayed but elevated steady-state. In severe intensity exercise, both VO2 
and Lac will increase over time until VO2max is reached and the exercise is terminated 
(Jones et al., 2007).  The term high intensity exercise has also been  used to define 
exercise above or around VO2max that is non-sustainable (Brickley et al., 2007). It might 
be expected that high intensity intermittent exercise would induce a higher VO2 and 
Lac response when compared to continuous moderate intensity exercise. However, in 
 lower than that recorded at VT during an incremental exercise test 
(Meyer et al., 1997b). The implication of these studies is that intermittent exercise 
training allows a more intense exercise stimulus to be applied than the traditionally 
prescribed steady-state or continuous exercise, without compromising LV function.   
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healthy individuals if the total workload is matched, large variations in exercise 
intensity have no significant effect on exercise metabolism (Essen et al., 1977; Brickley 
et al., 2007), while VO2 may be lower if the exercise is intermittent (Astrand et al., 
2003).  
Current guidelines recognise the potential benefits of intermittent training in CHF 
(Giannuzzi et al., 2001), but it is questionable whether this type of training is being 
implemented in practice.  UK guidelines for CR exercise instructors do not explain how 
this type of training mode can be applied to CHF (British Association for Cardiac 
Rehabilitation, 2006).  A survey of CR programmes in Sussex revealed that intermittent 
exercise is not incorporated into training for CHF.  Examining acute responses to both 
intermittent and continuous exercise in CHF patients benefiting from up-to-date 
medication is an important prelude to designing and implementing an optimised 
exercise training programme. To date, only one study has compared the acute responses 
to intermittent and continuous exercise of matched total work in this population, and 
this was at a continuous exercise intensity above VT (Meyer et al., 1998a).  This, and 
studies examining the longitudinal effects of intermittent compared with continuous 
exercise, have set the intermittent work intensities first, e.g. at 100% maximum 
workload or 50% if a steep test is used, then matched the continuous workload to this. 
This study used a different approach; the continuous exercise was set in the moderate 
domain, at 90% VT, which, in theory, allows a steady-state to be achieved, is 
sustainable and appropriate for CHF (McConnell et al., 1993; Meyer et al., 2005a); the 
intermittent work bouts were set in the severe domain in order to challenge the 
physiological responses to exercise.  The aim of this study was to compare the acute 
respiratory, cardiovascular and metabolic responses to matched workloads of moderate 
continuous and intermittent exercise in CHF and age-matched control participants.  
Hypotheses 
In CHF patients intermittent exercise will elicit similar cardiovascular and respiratory 
responses, but higher metabolic and RPE responses, than continuous exercise.    
In control participants there will be no difference in cardiovascular, respiratory, 
metabolic or RPE responses to intermittent or continuous exercise.  
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5.1 Methods 
5.1.1 Participants 
Ethical procedures and patient inclusion and exclusion criteria were adhered to as 
detailed in the General Methods (Chapter 3). Ten CHF and 7 control participants, as 
described in Study 1 (Chapter 4), participated.   
5.1.2 Experimental design 
General methods were followed as described in Chapter 3.  CON and MED were 
performed in this study,  as described in Section 3.4. 
 5.1.3 Data analysis 
Respiratory gas exchange variables (VO2, VCO2, VE) were calculated, displayed for 
every breath and then interpolated to provide one value per second. Following the 
removal of outlying breaths (value ± 500 ml different from the previous and following 
breaths), breath-by–breath respiratory gas exchange variables (VO2, VCO2, VE) were 
interpolated to give second-by-second values.  Resting values were taken from a 30s 
rolling average during min 4-5 of rest, and unloaded values were taken from a 30s 
rolling average during the final minute of unloaded cycling.  Exercise VO2 was 
calculated as the average of the measured VO2 value minus the value for unloaded 
cycling, during min 1-5, 5-10, 10-15 and 15-20.  The oxygen cost of exercise, or 
exercise “economy”, was calculated as total VO2 above unloaded cycling divided by 
the total work done (ml/W). The recovery VO2 was determined as the VO2 during the 
first 3 minutes of recovery above the resting VO2.  HR was recorded at rest, at the end 
of the final minute of unloaded cycling, and at the end of minutes 5, 10, 15 and 20 
during CON, and during the same time period during MED, at the end of both work 
and recovery phases 4, 7, 10 and 13. Values for the work and recovery periods in MED 
were averaged for the purpose of comparison with CON (work phase + (2 x recovery 
phase)/2).  BP was recorded with a sphygmomanometer at rest, and during minutes 10 
and 20 of exercise. Rate pressure product (RPP) was calculated at rest, and during 
minutes 10 and 20 of exercise (BP x HR/100).  RPE on the Borg 6-20 Scale was 
measured after every 5 minutes of continuous exercise, and during the same time 
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period during intermittent exercise, at the end of both recovery and work phases 4, 6, 
10 and 13, with values being averaged in the same way as HR.  Five μl venous blood 
samples were taken according to the methods described in Chapter 3, and analysed for 
lactate (Lac) (YSI Yellow Springs Instruments, Ohio). 
5.1.4 Statistical analysis 
A two-way mixed design analysis of variance (ANOVA) was used to detect within 
subject (difference between CON and MED) and between subject variation (difference 
between Controls and CHF). Where appropriate, a three-way mixed design ANOVA, 
with repeated measures across time, was used to detect within subject and between 
subject variations in dependent variables at different time points. Where significant 
differences were indicated, follow-up t-tests with a Bonferroni adjustment for multiple 
comparisons were performed to see where they differences lay.  Mauchly’s test was 
used to check the sphericity of the data, and the Greenhouse-Geisser adjustment was 
made for non-spherical data. Levene’s test was used to test homogeneity of variance, 
and the equal variance not assumed statistic was used where the assumption of 
homogeneity was violated.  Where the data were not parametric, Wilcoxon’s test for 
matched pairs or Friedman’s test for 3 or more samples was used to detect differences 
between CON and MED, and at different time points during exercise, for CHF and 
controls. The Mann-Whitney test was used to compare differences between exercise 
bouts and groups for non-parametric data.   
5.2 Results 
Participant characteristics are shown in Table 5.1.  
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Table 5.1: Characteristics (mean ± SD) of CHF patients and healthy controls 
 
Characteristic CHF (n=10) Controls (n=7) 
Age (years)         75 ± 8 67 ± 7  
Male/ Female 8/2 4/3 
Height (cm) 172 ± 11 173 ± 10 
Body Mass (kg) 86 ± 18 79 ± 13 
NYHA Class II/III 8/2 - 
Ejection Fraction (%) 36 ± 9 69 ± 7 
Aetiology (ischaemic/dilated cardiomyopathy) 5/5 - 
Co-morbidities   
COPD 1 - 
Diabetes 1 - 
Hypertension 1 - 
Medication   
ACE inhibitor 4 - 
Angiotensin II receptor blocker 4 - 
Anti-arrhythmic 3 - 
β blocker 9 - 
Calcium channel blocker 2 - 
Diuretic 8 - 
 
The Q-Q plots of normality and Kolmogorov-Smirnov tests showed that the assumption 
of normality had been met in all variables except RPE, where non parametric tests were 
therefore used. The assumption of sphericity was violated for the change in La and HR 
over time, hence the Greenhouse Geisser adjustment was applied. Levene’s test showed 
variances were homogenous for all levels of the repeated measures variables.  
Maximum exercise capacity measured during CPET and work rates for CON and MED 
are shown in Table 5.2.  Exercise was well-tolerated by all CHF and controls.  All 
controls and 8 out of 10 CHF completed both 20 minute exercise bouts.  Due to fatigue, 
one CHF stopped CON after 17 min and MED after 16 min, and another CHF stopped 
MED after 16 min.  In these cases, the gas exchange data from 11-16 min instead of 15-
20 min were used for both exercise bouts.   
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Table 5.2: Maximum exercise capacity and training work rate (mean ± SD) 
 
 CHF  Control 
Maximum exercise capacity    
VO2peak (ml.min-1 1,310 ) ± 432 1,973 ± 505 
VO2peak (ml.kg-1.min-1 15.4 ) ± 4.2 24.7 ± 3.7 
Peak work rate (W) 81 ± 30 142 ± 42 
Exercise training work rate   
CON (W) 34 ± 12 55 ± 15 
MED (W): work phase 72 ± 6 116 ± 32 
MED (W): recovery phase 18 ± 6 28 ± 7 
 
Table 5.3 presents data collected during CON and MED, for CHF and controls.  Further 
details of statistical results are included in Appendix 5.  VE, RER, HR, BP, Lac & RPE are 
presented as average values during each exercise bout.  VE was higher in MED than CON 
(P = .034) in both groups.  There were no significant differences in any other variable 
between CON and MED in either group (P > 0.05).  VO2 in CHF was lower than controls 
during exercise, and HR and BP were lower at rest and during exercise, while RPE was 
higher for CHF than for controls in CON (P = .045) and MED (P = .001). 
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Table 5.3: Responses to continuous (CON) and intermittent (MED) exercise in CHF patients and control participants 
Values for Ventilation, RER, Heart Rate, Blood Pressure, Blood Lactate Concentration and Rating of Perceived 
Exertion are mean values for the 20 min exercise bout. 
 CHF CONTROL  
 CON MED CON MED  
Resting VO2 (ml.min-1 265 ± 14 ) 261 ± 15 298 ± 22 313 ± 27  
Unloaded VO2 (ml.min-1 422 ± 30 ) 431 ± 38 562 ± 62 650 ± 56 † 
Total net exercise VO2 (ml) (work-rest) 11,098 ± 1,441 11,228 ± 1,309 15,969 ± 1,541 16 ,237 ± 1,607 † 
Average 15-20 min net VO2 (ml.min-1 462 ± 67 ) 445 ± 44 605 ± 67 618 ± 64 † 
% VO2peak 64 ± 3 65 ± 1 57 ± 3 57 ± 3  
Exercise economy (VO2/W) 11.7 ± 1.1 12.2 ± 0.9 9.9 ± 0.8 9.2 ± 0.3 † 
Recovery VO2 (3 min) (ml) 962 ± 159 896 ± 125 887 ± 122 1,085 ± 169  
Ventilation (L.min-1 27 ± 0.7 ) 28 ± 0.7  * 32 ± 1.0 34 ± 1.1  *  
RER 0.92 ± 0.01 0.93 ± 0.01 0.91 ± 0.01 0.94 ± 0.01  
Heart Rate (beats. min-1 78 ± 3 ) 76 ± 3 112 ± 9 113 ± 8 † 
% Peak Heart Rate  76 ± 3 74 ± 3 70 ± 3 71 ± 4  
% Heart Rate Reserve 46 ± 4 43 ± 5 47 ± 5 48 ± 5  
Blood Pressure (systolic) (mmHg) 127 ± 5 127 ± 4 151 ± 6 153 ± 5 † 
Rate Pressure Product  101 ± 8 99 ± 7 182 ± 10 187 ± 8 † 
Blood Lactate Concentration (mmol.L-1 1.9 ± 0.2 ) 2.2 ± 0.3 2.1 ± 0.4 2.6  ± 0.6  
Rating of Perceived Exertion 11.8 ± 0.2 12.2 ± 0.2 10.9 ± 0.3 9.8 ± 0.3   † 
Difference between exercise bouts: * P < 0.05 CON vs MED  
Difference between groups † P < 0.05 CHF versus Controls in CON & MED 
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Analysis of VO2 at 5, 10, 15 and 20 min did not reveal any significant difference between 
CON and MED (P = 0.425).   Analysis of average VO2 between 5-10 min and 15-20 min 
showed a significant main effect of time (P < 0.001) and a significant interaction between 
time, exercise protocol and group (P = 0.015).  Follow-up tests (Bonferroni adjustment: α 
level P ≤ 0.0125)  showed that VO2 did not increase significantly in CHF from the first to 
the second half of the 20 min exercise bout in either CON (P = 0.053) or MED (P = 0.558), 
whereas in controls VO2 increased in MED (P = 0.001) but not in CON (P = 0.493).  This 
response is illustrated in Figure 5.1 with data from one CHF and one control participant.  
 
 
Figure 5.1: Example of oxygen uptake response to CON and MED in one CHF 
and one control participant (CTRL) 
 
Average HR values were not different between MED and CON in controls or CHF (P = 
0.765). There was an upward drift in HR in both groups over time, with  but there were no 
significant differences in HR at 5, 10, 15 and 20 min between exercise modes once the rest 
and recovery phase values were averaged (P > 0.05)   Figure 5.2 illustrates the significantly 
lower HR (P =0.001) in CHF compared with controls, and the blunted HR response between 
work and rest phases in CHF.  When average HR during CON and MED was calculated as a 
percentage of HRpeak and HRR, values for CHF were slightly, but not significantly, higher 
than for controls (Table 5.2).  
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Figure 5.2: Heart rate response (mean ± SEM) to CON and MED during work 
and recovery phases at 5, 10, 15 and 20 min during exercise in CHF and controls.   
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Lac values increased significantly above baseline at 10 min (P < 0.001) and 20 min (P = 
0.002).  There was no difference between CON and MED (P = 0.383), or between controls 
and CHF (P = 0.863).  There was a significant interaction between time (rest, 10 min and 20 
min) and exercise protocol (CON and MED) (P = 0.030).  However, follow-up tests showed 
that, although Lac increased to a greater extent in MED at 20 min (Figure 5.3), the difference 
did not reach statistical significance (P = 0.079).  
 
 
Figure 5.3: Blood lactate concentration (mean ± SEM) in CON and MED in CHF 
Patients (A) and Controls (B).   
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5.3 Discussion 
Intermittent training allows individuals to exercise at high work loads and, when compared 
with continuous training, can result in greater improvements in peak exercise capacity than 
continuous exercise, both in healthy individuals (Gorostiaga et al., 1991) and in CHF 
(Meyer et al., 1996c).   When compared to continuous exercise of the same total work 
done, short intermittent work bouts appear to impose similar cardiovascular and metabolic 
demands in healthy individuals (Astrand et al., 1960a; Essen et al., 1977; Foster et al., 
1999)  and similar cardiovascular, but increased metabolic demands in CHF (Meyer et al., 
1998a). In this study, there was no detectable difference in respiratory, cardiovascular or 
metabolic responses, or perception of effort, during a 20 min bout of either moderate 
continuous or intermittent exercise in CHF or controls, with the exception of VE, which 
was higher in MED.  
During CON and MED, there was an upward drift in HR, but no significant increase in 
respiratory variables, BP, Lac or RPE from the first to the second half of the exercise bout, 
apart from an increase in VO2 in MED in the control group.  As CON was set at 90% VT, 
it was anticipated that a steady state would be achieved, that BP and HR responses would 
be moderate, and that RPE would indicate a moderate level of exercise intensity (i.e. a 
score between 12 and 14 on the Borg scale) (Ingle, 2007).  In MED, the 30s work phases 
reached 80-90% of VO2peak work rate, yet the exercise response was similar to CON.  Our 
results agree with previous studies in healthy participants reporting that, at an equal total 
workload, physiological responses to intermittent exercise with short-moderate work 
phases are very similar to steady-state exercise. This was first demonstrated by Astrand and 
Christensen, who found that when cycling work at 98% of VO2max power in healthy 
individuals was split into short periods of work and rest, it was transformed into a sub-
maximal load, reflected by a VO2 of 63% max and Lac of 2 mmol.L-1 (Astrand et al., 
1960a).  Reloading of myoglobin stores during the recovery period allows a greater aerobic 
energy output, giving a higher ATP production per glucose unit compared with lactate 
formation (Christensen et al., 1960).  When the same total amount of work was performed, 
i.e. 60 min intermittent exercise at a high workload with alternating 15s work and recovery 
phases and 60 min continuous exercise at half the workload, the overall metabolic response 
was similar (Essen et al., 1977).  Brickley et al (2007) confirmed that muscle metabolic 
responses to high intensity intermittent exercise were similar to those during continuous 
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exercise matched for total workload in well-trained athletes. This finding was attributed to 
three possible mechanisms; the low-intensity recovery phase allowing sufficient recovery 
of metabolites, a dampening effect of the metabolic responses to low-intensity exercise 
following the prior high intensity exercise, or a dampening effect on the high intensity 
exercise due to the prior alternating intermittent exercise phases. The apparent dampening 
of physiological responses during repeated hard-easy transitions, with a balance in 
metabolic demand achieved during the recovery period, has also been demonstrated in 
CHF by Meyer et al (1997) in a study where the workloads were comparatively higher than 
in this study.  Although Lac increased from 1.3 mmol.L-1 at 6 min to 1.6 mmol.L-1
In Meyer’s study the responses to intermittent exercise were compared to responses 
measured at 75% VO2peak during an incremental exercise test.  Cardiac stress, assessed 
by rate-pressure product, was lower during intermittent exercise despite the work rate 
being more than double than at 75% VO2peak, while Lac, catecholamines and RPE did 
not differ. The authors did not detect any significant differences in variables between 
the work and recovery periods. Similarly, in the current study only minor changes were 
observed in CHF in respiratory gas exchange, HR or BP between work and recovery 
phases. In addition to the dampening of responses typically seen in intermittent 
exercise, this might also be due to the small VO2 and HR reserve in CHF patients, the 
HR and BP moderating effects of medication (β-blockers in particular)  or to 
chronotropic incompetence (Witte et al., 2006).  Even if fluctuations do occur, the time 
  at 15 
min, and RPE from 10.7 to 11.5 for leg fatigue, and 10.0 to 11.2 for dyspnea, these values 
show that the exercise was easily tolerated (Meyer et al., 1997b). In the current study, VE 
was higher in MED than in CON.  CHF had lower VE than controls, and neither group 
demonstrated abnormally high values.  Dyspnea was not assessed separately, but overall 
RPE was not different between exercise bouts.  It has been suggested that patients with a 
low exercise tolerance might find intermittent training subjectively easier than continuous 
training (Puhan et al., 2004).  In this study mean RPE in both exercise protocols was 12 in 
CHF,  between “light” and “somewhat hard”, and within the guidelines of 11-14 for 
moderate exercise (Ingle, 2007).  RPE was significantly lower in controls, and the mean 
value of 10, “very light” to “light”, indicates that they perceived the exercise to be 
significanty easier than CHF did.   It has previously been reported that RPE at VT is 11.0 ± 
2.1, and does not differ between cardiac patients taking β-blockers, those not taking β-
blockers or younger healthy individuals (McConnell et al., 1993). 
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lag for each variable might vary making it difficult to draw specific conclusions from 
any observed differences.  The data from controls showed a distinct fluctuation in VO2 
and HR response to the changes in workload during MED, but the mean values for the 
duration of exercise were no different to CON. The limited capacity for HR increase 
during exercise in CHF means that it is difficult to use HR to guide or estimate exercise 
intensity (Beale et al., 2010), although it does not appear to limit exercise tolerance 
(Witte et al., 2005) or the benefits of exercise training in CHF (Forissier et al., 2001).   
However, although the absolute HR values during CON and MED were lower in CHF 
than controls, the percentages of HRpeak and HRR were not different between groups 
(CHF ~75%  HRpeak and ~45% HRR; controls ~71% HRpeak and ~47% HRR).  
Similarly, the VO2 during CON and MED relative to VO2peak was slightly, but not 
significantly, higher for CHF than for controls (CHF ~65% VO2peak; controls ~57% 
VO2peak).  This indicates that, when exercise is prescribed at 90% VT, the average 
relative intensity in terms of HR and VO2 will be similar for CHF and controls.    
Exercise practitioners may questions whether patients with low VO2peak can practically 
participate in moderate intensity activity, either in a CR setting or during activities of 
daily living. This study demonstrates that patients are able to perform 20 min cycling at 
an intensity just below  VT while maintaining a steady-state in VO2, HR and Lac, at an 
RPE of 11.  This lends further support to the usefulness of identifying VT via CPET for 
exercise prescription.  Six CHF had a VO2peak < 15 ml.kg-1.min-1
There was no difference in the oxygen cost of exercise between modes of exercise, 
although CHF did have higher values than controls (11-12 vs 9-10 ml.W
, and VT in these 
patients ranged from 55-76% VO2peak, and work rate at VT from 17-50 W.  Clearly, for 
patients who reach their VT at work rates as low as 20W, many daily activities will be 
higher than moderate intensity. 
-1), or in the 
recovery VO2.  This is in agreement with previous research suggesting that CHF 
consume more VO2 than control subjects for the same unit of work during exercise. 
Levy et al (2004) reported that, at the same submaximal steady-state workload of 35W, 
CHF patients consumed 14.9 ± 1.2 ml/W compared with 9.7 ± 0.7 ml/W in control 
subjects. The authors hypothesised that this is due to the decrease in Type I oxidative 
fibres, oxidative enzymes and mitochondrial density, plus chronic sympathetic 
activation, reported in CHF (Clark et al., 1996).  VO2 kinetics are slower in CHF than 
in healthy controls, both at the same constant and relative work rates, meaning that 
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patients take longer to reach a steady state for VO2 due to  impaired oxygen delivery to 
the exercising muscles (Sietsema et al., 1994).   Recovery of VO2 to baseline values is 
also reportedly higher in CHF than in controls, possibly to compensate for the slowed 
attainment of steady state and consequent oxgyen debt that is repaid following 
completion of exercise (Sietsema et al., 1994; Levy et al., 2004).  In the current study 
there was no difference in VO2 during 3 minutes of recovery. However, in Levy et al’s 
(2004) study CHF were exercising at a relatively higher intensity (67% VO2peak) than in 
the current study, with 11 of the 15 patients above VT, where the oxygen cost of 
exercise is increased, while control subjects were exercising at a relatively lower 
intensity (32% VO2peak).  Mitchell et al (2003) reported that during maximal 
incremental exercise CHF may appear to be “economical” by having a low VO2 per 
Watt, but that in fact they accumulate a large oxygen debt (Mitchell et al., 2003). The 
same study also found that CHF became less “economical” above VT.  By contrast, the 
current study demonstrates that, when exercising below VT, CHF use more oxygen per 
unit of work when compared with controls, but that their early recovery is not delayed 
in either continuous or intermittent exercise. The additional oxygen cost, and thus the 
lower economy of energy expenditure in CHF might be partly explained by lack of skill 
or technique.  It is not clear to what extent economy can be improved following 
training in CHF through optimisation of technique as well as improvement in oxidative 
capacity. This adaptation in healthy individuals results in the ability to maintain 
exercise for a longer time at the same intensity, or at an increased intensity for the same 
period of time (Cooke, 2001). Future studies should address this issue, using 
appropriate measurements for economy, i.e. VO2 at a given work rate (Cooke, 2001), 
and aerobic work “efficiency” (Levy et al., 2004; Wasserman et al., 2005).    
Meyer et al (1998) reported that intermittent exercise appeared to be more strenuous than 
continuous exercise of matched total work, as HR was higher, and Lac continued to 
increase whereas it was stable in continuous exercise. However, as shown in Study 1, the 
16 min exercise bouts were performed at a higher relative intensity than in this study, as the 
continuous exercise workload was matched to the total intermittent exercise workload, 
calculated from a steep test, rather than being set below VT as in this study. Lac at the end 
of exercise was 3.5 mmol.L-1 for continuous and 4.1 mmol.L-1 for intermittent exercise, 
compared with values of 1.9 and 2.2 mmol.L-1 respectively in this study. The authors 
estimated that the intensity was likely to be close to maximal lactate steady state (MLSS) 
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(Meyer et al., 1998a), that is the highest work rate that can be maintained over time without 
continual blood lactate accumulation (Billat et al., 2003).  The work rate at MLSS is 
assumed to correspond to the work rate at RCP, although in trained individuals RCP 
occurrs at approximately 10% VO2max higher than MLSS (RCP: 85% VO2max vs MLSS: 
74% VO2max) (Dekerle et al., 2003).  In the current study, Lac tended to be higher during 
intermittent exercise than during continuous exercise at 20 min, but not at 10 min.  
Although there was no statistically significant difference, it is possible that even small 
increases in Lac could influence exercise tolerance over a longer period. A limitation of 
this study was that the exercise duration was limited to 20 min.  In addition, no lactate 
threshold measurement was performed, hence it is not possible to interpret Lac values in 
relation to the lactate threshold, an alternative demarcation for moderate intensity exercise.   
5.4 Conclusion 
This study investigated the cardiovascular, respiratory, metabolic and RPE responses to 
continuous and  intermittent exercise of matched total workload.  The results support 
the hypothesis that there is no difference in cardiovascular and respiratory responses 
between continuous and intermittent exercise in CHF.  However, the results do not 
support the hypothesis that metabolic and RPE responses are higher during intermittent 
exercise than during continous exercise in CHF.  The hypothesis that, in control 
participants, there is no difference in cardiovascular, respiratory, metabolic or RPE 
responses between continuous and intermittent exercise is supported.   
The results of this study complement previous research in this area and show that both 
continuous and intermittent exercise of matched total work, equal to 90% VT, elicit 
similar responses in respiratory, cardiovascular and metabolic variables and RPE in 
both CHF patients and control participants.   
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CHAPTER 6: THE EFFECT OF VOLATILITY ON 
ACUTE RESPONSES TO INTERMITTENT 
EXERCISE IN CHF AND HEALTHY CONTROLS 
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6.0  Introduction 
Intermittent exercise allows both healthy individuals and cardiac patients to exercise at 
a higher intensity than it would be possible to maintain continuously (Christensen et al., 
1960; Meyer et al., 1997b; Billat et al., 2000; Astrand et al., 2003).  It may be possible 
to enhance the training adaptation by increasing the intensity of the work phases to 
impose a greater exercise stimulus, while still allowing a balance in metabolic demand 
to be achieved during the recovery phases.  In coronary bypass patients, intermittent 
training resulted in a greater increase in physical performance than continuous training, 
even though the mean total workload over 20 minutes was lower in the intermittent 
training condition (Meyer et al., 1990).  The authors concluded that improvement in 
patients with impaired capacities appears to be due to the higher intensity of work in 
the intermittent training. Subsequent studies by the same group in CHF patients 
demonstrated that intermittent exercise was more strenuous than continuous exercise, 
as RPP, La and RPE were all higher, despite the average workload being the same for 
both types of exercise (Meyer et al., 1998a).  Chapter 5 illustrated that the acute 
responses to intermittent exercise where the 30s work intervals reached 80-90% of 
VO2peak power did not differ to those during moderate continuous exercise of matched 
total work load.  Other studies of CHF patients have used 30s work intervals of 100% 
of the workload achieved at VO2peak, or 50% of that achieved in a steep ramp test 
which, as demonstrated in Chapter 4, is likely to be similar to 100% VO2peak work rate 
in CHF.   
It is not known if manipulating the intensity of the work and rest phases while 
maintaining the same total workload alters cardiovascular, respiratory and metabolic 
responses or perception of effort.  Only one previous study has investigated the effects 
of manipulating the intensity of the work intervals in CHF. Meyer et al. (1996a) 
compared the response to work intervals of 50%, 70% and 80% of steep ramp test 
WRmax, with work phase durations of 30s, 15s and 10s respectively, interspersed with 
60s recovery at 15W, thereby decreasing the duration of the work phase to compensate 
for the increase in intensity (Meyer et al., 1996b).  There were no differences in 
cardiovascular or metabolic responses between the different intermittent protocols, and 
although the highest work rate induced greater leg fatigue, and an upward drift in HR 
and BP during the exercise, the exercise was well tolerated. Rate-pressure product 
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remained within acceptable levels, and  VO2 and Lac did not increase during the course 
of exercise in any of the 3 protocols.   
The aim of the current study was to examine the effect of volatility on cardio-
respiratory and metabolic responses to exercise by comparing a high volatility exercise 
bout (HIGH), where the amplitude of the work phases above the mean (i.e. the 
volatility) was increased, with a low volatility exercise bout (LOW), where the 
amplitude of the work phases was decreased, whilst maintaining the same total work by 
adjusting the workload of the recovery phase.  As described in Chapter 5, a continuous 
bout of moderate intensity exercise (90% VT) was set, and the total workload of the 
intermittent exercise bouts was matched to this.  The work phase for HIGH was set  in 
the extreme exercise intensity domain, while the work phase for LOW was set in the 
heavy exercise intensity domain.   
Hypothesis: High volatility intermittent exercise will elicit higher cardiovascular,  
respiratory, metabolic and RPE responses than low volatility intermittent exercise or 
continuous exercise of matched total workload  in CHF and control participants.   
6.1 Methods 
6.1.1 Participants 
Ethical procedures and patient inclusion and exclusion criteria were adhered to as 
detailed in the General Methods.  Nine CHF and 5 controls from those described in 
Study 1 (Chapter 4) participated. 
6.1.2 Experimental design 
General methods were followed as described in Chapter 3. Participants performed 
CON, LOW and HIGH, as described in Section 3.4.  The same methods for data and 
statistical analysis described in Study 2 (Chapter 5) were used, i.e. variables during 
LOW and HIGH were measured and analysed in the same way as those during MED.  
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6.2 Results 
Participant characteristics are shown in Table 6.1 
Table 6.1: Characteristics (mean ± SD) of CHF patients and healthy controls 
 
Characteristic CHF (n=9) Controls (n=5) 
Age (years)         75 ± 9 63 ± 2  
Male/ Female 8/1 3/2 
Height (cm) 176 ± 11 174 ± 11 
Body Mass (kg) 85 ± 17 79 ± 16 
NYHA Class II/III 7/2 - 
Ejection Fraction (%) 36 ± 9 70 ± 7 
Aetiology (ischaemic/dilated cardiomyopathy) 5/4 - 
Co-morbidities   
COPD 1 - 
Diabetes 1 - 
Hypertension 1 - 
Medication   
ACE inhibitor 3 - 
Angiotensin II receptor blocker 4 - 
Anti-arrhythmic 3 - 
β blocker 8 - 
Calcium channel blocker 2 - 
Diuretic 7 - 
 
Table 6.2 describes the maximum exercise capacity measured during CPET, and the 
derived work rates for CON, LOW and HIGH.  In order to maintain equality of total 
workload in all three exercise bouts, 2 CHF with low functional capacity rested without 
pedalling during the recovery phase in HIGH.  Exercise was well-tolerated by all CHF 
patients and control participants (RPE ≤ 13).  Seven  out of 9 CHF patients and all 5 
controls completed all three 20 minute exercise bouts.  One CHF stopped CON after 17 
minutes, and another stopped HIGH after 13 minutes, due to leg fatigue.  In these cases, 
the respiratory data from 11-16 min and 5-10 minutes respectively, instead of 15-20 
min, were used to compare values across all 3 exercise bouts.  All CHF achieved 20 
minutes of exercise in LOW.   
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Table 6.2: Maximum exercise capacity and training work rate (mean ± SEM) 
 CHF Control 
Maximum exercise capacity    
VO2peak (ml.min-1 1,363 ) ± 150 2,034 ± 232 
VO2peak (ml.kg-1.min-1 15.9 ) ± 1.5 25.5 ± 1.6 
Peak work rate (W) 86 ± 10 150 ± 17 
Exercise training work rate   
CON (W) 36 ± 4 58 ± 5 
LOW (W): work phase 58 ± 8 85 ± 10 
HIGH (W): work phase 95 ± 10 148 ± 17 
LOW (W): recovery phase 26 ± 3 46 ± 4 
HIGH (W): recovery phase * 11 ± 3 18 ± 2 
* recovery phase for 2 CHF = rest       
 
The Q-Q plots of normality and Kolmogorov-Smirnov tests showed that the assumption 
of normality had been met in all variables except RPE, where non parametric tests were 
therefore selected. The assumption of sphericity was violated for the change in Lac and 
HR over time, hence the Greenhouse Geisser adjustment was applied.  
Table 6.3 presents the data for CON, LOW and HIGH for CHF and controls.  There was 
no significant difference in respiratory variables or in HR or BP between exercise 
protocols in CHF or controls (P > 0.05). Lac was significantly higher in HIGH than in 
CON (P = 0.002) and LOW (P = 0.023) in CHF and controls.  RPE was not 
significantly different between exercise protocols, or between CHF and controls, with 
the exception of LOW, where RPE was significantly higher in CHF than controls (P = 
0.012). 
Figure 6.1 illustrates Lac over time for the 3 exercise protocols. Lac values increased 
significantly above baseline at 10 min (P < 0.001) and 20 min (P < 0.001) in all 
exercise protocols.  There was no significant difference between controls and CHF (P = 
0.286).  There was a significant difference in Lac between CON, LOW and HIGH (P = 
0.004), with a moderate effect size (η2 = 0.341), and a significant interaction between 
time and exercise protocol (P = 0.001).  Follow-up tests (Bonferroni adjustment: α level 
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P ≤ 0.0167) showed that in CHF Lac at 10 min and 20 min was greater in HIGH than 
LOW (P < 0.001 and  P = 0.012 respectively).  In controls Lac was significantly greater 
in HIGH compared  to CON at 20 min (P = 0.011) .   
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Table 6.3: Responses to continuous (CON), low volatility (LOW) and high volatility (HIGH) intermittent exercise in CHF patients 
and controls 
Values for Ventilation, RER, Heart Rate, Blood Pressure, Blood Lactate Concentration and Rating of Perceived Exertion are mean values 
for the 20 min exercise bout. 
 CHF 
 CONTROL   
 CON LOW HIGH CON LOW HIGH  
Resting VO2 (ml.min-1 260 ± 14 ) 268 ± 18 274 ± 19 304 ± 38 331 ± 42 307 ± 48  
Unloaded VO2 (ml.min-1 449 ± 30 ) 434 ± 34 437 ± 36 598 ± 99 596 ± 89 602 ± 103  
Average exercise VO2 (ml.min-1 859 ± 92 ) 837 ± 97 858 ± 115 1,201± 92 1,252 ± 142 1,233 ± 138 † 
Total net exercise VO2 (ml) (work-rest) 11,820 ± 1,656 11,548 ± 1,767 11,675 ± 1,992 17,940 ± 1,103 18,400 ± 2,034 18,508 ± 1,741 † 
% VO2peak 67 ± 3 65± 5 66 ± 4 57 ± 3 59 ± 2 58 ± 3  
Average 15-20 min net VO2 (ml.min-1 457 ± 91 ) 435 ± 95 457 ± 94 682 ± 60 757 ± 104 756 ± 60 † 
Exercise economy (VO2/W) 11.7 ± 1.3 11.8 ± 1.6 11.2 ± 1.7 10.1 ± 1.1 10.8 ± 0.8 10.4 ± 0.7  
Recovery VO2 (3 min) (ml) 1,037 ± 192 1,159 ± 222 1,028 ± 173 1,030 ± 102 1,088 ± 175 1,147 ± 158  
Ventilation (L.min-1 27 ± 2 ) 27 ± 3 28 ± 3 35 ± 4 39 ± 5 39 ± 5 † 
RER 0.93 ± 0.02 0.93 ± 0.02 0.93 ± 0.01 0.91 ± 0.03 0.94 ± 0.04 0.93 ± 0.04  
Heart Rate (beats. min-1 78 ± 3 ) 78 ± 2 78 ± 3 115 ± 9 115 ± 8 116 ± 8 † 
% Peak Heart Rate 75 ± 3 74 ± 3 75 ± 3 73 ± 3 71 ± 2 75 ± 3  
% Heart Rate Reserve 46 ± 3 44 ± 3 45 ± 4 47 ± 4 49 ± 3 50 ± 5  
Blood Pressure (systolic) (mmHg) 125 ± 6 122 ± 6 123 ± 5 151 ± 7 147 ± 5 159 ± 6 † 
Blood Lactate Concentration (mmol.L-1 1.8 ± 0.2 ) 1.9 ± 0.2 2.4 ± 0.2 * 2.2 ± 0.5 2.5 ± 0.3 3.1 ± 0.6 *  
Rating of Perceived Exertion 11.8 ± 0.2 12.3 ± 0.3 11.5 ± 0.6 10.9 ± 0.3 11.0 ± 0.3   10.3 ± 0.5 †† 
Difference between exercise bouts: * P < 0.05 HIGH vs CON and LOW 
Difference between groups † P < 0.05 CHF versus Controls; †† P < 0.05 CHF versus Controls in CON and LOW 
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Figure 6.1: Blood lactate response (mean ± SEM) to CON, LOW and HIGH in (A) 
CHF and (B) Controls  
* P < 0.05 HIGH vs LOW in CHF at 10 min 
** P < 0.05 HIGH vs LOW in CHF at 20 min 
‡ P < 0.05 HIGH vs CON in controls at 20 min 
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Analysis of variables at 5, 10, 15 and 20 min did not reveal any significant difference 
between CON, LOW and HIGH.  There was an upward drift in HR in both groups, but 
there was no significant difference in HR at 5, 10, 15 and 20 min between exercise 
protocols once the rest and recovery phase values were averaged (P > 0.05).  Figure 6.2 
illustrates the HR response during CON LOW and HIGH.  HR was significantly lower 
(P<0.05) in CHF than controls, and CHF demonstrated a blunted HR response between 
work and rest phases compared with controls.  
 
 
Figure 6.2: Heart rate response (mean ± SEM) to CON, LOW and HIGH during 
work and recovery phases at 5, 10, 15 and 20 min during exercise in CHF and 
controls 
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6.3 Discussion 
The current study demonstrates that, if the total workload is kept equal, respiratory and 
cardiovascular responses, and RPE, are not different in continuous exercise at 90% VT, 
high or low volatility intermittent exercise.  However, high volatility exercise induces a 
significantly greater increase in Lac, suggesting that the exercise stimulus to the 
peripheral muscles is greater in this condition.  
It has been reported that, in healthy individuals, high intensity work phases of 60s or 
more produce a different metabolic response to shorter work phases, with Lac values 
continuing to increase, whereas in shorter work phases and continuous exercise it 
remains stable (Astrand et al., 1960a; Foster et al., 1999). The data in the current study 
suggest that, in CHF patients and older individuals, even in 30s work phases, when the 
work load is increased beyond a certain level the increased metabolic demand cannot 
be fully compensated during the recovery phases, even if these impose minimal work 
or rest.  One CHF was unable to continue HIGH after 13 minutes due to self-reported 
leg fatigue.  Imposing too high a work rate in the work phase can lead to localised 
peripheral fatigue which ultimately compromises exercise tolerance, although this was 
not seen in the other 8 CHF.  A recent review paper suggests that lactate plays a role in 
the detection of severe exercise stress, signalling to nerve cells, and ultimately leading 
to reduction or cessation of exercise (Philp et al., 2005).  The same reviewers also 
propose that the presence of lactate mimics hypoxic conditions, and triggers adaptive 
responses in the muscle, including angiogenesis and oxidative defence mechanisms, 
thus supporting the idea that HIGH applies a greater training stimulus than LOW or 
CON.   
The response to high volatility intermittent and continuous exercise agree with those 
reported by Meyer et al (1990) in coronary bypass patients, where high intensity 
intermittent exercise induced significantly greater increases in Lac than continuous 
training, although cardiovascular responses were similar. A study in trained athletes 
also demonstrated that average HR, VO2, energy cost and RPE were the same in 
response to continuous and intermittent cycling of the same average intensity, but Lac 
was higher during intermittent training (Palmer et al., 1999).  Left ventricular function 
is similar in continuous and intermittent exercise, in both healthy individuals and CHF, 
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and there appears to be a dampening in haemodynamic response similar to the 
dampening in VO2 (Meyer et al., 1998a; Foster et al., 1999). 
Only one study in CHF has previously manipulated the workload of intermittent 
exercise bouts, by comparing three protocols with work bouts set at different 
percentages of steep test WRmax: 50% for 30s duration, 70%  for 15s and 80% for 10s, 
interspersed with 60s recovery (Meyer et al., 1996b).  As discussed in Chapter 4, 
Meyer et al’s 30s intermittent work rate was higher than the high volatility work rate 
for CHF in the current study.  Even at these higher work rates, Meyer et al reported no 
significant difference, or increase during exercise, in VO2, VCO2, VE, RPP or 
catecholamines, suggesting that increased intensity can be compensated for by reducing 
duration.  In contrast to the results in the current study, Lac in Meyer et al’s study did 
not differ between exercise protocols.  Values remained close to resting levels, and 
were between 1.2 ± 0.1 and 1.3 ± 0.1 mmol.L-1
HR increased by a maximum of 5 beats.min
 lower than in the current study.  
However, Meyer et al sampled capillary blood from the ear lobe whereas forearm 
venous blood was sampled in the current study. Different sampling sites and methods 
may influence  lactate values, with finger capillary blood taken during cycle and 
treadmill exercise showing higher values that venous or ear lobe samples (Dassonville 
et al., 1998). 
-1 in LOW and 9 beats.min-1 in HIGH in 
CHF, but there was no difference in average values between exercise protocols, nor 
was there a difference in BP.  In Meyer et al’s study HR and BP were also stable 
throughout the 50 and 70% intensities, and, although they increased towards the end of 
the 80% intensity, RPP was only 83-88% of the value reached at 75% VO2peak. Leg 
fatigue was also higher at the end of the 80% intensity indicating that very high work 
loads may induce local fatigue and perception of effort.  Nevertheless, the highest value 
of 12.4 was similar to the results of the current study, where there was no difference in 
RPE between exercise protocols, and mean values were between 11.5 and 12.3. These 
values indicate a moderate level of effort, and correspond RPE values previously 
reported at VT (McConnell et al., 1993).  As described in Chapter 5, RPE values for 
controls were lower than for CHF in CON and LOW, indicating that they perceived the 
exercise to be easier, even though the relative intensity was set at the same level for 
both groups.   However, there was no difference in RPE between controls and CHF in 
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HIGH.  It is interesting  that, despite the higher Lac, this was the only exercise protocol 
in which CHF did not rate the exertion higher than controls did.  
A further study by Meyer et al (1998) compared 16 min intermittent exercise at 50% 
steep ramp for 30s and 60s recovery phases of 10W with continuous exercise set at the 
same mean work load. Intermittent training appeared to be more strenuous than 
continuous exercise, reflected by a higher HR, and a continuing increase in Lac 
compared with a stable Lac response in continuous exercise.  Once again, the mean 
work load was higher than in the current study, and the continuous exercise was 
matched against the intermittent exercise, rather than being set below VT.  This is 
reflected by the higher Lac levels (intermittent: 4.1 ± 0.4, continuous: 3.5 ± 0.4 
mmol.L-1). The authors estimated the intensity to be at or below maximum lactate 
steady state (Meyer et al., 1998a).  The values were obtained from arterialised blood, 
compared with capillary blood in their earlier study, and the differences in the method 
of blood sampling might explain why the values were considerably higher in the second 
study, although the 30s work load was set at the same intensity (Yoshida et al., 1982).   
In the current study it was not straightforward to match the total workload in HIGH to 
CON and LOW, particularly in patients with a low exercise capacity.  The average 
workload for CON, i.e. 90% VT, was 36W, thus the range of adjustments to the 
amplitude below the mean for the recovery phases is very limited in CHF.  The two 
CHF with the lowest exercise capacities stopped pedalling during the rest phase in 
order that the total work done for all 3 protocols was equal.  Active recovery from 
intermittent exercise is recommended rather than rest in order to facilitate blood flow 
and lactate removal (McLellan and Skinner, 1982).  For the purpose of this study, i.e. to 
compare the acute responses to intermittent versus continuous exercise, and to examine 
the effects of volatility, we ensured that the total work done was equal across CON, 
LOW, and HIGH. In practice, it may be better to perform an active recovery with 
unloaded pedalling, even if this results in a greater total amount of work done. In fact, 
greater training adaptations are reportedly achieved after high intensity intermittent 
training compared with continuous training because it allows a greater amount of work 
to be achieved.   Meyer et al (1997) noted that the amount of work achieved during 
high intensity intermittent training, with recovery phases set at 15W, was much greater 
than would be achieved by exercising continuously at 75% VO2peak.  
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As reported in Chapter 5, although the absolute values for HR were lower in CHF than 
controls, presumably due to the effect of β-blockers and chronotropic incompetence, 
there was no significant difference in relative exercise intensity, in terms of % HR, % 
HRR or % VO2peak, between CHF and controls during CON, LOW or HIGH.  In the 
current study there was no difference in exercise “economy” between CHF and 
controls.  This is in contrast to the higher oxygen cost of work in CHF reported in 
Chapter 5.  Observation of the VO2 response to intermittent exercise in these studies 
shows minor fluctuations in CHF in response to the work and rest phases, whereas in 
controls the fluctuations are more pronounced (Figure 5.1). It is beyond the scope of 
these studies to assess VO2 kinetics during intermittent exercise, but future studies 
should investigate whether slowed VO2 kinetics explain the blunted VO2 responses 
between work and rest phases, and how this relates to the underlying pathophysiology.  
Methodological issues as well as physiological determinants and clinical relevance of 
VO2 kinetics measurement are discussed in a recent review (Kemps et al., 2009). It is 
possible that a greater oxygen “debt” accrued during the work phase is repaid during 
the recovery phase, resulting in the minimal changes in VO2 between phases.  Although 
slowed VO2 kinetics have been reported in CHF during incremental exercise (Cohen-
Solal et al., 1997), and patients may show a prolonged VO2  kinetics response 
compared to controls at the same absolute work rate, the response appears to be similar 
at the same relative work rate (Sietsema et al., 1994; Hepple et al., 1999).  Future work 
could assess the effect of a longer active recovery on the VO2 response, and the 
implications for exercise training.   
6.4 Conclusion 
The aim of this study was to investigate the effect of adjusting the volatility of 
intermittent exercise, while maintaining the same total work (equal to continuous 
exercise at 90% VT), on cardiovascular, respiratory, metabolic and RPE responses. Lac 
was significantly higher in HIGH compared to LOW and CON, supporting the 
hypothesis that high volatility intermittent exercise elicits higher metabolic responses 
than low volatility intermittent exercise or continuous exercise of matched total 
workload in CHF and control participants.  However, the hypothesis that high volatility 
intermittent exercise also elicits higher respiratory, cardiovascular and RPE responses 
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than low volatility intermittent exercise or continuous exercise of matched total 
workload  is not supported.    
A 20 minute intermittent exercise bout with work phases set in the extreme exercise 
intensity domain, 10% above the highest work rate reached during a standard maximal 
incremental exercise test, was well tolerated by CHF patients, and would be an 
appropriate protocol for a training programme.  The increased Lac in these high 
volatility work phases suggests that the challenge to cellular homeostasis was higher 
than when the volatility was reduced, which could theoretically induce greater 
adaptations after a period of training by this method. Previous studies have reported 
that intermittent exercise training results in greater increases in aerobic exercise 
performance than continuous training in healthy individuals (Gorostiaga et al., 1991), 
in patients after coronary bypass surgery (Meyer et al., 1990)  and in CHF patients 
(Meyer et al., 1997b).   
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CHAPTER 7: COMPARISON OF HIGH 
INTENSITY INTERMITTENT TRAINING TO 
CIRCUIT-BASED AEROBIC TRAINING AT 
IMPROVING FUNCTIONAL CAPACITY, 
VENTILATORY EFFICIENCY, BNP AND 
QUALITY OF LIFE IN CHF 
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7.0 Introduction 
Despite the growing body of evidence in favour of exercise training for CHF, there is 
less evidence that study findings are transferable to clinical practice. Firstly, it has been 
reported that the exercise dose in randomised controlled trials of CR is more than four 
times greater than is usual UK practice (Taylor et al., 2007).  Secondly, the majority of 
studies are not representative of the total population of CHF patients. Older patients, 
females, individuals with implantable devices and those with more severe heart failure 
and/or co-morbidities tend to be excluded (Rees et al., 2004). More than half of the 
exercise training studies in CHF have been published since 2000, with the greatest 
proportion appearing in the past 5 years (Figure 7.1), i.e. post-dating the start of this 
thesis in 2004. The majority of these studies have focussed on aerobic training at a 
steady-state intensity expressed as a percentage of VO2peak (range 50-80%), of HRmax 
(range 60-80%) or of HRR (range 60-80%) (van Tol et al., 2006). More recent studies 
have included different methods to achieve training adaptations, including intermittent 
and resistance as well as aerobic training. Details of exercise training studies in CHF 
are presented in Appendix 1 (Tables A1 and A2), and several of these have been 
discussed in the Review of Literature. 
  
Figure 7.1: Estimation of number of studies on exercise training in CHF patients 
published between 1980 and 2009  
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Meyer’s landmark study in 1996 suggested that short-term intermittent exercise 
training is more effective at improving cardio-respiratory fitness than longer-duration 
moderate intensity exercise for CHF patients as it provides a greater stimulus to the 
peripheral muscles (Meyer et al., 1996b).  ESC and AHA guidelines suggest that 
intermittent exercise, based on Meyer et al’s protocols, may be appropriate for CHF 
(Giannuzzi et al., 2001; Pina et al., 2003). Studies 1-3 of this thesis demonstrate that the 
traditional method of setting intermittent work intensity at 100% workload achieved at 
VO2peak is based on sound physiological principles, is reproducible and achievable by 
CHF. Since Meyer’s study a handful of other studies have investigated the 
effectiveness of intermittent training for CHF.  These include one observational (Meyer 
and Laederach-Hofmann, 2003) and one cross-over study (Meyer et al., 1996c), two 
RCTs comparing intermittent with no training (Willenheimer et al., 1998; Sabelis et al., 
2004), three RCTs comparing intermittent with continuous training (Dimopoulos et al., 
2006; Roditis et al., 2007; Wisloff et al., 2007) and one comparing intermittent with 
continuous and with no training (Nechwatal et al., 2002). The latter 4 studies have been 
published since the current series of studies. A variety of intermittent protocols have 
been employed, including 50% WRpeak in Meyer’s steep ramp test, 100% WRpeak in a 
maximal CPET, or a percentage of maximal HR in studies where the work phases are ≥ 
90s. Table 7.1 summarises the studies applying intermittent work phases of ≤ 90s. 
 
Although they demonstrate the benefits of intermittent training compared with usual 
care, these studies offer conflicting information about whether it has any benefits over 
moderate continuous training. A short-duration RCT reported that intermittent and 
continuous training improved maximal and sub-maximal exercise capacity to a similar 
extent, but that intermittent improved central haemodynamics to a greater extent, while 
continuous had a more beneficial effect on psychological well-being (Nechwatal et al., 
2002).  Although the duration of this study was only 3 weeks, training frequency was 
high at 5-6 times per week, similar to Meyer’s study. When training was applied 3 
times per week for 12 weeks, high intensity intermittent training resulted in similar 
increases in VO2peak and VT compared with continuous training (Dimopoulos et al., 
2006; Roditis et al., 2007). However, longer work phases of 4 minutes, performed at a 
lower intensity, were more effective than continuous training at increasing VO2peak and 
LV and mitochondrial function as well as reducing BNP, a marker of LV stress 
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 Table 7.1: Summary of intermittent exercise training studies (with work phases of 30s -90s) in CHF patients.   
 
Study Design Sample Exercise Intervention Outcome Variables Results 
Dimopoulos et al 
(2006) 
 
 
 
 
 
 
 
 
 
Roditis et al 
(2006) 
RCT parallel 
two-group study 
comparing 
continuous (C) 
to interval (I) 
training 
Randomised n=29 CHF; 
completed n=24  (C/I) 14/11, Age 
(C/I) 61 ± 10/62 ± 7 yrs; Men/ 
women (C vs I)14/0 vs 9/1; 
NYHA I/II/III 4/9/1 vs 3/6/1, 
LVEF (C/I) 31 ± 10/ 35 ± 11 %; 
aetiology (C/I) ischaemic  5/14, 
DCM 8/6, valvular 1/1; 
medication (C/I): ACE inhibitors 
13/10, diuretics 11/10, digitalis 
6/4, β-blockers 12/8 
Randomised n=21 CHF (C/I) 
11/10 
3 x 40 min sessions 
per week for 12 
weeks. C: 50% peak 
work rate, increased 
by 5% every 4 weeks; 
I:30s @ 100% peak 
work rate, increased 
by 10% every 4 
weeks, alternated with 
30s rest 
CPET on cycle 
ergometer, chronotropic 
response, heart rate 
recovery at 1 min 
 
 
 
 
 
 
 
Oxygen uptake kinetics 
Significant improvement in 
VO2peak (C 6% ,I: 8%) and VT (C 
10%  I: 6%). Only C showed 
significant improvements in 
chronotropic response (26%) and 
heart rate recovery (61%)   
 
Significant increase in phase I 
oxygen uptake kinetics in both 
groups. Only C showed 
significant improvements in 
phase II oxygen uptake kinetics  
Meyer et al 
(1996) 
Crossover RCT 
comparing 
combined 
aerobic interval 
and resistance 
training with 
usual care 
Randomised n=18  male  CHF 
NYHA II/III (8/10), Age (mean  ± 
SEM) 52 ± 2 yrs;  LVEF 21 ± 2 
%; aetiology: ischaemic 9, dilated 
cardiomyopathy; medication 
(E/C): ACE inhibitors 16, 
diuretics 16, digoxin/digitalis 14, 
β-blockers 7 
5 x 15 min cycle 
ergometer  (30s work 
@ 50% steep ramp test 
peak work rate: 60s @ 
15W) 3 x 10 min 
treadmill (60s work: 
60s low speed) 3 x 20 
min flexibility, 
strength + inspiratory 
exercises per week for 
3 weeks 
CPET on cycle 
ergometer (12.5 W.min-1
Significant improvement in 
VO2peak (20%) & VT (24%) after 
exercise compared with activity 
restriction 
) 
Meyer et al 
(2003) 
Observational 
study measuring 
improve-ments 
in quality of life 
after cardiac 
rehab. 
n=51  CHF NYHA I/II/III  
3/26/22, Male/female 43/8, Age 
59 ± 11 yrs;  LVEF (E/C) 30 ± 
13/32 ± 15 %; aetiology: 
ischaemic 28, dilated 19, valvular 
heart disease 4; medication: ACE 
inhibitors, diuretics, β-blockers, 
angiotensin II inhibitors 
3 sessions per week 
(30 min cycle 
ergometer interval 
training, 30-45 min 
calisthenics, resistance 
and respiratory 
training and 1 
hour/week 
multidisciplinary 
education for 12 wks 
CPET on cycle 
ergometer (12.5 W.min-1
Significant improvement in VT 
(12%), VO2peak (11%), SF-36 
physical functioning, role 
physical and mental health and 
MLHFQ sum (29%) and physical 
scores (37%)  
), 
6 min walk distance, and 
QoL via SF-36 and 
MLHFQ 
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Study Design Sample Exercise Intervention Outcome Variables Results 
Nechwatal et al 
(2002) 
RCT comparing 
interval and 
continuous 
training 
Randomised E1 (continuous: 
n=20) E2 (interval n=20) E3 
(control: n=10) CHF NYHA I-III ;  
LVEF (E1/E2/C) 27/29/27 %; 
aetiology: ischaemic/DCM, 9 
evaluated for heart transplant 
E1: 6 x 15 min cycle 
ergometer sessions @ 
75% HRmax for 3 
weeks; E2: 6 x 15 min 
cycle ergometer 
sessions with intervals 
@ 50% Steep ramp 
test peak work rate for 
3 weeks 
CPET on cycle 
ergometer, 
haemodynamic 
measurements and QoL 
via SF-36 
Significant increase in VO2peak 
(E1: 14%; E2: 14%) and VT (E1: 
9%; E2: 8%). No difference 
between groups. No change in 
central haemodynamics in E1, 
but significant improvement in 
cardiac index, stroke volume 
index, and peripheral resistance 
in E2. QoL improved 
significantly in both groups; 
psychological sum factor 
improved more in E1.   
Sabelis et al 
(2004)   
RCT comparing 
exercise with 
usual care 
Randomised  n=77 CHF NYHA 
II-III  LVEF < 35%  age 40-70 
years, completed n=61 (E/C) 
36/25; male/female (E vs C) 25/11 
vs 20/5 aetiology (E/C): ischaemic 
53/52%, dilated 47/48%; 
medication (E/C): ACE inhibitors 
75/84%, diuretics 53/60%, 
digoxin 13/31%, β-blockers 
50/52% 
2 x 60 min supervised 
sessions/week (warm-
up, interval training 
30s work @ 50% steep 
test peak work rate/60s 
recovery  plus strength 
and endurance 
exercises @ 70% steep 
test HRmax) and 2 x 11 
min home-based 
sessions for 6 months 
CPET on cycle 
ergometer (20W every 3 
min), insulin sensitivity 
(euglycaemic 
hyperinsulinaemic 
clamp) 
Significant increase in VO2peak 
(6%) in E vs C. No significant 
effect of training on insulin 
sensitivity, although change in 
insulin sensitivity correlated 
positively with change in VO2peak 
 
Willenheimer et 
al (1998) 
RCT comparing 
interval exercise 
training with 
usual care 
Randomised n=54 CHF; 
completed n= 49 (E/C) 26/23 ; 
Age (E/C) 64 ± 9/ 64 ± 5 yrs; 
NYHA I/ II/III (E/C) 3/8/16 vs 
3/11/8; LVEF (E/C) 36 ± 11/35 ± 
11 %; ischaemic aetiology (E/C) 
78/73; medication: ACE inhibitors 
100/100 %, diuretics 93/95 %, 
digitalis 30/50% 
3 x 15-45 min sessions 
per week interval 
training (90s @ 80% 
VO2peak HR ± 5 
beats.min-1,
CPET on cycle 
ergometer (30W start, 
10 W.min
 or RPE 15, 
for as long as possible, 
30s rest) for 16 weeks 
-1
No significant improvement in 
VO2peak or VT  in E (5%) vs C, 
despite significant increase in 
exercise duration (7W, 6%) and 
global QoL. Men with ischaemic 
aetiology (n=11)  improved 
significantly more  than  non-
ischaemic aetiology and women.    
 increments), 
LV function via 
echocardiography, 
dyspnea-fatigue index, 
QoL and habitual 
physical activity 
 
Abbreviations: ACE angiotensin converting enzyme; CPET cardiopulmonary exercise test; C control group; E exercise group; HR heart rate; LVEF left ventricular; 
MLHFQ Minnesota Living with Heart Failure Questionnaire; NYHA New York Heart Association; QoL quality of life; RCT randomised controlled trial; SF-36 
Short-Form 36 Questionnaire; VO2peak  peak oxygen uptake; VT ventilatory threshold 
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(Wisloff et al., 2007).  When the intermittent work phases were lower in intensity and 
duration, neither VO2peak or VT increased (Willenheimer et al., 1998).  
An observational study reported increases in QoL as well as cardio-respiratory fitness 
following intermittent training (Meyer and Laederach-Hofmann, 2003).  Sabelis et al 
(2004) reported that intermittent training twice per week, a frequency more in line with 
UK current practice, increased VO2peak compared with no training, but the 6 month 
study duration is considerably longer than current UK programme duration.  
Furthermore, in all these studies, with the exception of Wisloff et al (2007), the 
patients’ mean age was approximately 60 years, younger than the majority of CHF who 
might benefit from exercise training.   
Many UK CR exercise classes comprise circuit-training where patients move around a 
series of different work stations to perform aerobic and muscular strength and 
endurance exercises for a pre-determined period, usually 1-2 min.  The British 
Association for Cardiac Rehabilitation (2006) recommends an intensity for aerobic 
exercise of 60-80% HRmax or 40-70% HRR and an RPE of 12-15, although, it is 
unlikely that these targets can be accurately adhered to in practice (Beale et al, 2010, 
Appendix 7). Circuit training is, arguably, a form of intermittent training in that there 
are periods of aerobic exercise interspersed with active recovery and/or muscular 
strength and endurance exercises.  Nevertheless, this differs from high intensity 
intermittent exercise because the intensity of the work phases is intended to be 
moderate. There is some evidence confirming that circuit-training is appropriate for 
CHF, and that it induces a similar oxygen and haemodynamic demand to continuous 
cycle ergometer exercise at 70-80% HRmax (Green et al., 2001).  However, given the 
low frequency and duration of UK CR programmes (~ 1.6 sessions per week for 7 
weeks) (Taylor et al., 2007), high intensity intermittent exercise might compensate for 
this low exercise dose.   
Given the compelling body of evidence supporting the benefits of exercise training for 
CHF patients, and the recommendation that clinically stable patients should undertake 
exercise training, it would not be ethical to have a control group from who exercise 
training is withheld.  CR programmes are increasingly inclusive of this population, and 
“usual care” now includes an optional short-term exercise programme, based on 
moderate intensity exercise which is commonly circuit-based.  In the light of previous 
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studies that have demonstrated either no change or a decline in health in CHF who are 
inactive for several weeks (Hambrecht et al., 1995a; Meyer et al., 1996c; Maiorana et 
al., 2000), this study proposes to investigate differences in response to different types 
of training, rather than between training and no training. Evidence-based practice is 
now mandatory, supporting the need to compare new treatment strategies with current 
therapy (Beckers et al., 2008), in this case comparing a novel training method with 
existing CR exercise training. 
 Aim 
The aim of this study is to investigate whether high intensity intermittent exercise 
training is different to moderate intensity circuit-based training at improving functional 
capacity, ventilatory efficiency, BNP and QoL in chronic heart failure patients in a 
short-term twice-weekly CR programme.   
Hypothesis 
There will be no difference between traditional circuit-based and high intensity 
intermittent exercise training in improving functional capacity, ventilatory efficiency, 
BNP and quality of life in CHF on a 6 week CR programme.  
7.1 Methods 
7.1.1 Participants 
The study population was obtained by screening all clinically stable patients with CHF 
under the care of the Specialist Heart Function Nurse at Eastbourne District General 
Hospital.  Patients who met the inclusion criteria (described in the General Methods) 
were approached by telephone to establish initial willingness to participate.  Full study 
details were sent to those who indicated this willingness.  A minimum of one week 
later, these patients were contacted by telephone and those who volunteered to 
participate were invited to a familiarisation exercise testing session.  Provided that there 
were no reasons to exclude these patients following this initial session, they were 
enrolled in the study.  Ethical approval and participant informed consent was obtained 
as described in the General Methods. 
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Fifty CHF were screened as meeting the inclusion criteria. Of these, 32 patients agreed 
to take part in the study.  26 of these met the inclusion criteria, and were enrolled in the 
study. Patients were evaluated at baseline and after 12 sessions of exercise training 
performed twice weekly for 6 weeks.  Data collection was carried out over a period of 
16 months, from July 2008 to October 2009.   
7.1.2 Experimental design 
The study involved baseline testing, randomisation to one of two exercise training 
groups for 6 weeks, and follow-up testing.  It was not possible to blind either the 
patients or the assessors to the group assignment.  A schematic of the experimental 
design is shown in Figure 7.2. 
 
Figure 7.2: Schematic of experimental design 
 
   
6 weeks’ training in Phase 3 
(hospital outpatient) cardiac 
rehabilitation setting 
1 week 
Familiarisation 
session 
Maximal cardiopulmonary exercise tests 
Blood sample: BNP 
Health & Quality of Life questionnaires 
Physical Activity record 
 Traditional circuit-based training 
25 min exercise @ 40-70% HRR  RPE 11-13 
Intermittent training:  
25 min exercise: 30s work phase @ 100% VO2peak 
work rate: 60s recovery unloaded pedalling  
OR 
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7.1.3 Cardiopulmonary exercise test 
Standardisation procedures, as described in the General Methods were followed. Based 
on the findings in Chapter 4, which demonstrated a learning effect between the first and 
second attempts at a maximal exercise tests, the current study included familiarisation 
tests for patients who had  not previously performed a maximal test on a cycle 
ergometer.   
 
The equipment used in this study differed from studies 1-3. The ergometer was a semi-
recumbent cycle (semi-couch Schiller, Baar, Switzerland, safety ergometer 911 BP/LS, 
including ergosana measuring system, ergosana Ganshorn Medizin Electronic (GmbH), 
Bitz, Germany). The initial resting phase was 3 minutes, followed by a starting 
workload of 10 W, with increments of 10 W.min-1 as recommended by the ESC 
(Tavazzi et al., 2001). Patients were asked to maintain a pedal cadence of 
approximately 60 rpm, and were verbally encouraged to exercise to exhaustion, as 
defined by intolerable leg fatigue or dyspnoea.   Patients stopped pedalling when 
exhaustion was reached.  During the recovery period, patients were advised to pedal 
with no added resistance at a self-selected cadence in order to avoid venous pooling in 
the legs and subsequent hypotension.   
 
Ventilatory expired gases were obtained at rest and during exercise via a face mask 
using a breath-by-breath respiratory gas analysis system (Schiller ergo-spirometry unit 
with Ganshorn Power Cube gas analysis). Respiratory gas exchange variables were 
produced automatically over a 10s average. VT was identified by computerised V-slope 
method (Katz et al., 1992), and this was cross-checked and confirmed by an 
experienced observer, in conjunction with plots of ventilatory equivalents and end tidal 
gas tensions for VO2 and VCO2, as recommended in the literature (Meyer et al., 2005b; 
Myers et al., 2010). VO2peak and VE/VCO2 slope were analysed according to the 
methods described  Chapter 4 (paragraph 4.1.3).  
 
Respiratory gas measurements were not continued beyond 60s into the recovery period 
since feedback from patients during the familiarisation sessions indicated that wearing 
the mask while recovering from maximal exertion caused intolerable discomfort.   
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7.1.4 Cardiac rehabilitation 
In Eastbourne, the majority of patients attend twice weekly CR sessions for a period of 
6 weeks. This is similar to the frequency (~1.6 sessions per week) and duration (~ 7 
weeks) of other UK CR programmes, but lower than the average 2.8 sessions per week 
for 18 weeks reported in clinical trials of CR (Taylor et al., 2007).  Many of the clinical 
studies in CHF also comprise higher frequencies and duration of training.  However,  
several studies have, like the current study, specifically investigated the benefits of 
exercise programmes in current practice, including once or twice weekly sessions 
(Owen and Croucher, 2000; Austin et al., 2005b; Van Laethem et al., 2007; Nilsson et 
al., 2008b).   
 
Due to lack of resources exercise training for high risk patients, including CHF, and 
those limited by orthopaedic limitations and/or with a very low functional capacity is 
limited to once weekly sessions.  As part of this study, an additional session was added 
to the CR programme for these “high risk” patients, so that they too could attend twice 
weekly. The sessions were run by specialist cardiac nurses and included educational 
sessions on anatomy and physiology, surgical procedures, medication, monitoring and 
interpreting symptoms, stress reduction, dietary behaviour and physical activity. 
Patients were encouraged to perform regular daily moderate physical activity in 
addition to the exercise sessions.   
7.1.5 Exercise training 
Patients were supervised during exercise sessions by CR specialist nurses, exercise 
physiologists and specialist heart function nurses at a staff:patient ratio of 1:4.  BP and 
HR were measured prior to exercise to check for contraindications.  All patients 
performed a gradual warm-up and cool-down prior to and following the circuit or 
intermittent training, in accordance with current guidelines (British Association for 
Cardiac Rehabilitation, 2006; Association of Chartered Physiotherapists in Cardiac 
Rehabilitation, 2009).  HR was monitored throughout via telemetry, and was recorded 
at 5s intervals (Polar Electro 610, Polar Electro, Finland) for each individual during 
their final exercise session, and downloaded for analysis by Polar Precision 
Performance Software (S-Series Precision Toolkit) accessed using a Polar USB IR 
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interface.  Minimum, maximum and average values were calculated for the 25 min 
circuit or intermittent section.   
 
Patients were randomly assigned, in blocks of 4 patients at a time, to circuit or 
intermittent training.  
 
The circuit training protocol followed the existing format for the exercise component of 
Phase III CR at Eastbourne DGH, based on the guidelines from the British Association 
for Cardiac Rehabilitation (2006) and the Association of Chartered Physiotherapists in 
Cardiac Rehabilitation (2009). Following the warm-up component of the exercise class, 
circuit training comprised 10 x 2 min aerobic stations (e.g. walking, cycling, stepping, 
arm ergometer) interspersed with active recovery stations (upper body muscular 
exercises, e.g. biceps curls and chest press, using light hand weights or therabands).  
All patients started with a ratio of 1 aerobic station to 1 active recovery station. Target 
HRs for the aerobic stations were 40-70% HRR, according to current standards and 
guidelines, with an adjustment in the calculation of 20-30 beats.min-1 
If training sessions could not be attended for various reasons (e.g. public holidays), 
extra sessions were added until 12 sessions were completed, within a maximum 
duration of 8 weeks.   
reduction for 
patients on β-blockers (British Association for Cardiac Rehabilitation, 2006; 
Association of Chartered Physiotherapists in Cardiac Rehabilitation, 2009).  In addition 
to target HR, or in cases where patients were unable to achieve target HR, or HR values 
could not be obtained by telemetry, patients were instructed to exercise at RPE 11-13.  
Depending on individual progress, patients progressed from arm ergometry to rowing, 
and then increased the ratio of aerobic stations to active recovery stations.   
 
High intensity intermittent training was performed on a cycle ergometer following the 
warm-up component of the exercise class.  Following a 2 minute phase of unloaded 
cycling, patients performed 10–15 repetitions of 30s work phases @ 100% work rate 
achieved in the maximal CPET, interspersed with 60s of unloaded pedalling at a self-
selected cadence.   This protocol was chosen after Studies 2 and 3 demonstrated that it 
was achievable for CHF, but induced a higher Lac than lower intensity work phases, 
suggesting that the stimulus to the peripheral muscles was higher. 
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7.1.6 Blood sampling and analysis 
Blood samples were taken from 15 CHF (circuit n = 7, intermittent n = 8) for analysis 
of B-type Natriuretic Peptide (BNP). At the same time of day at baseline and post-
training, after 30 min seated rest, a 5ml venous sample was drawn from the ante-cubital 
vein into a sterile syringe by a trained phlebotomist. The whole blood was then 
immediately analysed for BNP by The Triage®
7.1.7 Quality of life measures 
 BNP Test (Biosite Ltd, Belfast, or 
Biosite Diagnostice Inc, San Diego, California), a rapid point-of-care fluorescence 
immunoassay, a sensitive and specific test used to diagnose CHF in a point-of-care 
setting (Dao et al., 2001). This test is reported to be reproducible, with an interassay 
coefficient of variation (n=10) of 8.4% and 8.0% at concentrations of 19.3 ng/l and 392 
ng/l, respectively (r=0.998, from 5 pg/ml to 818 pg/ml) (Vogeser and Jacob, 2001).   In 
the current study, duplicate testing was carried out on two different samples, with 
coefficients of variation of 4.8% for a mean value of 176 pg/ml and 3.6% for a mean 
value of 277 pg/ml.  
 
The BNP test kit includes built in controls to check that the control value results are 
within the limits set during manufacturing. Two external liquid control solutions were 
used to calibrate the test meter with each new lot of test devices. The Quality Control 
Device was used before each testing session to verify instrument performance, and it 
was ensured that each parameter passed this calibration test before analysis of blood 
samples.   
7.1.7.1 Minnesota Living with Heart Failure Questionnaire 
At baseline and at the end of the training programme, QoL was assessed with the 
Minnesota Living with Heart Failure Questionnaire (MLHFQ) (Rector et al., 1987a; 
Rector et al., 1987b; Rector, 2005) (Appendix 6), according to current guidelines 
(Rector and Cohn, 2004).  This self-administered disease-specific questionnaire 
consists of 21 items recording patients’ perceptions of how CHF affects their physical, 
psychological and socioeconomic lives. Using a Likert scale, answers are given a score 
from 0 (no effect) to 5 (severe effect), resulting in a total scoring range from 0 to 105, 
with lower scores indicating a better QoL.  Separate physical and emotional dimension 
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scores may also be identified to further characterize the effect of heart failure on a 
patient’s life.  Patients were asked to mark zero for any items that did not apply to 
them, to avoid the problem of missing data affecting within-patient scores.   
7.1.7.2 Medical Outcomes Study Short Form Health Survey (SF-36)  
At baseline and at the end of the training programme, QoL was assessed with the 
Medical Outcomes Study Short Form Health Survey (SF-36) (Appendix 6).  This self-
administered questionnaire consists of 36 items recording patients’ perceptions of their 
health, with higher scores indicating a better health state.  After data entry, according to 
the manual and interpretation guide (Ware et al., 1993), 10 items were re-coded, scale 
scores were computed by summing items in the same scale, and raw scale scores were 
transformed to a 0-100 scale.  Normative scores from the general population are 
provided for reference. 
7.1.8 Physical activity record  
Patients completed a physical activity record for the 8 week study period by making a 
note of any physical activity undertaken (for a period of ≥ 5 minutes), and listing the 
type and intensity of activity (e.g. 10 minutes weeding and pruning, light intensity).  
From the information provided, the metabolic equivalent values (METs) were 
estimated from the Compendium of Physical Activities (Ainsworth et al., 2000), and 
number of minutes of light (< 3 METS) or moderate (3-6 METS) activity were 
classified, and the total duration calculated for each week (Macfarlane et al., 2006).   
7.1.9 Statistical analysis 
The Kolmogorov-Smirnov and Levene tests were used to test for normality of 
distribution and homogeneity of variance of the data between the circuit and 
intermittent training groups. Where the assumptions of normality were violated, a non 
parametric test was used to compare the difference between groups and effect of 
training.  Where the data was normally distributed, but the variance was significantly 
different between groups, the “equal variances not assumed” t test statistic was used to 
test for differences between groups at baseline.  At baseline, after randomisation, group 
differences were compared using independent samples Student’s t-tests or Mann-
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Whitney U tests as appropriate.  Two way repeated measures analyses of variance were 
used to calculate the effect of training and any interaction (difference in the effect of 
training between groups).  The Mann-Whitney U test was used to compare the 
difference between groups in changes in QoL from pre- to post-training.  The 
relationship between changes in cardiorespiratory fitness and QoL following training 
was determined by Pearson’s correlation coefficient, or, where data was not normally 
distributed, by Spearman’s correlation coefficient.   
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7.2 Results 
7.2.1 Participants 
The flow chart in Figure 7.3 describes the participant recruitment process. Twenty six 
CHF (19 men and 7 women, age 73 ± 7 years) in NYHA class II (n=20) or III (n=6) 
commenced the study.  Patients were classified as having ischaemic cardiomyopathy if 
they had experienced a myocardial infarction or had angiographic evidence of coronary 
heart disease.  If they did not meet these criteria, they were classified as having 
idiopathic dilated cardiomyopathy. The aetiology was ischaemic heart disease (n=18) 
or idiopathic dilated cardiomyopathy (n=8), and the following co-morbidities were 
present: hypertension (n=3), diabetes (n=3), intermittent claudication (n=1), COPD 
(n=3).  8 CHF were in atrial fibrillation, 8 had cardiac resynchronisation devices with 
implantable cardioverter defibrillators (CRT-D), and 3 had biventricular pacemakers.  
Mean LVEF as determined by echocardiography was < 40%.  All patients had been in a 
stable condition for the preceding 4 weeks and were on optimal medication doses: ace 
inhibitor (15), angiotensin receptor antagonist (9), anti-arrhythmic (11) [amiodarone 6/ 
digoxin 5], beta-blocker (21), diuretic (17), statin (18), calcium-channel blocker (1), 
alpha-blocker (1), aldosterone antagonist (1) and potassium channel activator (3). 20 
patients (14 men and 6 women, age 73 ± 7 years) completed the study and their data is 
included in the statistical analysis.  
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Figure 7.3: Participant recruitment flow chart 
CPET cardiopulmonary exercise test; HRR heart rate reserve  
Assessed for eligibility and approached by telephone (n = 50) 
Declined  to participate (n = 18) 
Met inclusion criteria and performed 2nd 
CPET: randomised (n = 26)  
Accepted and attended familiarisation  CPET  (n=32) 
Did not meet inclusion criteria: excluded (n = 6) 
Intermittent training group (n = 13)              
2 x 45 min sessions per week for 6 weeks             
10 min warm up/cool down                                           
cycle ergometer: 10-15 x 30s work phases 
@ 100% VO2peak work rate with 60s 
recovery phases unloaded 
Circuit training group (n = 13)                             
2 x 45 min sessions per week for 6 weeks             
10 min warm up/cool down                                           
10 x 2 min aerobic (e.g. walking, cycling, 
stepping @ 40-70% HRR) and active recovery 
(upper body muscular exercises) stations 
Discontinued  (n = 1) Discontinued  (n = 3) 
Completed training, data included in 
analysis (n = 11)                
Completed training, unable to attend 
exercise test (n = 1)  
Completed training, data included in 
analysis (n = 9)                  
Completed training, unable to attend 
exercise test (n = 1)  
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Table 7.2: Baseline characteristics of CHF who did and did not complete the study 
(mean ± SD) 
 
Characteristic Completed 
(n = 20) 
Did not complete 
(n = 6) 
Age (years) 73 ± 7 76 ± 7 
Male/female 14/6 5/1 
Height (m) 1.71 ± 0.09 1.73 ± 0.06 
Body mass (kg) 83 ± 21 82 ± 6  
NYHA class II/III 18/2 2/4 
Ejection fraction (%) 29 ± 10 35 ± 6 
Aetiology (ischaemic/DCM) 13/7 5/0 
VO2peak (ml.kg-1.min-1 13.84 ± 4.08 ) 12.87 ± 2.97 
Peak RER 
Peak work rate (W) 
1.11 
69 ± 19 
1.12 
58 ± 19 
VO2 at VT (ml.kg-1.min-1 9.07 ± 2.33 ) 8.85  ± 1.06 
VE/VCO2 slope 30.42 ± 3.6 33.8 ± 1.6 
BNP (pg/ml) 346 ± 295 665 ± 456 
MLHFQ    Total score 29 ± 16 44 ± 11 
                   Physical 15 ± 9 22 ± 5 
                   Emotional 7 ± 6 14 ± 3* 
DCM: idiopathic dilated cardiomyopathy; BNP: B-type natriuretic 
peptide; MLFHQ: Minnesota Living with Heart Failure Questionnaire 
* P < 0.05 different from Completed 
 
 
Patients who did not complete the study tended to be older, were more likely to be in 
NYHA class III and have CHF of ischaemic aetiology, and achieved a lower peak work 
rate, a lower VO2 at peak exercise and at VT, a higher VE/VCO2 slope and BNP value, 
and a poorer QoL, as measured by the MLFHQ.  However, only the emotional 
component MLFHQ score was significantly different between groups (P = 0.016) 
(Table 7.2) 
 
There were no significant differences between the circuit and intermittent groups in 
baseline measures (Table 7.3).  The data was normally distributed and homogenous in 
variance, unless stated otherwise below. 
 
  
159 
 
 
 
Table 7.3: Baseline characteristics of CHF in the circuit and intermittent training 
groups (mean ± SD).   
There were no significant differences between groups. 
 
Characteristic Circuit group 
(n=9) 
Intermittent 
group (n=11) 
Age (years) 73 ± 7 73 ± 7 
Male/female 7/2 7/4 
NYHA class II/III 8/1 10/1 
Ejection fraction (%) 27 ± 9 32 ± 9 
Resting heart rate (beats.min-1 68 ± 11 ) 67 ± 15 
Systolic blood pressure (mm.Hg-1 114 ± 19 ) 120 ± 22 
Diastolic blood pressure (mm.Hg-1 69 ± 13 ) 72 ± 12 
Aetiology (ischaemic/DCM) 5/3 7/4 
Medication:   
     α-blocker 1 0 
     ACE inhibitor 5 6 
     Aldosterone antagonist  0 1 
     Angiotension II receptor blocker 4 5 
     Anti-arrhythmic 
(amiodorone/digoxin)  2/3 2/1 
     β-blocker 8 10 
     Calcium channel blocker 1 0 
     Diuretic 5 9 
     Potassium channel activator 0 1 
     Statin 6 8 
BNP (pg/ml) 420 ± 136 274 ± 45 
MLHFQ  Total score 25 ± 5 32 ± 5 
                 Physical component 13 ± 3 16 ± 3 
                 Emotional component 6 ± 2 8 ± 2 
ACE: angiotensin converting enzyme; DCM: idiopathic dilated cardiomyopathy; BNP: B-
type natriuretic peptide; MLHFQ: Minnesota Living with Heart Failure Questionnaire 
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7.2.2 Medication 
At baseline medication was similar between groups (Table 7.3). During the intervention 
period there were minor changes in medication in some patients; in two patients, one of 
whom did not complete the final exercise test, the β-blocker dose was increased.  In one 
patient, the dose of diuretics was increased, and in another the brand of angiotensin II 
receptor blocker was changed. 
7.2.3 Safety 
There was one case of post-exercise hypotension resulting in syncope and admission to 
hospital for 24 hours’ observation in a patient with an ICD in the intermittent group.  
Clinical investigations revealed no effects beyond the brief period of hypotension, but it 
was recommended that the patient withdraw from the study as a precaution.  No other 
adverse events occurred during exercise training.  
7.2.4 Compliance 
In addition to the patient described above, 3 further patients withdrew from the study 
within the first 2 weeks of training, 2 from the circuit and 1 from the intermittent group, 
for medical reasons unrelated to cardiac health (removal of ingrown toenail, 
incapacitating arthritis and newly diagnosed Pagett’s disease).  One patient in the 
intermittent group and 1 patient in the circuit group were not well enough to participate 
in the post-training exercise test (due to worsening breathlessness in both cases).  
Twenty patients randomly assigned to the circuit (n=9) or intermittent (n=11) training 
attended > 80% of the sessions (mean attendance 96 ± 2% of sessions) and were 
included in the analysis of baseline and post-testing values.   
 
Patients in the circuit group exercised for 20-25 min (10 exercise stations, 2 min per 
station plus 30s change-over time) at a mean HR of 97 ± 6 beats.min-1.  All patients 
started with 2 min aerobic exercise:2 min active recovery. Seven patients progressed to 
4 min aerobic exercise:2 min active recovery.  Patients in the intermittent group 
exercised for 20-25 at a mean HR of 106 ± 7 beats.min-1 and performed 10-15 30s work 
intervals at 100% WRpeak achieved on the CPET.  Seven patients started with 10 work 
intervals and progressed to 15 by the end of the programme.  Patients (n = 4) who were 
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unable to complete 10 work intervals in succession were permitted a 2-4 min recovery 
period of low-intensity walking and/or arm ergometer exercise half way through the 
intermittent exercise session.  All of these patients were able to complete ≥ 10 work 
intervals on the cycle ergometer by the end of the 6-week training programme.  All 
patients maintained a RPE between 11 and 14 during the training sessions.  
7.2.5 Effect of exercise training on CPET variables 
CPET results at baseline and after 6 weeks’ training in the circuit and intermittent 
training groups are shown in table 7.4.  There was a significant main effect of training 
on VT (P = 0.010) and on WRpeak (P = 0.023) but no interaction (P = 0.573 and P = 
0.368 respectively) and no difference between the circuit and intermittent groups (P = 
0.540, P = 0.717 respectively).  There were no significant differences in any other 
variable. Further details of statistical results are included in Appendix 5.  The effect 
size was moderate for VT (partial η2 = 0.545) and small for WRpeak (partial η2 
  
= 0.256). 
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Table 7.4: Cardiopulmonary exercise data in the circuit and intermittent training groups at baseline and after 6 weeks’ training  
 
 Circuit Group (n=9) Intermittent Group (n = 11)  P value  
Exercise test variables Baseline Post-Training % change Baseline Post-Training % change main 
effect 
inter-
action 
between 
subjects 
          
Test duration (s) 413 ± 22 428 ± 35 3 ± 5 408 ± 39 440 ± 41 9 ± 5 .084 .509 .950 
Peak work rate (W) 68 ± 4 71 ± 6 4 ± 5 69 ± 7 76 ± 7 14 ± 6 .023 .368 * .717 
VO2peak (ml.min-1 1,054 ± 65 ) 1.157 ± 107 8 ± 5 1,167 ± 114 1,206 ± 104 6 ± 6 .081 .418 .569 
VO2peak (ml.kg-1.min-1 13.5 ± 1.2 ) 15.0 ± 1.5 11 ± 4 14.1 ± 1.4 14.4 ± 1.2 5 ± 6 .064 .205 .976 
 Peak RER 1.08 ± 0.03 1.11 ± 0.02  1.14 ± 0.03 1.09 ± 0.03     
VO2 at VT  (L.min-1 0.716 ± 0.045 ) 0.803 ± 0.052 13 ± 7 0.738 ± 0.070 0.871 ± 0.078 19 ± 5 .008 .893 * .747 
VO2 at VT (ml.kg-1.min-1 9.27 ± 0.72 ) 10.24 ± 0.92 11 ± 6 8.90 ± 0.77 10.55 ± 0.98 18 ± 5 .010 .573 * .540 
VE/VCO2 slope 31.8 ± 1.5 31.7 ± 1.8 0 ± 3 29.6 ± 1.4 28.7 ± 1.4 -2 ± 4 .614 .880 .174 
*P < 0.05            
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7.2.5.1 Inter-individual variation 
Inter-individual variation was seen in changes in VT and VO2peak in response to training 
(table 7.5) 
 
Table 7.5: Inter-individual variation in change in VT and VO2peak in response to 
training 
 
Change from 
baseline to post- 
training  
Circuit 
(n = 9) 
Intermittent 
(n = 11) 
VT  VO2peak VT  VO2peak 
Decrease 0-9%  2 1 2 
Decrease ≥ 10% 1   2 
Increase 0-9% 5 3 2 4 
Increase 10-19% 2 2 2  
Increase 20-29%  1 4 3 
Increase 30-39%  1 1  
Increase 40-49%     
Increase 50-59% 1    
 
 
Two patients in the intermittent group showed decreases of 21% and 30% in relative 
VO2peak following training, despite no change in body mass.  They were aged 66 and 75 
years respectively, both had ICDs. One had ischaemic and the other had non-ischaemic 
heart failure. 
 
The relationship between VO2peak and change in VO2peak in the 2 groups is illustrated in 
Figure 7.4.  There was a moderate negative correlation in the intermittent group but this 
was not statistically significant (circuit group: r = .365, P = 0.334; intermittent group: r 
= - .428, P = 0.189).   
 
The relationship between VT and change in VT in the 2 different groups is illustrated in 
Figure 7.5. There was a moderate correlation in the intermittent group but this was not 
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statistically significant (circuit group: r = .146, P = 0.708; intermittent group: r = .410, 
P = 0.210).   
 
The relationship between baseline VO2peak and change in VO2peak in CHF with 
ischaemic and non ischaemic aetiology is illustrated in Figure 7.6. There was a weak 
positive correlation between change in VO2peak relative to baseline VO2peak in patients 
with CHF of ischaemic aetiology (r = .354, P = 0.259).  By contrast, in patients with 
CHF of non-ischaemic aetiology there was a strong and significant negative correlation 
(r = -.885, P = 0.004), indicating that a higher baseline value were associated with a 
lower, possibly negative, training response. 
  
The relationship between baseline VT and change in VT in CHF with ischaemic and 
non ischaemic aetiology is illustrated in Figure 7.7. There was a moderate non-
significant correlation between change in VT relative to baseline VT in patients with 
CHF of ischaemic aetiology (r = .553, P = 0.062).  In patients with CHF of non-
ischaemic aetiology there was a weak negative correlation (r = -.145, P = 0.731). 
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Figure 7.4: Change in VO2peak following exercise training versus baseline VO2peak 
in circuit and intermittent groups  
 
 
Figure 7.5: Change in VT following exercise training versus baseline VT in circuit 
and intermittent groups 
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Figure 7.6: Change in VO2peak following exercise training versus baseline VO2peak 
in patients with ischaemic and non-ischaemic aetiology 
** P < 0.01 
 
Figure 7.7: Change in VT following exercise training versus baseline VT  in 
patients with ischaemic and non-ischaemic aetiology 
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7.2.6 BNP 
BNP decreased from 420 ± 136 to 383 ± 86 pg.ml-1 in the circuit group (n=7) and 
increased from 274 ± 45 to 307 ± 50 pg.ml-1 in the intermittent group (n=8).  There was 
no main effect from training (P = 0.738), and no interaction (P = 0.355) or difference 
between groups (P = 0.565).  The range of values was large (circuit group 78 – 1210 
pg.ml-1; intermittent group 103 – 508 pg.ml-1
7.2.7 Heart rate  
) and the change following training was > 
10%, both positive and negative, in 10 out of 14 patients.  
Measurement of HRpeak was compounded by interference to the ECG signal by 
muscular movement during peak exercise.  In addition, accurate HR measurements 
could not be taken during exercise for the 8 patients in atrial fibrillation.  HR data 
during exercise training is presented in section 7.2.10. 
7.2.8 Quality of life 
7.2.8.1 Minnesota Living with Heart Failure Questionnaire (MLHFQ) 
The MLHFQ data was not normally distributed. The non parametric Mann Whitney U 
test showed that there was no significant difference in total MLHFQ scores between 
groups at baseline (P = 0.235), nor in physical or emotional component scores (P = 
0.487 and 0.265 respectively).   
 
MLHFQ scores for the circuit and intermittent groups, and for individuals within the 
groups, are illustrated in Figures 7.8-7.11. The Wilcoxon Signed Ranks test showed a 
significant improvement in total MLHFQ score in both groups following training 
(circuit P = 0.017, intermittent (P = 0.050).  Physical component score improved 
significantly in the circuit group only (P = 0.038) , while emotional component score 
improved significantly in the intermittent group only (P = 0.024).  Seven out of ten 
patients in the circuit group and six out of ten in the intermittent group showed a 
reduction in total MLHFQ of ≥ 5 points which is con sidered to be clinically relevant.  
There was no significant difference between groups in changes in MLHFQ scores. 
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Figure 7.8: Minnesota Living with Heart Failure Questionnaire total and 
component scores before and after training in the circuit group (mean ± SEM).  
** P = 0.017, * P = 0.038 
 
Figure 7.9: Minnesota Living with Heart Failure Questionnaire total scores for 
individual patients before and after training in the circuit training group.  
The squares and black line denote the mean values. 
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Figure 7.10: Minnesota Living with Heart Failure Questionnaire total and 
component scores before and after training in the intermittent group (mean ± 
SEM).  
* P = 0.050, † P = 0.024  
 
Figure 7.11: Minnesota Living with Heart Failure Questionnaire total scores for 
individual patients before and after training in the intermittent group.  
The squares and black line denote the mean values. * P = 0.050 
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7.2.8.2 Short-Form 36 (SF-36) 
SF-36 scores for the intermittent and circuit groups are illustrated in Figures 7.12 and 
7.13. The Kolmogorov-Smirnov test showed that the data for 5 of the 8 scales were not 
normally distributed in one or both groups,  therefore non-parametric tests were used. 
The Mann Whitney U test showed no significant difference in SF-36 scales between 
groups at baseline, with the exception of Bodily Pain (P = 0.02) 
 
The Wilcoxon Signed Ranks test showed no significant difference in baseline and post-
training scores in any of the SF-36 scales (Table 7.7). The Mann Whitney U test 
showed no significant difference in change in SF-36 between the two groups.   
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Table 7.6: SF-36 scores at baseline and after training in the circuit and intermittent groups 
 
 
Circuit Group (n=9) Intermittent Group (n=10) 
 
SF-36 Scale Baseline 
Post-
Training 
Change 
in score 
P 
value  Baseline  
 Post-
Training  
 
Change 
in score  
P 
value 
Normative 
scores 
Physical 
Functioning 61 ± 15 64 ± 16 3 ± 10 
 
0.343  53 ± 23   59 ± 22   6 ± 14  
 
0.233 85 ± 23 
Role-
Physical 53 ± 44 64 ± 40 11 ± 20 
 
 
0.157  43 ± 50   60 ± 41   18 ± 31  
 
 
0.102 81 ± 34 
Bodily Pain 31 ± 8 31 ± 9 0 ± 10 
 
1.000  20 ± 11   24 ± 11   4 ± 7  
 
0.102 76 ± 24 
General 
Health 56 ± 24 59 ± 24 2 ± 19 
 
0.723  48 ± 16   59 ± 21   11 ± 18  
 
0.109 72 ± 20 
Vitality 54 ± 18 65 ± 20 11 ± 19 
 
0.091  41 ± 26   51 ± 21   10 ± 20  
 
0.072 61 ± 21 
Social 
Functioning 83 ± 26 89 ± 16 6 ± 24 
 
0.892  81 ± 14   83 ± 16   1 ± 15  
 
0.750 84 ± 22 
Role-
Emotional 56 ± 47 74 ± 36 19 ± 31 
 
0.109  70 ± 37   80 ± 36   10 ± 27  
 
 
0.257 81 ± 33 
Mental 
Health 78 ± 24 77 ± 18 -1 ± 14 
 
0.461  69 ± 21   75 ± 15   6 ± 18  
 
0.396 75 ± 18 
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Figure 7.12: SF-36 scores before and after training in the circuit group (mean ± 
SEM). 
No significant differences were found 
 
Figure 7.13: SF-36 scores before and after training in the intermittent group (mean ± 
SEM).  
No significant differences were found. 
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7.2.9 Relationship between change in functional capacity and quality of life in 
the circuit and intermittent groups 
There were no significant correlations between changes in VO2peak, VT and QoL after 
training, nor were changes in these variables significantly correlated with age (Table 
7.8).     
Table 7.7 Correlations between change in functional capacity, quality of life and 
age in the circuit and intermittent groups 
 
   Change in VT (ml.kg-1.min-1) 
Change in 
MLHFQ score Age 
Circuit 
n=9 
Change in VO2peak 
(ml.kg-1.min-1
Correlation
) 
.644 
0.061 
‡ 
P value 
-.502 
0.168 
.140 
0.720 
 Change in VT  (ml.kg-1.min-1
Correlation
) 
‡
P value  
-.628 
0.070 
.296 
.440 
 Change in  MLHFQ score 
Correlation‡ 
P value   
-.059 
0.881 
Intermittent 
n=11 
Change in VO2peak 
(ml.kg-1.min-1
Correlation
) 
‡ -531 
0.093 P value 
.129 
0.723 
.195 
0.565 
 Change in VT  (ml.kg-1.min-1
Correlation
) 
‡
P value  
.190 
0.599 
-.157 
0.645 
 Change in  MLHFQ score 
Correlation‡
P value   
.464 
0.177 
‡ Pearson’s for parametric data and Spearman’s for non-parametric (MLHFQ) data 
 
7.2.10 Training data 
Mean ± SD work phases in the intermittent group, set at 100% WRpeak, were 70 ± 25 W 
(range 40 - 90 W).  RPE for both groups during training was maintained at 11-13.  In 
patients in AF, and in some patients with implantable devices, HR could not be 
accurately recorded during exercise.  Although theoretical HR training zones were 
calculated at the beginning of the programme for patients in the circuit training group, 
in practice it was not useful to use these to monitor the intensity of training due to 
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inability of patients to achieve exercising HR that corresponded to prescribed HR in the 
minority of patients for whom accurate HR telemetry data could be obtained.   
 
Values for average, minimum and maximum HR during the final training session for 
patients, excluding those in AF, or with non-rate responsive pacemakers, are shown in 
Table 7.9. The Mann Whitney U test showed no significant differences between groups 
in resting HR, average HR during exercise or average, minimum and maximum HR 
expressed as % HRpeak (P > 0.05).  In both groups the mean HR (averaged over the 20 
min session) exceeded 90% of the HRpeak achieved during CPET, and the highest HR 
during training was close to, or higher than HRpeak.  The larger HR range during 
training in the circuit group (77 ± 5 - 103 ± 7% HRpeak) compared with the intermittent 
group (85 ± 4 - 99 ± 4% HRpeak) reflects the different types of exercises performed in 
this group, e.g. active recovery exercises with light hand weights and stepping.  Figures 
7.15 and 7.16 show examples from one patient in each group.   
 
Table 7.8: Heart rate during the “aerobic” component of training in the circuit 
and intermittent groups.   
Patients in AF or with non rate-responsive pacemakers are excluded. 
 
Heart Rate (beats.min-1)   Circuit group 
(n=4) 
Intermittent 
group (n=6) 
Average 97 ± 6 106 ± 7 
Expressed as % peak heart rate achieved during CPET 
Average 91 ± 6% 92 ± 3% 
Minimum 77 ± 5% 85 ± 4% 
Maximum 103 ± 7% 99 ± 4% 
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Figure 7.14: Exercise session heart rate data for patient in intermittent group 
(female, aged 70 years). 
 
 
Figure 7.15: Exercise session heart rate data for patient in circuit group (female, 
aged 62 years). 
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7.2.11  Physical activity record 
Time spent in physical activity outside the CR classes is shown Figure 7.17.   There 
was substantial intra-individual variability; minutes spent in light (< 3 METS) activity 
ranged from 0 – 720 min (circuit: 211 ± 93, intermittent: 274 ± 59) and moderate (3-6 
METS) activity from 60 to 600 min in different patients (circuit: 298 ± 72, intermittent: 
234 ± 97).  There was evidence of differences in subjective interpretation of what 
constitutes light or moderate physical activity. Some patients listed housework & meal 
preparation as light activity, others did not consider it to “count” as activity, so did not 
include it.  Nevertheless, the data collected indicates that physical activity habits did 
not change significantly during the 6 week training intervention (P = 0.617), and that 
there were no significant differences in physical activity levels between the circuit and 
intermittent groups (P = 0.742).   
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A 
  
B 
Figure 7.16: Minutes (mean ± SEM) spent in light (< 3 METS) and moderate (3-6 
METS) physical activity each week in the circuit (A) and intermittent (B) groups  
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7.3 Discussion 
This study is the first to compare a high intensity intermittent training programme with 
traditional circuit-based training in a UK CR hospital-based outpatient setting in a 
representative sample of the general CHF population. In agreement with previous 
studies of longer duration, this study demonstrates that both circuit training, set at 
moderate intensity, and high intensity intermittent training significantly improve sub-
maximal exercise capacity and disease specific QoL in CHF after only 6 weeks. 
However, neither training method resulted in the 10-30% increase in VO2peak commonly 
reported following exercise interventions, nor in a reduction in BNP, VE /VCO2 slope 
or generic QoL.  
7.3.1 Recruitment and compliance 
The recruitment and compliance of participants to exercise training studies can be 
challenging, and particularly so in an elderly population with chronic disease.  This 
study provides interesting information on patient recruitment for exercise training 
studies in a clinical setting.  64% of eligible patients volunteered to participate, which 
is higher than the 40-45% reported in similar studies (Jolly et al., 2007; Prescott et al., 
2009).  Although 64% of the 50 patients invited to participate agreed to do so, 52% 
actually started the study, and 40%, or 77% of those who started, completed.  
Adherence to supervised exercise training has previously been reported as 75% in a 16 
week study (Willenheimer et al., 1998) to > 80% for  shorter studies (Wielenga et al., 
1999; Dimopoulos et al., 2006).  In a UK CR programme, 12 patients out of 100 
withdrew from the exercise intervention due to onset of severe co-morbidity or anxiety 
about exercise, typical reasons for non-compliance in an elderly population with 
physical and psychological frailty (Austin et al., 2005b).  The reasons for non-
completion in the current study were worsening heart failure and other co-morbidities.  
Only one patient stopped training due to an adverse reaction (hypotension).  Patients 
with ischaemic rather than non-ischaemic CHF are more likely to “drop out” of 
exercise training studies (44% vs 17%) (Keteyian et al., 1996), and all 6 non-
completers in the current study had ischaemic CHF.  Interestingly, non-completers had 
a significantly higher emotional component MLFHQ score than completers, which 
might have affected their confidence to continue training.  Alternatively the poorer 
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emotional QoL could reflect that they were more affected by their CHF and co-
morbidities.  In general, non-completers did tend to be older, in a higher NYHA class, 
and have poorer functional capacity and higher BNP values, as well as poorer QoL.  
7.3.2 Exercise performance 
A recent systematic quantitative review reports a 13% significant increase in VO2peak 
(+2.06 ml.kg-1.min-1) , with a pooled effect size of 0.60 and 95% confidence intervals 
of 0.42–0.79 ml.kg-1.min-1 (van Tol et al., 2006). In the current study the increase in 
VO2peak did not reach statistical significance (circuit: 1.53 ± 0.54 ml.kg-1.min-1 (11± 4 
%), intermittent 0.30 ± 0.70 ml.kg-1.min-1 (5 ± 6%), although the WRpeak was 
significantly higher after training. Several previous studies have also reported small 
increases in VO2peak alongside significant increases in WRpeak (Kiilavuori et al., 1996; 
Willenheimer et al., 1998; Wielenga et al., 1999; Larsen et al., 2001; Conraads et al., 
2004; Jonsdottir et al., 2006).   
VO2peak is the most commonly reported outcome measure in exercise training studies in 
CHF, and has prognostic value, but day-to-day limitations in function are more likely to 
be related to VT. van Tol et al’s systematic quantitative review reports a 17.4% 
significant increase in VT (+1.91 ml.kg-1.min-1), with a pooled effect size of 0.84 and 
95% confidence intervals of 0.48 –1.20 ml.kg-1.min-1. The current study demonstrates 
improvements of a similar size (circuit: 0.97 ± 0.47 ml.kg-1.min-1 (11± 6 %), 
intermittent 1.64 ± 0.40 ml.kg-1.min-1
 
 (18 ± 5%), with no significant difference between 
groups.  The implication is that both modes of exercise training will enable patients to 
achieve routine daily activities with fewer symptoms, but that high intensity 
intermittent training offers no advantage.  
 This finding is contrary to the view that short-term high intensity intermittent exercise 
training is particularly effective at increasing VO2peak and VO2 at VT  (Meyer et al., 
1996c).  A more recent 6 month intervention using Meyer’s intermittent training 
protocol, but during twice weekly sessions rather than Meyer’s five sessions per week, 
and supplemented with home-based strength and endurance training, reported a smaller 
increase in VO2peak (6%) (Sabelis et al., 2004).  Both studies compared intermittent 
training with no training, rather than with an alternative mode of training.   
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Other studies have specifically compared high intensity intermittent with moderate 
continuous cycle training, and have reported no advantage of intermittent training in 
improving maximal or sub-maximal exercise capacity.  Dimopoulos et al (2006) 
reported significant increases in WRpeak of 20% and 30%, in VO2peak of 6% and 8%, 
and in VT of 10% and 6% after 12 weeks’ continuous and intermittent training 
(Dimopoulos et al., 2006). A 3 week intervention resulted in improvements in VO2peak 
of 14% in both the continuous and the intermittent group, and increases in VT of 9% 
and 8% respectively (Nechwatal et al., 2002).  However, some exercise interventions,  
including moderate continuous (Keteyian et al., 1999) and intermittent (Willenheimer 
et al., 1998) exercise have failed to improve VT, despite being considerably longer in 
duration and including more frequent training sessions.  
One study comparing intermittent to continuous training, in CHF with similar baseline 
exercise capacity to those in the current study,  has reported greater improvements in 
VO2peak following intermittent exercise (46% vs 14%)  (Wisloff et al., 2007).  The 
larger improvements may be explained by the increased duration of the intermittent 
work phases (4 min at 90-95% HRmax) as well as the additional training session per 
week and the 12 week study duration. This exercise stimulus resulted in substantial 
improvements in exercise capacity, and these were matched by improvements in LV 
diameters and volumes, myocardial contractile function, endothelial function and BNP, 
suggesting that haemodynamic and myocardial abnormalities were particularly 
responsive to this stimulus and contributed to the improvement in VO2peak.   
The current study set out to compare high intensity intermittent training with circuit 
training in which the intensity was intended to be moderate (Association of Chartered 
Physiotherapists in Cardiac Rehabilitation, 2009). However, the HR data recorded 
during the circuit training suggests that the intensity is variable, and is not necessarily 
moderate.  Although the exercise intensities of the two different training interventions 
were pre-determined, in practice it is difficult to ensure that this intensity is maintained, 
and to measure the total amount of work achieved.  The intensity of the intermittent 
training was set (30s at 100% WRpeak), although the number of repetitions performed 
depended on individual capabilities.  The intensity of the circuit training was, in theory, 
set at 40-70% HRR.  HR was recorded throughout the final exercise session as an 
indicator of the intensity of exercise performed.  After excluding patients in AF and 
those with non-rate responsive pacemakers, data was only available for 4 patients in the 
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circuit group and 6 in the intermitent group. In both groups, the mean training HR 
exceeded 90% HRpeak achieved during CPET, and the highest training HR was close to, 
or higher than this HRpeak.  This was possibly due to the difference in haemodynamics 
between semi-recumbent cycling in the CPET and upright cycling and/or weight 
bearing exercise performed during the training session, and is  discussed further in 
Chapter 8 (Section 8.4). Alternatively, the short duration of the CPET (7 ± 2 min) 
compared with the 20 exercise session, which was preceded by a 10 min warm-up, 
might not have allowed adequate time for the chronotropic response. Average HR was 
not different between groups, but HR was more variable in the the circuit group, 
ranging from 77-103% HRpeak compared to 85-99% HRpeak in the intermittent group.  
This is probably a reflection of the different types of exercises performed in this group, 
e.g. active recovery exercises with light hand weights and weight-bearing exercises, 
such as walking or stepping,  engaging a greater active muscle mass than cycling.  One 
small study of 6 CHF  has previously reported no differences in VO2, HR, BP or RPE 
between circuit training and continuous cycling exercise at 70-80% HRmax (Green et al., 
2001).  Interestingly, in patients performing continuous exercise on a cycle ergometer, 
HR correlated with VO2, but not with RPE, whereas in the circuit group HR correlated 
with RPE, but not with VO2.  This highlights the practical difficulties of setting and 
monitoring exercise intensity in this population, where the relationship between 
percentages of HRpeak and VO2peak, HRR and VO2R, and RPE do not conform to those 
observed in the general population (Coplan et al., 1986; Brawner et al., 2002; Mezzani 
et al., 2007).  Existing guidelines based on estimated HRmax are unlikely to provide a 
meaningful guide to exercise intensity (Beale et al., 2010), and the current study 
indicates that even if HRpeak is measured the exercising HR may bear little relationship 
to it.   In future, a comprehensive analysis of circuit and intermittent training, using 
measurements of VO2, HR, Lac and motion analysis should be undertaken to describe 
the physiological intensity of each type of exercise.  
7.3.3 Changes in ventilatory response to exercise 
The current study did not find any change in VE/VCO2 slope after either circuit or 
intermittent training.  Previous studies have reported mixed findings on the effect of 
exercise training on VE/VCO2 slope.  The current study agrees with others that have 
reported no change (Keteyian et al., 1996), including studies of older patients 
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(Brubaker et al., 2009) and those on optimal medication (Passino et al., 2006b). 
Similarly Dimopoulos et al’s study (2006) comparing continuous and intermittent 
exercise reported no change in either group, despite improvements in VO2peak and VT.  
By contrast, one older study  (Coats et al., 1992a) and two more recent studies of CHF 
on optimal medical therapy (Klecha et al., 2007; Van Laethem et al., 2007) have 
reported improvements in VE/VCO2 slope following 2–6 months’ training.   Reductions 
in VE and VE/VCO2 during sub-maximal exercise have also been reported, most likely 
due to an increase in VT, meaning that, at a given intensity, a reduced amount of CO2 is 
required for buffering, therefore reducing the drive to increase ventilation (Kiilavuori et 
al., 1996).  
 
It is possible that the benefits of current medical therapy limit the additional benefits of 
exercise training on ventilatory efficiency. β-blockers improve the ventilatory response 
in CHF, due to a combintaion of attenuated β-adrenergic response to catecholamines, 
alterations in muscle metabolism that decrease ergoreflex stimulation, and improved 
ventilation-perfusion matching (Wolk et al., 2005).  Piepoli et al. (1996) argue that the 
improvement in symptoms following exercise training, or other treatment, in CHF is 
dependent on the resolution of skeletal muscle abnormalities and the associated 
exaggerated ergoreflex response (Piepoli et al., 1996).  They demonstrated that training 
reduced the ergoreflex contributions (diastolic pressure, ventilation and leg vascular 
resistance) more in CHF than in control subjects.  The lack of improvement in 
VE/VCO2 slope in the current study could be due to an inadequate training stimulus to 
reduce the ergoreflex response. Although the study duration of 6 weeks was the same,  
the exercise dose in Piepoli et al’s 1996 study was higher, comprising 2-3 sessions per 
day, specifically targeting the  forearm muscles.  The exercise dose in other studies 
reporting an improvement in VE/VCO2 slope was also higher, in terms of frequency 
and/or duration, than the current study (Coats et al., 1992a; Klecha et al., 2007; Van 
Laethem et al., 2007). 
Another issue for consideration is the report that the ventilatory response to exercise 
and VE/VCO2 slope are higher in weight-bearing, i.e. treadmill protocols, which  appear 
to increase the ergoreflex activation to a greater extent than weight-supported exercise 
(Witte and Clark, 2005). It is possible that, by imposing a greater stimulus on the 
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erogreflex response, weight-bearing exercise training might be more effective at 
improving ventilatory efficiency.  This is speculative, and requires further 
investigation.   
7.3.4 Inter-individual response to training 
Experts in the field have highlighted the importance of reporting the individual 
variation in responses to exercise training as well as the mean change, and investigating 
the personal characteristics which influence inter-individual variation in dose-response 
(Haskell, 2001).  Despite significant mean increases in VO2peak in the majority of 
studies, not all patients respond to exercise training (Coats et al., 1992a; Belardinelli et 
al., 1995a).  Some studies have reported “responders” and “non-responders” to training.  
Although CR failed to improve mean VO2peak in older CHF, it  increased by > 10% in 6 
out of 30 patients, and by 0 – 10% in another 9 patients, whereas it decreased in 8 
patients (Brubaker et al., 2009).  Similarly, in the current study there was evidence of 
inter-individual response to training in both groups. In 2 CHF in each group, VO2peak 
showed small decreases, whereas in 2 further patients in the intermittent group VO2peak 
decreased by 20-30%.  Both these patients were fitted with an ICD and it is possible 
that the severity of heart failure influenced the training response.  However, VO2peak 
increased by 25% and 33% in 2 CHF with ICDs in the circuit group, suggesting that the 
mode of exercise might have played a part. The heterogeneity of CHF patients prevents 
any conclusions being drawn as to the reasons for finding “responders” and “non-
responders”.  Further studies comparing different modes of training in patients with 
ICDs may clarify this.  
There is conflicting information in the literature about whether aetiology, specific 
limitations or age affect the outcome of exercise training.  It has been suggested that 
patients with ischaemic aetiology are more responsive to exercise training 
(Willenheimer et al., 1998), although non-ischaemic aetiology has also been associated 
with a positive training response (Forissier et al., 2001). Neither the aetiology of CHF 
nor age was associated with the response to training in the current study.  The few 
studies that have, like this one, focussed on older CHF with co-morbidities, suggest that 
training effects are less pronounced in the wider CHF population than in the earlier 
studies restricted to homogenous samples of  younger CHF   (Owen and Croucher, 
2000; McKelvie et al., 2002). Exercise training was less effective at increasing VO2peak 
184 
 
 
 
in CHF patients over 65 years, with reported average improvements of 0.5 ml.kg-1.min-
1 compared with 1.2 ml.kg-1.min-1 in patients under 65 years (Wielenga et al., 1998).  
Lack of improvement in inflammatory and endothelial function, and NT-pro BNP after 
exercise training in older CHF has also been reported, although an inadequate exercise 
dose might have been a contributing factor here (Prescott et al., 2009).  Patients 
exercised twice weekly for 8 weeks at an intensity of 70-80% VO2peak, a slightly higher 
dose than the current study.   
Alternatively, the severity of CHF rather than aetiology or age might play a role. In 
mildly symptomatic CHF, the major determinant of exercise tolerance is usually 
cardiac output reserve (i.e. VO2 delivery) whereas abnormal peripheral mechanisms 
play a greater role with increasing severity of CHF (Tavazzi et al., 2001). Therefore, 
patients with moderate and severe CHF have a greater potential to benefit from exercise 
training. Hambrecht et al (1995) reported that the greatest improvements in exercise 
capacity and muscle oxidative capacity were reported in those patients with the most 
severe exercise intolerance and/or LV dysfunction.  Jette et al (1991) reported that post 
myocardial infarction CHF with poor LV function (EF < 30%) significantly improved 
VO2peak following a 4 week exercise programme compared with a decline in the non-
training control group, whereas patients with low-moderate LV function (EF 31-50%) 
showed no change in either the exercise or control group (Jette et al., 1991). In Meyeret 
al’s study, patients had a mean EF of 22%, and half were awaiting heart transplantation.  
The greatest improvements were demonstrated by those whose initial exercise capacity 
was lowest (Meyer et al., 1996c).  
However, Wilson et al (1996) postulated that patients with reduced cardiac output 
responses are limited by skeletal muscle under-perfusion and would not improve with 
exercise training whereas patients with preserved cardiac output responses to exercise 
are limited by deconditioning, and would respond to exercise training. The results of 
their study support this hypothesis, with improved exercise performance in patients 
with preserved cardiac output responses, but not in those with severe haemodynamic 
dysfunction (Wilson et al., 1996).  Furthermore, myocardial function at baseline has 
also been positively related to change in VO2peak following exercise training (Smart et 
al., 2006).  
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7.3.5 Potential mechanisms for response to exercise training 
The theoretical underlying mechanisms responsible for improvements in exercise 
capacity are discussed in the Review of Literature (Chapter 2, Section 2.5), and include 
improvements in cardiac output, oxygen extraction & utilisation, endothelial function, 
and attenuation of excessive ergoreflex activation. In longer duration studies, 
improvements in VO2peak and VT are associated with changes in the oxidative capacity 
of skeletal muscles (Hambrecht et al., 1995a), and reduced total peripheral resistance, 
enhanced endothelium-dependent vasodilation and peripheral blood flow (Hambrecht 
et al., 1998; Hambrecht et al., 2000). Further analysis via ultrastructural morphometry 
reported enhanced oxidative enzyme activity and a characteristic reshift from type II to 
type I fibres, and these changes were unrelated to changes in peripheral perfusion 
(Hambrecht et al., 1997).  It is possible that the smaller dose of exercise in the current 
study led to improvements in some of these parameters, accounting for increases in VT 
and VO2peak in “responders”.  Studies using 3 x 15 min sessions per week of knee 
extensor exercise for 8 weeks, a smaller exercise stimulus than in the current study, 
have reported improvements in oxidative enzyme activity and VO2peak (Gordon et al., 
1996; Tyni-Lenné et al., 1996; Tyni-Lenné et al., 1997).  In the current study, the lack 
of improvement in VE/VCO2 slope suggests that there was no attenuation of ergoreflex 
activation.   
The majority of studies show that an increase in exercise capacity is achieved without 
changes to central haemodynamics. van Tol et al’s systematic quantitative review 
reports improvements at rest in diastolic BP and EDV only, with no changes in HR, 
systolic BP, LVEF or ESV.  However, at maximal exercise, HR, systolic BP and 
cardiac output increased significantly by 2.5, 3.3 and 21.3% respectively, with 
significant pooled effect sizes. Some short-duration studies have reported that cardiac 
adaptations can be achieved in as little as 8 weeks, but this was in response to an 
exercise dose of more than 2 hours per day (Dubach et al., 1997).  In older CHF,  LV 
volumes, LVEF and diastolic filling, measured by echocardiography, did not change 
after 16 weeks’ CR (Brubaker et al., 2009).  MRI is more precise and reproducible for 
assessing LV function, and two recent studies have used this method. One found no 
significant changes in LV parameters after 6 months’ training, although there was a 
trend for improvement in EDV, LVEF and wall motion score index (Klecha et al., 
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2007).  The other, which included 5 training sessions per week,  reported improvements 
in ESV and LVEF after 6-8 months, but not after 2 months (Beer et al., 2008).  It 
therefore seems unlikely that any improvements in exercise capacity achieved in the 
current study are due to improvements in central haemodynamics.  
Previous studies have suggested that exercise training partially reverses chronotropic 
incompetence   Hambrecht et al (2000) reported that 46% of the increase in VO2peak 
was explained by an increase in HRpeak, although it is not clear if the reported increase 
in HRpeak was simply due to improved exercise tolerance. Keteyian et al (1999) 
reported a 7% increase in HRpeak.  The authors used an indirect index of sinoatrial node 
sympathetic responsiveness by determining the ratio of HR reserve to plasma 
noadrenaline reserve, for which there was no change.  They therefore speculated that, 
rather than an increase in alpha-adrenergic receptor sensitivity, the increase in HR was 
due to increased leg strength permitting the patients to exercise for longer during the 
test, thus providing a longer period for chronotropic response to noradrenaline  
(Keteyian et al., 1999).  Myers et al (2007) reported that intensive exercise training 
induced a more rapid HR recovery, reflecting improved vagal reactivation, after 
training.  However, these patients had a considerably higher baseline exercise capacity 
than those in the current study, and none were taking β-blockers. 70% of the change in 
HR recovery was attributable to a widening in HRR (mean 18 beats.min-1), due to an 
increased HRpeak of 7 beats.min-1 and a decreased resting HR of 11 beats.min-1
Different physiological responses to continuous and intermittent training have been 
reported in previous studies despite similar improvements in functional capacity.  
Dimopoulos (2006) reported that continuous training significantly increased 
chronotropic reserve (HRpeak - resting HR) x100/(220 - age - resting HR) by 26% and 
HR recovery (61%) at 1 min, whereas there was no change following intermittent 
training.  These patients were on current medication, including β-blockers. The authors 
.  
However, these changes are unlikely to occur in patients taking β-blockers, as this 
medication reduces sympathetic drive and increases in HR, thus would limit the 
benefits of training on improving autonomic nervous system balance.  A significant 
reduction in central sympathetic neural outflow, measured directly via 
microneurography, to levels comparable to healthy controls was recorded in 7 CHF 
after a 4 month training programme (Roveda et al., 2003), but, once again, these 
patients were not taking β-blockers. 
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speculated that interval training may not provide an adequate stimulus to the autonomic 
nervous system.  However, the measure of chronotropic reserve used in this study is a 
crude indirect measure of parasympathetic activity and may be influenced by numerous 
factors, including posture, blood pooling, recovery activity and heat. HR variability is a 
more sophisticated tool for assessing autonomic balance (Malfatto et al., 2002). 
Furthermore  comparisons between studies are difficult due to differences in the mode 
of recovery. Dimopoulos et al (2006) set 30s work phases at 100% WRpeak, the same as 
in the current study, but recovery phases were 30s compared to 60s active recovery in 
this study, and the authors did not clarify whether the post exercise recovery period 
consisted of complete rest. Nechwatal (2002) demonstrated improvements in central 
haemodynamics (cardiac index, stroke volume index and peripheral resistance) after 3 
weeks’ intermittent but not continuous training. Patients trained 6 times per week in 
this study, compared to twice weekly in the current study.  Wisloff and colleagues are 
the only group who have demonstrated significantly greater improvements in functional 
capacity and associated mechanistic parameters, including LV, endothelial and 
mitochondrial function, and BNP,  after intermittent rather than continuous training 
(Wisloff et al., 2007). However, as discussed previously, the exercise stimulus differed 
from the current study as the work phases were of a longer duration and lower 
intensity. 
7.3.6 Methodological issues 
Differences in the extent of improvement in VO2peak following exercise training may be 
due in part to methodological issues.  In studies reporting increases of approximately 
30%, patients did not undergo familiarisation exercise tests (Hambrecht et al., 1995a; 
Gielen et al., 2003; Klecha et al., 2007). Thus the improvements may be attributed in 
part to a learning effect, as acknowledged by some authors (Arad et al., 2008).  Where a 
familiarisation maximal exercise test was specifically included, as in the current study, 
there were smaller improvements (Maiorana et al., 2000), or no improvements  in 
VO2peak (Hambrecht et al., 1995a; Tyni-Lenné et al., 1996; Wielenga et al., 1998; 
Willenheimer et al., 1998; Gielen et al., 2003; Klecha et al., 2007).  Nevertheless, 
improvements of approximately 20% have also been reported in studies which included 
a familiarisation test. 
188 
 
 
 
Another possible influencing factor on patient effort in the maximal CPET came to 
light during anecdotal conversations with patients who said that the training programme 
had increased their confidence to to exercise for longer during the maximal test. 
Improvements in physical component MLHFQ scores, discussed later in this chapter, 
might, to some extent, reflect this new-found confidence.   
The use of absolute or relative values will also influence the findings. For example, 
absolute VO2peak increased by 4 ± 5 % in the circuit group and 6 ± 6 % in the 
intermittent group, whereas increases in relative VO2peak were 11 ± 4 % and 5 ± 6 % 
respectively. Two CHF in the circuit group decreased their weight by 2 kg whereas 3 
CHF in the intermittent group increased their weight by 1-2 kg. It is not clear if these 
changes in weight were due to fluctuations in fluid retention, muscle mass or fat mass, 
all of which may influence peak exercise capacity differently.  
It could be surmised that the current study has too few participants, is too short in 
duration, or that the volume of exercise is too low to provide conclusive evidence about 
the benefits of exercise training.  Similar conclusions have recently been drawn about a 
study on exercise training in elderly CHF (Brubaker et al., 2009; Lavie et al., 2009).  
Equally, the question of clinical meaningfulness must also be considered. Statistical 
analysis, particularly on studies with small sample sizes, may not reflect clinical or 
practical meaningfulness. The HF-ACTION trial, which had a sample size of  > 2000 
CHF, reported increases in V02peak of 4% (0.6 ml.kg.min-1), lower than the increases in 
the current study, and these were statistically significant (O'Connor et al., 2009). In 
common with this study, HF-ACTION patients were on optimal medical treatment, 
including β-blockers, ACE-inhibitors or angiotensin receptor blockers and biventricular 
pacemakers and ICDs, which may limit the additional benefits from exercise training.  
Nevertheless, small improvements in VO2peak, which may not be statistically 
significant, coupled with improvements in psychological well-being, may translate into 
a clinically meaningful effect.  For example, in coronary heart disease patients 
completing a CR programme, depressive symptoms were reduced equally effectively, 
with a subsequent improvement in survival,  in those who showed small improvements 
(0-10%) in VO2peak and those who achieved larger improvements (>10%)  in VO2peak 
(Milani and Lavie, 2007).  
  
189 
 
 
 
7.3.7 BNP 
It has been argued that, because there is limited information about the stability or 
reproducibility of BNP over time in patients who are clinically stable, serial BNP 
measurements cannot accurately be interpreted to assess the effect of interventions 
(Packer, 2003).  Some authors suggest that therapeutic interventions aimed more 
clearly at the myocardium are more likely than exercise to elicit changes in BNP and 
NT-BNP (Meyer et al., 2004b). BNP levels can very over a short period of time due to 
biological variation, physical activity, and change in medication (Hogenhuis et al, 
2006, Smart and Steele, 2009).  Although measurements were taken at rest, it is 
conceivable that increased activity levels resulting from exercise training could increase 
BNP levels even at rest, thus confounding the issue further (Kjaer et al., 2004; Arad et 
al., 2008).   
However, a recent systematic review, which included 5 trials measuring BNP 
(Jonsdottir et al., 2006; Passino et al., 2006b; Butterfield et al., 2008; Malfatto et al., 
2009), concluded that exercise training does have a favourable effect on BNP (mean 
difference -79 pg/ml, 95% CI -141 to – 71 pg/ml) (Smart and Steele, 2009). The 
exercise dose was higher than in this study, with reported training intensities of 50-70% 
VO2peak for 2-7 sessions per week for duration of 3-9 months, and the authors 
concluded that a minimum weekly energy expenditure of 400-450 kcal per week was 
required to elicit changes in this parameter. Wisloff et al (2007) reported that 
intermittent but not continuous training improved cardiac function and reduced BNP by 
40%. It is possible that the frequency and/or duration of training in the present study 
were too low to elicit changes, or that older CHF are slower to show adaptations in 
these parameters.   
In the current study there was large variability in the point of care BNP measurement, 
both between patients and between the pre and post-training values.  Unpublished data 
presented at BACR study day (2009) from CR programme at the Heart & Lung Centre, 
Wolverhampton, also showed a large range of values (mean 1563 ± 664 pre-training, 
range 37-5525 ng.L-1 in 22 CHF.  It appears that this technique might not be sensitive 
enough to detect changes following short-term CR programmes. One small study has 
assessed the utility of point-of-care BNP measurement in a CR setting (Butterfield et 
al., 2008).  10 out of 13 CHF patients who completed a 12 week exercise programme 
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showed a decrease in BNP compared with an increase in 4 of the 6 non-exercising 
control patients, and this mirrored improvements in 6-minute walk distance, QoL, and 
stroke volume estimated by non-invasive thoracic impedance cardiography.  Future 
studies should address the reproducibility and thus the value of using this technique to 
assess changes following therapeutic interventions.  In addition, it is important to 
consider the evidence suggesting that changes in BNP do not reflect changes in clinical 
status (Spertus et al., 2005). 
7.3.8 Daily physical activity  
This study did not find any significant change in weekly physical activity levels outside 
the CR classes, or any difference between the circuit and intermittent groups.  This 
suggests that improvements in VT and physical QoL scales were due to exercise 
performed in the supervised classes, rather than any home-based increase in physical 
activity.   
Comparison with previous studies of CHF is difficult due to methodological 
differences, but other authors report that daily energy expenditure or activity, measured 
by doubly-labelled water and accelerometry, remain unchanged, despite improvements 
in exercise capacity (Gottlieb et al., 1999; Witham et al., 2005).  One study did use 
patients records of time spent on physical activity, which was classified as low (1 
point), moderate (2 points) or high (3 points), and a weekly physical activity score was 
calculated according to the formula time x intensity2/100 (Willenheimer et al., 2001).  
Total activity score only was reported, making it impossible to calculate the time spent 
in low or moderate activity.  In the current study, the majority of patients met UK 
Government guidelines of 30 minutes of moderate activity on most days of the week, 
i.e. 150 – 210 min.week-1).  It is possible that differences in patient perceptions of what 
to include as light or moderate activities, as well as inaccuracies when applying 
generalised MET intensities to the CHF population, might have disguised any changes.  
For example, for one patient walking at 2 miles per hour might equate to 2.5 METS as 
listed in Compendium (Ainsworth et al., 2000), but for a patient with very limited 
exercise tolerance this might be closer to be four times his/her resting metabolic rate.   
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All patients increased the amount of exercise achieved in the classes, either by 
progression to a greater ratio of aerobic to active recovery exercises in the circuit 
group, or by increasing the number of work phases performed in the intermittent group. 
7.3.9 Quality of life measures 
7.3.9.1 Minnesota Living with Heart Failure Questionnaire 
There is mixed evidence as to the effect of exercise training on disease-specific QoL.  
A systematic quantitative review reports a -9.7 point improvement in MLHFQ score, 
with a pooled effect size of -0.41 and 95% confidence intervals of -0.6 – -0.22 (van Tol 
et al., 2006).  However, several studies have reported non-significant reductions or no 
change in MLHFQ scores after training, despite improvements in exercise performance 
(Gottlieb et al., 1999; Keteyian et al., 1999; Owen and Croucher, 2000; McKelvie et al., 
2002; Arad et al., 2008).  Improvements in MLHFQ score and global QoL  have been 
reported following intermittent training interventions (Willenheimer et al., 1998; Meyer 
and Laederach-Hofmann, 2003). Similar improvements in QoL, assessed by the 
MacNew questionnaire, following intermittent and continuous exercise were reported 
by Wisloff et al (2007).  
The current study supports the finding that exercise training appears to improve QoL 
regardless of the mode of exercise.  There was a significant mean reduction of -8 points 
in both the circuit and intermittent groups. This exceeds the improvement reported in 
studies of older CHF similar in age (Austin et al., 2005a; Brubaker et al., 2009).  
Baseline scores were higher in these studies which, while offering greater potential for 
improvement, may also have limited the potential benefits of CR.  70% of patients in 
the circuit group and 60% in the intermittent group exceeded the 5 point reduction 
considered to be clinically relevant (Rector and Cohn, 1992).  Substantial reductions 
were seen in a few patients, the greatest of which was -23 in the circuit group and -43 
in the intermittent group. Both patients had a large improvement in their physical and 
emotional QoL, illustrating that even a short-term programme can offer sizeable 
benefits to some patients. Interestingly, both patients had ICDs and while VO2peak 
improved by 33% in the first, it decreased by 10% in the second patient.  An 8 week 
exercise programme resulted in a mean 22 point improvement in one study, due to 
improvements in physical capacity as well as patient confidence (Parnell et al., 2002).  
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On average, CHF in the current study showed small improvements in both physical and 
emotional scores; in the circuit group improvement in the physical component score 
was statistically significant, whereas in the intermittent group the improvement in 
emotional component score was significant.  
The current study agrees with previous studies that have failed to demonstrate a 
significant positive relationship between improvements in cardio-respiratory fitness and 
QoL, suggesting that QoL is determined by factors other than physical fitness alone 
(Quittan et al., 1999).  Participating in an exercise programme may have a positive 
effect on health-related QoL in the absence of any improvement in physical capacity 
owing to the attention, supervision and support offered by staff and peers.  In this study 
both training groups received similar levels of support from the investigator and CR 
staff, thus precluding the Hawthorne effect seen in studies comparing exercise training 
with a non-exercising control group.  However, the participant information sheet 
clearly explained the study aims, and included reference to previous work suggesting 
that intermittent training was more effective than other training methods.  It is therefore 
possible that patients in this group may have perceived that they were more likely to 
gain benefits, and therefore been more motivated to comply with the exercise 
prescription, which could have influenced the results.  A study comparing two leg 
training with one leg training as well as a control group reported that improvements in 
health related QoL, both in the physical and psychological dimensions, were 
significantly higher in the two leg group, whereas there was no significant difference 
between one leg training and control (Tyni-Lenné et al., 1996).  The authors suggest 
that this supports that the physical training exerts a beneficial effect over and above any 
Hawthorne effect from participating in a training programme.  Studies showing that 
home-based training results in similar improvements to supervised group training also 
indicate that benefits are not due to social support alone (Passino et al., 2006b). 
7.3.9.2 SF-36 
At baseline, CHF patients demonstrated relatively low scores, (indicating better QoL) 
in comparison to published norms for a healthy population in all scales apart from 
social functioning and mental health.  This is perhaps surprising given that the British 
Heart Foundation’s statistics that up to 40% of CHF are likely to suffer from depression 
which would be expected to reduce QoL.  However, the SF-36 is not disease-specific 
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and might not be sensitive to the various factors that contribute to QoL in CHF.  
Alternatively, the low SF-36 scores could reflect a self-selection bias; CHF with better 
perceptions of their state of health might be more likely to participate in the study.  
Although mean scores improved after training, particularly in the role-physical, vitality 
and role-emotional domains, there was inter-individual variability, and no statistical 
significance.  Nevertheless, mean scores post-training in vitality and role-emotional 
domains increased from baseline to reach close to normative values. 
Other authors have reported significant increases in scores for physical and social 
functioning, role-physical and vitality and mental health after exercise training 
compared to usual care (Quittan et al., 1999), and in an observational study after 
intermittent exercise.  However, 6 weeks’ CR had no effect on SF-36 scores measured 
at at 3, 6 or 12 months’ follow up in a large sample of cardiac patients, including those 
with CHF (Zwisler et al., 2008).  The authors commented that this generic QoL 
instrument may be less likely to show an effect, and that the 6 week programme was 
shorter than the recommended 8-12 weeks.  By contrast, 4 weeks’ CR, consisting of 
combined aerobic and resistance training and education sessions, in older CHF  did 
significantly improve physical summary scale score measured by the SF-36v2, but the 
improvements were not maintained 6 months later despite continued increases in 
functional capacity (Miche et al., 2009).  The SF-36v2 is the newer version of the 
survey.  It includes two summary measurement scales for physical health (physical 
functioning, role-physical, bodily pain, general health) and psychological health 
(vitality, social functioning, role-emotional, mental health), which facilitate a 
simplification of the statistical calculations without losing any of the individual 
information included within the questionnaire.  For licensing reasons, this version was 
was not used in the current study.   
 
There was no difference in change in SF-36 scores between the circuit and intermittent 
group in the current study.  Nechwatal (2002) reported that SF-36 summary scores 
improved significantly after continuous and intermittent training, but the improvement 
in psychological summary scale was more than 3 times higher in the continuous group, 
although it is not clear why.  
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7.3.10 Practical implications 
This study demonstrates the feasibility of including high intensity intermittent training 
in an existing hospital-based programme for a heterogeneous group representative of 
the general CHF population, including the elderly, patients with co-morbidities and on 
different pharmacological therapies, and those with implantable devices.  Despite the 
fact that these patients may have a poor prognosis, improvements in QoL and sub-
maximal exercise performance could translate into an improvement in ability to achieve 
and enjoy daily activities.  
7.3.11 Study limitations 
The small sample size in this exploratory study may have resulted in insufficient power 
to detect significant differences in some outcome measures. The HF ACTION trial 
recruited 2,331 CHF and reported a 4% improvement in VO2peak (a median increase of 
0.6 ml.kg-1.min-1
 
), which was statistically significant (O'Connor et al., 2009).  An 
alternative approach in future studies might be to assess whether intermittent training is 
“not clinically inferior” to existing interventions used in current practice. In this case, 
the study design should incorporate the recommendations of the extended Consolidated 
Standards of Reporting Trials (CONSORT) Statement for noninferiority and 
equivalence trials, and use a sample size appropriate for assessing whether the 95% CIs 
are above the boundaries of non-inferiority (Puhan et al., 2006). 
 
There was a change of circumstances shortly after data collection began.   Limited 
resources for CR services necessitated that a maximum of 4 study patients could 
participate in the exercise training sessions at one time, meaning that 4 was the 
maximum number who could logistically complete the study every 8 weeks.  After 
allowing for public holidays and experimenter/patient availability, the data collection 
period was 54 weeks, allowing a maximum of 28 patients (i.e. 7 groups of 4 patients). 
The sample size was also influenced by those who chose to participate, rather than 
being randomly selected from whole CHF population.  However, this study achieved a 
similar participant number and a similar completion rate per year to numerous 
published studies subject to the same limitations (Lloyd-Williams et al., 2004). 
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The high intensity intermittent training protocol used in this study was derived from the 
study results in Chapters 4-6 in which the characteristics of some of the CHF were 
different to the current study, which included patients with AF and implantable devices.  
It is not clear if these patients show the same responses to different volatilities of 
intermittent exercise.  Nevertheless, CPET values for these patients were similar to 
patients without implantable devices, and those in the intermittent training group were 
able to perform the prescribed exercise and demonstrated similar ratings of perceived 
exertion to patients without devices.      
It is recognised that a comprehensive exercise programme will include elements of 
aerobic and resistance/strength training (BACR Core standards).  A limitation of this 
study was that the intermittent training group did not perform any strength training 
exercises. If intermittent training were to be incorporated into CR exercise classes in 
the future, it would ideally be combined with resistance, balance and flexibility 
training.  
Due to the nature of the study, it was not possible to blind the intervention allocation to 
the patient or to the outcome assessor. Intention to treat analysis was not appropriate as 
only compliant patients attended the follow-up testing session.  Those who dropped out 
did so for medical reasons that prevented them from exercising, and thus from 
completing follow-up testing.  
7.4 Conclusions 
This chapter investigated  the effect of traditional circuit-based and high intensity 
intermittent training on functional capacity, ventilatory efficiency, BNP and QoL in 
CHF patients on a 6 week CR programme.  It tested the hypothesis that there would be 
no difference between the effect of training methods on these variables.  The results of 
this study support this hypothesis.  Traditional circuit-based training and high intensity 
intermittent training are equally effective at improving sub-maximal exercise 
performance and disease-specific QoL in a short-term twice-weekly exercise 
programme in a population of elderly CHF of mixed aetiology. Longer-term and/or 
more frequent training may be required to achieve improvements in maximum exercise 
capacity and VE/VCO2 slope.   Neither rapid point-of-care analysis of BNP nor the SF-
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36 health questionnaire appears to be an appropriate tool for assessing the effect of a 
short-term exercise programme. 
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CHAPTER 8: EXAMPLES OF FURTHER 
CHALLENGES IN THE EXERCISE TESTING OF 
CHF PATIENTS 
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8.0 Introduction 
In this thesis, several challenges associated with exercise testing in CHF have already 
been discussed in detail.  These include issues of reproducibility, limited exercise 
tolerance and the narrow range between the exercise intensity domains. The following 
chapter explores some further challenges encountered during the exercise testing of 
CHF in study 4, including testing of patients with implantable devices, and 
measurement of heart rate and lung function.  Where appropriate, case studies will be 
used to illustrate interesting or unexpected  responses to exercise testing.  All patients 
described in the case studies completed the exercise training intervention, and  are 
included in the data presented in Chapter 7.  
 8.1 Exercise testing in CHF with implantable devices 
Pacemakers, cardiac resynchronisation therapy and implantable cardioverter 
defibrillators are current treatments for the management of CHF (National 
Collaborating Centre for Chronic Conditions, 2003; Swedberg et al., 2005).  There is 
emerging evidence that exercise training offers additional improvements in functional 
capacity in patients with these devices, and should be recommended in clinical practice 
for this population (Conraads et al., 2007; Patwala et al., 2009).  However, exercise 
testing of patients with devices raises certain difficulties, as illustrated below.   
Pacemakers may be set in different modes, depending on the aim of the therapy.  The 
North American Society of Pacing and Electrophysiology and the British Pacing and 
Electrophysiology Group (NASPE/BPEG) use codes to describe pacing modes which 
are set out in Table 8.1.  A rate responsive device contains an activity sensor, e.g. an 
accelerometer in the pulse generator, to detect bodily movement and increase the 
pacing rate according to a programmable algorithm (Trohman et al., 2004). However, 
lack of activity of the upper extremities during cycle ergometry may mean that the HR 
response is not activated.  This has previously been reported in a case study in CHF 
(Nilsson et al., 2008a), and is illustrated in Case Study 1 below. 
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Table 8.1: NASPE/BPEG pacemaker generic codes  
The code to describe various pacing modes usually consists of three, four or five letters  
(adapted from Trohman et al, 2004).  
Letter 1 chamber that is paced (A=atria, V=ventricles, D=dual chamber)  
Letter 2 chamber that is sensed (A=atria, V=ventricles, D=dual chamber, 0=none)  
Letter 3 response to a sensed event (T=triggered, I=inhibited, D=dual - T and I, 
R=reverse)  
Letter 4:  rate responsive features; an activity sensor, e.g. an accelerometer in the 
pulse generator, in single or dual chamber pacemakers detects bodily 
movement and increases the pacing rate according to a programmable 
algorithm (R=rate responsive pacemaker)  
Letter 5  Anti-tachycardia facilities  
 
8.1.1 Case study 1: non-activation of heart rate response during cycle ergometer 
testing 
The patient was male, aged 71 years, and measured 182 cm with a body mass of 89 kg.  
Aetiology was dilated cardiomyopathy and asthma was the only co-morbidity.  A 
cardiac resynchronisation therapy device with a defibrillator (CRT-D) had been fitted 3 
years previously, with leads to the right atrium and right and left ventricles. The pacing 
was rate-modulated in VVI-R mode. Resting BP was 124/80 mm/Hg, and resting HR 
was 70 beats.min-1
In test 1, limited upper body movement failed to activate the movement sensors in the 
pacemaker at the onset of cycling.  At minute 6, the movement sensors were activated 
by manually tapping on the device.  This caused an almost immediate increase in HR of 
. Medication included antiarrhythmic (amiodarone), β-blocker 
(bisoprolol), angiotensin II receptor antagonist (irbesartan), statin (simvastatin), 
warfarin and a qvar corticosteroid inhaler.    
This patient performed 2 maximal tests one week apart.  Figure 8.1 illustrates the VO2 
and HR response to the incremental exercise tests. The test protocol involved 3 minutes 
at rest, then increments of 10W every minute, as described in the General Methods 
(Chapter 3).  Exercise duration in Test 1 was 9 min 31 s with a WRpeak of 100W.  
Exercise duration in Test 2 was 9 min 15 s with a WRpeak of 90W.   
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22 beats.min-1, accompanied by an increase in VO2.  There was no further tapping of 
the pacemaker, and the HR gradually returned to its pre-determined rate of 70 
beats.min-1 over a 4 minute period.  VO2 decreased between minute 8 and 9, despite the 
increase in exercise load, before increasing steadily again until the end of test.  In test 2, 
performed one week later, there was no manual interference to the pacemaker. HR 
remained constant at 70 beats.min-1
 
 and VO2 increased at a more constant rate until the 
peak value was reached.  VO2peak was ~100 ml lower in test 2.  
Figure 8.1 : Oxygen uptake and heart rate response to a maximal incremental test 
in a patient with a rate modulated pacemaker.  
In test 1 the pacemaker sensors activated manually. In test 2 the pacemaker sensors 
were not activated.  
 
It is not clear how exercise responses are affected by the activation or inactivation of 
the pacemaker HR response sensors, and this is an interesting topic for consideration in 
the management of CHF with these devices. 
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8.1.2 Case study 2: Cycle ergometer testing in 2 different pacemaker modes 
The patient in case study 2 also performed two tests one week apart.  This patient was 
male, aged 76 years, and measured 168 cm with a body mass of 74 kg.  Aetiology was 
ischaemic, and co-morbidities were Type II diabetes with mild peripheral neuropathy.  
The patient had suffered a myocardial infarction 10 years previously, had undergone an 
atrio-ventricular node ablation and CRT-D approximately 1 year prior to participating 
in the study, but the atrial lead did not function properly.  The pacemaker was set in 
VVI mode.  Resting BP was 127/85 mm/Hg, and resting HR was 70 beats.min-1
 
. 
Medication included, β-blocker (carvedilol), angiotensin II receptor antagonist 
(candesartan), diuretic (furosemide), statin (atorvastatin), aspirin, warfarin, metformin, 
anti-convulsant (pregabalin) and H2 antagonist (ranitidine) for gastro-oesophageal 
reflux.    
Test 1 was performed with the pacemaker in VVI mode (i.e. no HR response). Test 2 
was performed with the pacemaker in VVI R mode, i.e. rate responsive (Figure 8.2).   
Figure 8.2 : Oxygen uptake and heart rate response to a maximal incremental test 
in non-rate modulated (test 1) and rate modulated (test 2) pacemaker modes. 
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Exercise duration in Test 1 was 4 min 55 s with a WRpeak of  50W and VO2peak of 870 
ml.min-1 (11.8 ml.kg-1.min-1).  Exercise duration in Test 2 was 4 min 11 s with a WRpeak 
of 40 W and VO2peak of 760 ml.min-1 (10.3 ml.kg-1.min-1).  Neither VT nor VE/VCO2 
slope could be determined in either test.  This patient performed better when his 
pacemaker was in non-rate modulated mode.  Case Study 1 illustrated that, even if the 
pacemaker is rate-modulated, cycle ergometry exercise may not produce enough upper 
body movement to activate the sensors.  Figure 8.2 shows that in Case Study 2, HR 
does increase at the onset of exercise, but that it starts to decrease towards resting levels 
after 2 minutes of exercise. The increase in HR was not accompanied by an increase in 
VO2, as seen in Case Study 1. It is possible that the initial bodily movement to start 
turning the pedals was enough to trigger the sensors, but that lack of subsequent 
movement explains the later decrease in HR.  The patient’s pacemaker was switched 
from VVI to VVIR mode shortly after Test 1, meaning that the pacemaker was in the 
new mode for the week preceding Test 2.  The patient reported that he had felt less well 
than usual this week, although it is not clear whether this was due to the change in 
mode, or to non-related factors.  
An increase in HR during exercise usually contributes to a higher cardiac output, 
suggesting that rate-modulated pacing is more likely to benefit exercise performance.  
However, the evidence supporting an improvement in exercise capacity in DDDR-
paced patients when compared with DDD-paced patients is inconsistent (Lamas et al., 
2004) 
The case studies above illustrate potential difficulties of exercise testing in patients 
with pacemakers.  In addition to these, one further issue was experienced in a different 
patient with an ICD.   During the maximal CPET following the training intervention, 
this patient’s HR was approaching (within 5 beats.min-1) the threshold for 
defibrillation; hence the exercise test was terminated prematurely by the experimenters 
although the patient had not reached volitional exhaustion.  However, analysis of the 
data showed a plateau in VO2 had been achieved during the final 30s of the test, with 
an RER of 1.18, and these data were therefore considered valid and included in the 
results for Study 4.   
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8.2 Case study 3: Abnormal VO2 response at peak exercise 
Case study 3 was male, aged 70 years, and measured 170 cm with a body mass of  70 
kg.  Aetiology was dilated cardiomyopathy, with atrial fibrillation and hypertension.  
Resting BP was 150/71 mm/Hg, and resting HR was 48 beats.min-1
 
. Medication 
included antiarrhythmic (amiodarone), β-blocker (carvedilol), ACE inhibitor 
(lisinopril), aldosterone antagonist (eplerenone) and warfarin.    
This patient showed an interesting VO2 response to the maximal incremental exercise 
test both pre and post training.  As illustrated in Figures 8.3 and 8.4, there is a 
“rebound” in VO2 on cessation of exercise. This is evident in both tests, but is more 
pronounced in test 2: VO2 plateaus during the 90W stage, then decreases in the final 
stage (100W). An immediate rebound in VO2 is seen on cessation of exercise that 
persists for at least 1 min post exercise.  It  has previously been reported that, due to 
slowed VO2 kinetics, VO2peak may be reached in the 30s after exercise (Cohen-Solal et 
al., 1997), but VO2 values usually increase steadily until peak is achieved.  In this case 
study, VO2peak measured in recovery was 5% (77 ml or 1.1 ml/kg/min) higher than 
VO2peak measured during the test, or 12% higher (163 ml or 1.4 ml/kg/min) higher than 
the average VO2 value in final 30s of exercise.  
Figure 8.3: Oxygen uptake response to maximal incremental exercise test at 
baseline 
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Figure 8.4: Oxygen uptake response to maximal incremental exercise test after 6 
weeks’ intermittent exercise training 
 
The response in Figures 8.3 and 8.4 is similar to the rebound in LVEF at rapid off-
loading of exercise, described by Foster et al (1998), and illustrated in Figure 8.5.  
When exercise ceases suddenly, there is a significant increase in LVEF, most likely due 
to decrease in preload.  This effect is less apparent in the supine position, where preload 
remains high (Foster et al., 1998).  It is not clear how the semi-recumbent cycle 
ergometer used in the current study might influence haemodynamics in CHF, but a 
study comparing upright and semi-recumbent exercise in healthy children found no 
difference in echocardiographic measure, including LVEF, between the two modes 
(Chang et al., 2005).   Several other mechanisms might contribute to an increase in 
LVEF on cessation of exercise.  Coronary artery disease patients showed a sharp rise in 
stroke volume during recovery due to a decrease in end systolic volume, probably 
resulting from an immediate reduction in afterload coupled with a slower decrease in 
sympathetic activation (Koike et al., 1990). This “rebound” in LVEF on reduction or 
removal of workload has also been reported in more recent studies using various 
techniques, including first pass radionuclide ventriculography and echocardiography 
(Rozanski et al., 2001).  The authors report that, in cardiac patients, the regional wall 
motional abnormalities induced by exercise are resolved rapidly on removal of 
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workload.  These issues are beyond the scope of this thesis, but have implications for 
the timing of measurement of physiological responses during exercise testing. 
 
 
Figure 8.5 : Response of left ventricular ejection fraction to rapid off-loading of 
exercise in healthy individuals and CHF Patients  
(adapted from Foster et al, 1998) 
 
8.3 Heart rate response to exercise in patients with atrial fibrillation 
Atrial fibrillation is common in CHF, particular in older patients, yet  few exercise 
training studies have included CHF with atrial fibrillation (Willenheimer et al., 1998; 
Owen and Croucher, 2000). In the current study, 8 CHF were in atrial fibrillation and 
HR could not be accurately measured in these patients during exercise, either by 3 lead 
ECG during exercise testing or by telemetry during exercise. Figure 8.6 shows HR 
recorded during a training session for a patient in AF. 
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Figure 8.6: Exercise session heart rate data for patient with atrial fibrillation in 
intermittent group (female, aged 70 years). 
 
8.4 Heart rate guidelines for exercise intensity prescription 
Problems with using a percentage of HRmax to guide exercise intensity, including a 
narrow HRR and frequency of atrial fibrillation, have been recently reported (Prescott 
et al., 2009).    In agreement with this, data collected during studies 1-3 of this thesis 
have been published  to emphasise that current HR guidelines for prescribing moderate 
exercise in CR are likely to overestimate exercise intensity in CHF (Beale et al., 2010) 
(Appendix 7).  HR data measured during Study 4 raises some additional issues.  In both 
the circuit and intermittent training groups, the mean average training HR exceeded 
90% of the HRpeak achieved during CPET, and the highest training HR was close to, or 
higher than this HRpeak.  This might be due to the difference in haemodynamics 
between recumbent cycling in the CPET and upright cycling and/or weight bearing 
exercise performed during the training session (Walsh-Riddle and Blumenthal, 1989). 
The larger HR range during training in the circuit group (77 ± 5 - 103 ± 7% HRpeak) 
compared with the intermittent group (85 ± 4 - 99 ± 4% HRpeak) reflects the different 
types of exercises performed in this group, e.g. active recovery exercises with light 
hand weights and weight-bearing exercises, such as walking or stepping,  engaging a 
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greater active muscle mass than cycling. Another possible explanation might be that the 
longer duration of the training session allowed a greater period for the chronotropic 
response to noradrenaline than the short duration of the CPET.   
8.5 Heart rate recovery  
HR recovery has been proposed as a simple marker of autonomic function that can be 
used to assess outcomes during CR (Myers et al., 2007).  To provide optimal 
assessment HR should be recorded for the whole of the recovery period, or for a period 
of 6 minutes, with workload and pedal cadence controlled if the recovery is active.  The 
protocol for the current study involved an optional active recovery with no added 
resistance at a self-selected pedal cadence from 90s after exercise cessation (to allow 
for echocardiography data collection), therefore HR recovery could have been 
calculated as the difference between HRpeak and HR 60s from the end of exercise, as 
proposed in previous studies (Dimopoulos et al., 2006). However, accurate 
measurements of both HRpeak and/ recovery HR could not be made in 16 out of 26 
CHF, due to atrial fibrillation or muscular movement interfering with the ECG HR 
signal.  Therefore this measurement was not included in the study results.   
8.6 Lung function  
In a clinical setting, it is recommended that, prior to CPET, inspiratory capacity (IC), 
forced expired volume in 1 s (FEV1) and forced vital capacity (FVC) are assessed to 
identify patients with restrictive lung disease (Ingle, 2008).  The majority of patients 
had difficulty performing the lung function test. Although patients were given the 
opportunity to practise the test, poor technique and patient discomfort limited the 
validity and usefulness of the tests, hence the results have not been reported. 1 patient 
participating in studies 1-3 and 1 patient in study 4 had been previously diagnosed with 
COPD, and 2 patients in study 4 had previously been diagnosed with mild asthma.   
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CHAPTER 9: GENERAL DISCUSSION & 
CONCLUSIONS 
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9.0 Introduction 
Exercise training can reduce morbidity and mortality, improve functional capacity and 
enhance QoL in CHF.  Supervised training programmes results in better compliance 
and the most favourable outcomes in CHF patients in the UK (Jolly et al., 2009), and 
the multidisciplinary approach offered by CR schemes offers the ideal environment for 
safe exercise, education and the management of CHF and its co-morbidities (Boudreau 
and Genovese, 2007).  Standardised exercise recommendations for CHF have been 
published by the ESC, and ACPICR & BACR have published exercise guidelines for 
UK CR programmes, but experts agree that more research is warranted into the optimal 
exercise dose for these patients.   
The existing body of literature indicates that the benefits of exercise training in CHF 
are due to a combination of mechanisms.  These include improvements in cardiac 
output and oxygen extraction & utilisation.  Underlying these changes are  increased 
skeletal muscle blood flow, capillary density, mitochondrial volume and density and 
oxidative enzyme activity, improved endothelial function, and attenuation of excessive 
ergoreflex activation (Lloyd-Williams et al., 2004; Piepoli et al., 2004; Rees et al., 
2004; van Tol et al., 2006). The greatest benefits from exercise training are due to 
peripheral rather than central adaptations in CHF (McConnell, 2005). The aim of 
exercise training is to apply sufficient stimuli to skeletal muscles without overloading 
the cardiovascular system (Giannuzzi et al., 2001).  However, achieving the optimal 
exercise dose is not easy. Firstly, patients may not be able to achieve continuous 
endurance training workloads high enough to have an optimal training effect on the 
peripheral muscles without experiencing cardiac symptoms or local muscular fatigue.  
Secondly, the exercise dose used in clinical trials reporting benefits is higher than that 
in most UK CR settings (Taylor et al., 2007).  A possible solution might be to increase 
the exercise dose by using high intensity intermittent exercise, which allows more work 
to be accomplished and therefore a greater training response (Christensen et al., 1960; 
Meyer et al., 1996c).  This might compensate for a low frequency and duration of 
training.   
This thesis had two key aims: 1) to examine the methodology for setting intermittent 
exercise intensity in order to find a reproducible and valid protocol; 2) to assess the 
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effect of an intermittent exercise intervention compared with an existing exercise 
intervention used in current practice 
9.1 Limitations of maximal CPET for exercise intensity prescription 
CPET is useful for aiding diagnosis and prognosis in CHF,  for establishing exercise 
training protocols and for assessing the effect of therapeutic interventions, including 
exercise training (Ingle, 2007).  Chapter 4 demonstrated that, although the mean 
difference between parameters measured in duplicate tests was < 10%,  there appears to 
be a learning effect between the first and second attempts at a maximal CPET.  It 
agrees with the consensus of opionion on the importance of familiarisation to exercise 
testing to obtain reproducible results in the general population, and  proposes that a 
familiarisation test should be standard practice in CHF and older individuals, in line 
with previous opinion (Agostoni, 2006).  This is in contrast to recent suggestions, based 
on data from the HF-ACTION trial, that there is no need to perform more than one 
baseline cardiopulmonary exercise test (Bensimhon et al., 2008).  In this large 
multicentre trial there was substantial within-subject variability in VO2peak, VO2 at VT 
and VE/VCO2 slope in repeated tests.  The variation appeared to be due to daily 
haemodynamic and volume status fluctuations, rather than a learning effect, since half 
of the patients increased and half decreased their VO2peak and VT on the second test.  
Chapter 4 of this thesis demonstrated that sub-maximal measures, which are less 
dependent on subject motivation, showed better reproducibility than peak measures, but 
were still prone to variability between tests.  The biological variability of 
cardiorespiratory measures has implications when using serial assessment to evaluate 
the effect of therapeutic interventions.  Nevertheless, the numerous methodological 
differences in this thesis make it difficult to compare with other studies. The HF-
ACTION  trial took place at 83 different clinical sites, where variations in testing 
conditions could influence the results, and only 12% patients performed cycle 
ergometer rather than treadmill tests (Bensimhon et al., 2008).  Furthermore, it is 
possible that some of the variability may be eliminated when patients are more familiar 
with the equipment and testing procedure, which could only be confirmed by a study 
comparing the results from 3 or more exercise tests.   
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Chapter 4 shows that the gas exchange thresholds (Meyer et al., 2005b) can be 
identified in the majority of CHF and older individuals.  VT and RCP occurred at 62 ± 
9% and 84 ± 6 % of VO2peak in CHF, and 54 ± 6% and 82 ± 6 % in controls, which 
agrees with values reported in the literature (Simonton et al., 1988; Cohen-Solal et al., 
1990; Meyer et al., 1997c; Marburger et al., 1998).   Normative values for the 
percentage of VO2peak at which VT will occur are ~ 58% men and 62% in women aged 
70 years, but it is well known that there is considerable variability in both healthy and 
diseased populations (Wasserman et al., 2005).  An interesting finding in Chapter 4 is 
that it is difficult to accurately prescribe exercise work rates in individual intensity 
domains in CHF compared to healthy controls because the range of work rate in each 
domain is very narrow (< 20 W), and the test-retest variability is relatively high.  
9.2 Limitations of the steep test (Meyer et al, 1997) for intermittent exercise 
prescription 
For intermittent exercise prescription in CHF, a simple incremental exercise test with 
large increases in work rate over a short duration (25W every 10s) has been devised 
(Meyer et al., 1997b). The work phase is set at 50% of the maximum work rate 
achieved in the test. There is no published literature on the validity or reproducibility of 
this test.  Chapter 4 illustrated that in a repeat test 30% of CHF and 70% controls 
achieved a difference in WRpeak of one or two test stages, i.e. 25 or 50 W. This could 
translate to an increase in intermittent training workload of 12.5 or 25 W, potentially a 
substantial increase for CHF patients with a low initial WRpeak.  Alternatively, it could 
reduce the workload by the same amount, thus reducing the exercise stimulus.  Once 
again, this illustrates the difficulty of determining precise training workloads in this 
population, and demonstrates that reproducibility of this test is lower in older healthy 
individuals than in CHF.   
There are no published studies comparing Meyer’s intermittent training protocol with 
the method commonly used by exercise physiologists, which is to set the work phase 
intensity at VO2peak work rate (Billat, 2001).  Chapter 4 addressed this gap in the 
literature, and showed that intermittent exercise workloads prescribed by the different 
methods are not significantly different in CHF.  However, in healthy older individuals 
an intermittent work rate set at 100% VO2peak was significantly higher than 50% WRpeak 
in Meyer’s steep test.  
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Although Meyer’s steep test was not designed to measure VO2peak, Chapter 4 found that 
CHF reached similar VO2peak values in this test to values achieved in the standard 
CPET, and healthy older individuals achieved 91% of standard test VO2peak.  The 
relatively higher performance by CHF in the steep test suggests that these patients are 
less limited by their symptoms in short duration high intensity exercise.  CHF with 
lower initial functional capacity were more likely to achieve a higher work rate in 
relation to the standard ramp and a higher VO2peak in a short duration test than in a 
standard test compared with CHF with higher initial functional capacity and healthy 
controls.  With increasing severity of heart failure, cardiac output response and oxygen 
delivery to the exercising muscles are increasingly reduced, and peripheral 
abnormalities reduce aerobic capacity further (Wilson et al., 1996; Tavazzi et al., 
2001). Thus it is perhaps not surprising that these patients were more limited during the 
longer test which imposed a more prolonged stress on the aerobic energy system than 
the shorter test.  The patients in Meyer et al’s study (1997), who had severe CHF, 
reported that VO2peak in the steep test reached only 87% of the standard test value.  It is 
possible that the day-to-day variability and/or familiarisation effect discussed above, or 
could partly explain the difference between this thesis and Meyer’s study.   
9.3 Continuous and intermittent exercise of equal total workload elicit similar 
cardiorespiratory responses in CHF and healthy older individuals 
In healthy participants physiological responses to intermittent exercise with short-moderate 
work phases are very similar to steady-state exercise of an equal total workload (Astrand et 
al., 1960a; Essen et al., 1977; Brickley et al., 2007).  Chapter 5 confirmed that this also 
applies to CHF, agreeing with a single earlier study in CHF (Meyer et al., 1997b).  It 
appears that there is a dampening of cardiovascular, respiratory and metabolic responses 
during repeated hard-easy exercise transitions, and that the recovery phases allow sufficient 
recovery of metabolites.  It has been suggested that patients with a low exercise tolerance 
might find intermittent training subjectively easier than continuous training (Puhan et al., 
2004).  However, the perception of effort for CHF did not differ between exercise modes.   
For healthy older individuals RPE was also the same between exercise modes, but was 
lower than in CHF despite the fact that the workloads were set at the same relative intensity 
for both groups.  
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9.4 Changing the volatility of intermittent exercise intensity does not alter 
cardiorespiratory responses 
Prescribing high intensity intermittent exercise for CHF challenges the general 
principle of exercise training progression for cardiac patients which is to increase the 
duration and frequency before the intensity.  Due to the theoretical increased risk with 
high intensity exercise, few studies have examined the adaptation to high intensity 
intermittent training in older & cardiac populations, but those that do have done so 
safely and with no adverse affects (Meyer et al., 1996c; Wisloff et al., 2007).  Chapter 6 
demonstrated that manipulating the volatility of the intermittent work and recovery 
phases, so that they are either closer to or further from the mean exercise workload, 
while maintaining the same total workload, has no effect on acute cardiovascular and 
respiratory responses.  However, when the intensity of the work phase was increased to 
≥ VO2peak work rate, Lac increased in comparison to lower volatility intermittent 
exercise.  In theory, this indicates that high volatility intermittent exercise imposes a 
greater stimulus on the exercising muscles, by eliciting changes in cellular homeostasis, 
without increasing cardiac workload.  This is in line with the aims of exercise training  
in CHF, namely to apply sufficient stimuli to skeletal muscles without overloading the 
cardiovascular system (Giannuzzi et al., 2001).  CHF perceived high volatility 
intermittent exercise to be “somewhat hard”, which also fits in with current guidelines 
(British Association for Cardiac Rehabilitation, 2006).   
9.5 High intensity intermittent exercise training is an alternative training mode 
for cardiac rehabilitation programmes 
Based on the findings from Chapters 4, 5 and 6, the next stage of this thesis was to 
assess if high volatility intermittent exercise, derived from a maximal CPET (with a 
preceding familiarisation test), was an effective method of training in a UK CR 
programme.  Chapter 7 shows that, when transferred to a real-life setting, high intensity 
intermittent training had a similar effect to current circuit-based training methods at 
increasing sub-maximal exercise performance and QoL after a 6 week programme.  
This type of training may therefore offer an alternative and equally effective means of 
exercise training,  which some patients might find easier to achieve and/or more 
enjoyable.  Chapter 7 also demonstrated that neither high intensity intermittent nor 
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circuit training resulted in the improvements in VO2peak or ventilatory efficiency 
reported in several exercise training studies in CHF.   
9.6 The effect of the total exercise dose on the training response 
In the general population, there is a graded dose-response between the total volume of 
physical activity performed and cardiorespiratory fitness (Oja, 2001). The evidence for 
a dose-response for activity volume and measures of health is less strong.  The short 
time scale and low frequency of training in Chapter 7, which reflects the situation in 
current CR practice (Taylor et al., 2007), is likely to explain the limited improvements 
reported in this thesis.  It is difficult to assess how the dose of exercise, in terms of 
frequency, duration and intensity, influences the training effect.  These interrelating 
factors are discussed below.  Although all patients increased the amount of exercise 
achieved in the classes during the study duration, the daily records indicated that the 
amount of home-based physical activity did not change.   This highlights the 
importance of achieving an adequate exercise dose during supervised training, and 
suggests that an additional aim during supervised sessions should be to increase the 
amount of unsupervised exercise performed.   
9.6.1 Frequency and duration 
 No studies in CHF have compared different volumes of exercise in terms of training 
frequency and duration.  The majority of studies include 3-5 sessions per week, 
although a few less frequently.  There is some evidence that increased frequency and 
duration of training will result in greater training benefits: an intensive residential 
training programme involving 2-3 hours of exercise per day increased VO2peak by 26% 
after only 4 weeks (Myers et al., 2007).  Lavie et al (2009) argue that if patients in the 
HF-ACTION trial had adhered to their exercise prescription of 120 mins per week, 
rather than completing only half this amount, the higher exercise volume would have 
been more likely to elicit greater improvements in VO2peak, and reductions in 
cardiovascular events and mortality (Lavie et al., 2009).  This is confirmed by data 
from the trial showing that the volume of exercise completed each week was directly 
associated with the magnitude of the increase in VO2peak (Keteyian, 2010). 
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9.6.2 Intensity 
 In healthy individuals, the intensity of the the activity appears to be more important 
than the total volume for increasing cardiorespiratory fitness (Oja, 2001), and 
“vigorous” intensity activity is associated with a lower risk of cardiovascular disease, 
and of other chronic diseases (O'Donovan et al., 2010).  In studies of CHF, comparison 
between intensities is hampered by the different methods used to define intensity, e.g. 
% VO2peak, % HRpeak.  However, studies where the intensity is higher do not necessarily 
appear to be more effective.  One study concluded that an exercise intensity of 70% 
HRmax was too low to improve VO2peak, but also acknowledged that lack of patient 
compliance to the home-based exercise, or the short study study duration (6 weeks) 
could also explain this finding (Harris et al., 2003).  By contrast, 6 weeks’ low intensity 
cycle training at ≤ 50% VO 2peak resulted in a 22% increase in VO2peak (Demopoulos et 
al., 1997b).  Despite the low intensity of training, the frequency was relatively high, 
with 4 sessions per week, twice as often as the intervention in Chapter 7 of this thesis. 
9.6.3 Mode 
Previous studies have used various modes, or types, of exercise training, e.g cycling, 
walking or a combination, aerobic and resistance exercises, but there is a lack of 
information about how the mode influences the training response.  The current 
evidence suggests that it is beneficial for CHF to participate in an exercise programme, 
but that the mode is less important. The current thesis is not the only study to address 
this question and to find no difference between two types of training. Exercise capacity 
improved equally after either strength training, endurance training or combined strength 
and endurance training, in 45 CHF  compared to a non-exercising control group, but 
there were no differences between modes (Feiereisen et al., 2007). However, studies 
comparing intermittent with continuous training suggest that the two different types of 
exercise might influence the training benefits.  The limited evidence to date suggests 
that intermittent training appears to improve central haemodynamics, LV and 
mitochondrial function to a greater extent, while continuous exercise results in greater 
benefits in psychological well-being, phase II VO2 kinetics and chronotropic response 
(Nechwatal et al., 2002; Dimopoulos et al., 2006; Roditis et al., 2007; Wisloff et al., 
2007).  
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9.7 Inter-individual difference in training response  
The concept of inter-individual differences in response to exercise training across a 
variety of populations is not new, and is partly due to genetics (Bouchard and 
Rankinen, 2001). The proportion of individuals who do not show clinically meaningful 
improvements for a given physiological variable, e.g. VO2peak, is estimated at 10-40%.  
It is clear that some CHF will not respond to exercise training, and it has been proposed 
that those who see a ≤ 6% improvement in VO 2peak after 20 training sessions over 4-8 
weeks, have a poorer prognosis for adverse cardiac events (Tabet et al., 2008).  It has 
been reported that older patients show smaller improvements (Wielenga et al., 1998; 
McKelvie et al., 2002).  Some argue that those with better initial myocardial function 
will respond better to training (Wilson et al., 1996; Smart et al., 2006). However, others 
propose that CHF with worse LV function have the greatest potential to improve (Jette 
et al., 1991; Hambrecht et al., 1995b).  It is not yet clear if it can be predicted which 
patients will or will not respond, and current advice is that exercise training should be 
recommended to all patients who are free from contraindications to exercise (National 
Collaborating Centre for Chronic Conditions, 2003).   
The current study included patients who were representative of the CHF population in 
general, i.e. older individuals with co-morbidities, and its findings agree with the recent 
literature suggesting that training effects are less pronounced in the wider CHF 
population than in the earlier studies restricted to homogenous samples of younger 
CHF   (Wielenga et al., 1998; Owen and Croucher, 2000; McKelvie et al., 2002; 
Prescott et al., 2009).  The Medicare Beneficiaries study indicated that nearly 40% of 
CHF patients had ≥ 5 co-morbidities, and these exacerbated their condition and 
contributed to preventable hospitalisations  (Braunstein et al., 2003). It is likely that 
exercise training also improves these co-morbidities, and indirectly improves patient 
outcomes in this way.   
9.8 Effect of exercise training on quality of life  
CR programmes aim to increase functional capacity, and to improve well-being, which 
is equally important in this population where QoL is reduced.  This appears to be 
achieved by increasing patient confidence and motivation to exercise, regardless of the 
mode of exercise or the change in cardio-respiratory fitness.  Improvements in disease-
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specific QoL, measured with the MLHFQ have been reported by several authors 
(Belardinelli et al., 1999; Passino et al., 2006b).   These benefits can be achieved after a 
few weeks, and appear to be long term (Nilsson et al., 2008c). After a supervised 
training intervention, further  improvements have been reported after follow-on 
community-based (Austin et al., 2005b) and home-based (de Mello Franco et al., 2006) 
exercise.   By contrast, several studies report only minor reductions or no change in 
MLHFQ scores after training, despite improvements in exercise performance (Gottlieb 
et al., 1999; Keteyian et al., 1999; Owen and Croucher, 2000; McKelvie et al., 2002; 
Arad et al., 2008).  Assessment of generic QoL using the SF-36 has also yielded 
conflicting results in exercise training studies in CHF (Quittan et al., 1999; Zwisler et 
al., 2008). Both circuit and intermittent training reduced MLHFQ scores in Chapter 7, 
but had no significant effect on SF-36 scores.   
Conflicting research results may be partly due to the sensitivity of the tool used to 
assess QoL. The MLFHQ and SF-36 are derived from an expert medical viewpoint, and 
may not reflect the patient perspective.  For this reason, their validity has been 
questioned, and a patient-centred health related QoL measure is currently being 
developed for use in every day care (Dunderdale et al., 2007).  A qualitative study has 
identified seven themes for inclusion: changes in physical ability, emotional state, self-
awareness and self-perception, changes in relationships, symptoms, maintaining 
social/lifestyle status and cognitive aspects.  While some of these themes are reflected 
in previous QoL research in CHF, several previously unaddressed topics were revealed.  
These were: changes in relationships, maintaining social/lifestyle status, forgetting 
about the condition, and medication issues.  It will be interesting to include this new 
measure in future exercise training studies.  In the meantime, this thesis concludes that 
the SF-36 is not an appropriately sensitive tool for assessing changes in a short-duration 
CR programme.   
9.9 The time-course of benefits from exercise training in CHF 
In healthy individuals, the greatest training effects tend to be seen during the initial 
months of training.  In CHF, there is some indication that the maximum benefits are 
achieved during the first 3-6 months’ training (Hambrecht et al., 1995a; Hambrecht et 
al., 2000) . For example, twice weekly sessions over a 3 month period increased 
VO2peak by 18% and VT by 20%, and decreased VE/VCO2 slope by 6%.  After a further 
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3 months’ training, only VT showed a further significant increase of 12% (Van 
Laethem et al., 2007). This is supported by Kavanagh et al (1996) who reported that 
VT continued to improve up to 1 year, whereas improvements in VO2peak peaked at 16 
weeks (Kavanagh et al., 1996).   One study suggests that age might be an influencing 
factor on the time course of benefits after short-term training.  CHF over 70 years 
increased their VO2peak by a further 13% (in addition to an initial increase of 9%) at a 6 
month follow-up from a 4 week CR programme.  By contrast, CHF under 70 years 
increased VO2peak by 17% after 4 weeks, but did not show any further improvements 
after 6 months (Miche et al., 2009).  Therefore, the short-duration of exercise training 
in the current thesis is a likely explanation for the minimal physiological 
improvements.    
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9.10 Conclusion 
The aims of this thesis were to determine appropriate methods for intermittent exercise 
prescription, and to assess the benefits of high intensity intermittent exercise in a UK 
CR setting.   
The response to the thesis hypotheses are set out in table 9.1  In summary, the key 
conclusions drawn are as follows:- 
1. In CHF and age-matched controls, there is a learning effect in a repeated maximal 
cycle ergometer CPET. Although the difference between tests is < 10%, within-
subject variability in VO2peak (LOA bias ± systematic error 1.57 ± 1.88 ml.kg-1.min-1
 
) 
should be taken into consideration when using it to assess the effectiveness of a 
therapeutic intervention.   
2. It is difficult to accurately prescribe exercise in individual intensity domains 
derived from gas exchange thresholds in CHF compared to healthy controls because 
the range of work rates in each domain is very narrow (< 20 W), and the test-retest 
variability is relatively high (LOA between – 13 and 7W for VT, and between -18 
and 27 W for RCP) . 
 
3. The steep test for intermittent exercise prescription (Meyer, 1997) will prescribe lower 
work rates than a standard test for healthy controls, but similar work rates for CHF.  
CHF with a low exercise tolerance on the standard test will perform relatively better in 
the steep test.  
 
4. A continuous and an intermittent exercise bout of matched total work, equal to 90% 
VT, elicits similar cardiovascular, respiratory, metabolic and RPE responses in CHF 
and healthy controls.   
 
5. If the total workload is kept equal, low and high volatility intermittent exercise 
elicit similar cardiovascular, respiratory and RPE responses  in CHF and healthy 
controls. However, high volatility exercise induces a significantly greater increase 
in Lac.  
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6. High intensity intermittent training is as effective as traditional circuit-based 
training at improving sub-maximal exercise performance and disease-specific QoL 
in a short-term twice-weekly exercise programme in a population of elderly CHF of 
mixed aetiology and co-morbidities. 
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Table 9.1: Table of responses to hypotheses 
 
Study Hypothesis Response 
1a 
 Physiological parameters measured in duplicate standard and steep 
incremental cycle ergometer tests performed one week apart by CHF 
and control participants will show acceptable reproducibility in terms 
of statistical significance, re-test correlation and limits of agreement 
(LOA), and  a  difference < 10% between tests.   
Peak measures showed poor reproducibility in terms of statistical 
significance and LOA, but acceptable reproducibility in terms of re-
test correlation and  < 10% difference between the first and second 
test. 
Sub-maximal measures showed good reproducibility in terms of 
statistical significance, re-test correlation and  < 10% difference 
between the first and second test, but poor reproducibility in terms of 
LOA.   
1b 
Intermittent exercise training workloads derived from a steep test will 
differ to those derived from a standard test in CHF and control 
participants. 
Intermittent exercise training workloads derived from a steep test and 
a standard test are not different in CHF. 
Intermittent exercise training workloads derived from a steep test are 
lower than those derived from a standard test in controls 
2 
Intermittent exercise will elicit similar cardiovascular and respiratory 
responses, but higher metabolic and RPE responses than continuous 
exercise in CHF.   In control participants there will be no difference in 
cardiovascular, respiratory, metabolic or RPE responses to 
intermittent and continuous exercise. 
There is no difference in cardiovascular, respiratory, metabolic or 
RPE responses between continuous and intermittent exercise in CHF 
or control participants  
3 
High volatility intermittent exercise will elicit higher cardiovascular, 
respiratory, metabolic and RPE responses than low volatility 
intermittent exercise or continuous exercise of matched total 
workload in CHF and control participants.   
High volatility intermittent exercise elicits higher metabolic responses 
than low volatility intermittent exercise or continuous exercise of 
matched total workload in CHF and control participants. 
There is no difference in cardiovascular, respiratory or RPE responses 
between high and low volatility intermittent exercise or continuous 
exercise of matched total workload in CHF and control participants.   
4 
There will be no difference between the effect of traditional circuit-
based training and high intensity intermittent training on functional 
capacity, ventilatory efficiency, BNP and quality of life in CHF on a 6 
week CR programme. 
There is no difference between the effect of traditional circuit-based 
training and high intensity intermittent training on functional capacity, 
ventilatory efficiency, BNP and quality of life in CHF on a 6 week 
CR programme. 
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9.11 Future directions 
Given the limited resources for supervised CR, it is important to assess the long-term 
effects of short-term programmes, and this would be one key research direction to 
follow on from this thesis.  There is concern that short-term CR programmes followed 
by home-based training are ineffective in older CHF (Haykowsky et al., 2005; Witham 
et al., 2007), and that adherence to exercise decreases once a supervised programme 
ends (Willenheimer et al., 2001; McKelvie et al., 2002).   It appears that training 
benefits may continue to accrue as long as an adequate dose of exercise is maintained. 
For example, functional capacity and QoL remained significantly higher at 12 month 
follow-up in a group who followed a 4 month high intensity programme compared with 
a “usual care” control group.  The authors speculated that intensity might be the 
important factor in long-term improvements, and based on patient comments, that 
patients in the exercise group were motivated by the programme to continue exercising 
on their own (Nilsson et al., 2008c). Several other studies also demonstrate that 
improvements in exercise capacity and QoL after short-term supervised training can be 
maintained long-term (Kavanagh et al., 1996). A retrospective study reported that 
patients involved in an 8 week training programme with no formalised exercise 
intervention thereafter, demonstrated fewer cardiac events and  days in hospital when 
compared with their non-trained counterparts 5 years later (Hagerman et al., 2005).  
Another 5 year follow up study revealed that patients who had attended a CR 
programme were more likely to take regular exercise and maintain better functional 
capacity (Austin et al., 2008). A 6 year follow-up on a small sample of CHF after 
intensive residential rehabilitation reported that exercise capacity was preserved, and 
ventricular 
There is limited information about the volume or intensity of exercise achieved in a CR 
exercise session. Two studies have assessed the exercise dose in terms of energy 
expenditure, using indirect calorimetry, prediction equations and estimations based on 
and function size were maintained (Muller et al., 2009). The level of support 
from health professionals once an exercise programme has ended may be a factor in 
determining whether prolonged benefits can be gained even if the supervised 
programme is of a short duration (Austin et al., 2005b; Beer et al., 2008).  The next 
logical study would be to assess the effects of current circuit-based training and high 
intensity intermittent training after Phase 4 community-based CR, and beyond.   
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the HR/VO2 relationship from a cardiopulmonary exercise test (Schairer et al., 1998; 
Savage et al., 2000).  Both studies reported energy expenditures below the ~300 kcal 
required from each of the thrice weekly sessions to achieve the minimum 1,000 kcal 
per week recommended to benefit cardiovascular health (Balady et al., 2000).  Savage 
et al (2000) estimated an average energy expenditure of  270 ± 112 kcal in patients with 
coronary artery disease during a 48 ± 6 min “aerobic” session spent on a combination 
of  treadmill, rowing, stepping and arm ergometers.  Although UK surveys of CR 
(BACR Survey, Coronary Prevention Group Survey, NACR) provide some information 
on the frequency and duration of training, there is no information on estimated exercise 
intensity (Taylor et al., 2007). One small study of 6 CHF  has previously reported no 
differences in VO2, HR, BP or RPE between circuit training and continuous exercise at 
70-80% HRmax (Green et al., 2001).  Chapter 7 of this thesis suggested that the circuit-
based training methods commonly used in UK practice do not necessarily correspond 
with the concept of moderate intensity exercise, i.e. exercise below VT.  The different 
exercises that comprise the circuit are likely to produce an exercise dose of varying 
intensity, but this has not been previously evaluated.  A comprehensive assessment of 
the physiological intensity of a CR training session  is now required, using 
measurements of VO2, HR, Lac and  motion analysis.   
The optimal dose of exercise is not only the dose that provides the greatest health 
benefits while minimising the risks to the patient, but must also be achievable and 
enjoyable in order to encourage adherence.  Investigations into the link between 
exercise intensity, affective responses (e.g. pleasure-displeasure) and  adherence 
conclude that exercise above VT appears to reduce pleasure (Ekkekakis et al., 2008).  A 
psychophysiological investigation  into the cognitive and physiological factors that 
influence  affective responses during exercise in CHF patients is warranted.  More 
specifically, following on from Chapter 7 of this thesis, it would be interesting to 
compare the affective responses during circuit training and high intensity intermittent 
training in a CR setting.  
Recent studies that include a more heterogeneous CHF population tend to report 
smaller changes in physiological parameters than previous studies, and this may lead to 
a mistaken conclusion that exercise is of no benefit to many patients.  However, it is 
important to integrate clinical results and prognostic markers with measurement of 
health status in order to assess the true “value” of the intervention to the patient (Jette 
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and Downing, 1994).  An important goal in the health care of individuals with chronic 
disease is to improve function and well-being, which is indicated by an individual’s 
perception of his or her QoL.  It is clear that improvements in physiological measures 
are not necessarily a pre-requisite for improvements in QoL.  Despite the fact that CHF 
may have a poor prognosis, small increases in QoL and exercise tolerance could 
translate into meaningful improvements in a patient’s ability to enjoy daily activities. 
Traditional tools to assess health related QoL in CHF, such as MLHFQ and SF-36, 
have been criticised for being designed from the “expert” rather than the patient’s point 
of view, and for lacking sensitivity to detect clinically meaningful changes (Green et 
al., 2000; Dunderdale et al., 2007). Future studies investigating the effect of high 
intensity intermittent and circuit-based training on improvements in QoL of CHF 
patients should use the recently developed patient-centred tools in order expand current 
understanding of the true benefit of these exercise training interventions. Two such 
measurement tools are The Kansas City Cardiomyopathy Questionnaire (Green et al., 
2000) used in the HF-ACTION trial  (Flynn et al., 2009) and the patient-centred 
instrument currently being  developed by UK  health practitioners for CHF patients 
(Dunderdale et al., 2007). 
To summarise, the directions for future research  resulting from this thesis are:- 
1. An investigation into the long-term effects of current circuit-based training and 
high intensity intermittent training in CHF 
2. A comprehensive assessment of the physiological intensity of a CR training 
session, using measurements of VO2, HR, Lac and  motion analysis.   
3. An investigation into the affective responses during circuit training and high 
intensity intermittent training in a CR setting.  
4. The assessment of  health-related QoL following different CR exercise 
programmes using recently developed patient-centred tools that are sensitive to 
the detection of clinically meaningful improvements.  
225 
 
 
 
References 
 
Adamopoulos, S., Parissis, J., Karatzas, D., Kroupis, C., Georgiadis, M., et al. (2002) Physical 
Training Modulates Proinflammatory Cytokines and the Soluble Fas/Soluble Fasligand 
System in Patients with Chronic Heart Failure. J Am Coll Cardiol, 39: 653. 
Adamopoulos, S., Parissis, J., Kroupis, C., Georgiadis, M., Karatzas, D., et al. (2001) Physical 
Training Reduces Peripheral Markers of Inflammation in Patients with Chronic Heart 
Failure. Eur Heart J, 22: 791-797. 
Adamopoulos, S., Parissis, J. T. & Kremastinos, D. T. (2003) New Aspects for the Role of 
Physical Training in the Management of Patients with Chronic Heart Failure. Int J 
Cardiol, 90: 1-14. 
Agostoni, P. (2006) Cardiopulmonary Exercise Testing for Heart Failure Patients: A 
Hodgepodge of Techniques, Parameters and Interpretations. In Other Words, the Need 
for a Time-Break. Eur Heart J, 27: 633-634. 
Agostoni, P., Bianchi, M., Moraschi, A., Palermo, P., Cattadori, G., et al. (2005) Work-Rate 
Affects Cardiopulmonary Exercise Test Results in Heart Failure. Eur J Heart Failure, 
7: 498. 
Ainsworth, B. E., Haskell, W. L., Whitt, M. C., Irwin, M. L., Swartz, A. M., et al. (2000) 
Compendium of Physical Activities: An Update of Activity Codes and Met Intensities. 
Med Sci Sports Exerc, 32: S498-S516. 
American College of Sports Medicine (2006) Acsm's Guidelines for Exercise Testing and 
Prescription. 7th Edition., Philadelphia, Lippincott Williams & Wilkins. 
Anand, I. S., Fisher, L. D., Chiang, Y.-T., Latini, R., Masson, S., et al. (2003) Changes in Brain 
Natriuretic Peptide and Norepinephrine over Time and Mortality and Morbidity in the 
Valsartan Heart Failure Trial (Val-Heft). Circulation, 107: 1278-1283. 
Arad, M., Adler, Y., Koren-Morag, N., Natanzon, S., Sela, B.-A., et al. (2008) Exercise 
Training in Advanced Heart Failure Patients: Discordance between Improved Exercise 
Tolerance and Unchanged Nt-Probnp Levels. Int J Cardiol 126: 114-119. 
Arena, R., Guazzi, M., Myers, J. & Abella, J. (2007) The Prognostic Value of Ventilatory 
Efficiency with Beta-Blocker Therapy in Heart Failure. Med Sci Sports Exerc. , 39: 
213-9. 
Arena, R., Guazzi, M., Myers, J. & Peberdy, M. A. (2006) Prognostic Value of Heart Rate 
Recovery in Patients with Heart Failure. Am Heart J, 151: 851. 
Arena, R., Myers, J., Aslam, S. S., Varughese, E. B. & Peberdy, M. A. (2003) Technical 
Considerations Related to the Minute Ventilation/Carbon Dioxide Output Slope in 
Patients with Heart Failure. Chest, 124: 720-727. 
Association of Chartered Physiotherapists in Cardiac Rehabilitation (2009) Standards for 
Physical Activity and Exercise in the Cardiac Population 2009. ACPICR. 
Astrand, I., Astrand, P. O. & Christensen, H. (1960a) Circulatory and Respiratory Adaptations 
to Severe Muscular Work. Acta Physiologica Scandinavica, 50: 254-8. 
Astrand, I., Astrand, P. O., Christensen, H. & Hedman, R. (1960b) Intermittent Muscular 
Work. Acta Physiologica Scandinavica, 48: 448-53. 
Astrand, P., Rodahl, K., Dahl, H. & Stromme, S. (2003) Textbook of Work Phsyiology. 
Physiological Bases of Exercise, Champaign, IL, Human Kinetics. 
Atkinson, G. & Nevill, A. (2007) Method Agreement and Measurement Error. IN Winter, E. 
M., Jones, A. M., Davison, R. C., Bromley, P. D. & Mercer, T. H. (Eds.) Sport and 
Exercise Physiology Testing Guidelines. The British Association of Sport and Exercise 
Sciences Guide. Volume 2: Exercise and Clinical Testing. London, Routledge. 
Atkinson, G. & Nevill, A. N. (1998) Statistical Methods for Assessing Measurement Error 
(Reliability) in Variables Relevant to Sports Medicine. Sports Med, 26: 217-238. 
226 
 
 
 
Austin, J., Williams, R., Ross, L., Moseley, L. & Hutchison, S. (2005a) Randomised Controlled 
Trial of Cardiac Rehabilitation in Elderly Patients with Heart Failure. Eur J Heart Fail, 
7: 411 - 417. 
Austin, J., Williams, R., Ross, L., Moseley, L. & Hutchison, S. (2005b) Randomised Controlled 
Trial of Cardiac Rehabilitation in Elderly Patients with Heart Failure. Eur J Heart 
Failure, 7: 411. 
Austin, J., Williams, W. R., Ross, L. & Hutchison, S. (2008) Five-Year Follow-up Findings 
from a Randomized Controlled Trial of Cardiac Rehabilitation for Heart Failure. Eur J 
Cardiovasc Prev Rehabil, 15: 162-167. 
Balady, G. J., Ades, P. A., Comoss, P., Limacher, M., Pina, I. L., et al. (2000) Core 
Components of Cardiac Rehabilitation/Secondary Prevention Programs : A Statement 
for Healthcare Professionals from the American Heart Association and the American 
Association of Cardiovascular and Pulmonary Rehabilitation Writing Group. 
Circulation, 102: 1069-1073. 
Bard, R. L. (2005) Cardiopulmonary Exercise Testing in Patients with Heart Failure. J Am Coll 
Cardiol, 45: 163. 
Bassett, D. R. & Howley, E. T. (2000) Limiting Factors for Maximum Oxygen Uptake and 
Determinants of Endurance Performance. Med Sci Sports Exerc, 31: 70-84. 
Beale, L., Silberbauer, J., Lloyd, G., Carter, H., Doust, J., et al. (2010) Exercise Heart Rate 
Guidelines Overestimate Recommended Intensity for Chronic Heart Failure Patients. 
Brit J Cardiol, 17: 133-7. 
Beaver, W. L., Wasserman, K. & Whipp, B. J. (1986) A New Method for Detecting Anaerobic 
Threshold by Gas Exchange. J Appl Physiol, 60: 2020-2027. 
Beckers, P. J., Denollet, J., Possemiers, N. M., Wuyts, F. L., Vrints, C. J., et al. (2008) 
Combined Endurance-Resistance Training Vs. Endurance Training in Patients with 
Chronic Heart Failure: A Prospective Randomized Study. Eur Heart J, 29: 1858-1866. 
Beer, M., Wagner, D., Myers, J., Sandstede, J., Köstler, H., et al. (2008) Effects of Exercise 
Training on Myocardial Energy Metabolism and Ventricular Function Assessed by 
Quantitative Phosphorus-31 Magnetic Resonance Spectroscopy and Magnetic 
Resonance Imaging in Dilated Cardiomyopathy. J Am Coll Cardiol, 51: 1883. 
Belardinelli, R., Georgiou, D., Cianci, G., Berman, N., Ginzton, L., et al. (1995a) Exercise 
Training Improves Left Ventricular Diastolic Filling in Patients with Dilated 
Cardiomyopathy : Clinical and Prognostic Implications. Circulation, 91: 2775-2784. 
Belardinelli, R., Georgiou, D., Cianci, G. & Purcaro, A. (1999) Randomized, Controlled Trial 
of Long-Term Moderate Exercise Training in Chronic Heart Failure: Effects on 
Functional Capacity, Quality of Life, and Clinical Outcome. Circulation, 99: 1173-
1182. 
Belardinelli, R., Georgiou, D., Scocco, V., Barstow, T. & Purcaro, A. (1995b) Low Intensity 
Exercise Training in Patients with Chronic Heart Failure. Am J Coll Cardiol, 26: 975 - 
982. 
Bensimhon, D., R. , Leifer, E., S. , Ellis, S., J. , Fleg, J., L. , Keteyian, S., J. , et al. (2008) 
Reproducibility of Peak Oxygen Uptake and Other Cardiopulmonary Exercise Testing 
Parameters in Patients with Heart Failure (from the Heart Failure and a Controlled Trial 
Investigating Outcomes of Exercise Training). Am J Cardiol, 102: 712-717. 
Berent, R., von Duvillard, S., Crouse, S., Auer, J., Green, J., et al. (2009) Short-Term 
Residential Cardiac Rehabilitation Reduces B-Type Natriuretic Peptide. Eur J 
Cardiovasc Prev Rehabil. . 
Bethell, H., Lewin, R. & Dalal, H. (2004) Cardiac Rehabilitation in the United Kingdom. 
Heart, 95: 271-275. 
Bhatia, V., Nayyar, R. & Dhindsa, S. (2003) Brain Natriuretic Peptide in Diagnosis and 
Treatment of Heart Failure. J Postgrad Med, 49: 182-5. 
Billat, V., L. (2001) Interval Training for Performance: A Scientific and Empirical Practice. 
Special Recommendations for Middle- and Long-Distance Running. Part I: Aerobic 
Interval Training. Sports Med, 31: 13-31. 
227 
 
 
 
Billat, V., L. , Slawinski, J., Bocquet, V., Demarle, A., Lafitte, L., et al. (2000) Intermittent 
Runs at the Velocity Associated with Maximal Oxygen Uptake Enables Subjects to 
Remain at Maximal Oxygen Uptake for a Longer Time Than Intense but Submaximal 
Runs. Eur J Appl Physiol, 81: 188. 
Billat, V. L., Sirvent, P., Py, G., Koralsztein, J.-P. & Mercier, J. (2003) The Concept of 
Maximal Lactate Steady State: A Bridge between Biochemistry, Physiology and Sport 
Science. Sports Med 33: 407-426. 
Bland, J. M. & Altman, D. G. (1986) Statistical Methods for Assessing Agreement between 
Two Methods of Clinical Measurement. Lancet, 8. 
Borg, G. (1970) Perceived Exertion as an Indicator of Somatic Stress. Scand J Rehabil Med, 2: 
92. 
Borg, G. (1998) Borg's Perceived Exertion and Pain Scales Champaign, IL, Human Kinetics. 
Bouchard, C. & Rankinen, T. (2001) Individual Differences in Response to Regular Physical 
Activity. Med. Sci. Sports Exerc., 33: S446-S451. 
Boudreau, M. & Genovese, J. (2007) Cardiac Rehabilitation: A Comprehensive Program for 
the Management of Heart Failure. Prog Cardiovasc Nursing, 22: 88-92. 
Braith, R. W., Welsch, M. A., Feigenbaum, M. S., Kluess, H. A. & Pepine, C. J. (1999) 
Neuroendocrine Activation in Heart Failure Is Modified by Endurance Exercise 
Training. J Am Coll Cardiol, 34: 1170. 
Braunstein, J. B., Anderson, G. F., Gerstenblith, G., Weller, W., Niefeld, M., et al. (2003) 
Noncardiac Comorbidity Increases Preventable Hospitalizations and Mortality among 
Medicare Beneficiaries with Chronic Heart Failure. J Am Coll Cardiol, 42: 1226-1233. 
Brawner, C. A., Keteyian, S. J. & Ehrman, J. K. (2002) The Relationship of Heart Rate Reserve 
to Vo2 Reserve in Patients with Heart Disease. . Med Sci Sports Exerc. , 34: 418-22. 
Brickley, G., Green, S., Jenkins, D. G., McEinery, M., Wishart, C., et al. (2007) Muscle 
Metabolism During Constant- and Alternating-Intensity Exercise around Critical 
Power. Int J Sports Med.: 300. 
British Association for Cardiac Rehabilitation (2006) Bacr Phase Iv Instructor Training 
Module. 4th Edition., Leeds, UK, Human Kinetics Europe. 
British Heart Foundation (2009) National Audit of Cardiac Rehabilitation.  Annual Statistical 
Report 2009. 
Brodie, D., Bethell, H. & Breen, S. (2006) Cardiac Rehabilitation in England: A Detailed 
National Survey. Eur J Cardiovasc Prev Rehabil, 13: 122-128. 
Brubaker, P., H. , Moore, J. B., Stewart, K., P. , Wesley, D., J.  & Kitzman, D., W. (2009) 
Endurance Exercise Training in Older Patients with Heart Failure: Results from a 
Randomized, Controlled, Single-Blind Trial. Journal of the American Geriatrics 
Society, 57: 1982-1989. 
Buchfuhrer, M. J., Hansen, J. E., Robinson, T. E., Sue, D. Y., Wasserman, K., et al. (1983) 
Optimizing the Exercise Protocol for Cardiopulmonary Assessment. J Appl Physiol, 
55: 1558-1564. 
Buckley, J. (2006) Exercise Physiology and Monitoring of Exercise in Cardiac Rehabilitation. 
IN Throw, M. (Ed.) Exercise Leadership in Cardiac Rehabilitation: An Evidence-
Based Approach. Chichester, John Wiley & Sons, Ltd. 
Buckley, J. & Eston, R. (2007) Ratings of Perceived Exertion. IN Winter, E. M., Jones, A. M., 
Davison, R. C., Bromley, P. D. & Mercer, T. H. (Eds.) Sport and Exercise Physiology 
Testing Guidelines.  The British Associaton of Sport and Exercise Sciences Guide.  
Volume 2: Exercise and Clinical Testing. London, Routledge. 
Burnley, M., Doust, J. H. & Jones, A. M. (2006) Time Required for the Restoration of Normal 
Heavy Exercise Vo2 Kinetics Following Prior Heavy Exercise. J Appl Physiol, 101: 
1320-1327. 
Butterfield, J., Faddy, S., Davidson, P. & Ridge, B. (2008) Exercise Training in Patients with 
Stable Chronic Heart Failure: Effects on Thoracic Impedance Cardiography and B-
Type Natriuretic Peptide. J Cardiopulm Rehabil Prev. , 28: 33-37. 
228 
 
 
 
Chang, R.-K. R., Qi, N., Larson, J., Rose-Gottron, C. & Cooper, D. (2005) Comparison of 
Upright and Semi-Recumbent Postures for Exercise Echocardiography in Healthy 
Children. Am J Cardiol, 95: 918-921. 
Christensen, H., Hedman, R. & Saltin, B. (1960) Intermittent and Continuous Running. (a 
Further Contribution to the Physiology of Intermittent Work.). Acta Physiologica 
Scandinavica, 50: 269-86. 
Chua, B. M. D. M. T. P., Ponikowski, M. D. P., Harrington, M. D. & Anker, M. D. S. D. 
(1997) Clinical Correlates and Prognostic Significance of the Ventilatory Response to 
Exercise in Chronic Heart Failure. J Am Coll Cardiol, 29: 1585. 
Chua, T. P., Clark, A. I., Amadi, A. A. & Coats, A. J. S. (1996) Relation between 
Chemosensitivity and the Ventilatory Response to Exercise in Chronic Heart Failure. J 
Am Coll Cardiol, 27: 650-657. 
Clark, A. L. (2006) Origin of Symptoms in Chronic Heart Failure. Heart, 92: 12-16. 
Clark, A. L., Poole-Wilson, P. A. & Coats, A. J. S. (1996) Exercise Limitation in Chronic Heart 
Failure: Central Role of the Periphery. J Am Coll Cardiol, 28: 1092. 
Coats, A., Adamopoulos, S., Meyer, T., Conway, J. & Sleight, P. (1990a) Effects of Physical 
Training in Chronic Heart Failure. Lancet, 335: 63 - 66. 
Coats, A. J., Adamopoulos, S., Radaelli, A., McCance, A., Meyer, T. E., et al. (1992a) 
Controlled Trial of Physical Training in Chronic Heart Failure. Exercise Performance, 
Hemodynamics, Ventilation, and Autonomic Function. Circulation, 85: 2119-2131. 
Coats, A. J., Adamopoulos, S., Radaelli, A., McCance, A., Meyer, T. E., et al. (1992b) 
Controlled Trial of Physical Training in Chronic Heart Failure. Exercise Performance, 
Hemodynamics, Ventilation, and Autonomic Function. Circulation, 85: 2119 - 31. 
Coats, A. J. S., Adamopoulos, S., Meyer, T. E., Conway, J. & Sleight, P. (1990b) Effects of 
Physical Training in Chronic Heart Failure. The Lancet, 335: 63. 
Coats, A. J. S., Clark, A. L., Piepoli, M., Volterrani, M. & Poole-Wilson, P. A. (1994) 
Symptoms and Quality of Life in Heart Failure: The Muscle Hypothesis. British Heart 
Journal, 72: S36. 
Cohen-Solal, A., Chabernaud, J. M. & Gourgon, R. (1990) Comparison of Oxygen Uptake 
During Bicycle Exercise in Patients with Chronic Heart Failure and in Normal 
Subjects. J Am Coll Cardiol. , 16: 80-85. 
Cohen-Solal, A., Czitrom, D., Geneves, M. & Gourgon, R. (1997) Delayed Attainment of Peak 
Oxygen Consumption after the End of Exercise in Patients with Chronic Heart Failure. 
Int J Cardiol, 60: 23. 
Cohen-Solal, A., Zannad, F., Kayanakis, J. G., Gueret, P., Aupetit, J. F., et al. (1991) 
Multicentre Study of the Determination of Peak Oxygen Uptake and Ventilatory 
Threshold During Bicycle Exercise in Chronic Heart Failure: Comparison of Graphical 
Methods, Interobserver Variability and Influence of the Exercise Protocol. Eur Heart J, 
12: 1055-1063. 
Cohen, R. A., Moser, D. J., Clark, M. M., Aloia, M. S., Cargill, B. R., et al. (1999) 
Neurocognitive Functioning and Improvement in Quality of Life Following 
Participation in Cardiac Rehabilitation. Am J Cardiol, 83: 1374-1378. 
Commission for Healthcare Audit and Inspection (2007) Pushing the Boundaries: Improving 
Services for People with Heart Failure. Service Review. Commission for Healthcare 
Audit and Inspection. 
Conn, E. H., Williams, R. S. & Wallace, A. G. (1982) Exercise Responses before and after 
Physical Conditioning in Patients with Severely Depressed Left Ventricular Function. 
Am J Cardiol 49: 296-300. 
Conraads, V. M., Beckers, P., Vaes, J., Martin, M., Van Hoof, V., et al. (2004) Combined 
Endurance/Resistance Training Reduces Nt-Probnp Levels in Patients with Chronic 
Heart Failure. Eur Heart J, 25: 1797-1805. 
Conraads, V. M. A., Vanderheyden, M., Paelinck, B., Verstreken, S., Blankoff, I., et al. (2007) 
The Effect of Endurance Training on Exercise Capacity Following Cardiac 
Resynchronization Therapy in Chronic Heart Failure Patients: A Pilot Trial. Eur J 
Cardiovasc Prev Rehabil, 14: 99-106. 
229 
 
 
 
Cooke, C. B. (2001) Maximal Oxygen Uptake, Economy and Efficiency. IN Eston, R. & 
Reilly, T. (Eds.) Kinanthropometry and Exercise Physiology Laboratory Manual: 
Tests, Procedures and Data. Volume 2 Exercise Physiology. 3 ed. London, Routledge. 
Cooper, C. B. & Storer, T. W. (2001) Exercise Testing and Interpretation: A Practical 
Approach, Cambridge, Cambridge University Press. 
Coplan, N. L., Gleim, G. W. & Nicholas, J. A. (1986) Using Exercise Respiratory 
Measurements to Compare Methods of Exercise Prescription. Am J Cardiol, 58: 832. 
Corra , U., Giannuzzi, P., Adamopoulos, S., Bjornstad, H., Bjarnason-Weherns, B., et al. 
(2005) Executive Summary of the Position Paper of the Working Group on Cardiac 
Rehabilitation and Exercise Physiology of the European Society of Cardiology (Esc): 
Core Components of Cardiac Rehabilitation in Chronic Heart Failure. European 
Journal of Cardiovascular Prevention & Rehabilitation, 12: 321-325. 
Corra, U., Giordano, A., Bosimini, E., Mezzani, A., Piepoli, M., et al. (2002) Oscillatory 
Ventilation During Exercise in Patients with Chronic Heart Failure: Clinical Correlates 
and Prognostic Implications. Chest, 121: 1572-1580. 
Cowie, M., Collinson, P. O., Dargie, H., Hobbs, R., McDonagh, T. A., et al. (2010) 
Recommendations on the Clinical Use of B-Type Natriuretic Peptide Testing (Bnp or 
Ntprobnp) in the Uk and Ireland. Brit J Cardiol, 17: 76-80. 
Crimi, E., Ignarro, L., Cacciatore, F. & Napoli, C. (2009) Mechanisms by Which Exercise 
Training Benefits Patients with Heart Failure. Nat Rev Cardiol., 6: 292-300. 
Dao, Q., Krishnaswamy, P., Kazanegra, R., Harrison, A., Amirnovin, R., et al. (2001) Utility of 
B-Type Natriuretic Peptide in the Diagnosis of Congestive Heart Failure in an Urgent-
Care Setting. J Am Coll Cardiol, 37: 379-385. 
Dassonville, J., Beillot, J., Lessard, Y., Jan, J., Andre, A., et al. (1998) Blood Lactate 
Concentrations During Exercise: Effect of Sampling Site and Exercise Mode. J Sports 
Med Phys Fitness, 38: 39-46. 
Daussin, F., Ponsot, E., Dufour, S., Lonsdorfer-Wolf, E., Doutreleau, S., et al. (2007) 
Improvement of Vo2max by Cardiac Output and Oxygen Extraction Adaptation During 
Intermittent Versus Continuous Endurance Training. Eur J Appl Physiol, 101: 377-383. 
Daussin, F. N., Zoll, J., Dufour, S. P., Ponsot, E., Lonsdorfer-Wolf, E., et al. (2008) Effect of 
Interval Versus Continuous Training on Cardiorespiratory and Mitochondrial 
Functions: Relationship to Aerobic Performance Improvements in Sedentary Subjects. 
Am J Physiol Regul Integr Comp Physiol, 295: R264-272. 
Davies, E. J., Moxham, T., Rees, K., Singh, S., Coats, A. J. S., et al. (2010) Exercise Based 
Rehabilitation for Heart Failure (Review). The Cochrane Library. 
Davis, J. A., Whipp, B. J., Lamarra, N., Huntsman, D. J., Frank, M. H., et al. (1982) Effect of 
Ramp Slope on Determination of Aerobic Parameters from the Ramp Exercise Test. 
Med Sci Sports Exerc, 14: 339-343. 
De Backer, I. C., Schep, G., Hoogeveen, A., Vreugdenhil, G., Kester, A. D., et al. (2007) 
Exercise Testing and Training in a Cancer Rehabilitation Program: The Advantage of 
the Steep Ramp Test. Arch Phys Med and Rehabil, 88: 610-616. 
de Groote, P., Dagorn, J., Soudan, B., Lamblin, N., McFadden, E., et al. (2004) B-Type 
Natriuretic Peptide and Peak Exercise Oxygen Consumption Provide Independent 
Information for Risk Stratification in Patients with Stable Congestive Heart Failure. J 
Am Coll Cardiol, 43: 1584-9. 
de Mello Franco, F. G., Santos, A. C., Rondon, M. U. P., Trombetta, I. C., Strunz, C., et al. 
(2006) Effects of Home-Based Exercise Training on Neurovascular Control in Patients 
with Heart Failure. Eur J Heart Fail, 8: 851-855. 
Dekerle, J., Baron, B., Dupont, L., Vanvelcenaher, J. & Pelayo, P. (2003) Maximal Lactate 
Steady State, Respiratory Compensation Threshold and Critical Power. Eur J Appl 
Physiol, 89: 281-288. 
Demopoulos, L., Yeh, M., Gentilucci, M., Testa, M., Bijou, R., et al. (1997a) Nonselective ß-
Adrenergic Blockade with Carvedilol Does Not Hinder the Benefits of Exercise 
Training in Patients with Congestive Heart Failure. Circulation, 95: 1764-1767. 
230 
 
 
 
Demopoulos, M. D. L., Bijou, M. D. R., Fergus, M. D. I., Jones, R. N. M., Strom, M. D. F. J., 
et al. (1997b) Exercise Training in Patients with Severe Congestive Heart Failure: 
Enhancing Peak Aerobic Capacity While Minimizing the Increase in Ventricular Wall 
Stress. J Am Coll Cardiol, 29: 597. 
Dimopoulos, S., Anastasiou-Nana, M., Sakellariou, D., Drakos, S., Kapsimalakou, S., et al. 
(2006) Effects of Exercise Rehabilitation Program on Heart Rate Recovery in Patients 
with Chronic Heart Failure. Eur J Cardiovasc Prev Rehabil. , 13: 67-73. 
Drexler, H., Riede, U., Munzel, T., Konig, H., Funke, E., et al. (1992) Alterations of Skeletal 
Muscle in Chronic Heart Failure. Circulation, 85: 1751-1759. 
Dubach, M. D. P., Myers, P. F. J., Dziekan, M. D. G. & Goebbels, M. D. U. (1997) Effect of 
High Intensity Exercise Training on Central Hemodynamic Responses to Exercise in 
Men with Reduced Left Ventricular Function. J Am Coll Cardiol, 29: 1591. 
Dunderdale, K., Furze, G., Thompson, D. R., Beer, S. F. & Miles, J. N. V. (2007) Health-
Related Quality of Life from the Perspective of Patients with Chronic Heart Failure. Br 
J Cardiol, 14: 207-212. 
Dwyer, J. (1994) Metabolic Character of Exercise at Traditional Training Intensities in Cardiac 
Patients and Healthy Persons. J Cardiopulmonary Rehabil, 14: 189-96. 
Earnest, C. P. (2008) Exercise Interval Training: An Improved Stimulus for Improving the 
Physiology of Pre-Diabetes. Medical hypotheses, 71: 752-761. 
Ekkekakis, P., Hall, E. & Petruzzello, S. (2008) The Relationship between Exercise Intensity 
and Affective Responses Demystified: To Crack the 40-Year-Old Nut, Replace the 40-
Year-Old Nutcracker! Annals of Behavioral Medicine, 35: 136-149. 
Elborn, J. S., Stanford, C. F. & Nicholls, D. P. (1990) Reproducibility of Cardiopulmonary 
Parameters During Exercise in Patients with Chronic Cardiac Failure. The Need for a 
Preliminary Test. Eur Heart J, 11: 75-81. 
Ennezat, P. V., Malendowicz, S. L., Testa, M., Colombo, P. C., Cohen-Solal, A., et al. (2001) 
Physical Training in Patients with Chronic Heart Failure Enhances the Expression of 
Genes Encoding Antioxidative Enzymes. J Am Coll Cardiol, 38: 194-198. 
Essen, B., Hagenfeldt, L. & Kaijser, L. (1977) Utilization of Blood-Borne and Intramuscular 
Substrates During Continuous and Intermittent Exercise in Man. J Physiol, 265: 489-
506. 
Essen, B. & Kaijser, L. (1978) Regulation of Glycolysis in Intermittent Exercise in Man. J 
Physiol, 281: 499-511. 
Eston, R., Williams, J. G. & Faulkner, J. (2009) Control of Exercise Intensity Using Heart Rate, 
Perceived Exertion and Other Non-Invasive Procedures. IN Eston, R. & Riley, R. L. 
(Eds.) Kinanthropometry and Exercise Physiology Laboratory Manual. 3rd ed. 
London, Routledge. 
European Heart Failure Training Group (1998) Experience from Controlled Trials of Physical 
Training in Chronic Heart Failure. Protocol and Patient Factors in Effectiveness in the 
Improvement in Exercise Tolerance. Eur Heart J, 19: 466-475. 
Fan, S., Lyon, C., Savage, P., Ozonoff, A., Ades, P., et al. (2009) Outcomes and Adverse 
Events among Patients with Cardiac Defibrillators in Cardiac Rehabilitation: A Case-
Controlled Study. J Cardiopolm Rehabil Prev, 29: 40-43. 
Faude, O., Kindermann, W. & Meyer, T. (2009) Lactate Threshold Concepts: How Valid Are 
They? Sports Med, 39: 469-490. 
Feiereisen, P., Delagardelle, C., Vaillant, M., Lasar, Y. & Beissel, J. (2007) Is Strength 
Training the More Efficient Training Modality in Chronic Heart Failure? Med Sci 
Sports Exerc, 39: 1910-7. 
Fleg, J. L., Pina, I. L., Balady, G. J., Chaitman, B. R., Fletcher, B., et al. (2000) Assessment of 
Functional Capacity in Clinical and Research Applications : An Advisory from the 
Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical 
Cardiology, American Heart Association. Circulation, 102: 1591-1597. 
Fletcher, G. F., Balady, G. J., Amsterdam, E. A., Chaitman, B., Eckel, R., et al. (2001) Exercise 
Standards for Testing and Training: A Statement for Healthcare Professionals from the 
American Heart Association. Circulation, 104: 1694-1740. 
231 
 
 
 
Flynn, K. E., Pina, I. L., Whellan, D. J., Lin, L., Blumenthal, J. A., et al. (2009) Effects of 
Exercise Training on Health Status in Patients with Chronic Heart Failure: Hf-Action 
Randomized Controlled Trial. JAMA, 301: 1451-1459. 
Forissier, J. F., Vernochet, P., Bertrand, P., Charbonnier, B. & Monpere, C. (2001) Influence of 
Carvedilol on the Benefits of Physical Training in Patients with Moderate Chronic 
Heart Failure. Eur J Heart Failure, 3: 335. 
Foster, C., Georgakopoulos, N. & Meyer, K. (1998) Physiological and Pathological Aspects of 
Exercise Left Ventricular Function. Med Sci Sports Exerc, 10: S379-86. 
Foster, C., Meyer, K., Georgakopoulos, N., Ellestad, A., Fitzgerald, D., et al. (1999) Left 
Ventricular Function During Interval and Steady State Exercise. Med Sci Sports Exerc. 
, 31: 1157-62. 
Fraga, R., Franco, F. G., Roveda, F., de Matos, L. N. J., Braga, A. M. F. W., et al. (2007) 
Exercise Training Reduces Sympathetic Nerve Activity in Heart Failure Patients 
Treated with Carvedilol. Eur J Heart Fail, 9: 630. 
Freimark, D., Shechter, M., Schwamenthal, E., Tanne, D., Elmaleh, E., et al. (2007) Improved 
Exercise Tolerance and Cardiac Function in Severe Chronic Heart Failure Patients 
Undergoing a Supervised Exercise Program. Int J Cardiol, 116: 309. 
Gademan, M. G. J., Swenne, C. A., Verwey, H. F., van der Laarse, A., Maan, A. C., et al. 
(2007) Effect of Exercise Training on Autonomic Derangement and Neurohumoral 
Activation in Chronic Heart Failure. Journal of Cardiac Failure, 13: 294. 
Georgiou, D., Chen, Y., Appadoo, S., Belardinelli, R., Greene, R., et al. (2001) Cost-
Effectiveness Analysis of Long-Term Moderate Exercise Training in Chronic Heart 
Failure. Am J Cardiol, 87: 984-988. 
Giannuzzi, P., Saner, H., Bjornstad, H., Fioretti, P., Mendes, M., et al. (2003a) Secondary 
Prevention through Cardiac Rehabilitation: Position Paper of the Working Group on 
Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology. 
Eur Heart J, 24: 1273-1278. 
Giannuzzi, P., Tavazzi, L., Meyer, K., Perk, J., Drexler, H., et al. (2001) Recommendations for 
Exercise Training in Chronic Heart Failure Patients. Working Group on Cardiac 
Rehabilitation & Exercise Physiology and Working Group on Heart Failure of the 
European Society of Cardiology. Eur Heart J, 22: 125-135. 
Giannuzzi, P., Temporelli, P. L., Corra, U. & Tavazzi, L. (2003b) Antiremodeling Effect of 
Long-Term Exercise Training in Patients with Stable Chronic Heart Failure: Results of 
the Exercise in Left Ventricular Dysfunction and Chronic Heart Failure (Elvd-Chf) 
Trial. Circulation, 108: 554-559. 
Gibbons, R. J., Balady, G. J., Beasley, J. W., Faafp, J. W., Bricker, J. T., et al. (1997) Acc/Aha 
Guidelines for Exercise Testing: Executive Summary : A Report of the American 
College of Cardiology/ American Heart Association Task Force on Practice Guidelines 
(Committee on Exercise Testing). Circulation, 96: 345-354. 
Gielen, S., Adams, V., Mobius-Winkler, S., Linke, A., Erbs, S., et al. (2003) Anti-
Inflammatory Effects of Exercise Training in the Skeletal Muscle of Patients with 
Chronic Heart Failure. J Am Coll Cardiol, 42: 861. 
Gielen, S., Adams, V., Niebauer, J., Schuler, G. & Hambrecht, R. (2005) Aging and Heart 
Failure--Similar Syndromes of Exercise Intolerance? Implications for Exercise-Based 
Interventions. Heart Fail Monit., 4: 130-6. 
- , R., Persson, H., Kaijser, L., Hultman, E., et al. (1996) Markedly 
Improved Skeletal Muscle Function with Local Muscle Training in Patients with 
Chronic Heart Failure. Clinical Cardiology, 19: 568-74. 
Gordon, N. F. & Scott, C. B. (1995) Exercise Intensity Prescription in Cardiovascular Disease. 
Theoretical Basis for Anaerobic Threshold Determination. J Cardiopulmonary Rehabil, 
15: 193-196. 
Gorostiaga, E., Walter, C., Foster, C. & Hickson, R. (1991) Uniqueness of Interval and 
Continuous Training at the Same Maintained Exercise Intensity. Eur J Appl Physiol 
Occup Physiol., 63: 101-7. 
232 
 
 
 
Gottlieb, S. S., Fisher, M. L., Freudenberger, R., Robinson, S., Zietowski, G., et al. (1999) 
Effects of Exercise Training on Peak Performance and Quality of Life in Congestive 
Heart Failure Patients. Journal of Cardiac Failure, 5: 188. 
Green, C. P., Porter, C. B., Bresnahan, D. R. & Spertus, J. A. (2000) Development and 
Evaluation of the Kansas City Cardiomyopathy Questionnaire: A New Health Status 
Measure for Heart Failure. J Am Coll Cardiol, 35: 1245-1255. 
Green, D., Watts, K., Maiorana, A. & O'Driscoll, J. (2001) A Comparison of Ambulatory 
Oxygen Consumption During Circuit Training and Aerobic Exercise in Patients with 
Chronic Heart Failure. J Cardiopulm Rehabil., 21: 167-174. 
Guyatt, G. H., Feeny, D. H. & Patrick, D. L. (1993) Measuring Health-Related Quality of Life. 
Ann Intern Med, 118: 662-9. 
Hagberg, L. A. & Lindholm, L. (2006) Review Article: Cost-Effectiveness of Healthcare-Based 
Interventions Aimed at Improving Physical Activity. Scand J Public Health, 34: 641-
653. 
Hagerman, I., Tyni-Lenne, R. & Gordon, A. (2005) Outcome of Exercise Training on the Long-
Term Burden of Hospitalisation in Patients with Chronic Heart Failure. A 
Restrospective Study. Int J Cardiol, 98: 487. 
Hambrecht, M. D. R., Fiehn, M. D. E., Yu, M. D. J., Niebauer, M. D. J., Weigl, M. D. C., et al. 
(1997) Effects of Endurance Training on Mitochondrial Ultrastructure and Fiber Type 
Distribution in Skeletal Muscle of Patients with Stable Chronic Heart Failure. J Am 
Coll Cardiol, 29: 1067. 
Hambrecht, R., Fiehn, E., Weigl, C., Gielen, S., Hamann, C., et al. (1998) Regular Physical 
Exercise Corrects Endothelial Dysfunction and Improves Exercise Capacity in Patients 
with Chronic Heart Failure. Circulation, 98: 2709-2715. 
Hambrecht, R., Gielen, S., Linke, A., Fiehn, E., Yu, J., et al. (2000) Effects of Exercise 
Training on Left Ventricular Function and Peripheral Resistance in Patients with 
Chronic Heart Failure: A Randomized Trial. JAMA, 283: 3095-3101. 
Hambrecht, R., Niebauer, J., Fiehn, E., Kalberer, B., Offner, B., et al. (1995a) Physical 
Training in Patients with Stable Chronic Heart Failure: Effects on Cardiorespiratory 
Fitness and Ultrastructural Abnormalities of Leg Muscles. J Am Coll Cardiol, 25: 
1239-49. 
Hambrecht, R., Niebaure, J., Fiehn, E., Kalbere, B., Offner, B., et al. (1995b) Physical Training 
in Patients with Stable Chronic Heart Failure: Effects on Cardiorespiratory Fitness and 
Ultra-Structural Abnormalities of Leg Muscles. Am J Coll Cardiol, 25: 1239 - 1249. 
Harris, S., LeMaitre, J. P., Mackenzie, G., Fox, K. A. A. & Denvir, M. A. (2003) A 
Randomised Study of Home-Based Electrical Stimulation of the Legs and 
Conventional Bicycle Exercise Training for Patients with Chronic Heart Failure. Eur 
Heart J, 24: 871-878. 
Haskell, W. L. (2001) What to Look for in Assessing Responsiveness to Exercise in a Health 
Context. Med Sci Sports Exerc, 33: S454-S458. 
Haskell, W. L., Lee, I.-M., Pate, R. R., Powell, K. E., Blair, S. N., et al. (2007) Physical 
Activity and Public Health: Updated Recommendation for Adults from the American 
College of Sports Medicine and the American Heart Association. Circulation, 116: 
1081-1093. 
Haykowsky, M., Vonder Muhll, I., Ezekowitz, J. & Armstrong, P. (2005) Supervised Exercise 
Training Improves Aerobic Capacity and Muscle Strength in Older Women with Heart 
Failure. Can J Cardiol., 21: 1277-80. 
Haykowsky, M. J., Liang, Y., Pechter, D., Jones, L. W., McAlister, F. A., et al. (2007) A Meta-
Analysis of the Effect of Exercise Training on Left Ventricular Remodeling in Heart 
Failure Patients: The Benefit Depends on the Type of Training Performed. J Am Coll 
Cardiol, 49: 2329 - 2336. 
Hepple, R. T., Liu, P. P., Plyley, M. J. & Goodman, J. M. (1999) Oxygen Uptake Kinetics 
During Exercise in Chronic Heart Failure: Influence of Peripheral Vascular Reserve. 
Clin. Sci., 97: 569-577. 
233 
 
 
 
Hobbs, F. D. R., Kenkre, J. E., Roalfe, A. K., Davis, R. C., Hare, R., et al. (2002) Impact of 
Heart Failure and Left Ventricular Systolic Dysfunction on Quality of Life. A Cross-
Sectional Study Comparing Common Chronic Cardiac and Medical Disorders and a 
Representative Adult Population. Eur Heart J, 23: 1867-1876. 
Hopkins, W., Schabort, E. & Hawley, J. (2001) Reliability of Power in Physical Performance 
Tests. Sports Medicine, 31: 211-34. 
Hopkins, W. G. (2000a) Measures of Reliability in Sports Medicine and Science. Sports Med, 
30: 1-15. 
Hopkins, W. G. (2000b) A New View of Statistics: Calculations of Reliability. 
Http://Www.Sportsci.Org/Resource/Stats/Index.Html. 
Hornig, B., Maier, V. & Drexler, H. (1996) Physical Training Improves Endothelial Function in 
Patients with Chronic Heart Failure. Circulation, 25: 210 - 214. 
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., et al. (2005) 
Acc/Aha 2005 Guideline Update for the Diagnosis and Management of Chronic Heart 
Failure in the Adult--Summary Article: A Report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines (Writing 
Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart 
Failure): Developed in Collaboration with the American College of Chest Physicians 
and the International Society for Heart and Lung Transplantation: Endorsed by the 
Heart Rhythm Society. Circulation, 112: 1825-1852. 
Ingle, L. (2007) Theoretical Rationale and Practical Recommendations for Cardiopulmonary 
Exercise Testing in Patients with Chronic Heart Failure. Heart Failure Rev, 12: 12-22. 
Ingle, L. (2008) Prognostic Value and Diagnostic Potential of Cardiopulmonary Exercise 
Testing in Patients with Chronic Heart Failure. Eur J Heart Fail, 10: 112. 
Jette, D. U. & Downing, J. (1994) Health Status of Individuals Entering a Cardiac 
Rehabilitation Program as Measured by the Medical Outcomes Study 36-Item Short-
Form Survey (Sf-36). Phys Ther, 74: 521-527. 
Jette, M., Heller, R., Landry, F. & Blumchen, G. (1991) Randomized 4-Week Exercise 
Program in Patients with Impaired Left Ventricular Function. Circulation, 84: 1561-
1567. 
Johnson, J. S., Carlson, J. J., VanderLaan, R. L. & Langholz, D. E. (1998) Effects of Sampling 
Interval on Peak Oxygen Consumption in Patients Evaluated for Heart Transplantation. 
Chest, 113: 816-819  
Jolly, K., Taylor, R. S., Lip, G. Y. H., Davies, M., Davis, R., et al. (2009) A Randomized Trial 
of the Addition of Home-Based Exercise to Specialist Heart Failure Nurse Care: The 
Birmingham Rehabilitation Uptake Maximisation Study for Patients with Congestive 
Heart Failure (Brum-Chf) Study. Eur J Heart Fail, 11: 205-213. 
Jolly, K., Tayor, R., Lip, G., Greenfield, S., Davies, M., et al. (2007) Home-Based Exercise 
Rehabilitation in Addition to Specialist Heart Failure Nurse Care: Design, Rationale 
and Recruitment to the Birmingham Rehabilitation Uptake Maximisation Study for 
Patients with Congestive Heart Failure (Brum-Chf): A Randomised Controlled Trial. 
BMC Cardiovascular Disorders, 7: 9. 
Jondeau, G., Katz, S. D., Zohman, L., Goldberger, M., McCarthy, M., et al. (1992) Active 
Skeletal Muscle Mass and Cardiopulmonary Reserve. Failure to Attain Peak Aerobic 
Capacity During Maximal Bicycle Exercise in Patients with Severe Congestive Heart 
Failure. Circulation, 86: 1351-1356. 
Jones, A. M. & Poole, D. C. (2005) Oxygen Uptake Kinetics in Sport, Exercise and Medicine, 
London, Routledge. 
Jones, A. M., Vanhatalo, A. T. & Doust, J. D. (2007) Aerobic Exercise Performance. IN Eston, 
R. & Reilly, T. (Eds.) Kinanthropometry and Exercise Physiology Laboratory Manual: 
Tests, Procedures and Data. Volume 2 Exercise Physiology. 3 ed. London, Routledge. 
Jonsdottir, S., Andersen, K. K., Sigursson, A. F. & Sigursson, S. B. (2006) The Effect of 
Physical Training in Chronic Heart Failure. Eur J Heart Fail, 8: 97. 
Katz, S. D., Berkowitz, R. & LeJemtel, T. H. (1992) Anaerobic Threshold Detection in Patients 
with Congestive Heart Failure. Am J Cardiol, 69: 1565. 
234 
 
 
 
Kavanagh, T., Myers, M. G., Baigrie, R. S., Mertens, D. J., Sawyer, P., et al. (1996) Quality of 
Life and Cardiorespiratory Function in Chronic Heart Failure: Effects of 12 Months' 
Aerobic Training. Heart, 76: 42-49. 
Kemps, H., M. , Schep, G., de Vries, W. R., Schmikli, S. L., Zonderland, M. L., et al. (2008) 
Predicting Effects of Exercise Training in Patients with Heart Failure Secondary to 
Ischemic or Idiopathic Dilated Cardiomyopathy. Am J Cardiol, 102: 1073-1078. 
Kemps, H., M., Schep, G., Hoogsteen, J., Thijssen, E. J. M., De Vries, W. R., et al. (2009) 
Oxygen Uptake Kinetics in Chronic Heart Failure: Clinical and Physiological Aspects. 
Neth Heart J. , 17: 238-244. 
Kervio, G., Carre, F. & Ville, N. S. (2003) Reliability and Intensity of the Six-Minute Walk 
Test in Healthy Elderly Subjects. Med Sci Sports Exerc, 35: 169-174. 
Keteyian, S. (2010) Exercise in the Management of Patients with Chronic Heart Failure. 
Current Heart Failure Reports, 7: 35-41. 
Keteyian, S. J., Brawner, C. A., Ehrman, J. K., Ivanhoe, R., Boehmer, J. P., et al. (2010) 
Reproducibility of Peak Vo2 and Other Cardiopulmonary Exercise Parameters: 
Implications for Clinical Trials and Clinical Practice Chest. 
Keteyian, S. J., Brawner, C. A., Schairer, J. R., Levine, T. B., Levine, A. B., et al. (1999) 
Effects of Exercise Training on Chronotropic Incompetence in Patients with Heart 
Failure. Am Heart J, 138: 233. 
Keteyian, S. J., Levine, A. B., Brawner, C. A., Kataoka, T., Rogers, F. J., et al. (1996) Exercise 
Training in Patients with Heart Failure a Randomized, Controlled Trial. Ann Intern 
Med, 124: 1051-1057. 
Kiilavuori, K., Näveri, H., Ikonen, T., Leinonen, H. & Sovijärvi, A. (1996) Effect of Physical 
Training on Exercise Capacity and Gas Exchange in Patients with Chronic Heart 
Failure. Chest, 110: 985-91. 
Kiilavuori, K., Naveri, H., Salmi, T. & Harkonen, M. (2000) The Effect of Physical Training on 
Skeletal Muscle in Patients with Chronic Heart Failure. Eur J Heart Fail, 2: 53-63. 
Kiilavuori, K., Toivonen, L., Naveri, H. & Leinonen, H. (1995) Reversal of Autonomic 
Derangements by Physical Training in Chronic Heart Failure Assessed by Heart Rate 
Variability. Eur Heart J, 16: 490-495. 
Kim, S., Yamabe, H. & Yokoyama, M. (1999) Hemodynamic Characteristics During Treadmill 
and Bicycle Exercise in Chronic Heart Failure. Japanese Circulation Journal, 63: 965-
70. 
Kjaer, A., Appel, J., Hildebrandt, P. & Petersen, C. L. (2004) Basal and Exercise-Induced 
Neuroendocrine Activation in Patients with Heart Failure and in Normal Subjects. Eur 
J Heart Fail, 6: 29. 
Klecha, A., Kawecka-Jaszcz, K., Bacior, B., Kubinyi, A., Pasowicz, M., et al. (2007) Physical 
Training in Patients with Chronic Heart Failure of Ischemic Origin: Effect on Exercise 
Capacity and Left Ventricular Remodeling. Eur J Cardiovasc Prev Rehabil, 14: 85-91. 
Kobayashi, N., Tsuruya, Y., Iwasawa, T., Ikeda, N., Hashimoto, S., et al. (2003) Exercise 
Training in Patients with Chronic Heart Failure Improves Endothelial Function 
Predominantly in the Trained Extremities. Circ J, 67: 505-510. 
Koike, A., Itoh, H., Doi, M., Taniguchi, K., Marumo, F., et al. (1990) Beat-to-Beat Evaluation 
of Cardiac Function During Recovery from Upright Bicycle Exercise in Patients with 
Coronary Artery Disease. Am Heart J, 120: 316-323. 
Koike, A., Itoh, H., Taniguchi, K. & Hiroe, M. (1989) Detecting Abnormalities in Left 
Ventricular Function During Exercise by Respiratory Measurement. Circulation, 80: 
1737-46. 
Kruger, S., Graf, J. u., Kunz, D., Stickel, T., Hanrath, P., et al. (2002) Brain Natriuretic Peptide 
Levels Predict Functional Capacity in Patients with Chronic Heart Failure. J Am Coll 
Cardiol, 40: 718-22. 
Lamas, G. A., Ellenbogen, K. A., With the Assistance of Charles H. Hennekens, M. D. D. & 
Alicia Montanez, M. D. (2004) Evidence Base for Pacemaker Mode Selection: From 
Physiology to Randomized Trials. Circulation, 109: 443-451. 
235 
 
 
 
Larsen, A. I., Aarsland, T., Kristiansen, M., Haugland, A. & Dickstein, K. (2001) Assessing the 
Effect of Exercise Training in Men with Heart Failure. Comparison of Maximal, 
Submaximal and Endurance Exercise Protocols. Eur Heart J, 22: 684-692. 
Larsen, A. I., Lindal, S., Aukrust, P., Toft, I., Aarsland, T., et al. (2002) Effect of Exercise 
Training on Skeletal Muscle Fibre Characteristics in Men with Chronic Heart Failure. 
Correlation between Skeletal Muscle Alterations, Cytokines and Exercise Capacity. Int 
J Cardiol, 83: 25-32. 
Lavie, C., J. , Milani, R., V.  & Ventura, H., O. (2009) Exercise Training and Heart Failure in 
Older Adults - Dismal Failure or Not Enough Exercise? Journal of the American 
Geriatrics Society, 57: 2148-2150. 
Lee, A. P., Ice, R., Blessey, R. & Sanmarco, M. E. (1979) Long-Term Effects of Physical 
Training on Coronary Patients with Impaired Ventricular Function. Circulation, 60: 
1519-1526. 
Lee, S., Stevens, T. L., Sandberg, S. M., Heublein, D. M., Nelson, S. M., et al. (2002) The 
Potential of Brain Natriuretic Peptide as a Biomarker for New York Heart Association 
Class During the Outpatient Treatment of Heart Failure. Journal of Cardiac Failure, 8: 
149-154. 
Levy, W. C., Maichel, B. A., Steele, N. P., Leclerc, K. M. & Stratton, J. R. (2004) 
Biomechanical Efficiency Is Decreased in Heart Failure During Low-Level Steady 
State and Maximal Ramp Exercise. Eur J Heart Fail, 6: 917. 
Linke, A., Schoene, N., Gielen, S., Hofer, J., Erbs, S., et al. (2001) Endothelial Dysfunction in 
Patients with Chronic Heart Failure: Systemic Effects of Lower-Limb Exercise 
Training. J Am Coll Cardiol, 37: 392. 
Lloyd-Williams, F., Mair, F. & Leitner, M. (2004) Exercise Training and Heart Failure: A 
Systematic Review of Current Evidence. Brit J Gen Prac, 52: 47 - 55. 
Lloyd-Williams, F., Mair, F. S. & Leitner, M. (2002) Exercise Training and Heart Failure: A 
Systematic Review of Current Evidence. Br J Gen Pract, 52: 47-55. 
Lonsdorfer-Wolf, E., Richard, R., Doutreleau, S., Billat, V., Oswald-Mammosser, M., et al. 
(2003) Pulmonary Hemodynamics During a Strenuous Intermittent Exercise in Healthy 
Subjects. Med Sci Sports Exerc., 35: 1866-74. 
Lunde, P. K., Sjaastad, I., Schiotz Thorud, H. M. & Sejersted, O. M. (2001) Skeletal Muscle 
Disorders in Heart Failure. Acta Physiologica Scandinavica, 171: 277-294. 
Macfarlane, D. J., Lee, C. C. Y., Ho, E. Y. K., Chan, K. L. & Chan, D. (2006) Convergent 
Validity of Six Methods to Assess Physical Activity in Daily Life. J Appl Physiol, 101: 
1328-1334. 
Maiorana, A., O'Driscoll, G., Cheetham, C., Collis, J., Goodman, C., et al. (2000) Combined 
Aerobic and Resistance Exercise Training Improves Functional Capacity and Strength 
in Chf. J Appl Physiol, 88: 1565-1570. 
Malfatto, G., Branzi, G., Osculati, G., Valli, P., Cuoccio, P., et al. (2009) Improvement in Left 
Ventricular Diastolic Stiffness Induced by Physical Training in Patients with Dilated 
Cardiomyopathy. Journal of Cardiac Failure, 15: 327-333. 
Malfatto, G., Branzi, G., Riva, B., Sala, L., Leonetti, G., et al. (2002) Recovery of Cardiac 
Autonomic Responsiveness with Low-Intensity Physical Training in Patients with 
Chronic Heart Failure. Eur J Heart Fail, 4: 159-166. 
Marburger, C. T., Brubaker, P. H., Pollock, W. E., Morgan, T. M. & Kitzman, D. W. (1998) 
Reproducibility of Cardiopulmonary Exercise Testing in Elderly Patients with 
Congestive Heart Failure. Am J Cardiol, 82: 905. 
Maresh, C. M. & Noble, B. J. (1984) Utilisation of Perceived Exertion Ratings During Exercise  
Testing and Training. IN Hall, L., Meyer, G. & Hellerstein, H. (Eds.) Cardiac 
Rehabilitation: Exercise Testing and Prescription. New York, Spectrum. 
McConnell, T. R. (2005) A Review to Develop an Effective Exercise Training for Heart Failure 
Patients. Europa Medicophysica, 41: 49-56. 
McConnell, T. R., Clark, B. A., III, Conlin, N. C. & Haas, J. H. (1993) Gas Exchange 
Anaerobic Threshold: Implications for Prescribing Exercise in Cardiac Rehabilitation. 
J Cardiopulm Rehabil Prev, 13: 31-36. 
236 
 
 
 
McKelvie, R. S., Teo, K. K., Roberts, R., McCartney, N., Humen, D., et al. (2002) Effects of 
Exercise Training in Patients with Heart Failure: The Exercise Rehabilitation Trial 
(Exert). Am Heart J, 144: 23. 
McLellan, T. & Skinner, J. (1982) Blood Lactate Removal During Active Recovery Related to 
the Aerobic Threshold. Int J Sports Med., 03: 224-229. 
McMurray, J. J. V. & Pfeffer, M. A. (2005) Heart Failure. The Lancet, 365: 1877. 
McNairy, M., Gardetto, N., Clopton, P., Garcia, A., Krishnaswamy, P., et al. (2002) Stability of 
B-Type Natriuretic Peptide Levels During Exercise in Patients with Congestive Heart 
Failure: Implications for Outpatient Monitoring with B-Type Natriuretic Peptide. Am 
Heart J, 143: 406-111. 
Metra, M., Ponikowski, P., Dickstein, K., McMurray, J. J. V., Gavazzi, A., et al. (2007) 
Advanced Chronic Heart Failure: A Position Statement from the Study Group on 
Advanced Heart Failure of the Heart Failure Association of the European Society of 
Cardiology. Eur J Heart Fail, 9: 684. 
Meyer, K. (2001) Exercise Training in Heart Failure: Recommendations Based on Current 
Research. Med Sci Sports Exerc, 33: 525-531. 
Meyer, K., Foster, C., Georgakopoulos, N., Hajric, R., Westbrook, S., et al. (1998a) 
Comparison of Left Ventricular Function During Interval Versus Steady-State Exercise 
Training in Patients with Chronic Congestive Heart Failure. Am J Cardiol, 82: 1382. 
Meyer, K., Gornandt, L., Schwaibold, M., Westbrook, S., Hajric, R., et al. (1997a) Predictors of 
Response to Exercise Training in Severe Chronic Congestive Heart Failure. Am J 
Cardiol, 80: 56. 
Meyer, K., Hajric, R., Westbrook, S., Samek, L., Lehmann, M., et al. (1996a) Ventilatory and 
Lactate Threshold Determinations in Healthy Normals and Cardiac Patients: 
Methodological Problems. Eur J Appl Physiol Occup Physiol. 387-93., 72: 387-93. 
Meyer, K. & Laederach-Hofmann, K. (2003) Effects of a Comprehensive Rehabilitation 
Program on Quality of Life in Patients with Chronic Heart Failure Medscape 
http://www.medscape.com/viewarticle/464678. 
Meyer, K., Lehmann, M., Sunder, G., Keul, J. & Weidemann, H. (1990) Interval Versus 
Continuous Exercise Training after Coronary Bypass Surgery: A Comparison of 
Training-Induced Acute Reactions with Respect to the Effectiveness of the Exercise 
Methods. Clin Cardiol, 13: 851-61. 
Meyer, K., Samek, L., Schwaibold, M., Westbrook, K., Hajric, R., et al. (1996b) Physical 
Responses to Different Modes of Interval Exercise in Patients with Chronic Heart 
Failure - Application to Exercise Training. Eur Heart J, 17: 1040-1047. 
Meyer, K., Samek, L., Schwaibold, M., Westbrook, S., Hajric, R., et al. (1997b) Interval 
Training in Patients with Severe Chronic Heart Failure: Analysis and 
Recommendations for Exercise Procedures. Med Sci Sports Exerc. , 29: 306-12. 
Meyer, K., Schwaibold, M., Hajric, R., Westbrook, S., Ebfeld, D., et al. (1998b) Delayed Vo2 
Kinetics During Ramp Exercise: A Criterion for Cardiopulmonary Exercise Capacity in 
Chronic Heart Failure. . Med Sci Sports Exerc, 30: 643-648. 
Meyer, K., Schwaibold, M., Westbrook, S., Beneke, R., Hajric, R., et al. (1996c) Effects of 
Short-Term Exercise Training and Activity Restriction on Functional Capacity in 
Patients with Severe Chronic Congestive Heart Failure. Am J Cardiol, 78: 1017-1022. 
Meyer, K., Westbrook, S., Schwaibold, M., Hajric, R., Peters, K., et al. (1997c) Short-Term 
Reproducibility of Cardiopulmonary Measurements During Exercise Testing in 
Patients with Severe Chronic Heart Failure. Am Heart J, 134: 20. 
Meyer, T., Gorge, G., Schwaab, B., Hildebrandt, K., Walldorf, J., et al. (2005a) An Alternative 
Approach for Exercise Prescription and Efficacy Testing in Patients with Chronic Heart 
Failure: A Randomized Controlled Training Study. Am Heart J, 149: 926. 
Meyer, T., Kindermann, M. & Kindermann, W. (2004a) Exercise Programmes for Patients with 
Chronic Heart Failure. Sports Med, 34: 939-954. 
Meyer, T., Lucia, A., Earnest, C. P. & Kindermann, W. (2005b) A Conceptual Framework for 
Performance Diagnosis and Training Prescription from Submaximal Gas Exchange 
Parameters - Theory and Application. Int J Sports Med., 26: S38-S48. 
237 
 
 
 
Meyer, T., Schwaab, B., Garge, G., Scharhag, J., Herrmann, M., et al. (2004b) Can Serum Nt-
Probnp Detect Changes of Functional Capacity in Patients with Chronic Heart Failure? 
Zeitschrift fur Kardiologie, 93: 540. 
Meyer, T. I. M., Gabriel, H. H. W. & Kindermann, W. (1999) Is Determination of Exercise 
Intensities as Percentages of O2max or Hrmax Adequate? Med Sci Sports Exerc, 31: 
1342-45. 
Mezzani, A., Corrà, U., Bosimini, E., Giordanob, A. & Giannuzzi, P. (2003) Contribution of 
Peak Respiratory Exchange Ratio to Peak Vo2 Prognostic Reliability in Patients with 
Chronic Heart Failure and Severely Reduced Exercise Capacity Am Heart J, 145 1102-
7. 
Mezzani, A., Corra, U., Giordano, A., Cafagna, M., Adriano, E. P., et al. (2007) Unreliability of 
the %Vo2 Reserve Versus %Heart Rate Reserve Relationship for Aerobic Effort 
Relative Intensity Assessment in Chronic Heart Failure Patients on or Off Beta-
Blocking Therapy. Eur J Cardiovasc Prev Rehabil, 14: 92-98. 
Miche, E., Roelleke, E., Zoller, B., Wirtz, U., Schneider, M., et al. (2009) A Longitudinal Study 
of Quality of Life in Patients with Chronic Heart Failure Following an Exercise 
Training Program. Eur J Cardiovasc Nurs., 8: 281-7. 
Midgley, A. W., Bentley, D. J., Luttikholt, H., McNaughton, L. R. & Millet, G. P. (2008) 
Challenging a Dogma of Exercise Physiology: Does an Incremental Exercise Test for 
Valid V-Doto2max Determination Really Need to Last between 8 and 12 Minutes? 
Sports Med, 38: 441-447. 
Milani, R., V.  & Lavie, C., J. (2007) Impact of Cardiac Rehabilitation on Depression and Its 
Associated Mortality. The American Journal of Medicine, 120: 799-806. 
Mitchell, S. H., Steele, N. P., Leclerc, K. M., Sullivan, M. & Levy, W. C. (2003) Oxygen Cost 
of Exercise Is Increased in Heart Failure after Accounting for Recovery Costs. Chest, 
124: 572-579. 
Muller, L., Myers, J., Kottman, W., Luchinger, R. & Dubach, P. (2009) Long-Term Myocardial 
Adaptations after Cardiac Rehabilitation in Heart Failure: A Randomized Six-Year 
Evaluation Using Magnetic Resonance Imaging. Clinical Rehabilitation, 23: 986-994. 
Munkvik, M., Rehn, T. A., SlettalÃ¸kken, G., Hasic, A., Hallen, J., et al. (2010) Training 
Effects on Skeletal Muscle Calcium Handling in Human Chronic Heart Failure. Med 
Sci Sports Exerc, 42: 847-855. 
Myers, J. (2001) On the Uniformity of Cardiopulmonary Exercise Testing in Chronic Heart 
Failure. Am Heart J, 142: 384-387. 
Myers, J., Goldsmith, R. L., Keteyian, S. J., Brawner, C. A., Brazil, D. A., et al. (2010) The 
Ventilatory Anaerobic Threshold in Heart Failure: A Multicenter Evaluation of 
Reliability. J Cardiac Failure, 16: 76-83. 
Myers, J., Gullestad, L., Vagelos, R., Do, D., Bellin, D., et al. (1998) Clinical, Hemodynamic, 
and Cardiopulmonary Exercise Test Determinants of Survival in Patients Referred for 
Evaluation of Heart Failure. Ann Intern Med, 129: 286-293. 
Myers, J., Hadley, D., Oswald, U., Bruner, K., Kottman, W., et al. (2007) Effects of Exercise 
Training on Heart Rate Recovery in Patients with Chronic Heart Failure. Am Heart J, 
153: 1056-1063. 
National Collaborating Centre for Chronic Conditions (2003) Chronic Heart Failure: National 
Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. 
NICE guideline. 
Nechwatal, R., Duck, C. & Gruber, G. (2002) Physical Training as Interval or Continuous 
Training in Chronic Heart Failure for Improving Functional Capacity, Hemodynamics 
and Quality of Life--a Controlled Study. Z Kardiol, 91: 328-37. 
Nelson, M. E., Rejeski, W. J., Blair, S. N., Duncan, P. W., Judge, J. O., et al. (2007) Physical 
Activity and Public Health in Older Adults: Recommendation from the American 
College of Sports Medicine and the American Heart Association. Circulation, 116: 
1094-1105. 
Neubauer, S. (2007) The Failing Heart. An Engine out of Fuel. N Engl J Med, 356: 1140-1151. 
238 
 
 
 
Nilsson, B. B., Hellesnes, B., Westheim, A. & Risberg, M. A. (2008a) Group-Based Aerobic 
Interval Training in Patients with Chronic Heart Failure: Norwegian Ullevaal Model. 
Phys Ther, 88: 523-535. 
Nilsson, B. B., Westheim, A. & Risberg, M. A. (2008b) Effects of Group-Based High-Intensity 
Aerobic Interval Training in Patients with Chronic Heart Failure. Am J Cardiol, 102: 
1361-1365. 
Nilsson, B. B., Westheim, A. & Risberg, M. A. (2008c) Long-Term Effects of a Group-Based 
High-Intensity Aerobic Interval-Training Program in Patients with Chronic Heart 
Failure. Am J Cardiol, 102: 1220-1224. 
Noble, B. J. & Robertson, R. J. (1996) Perceived Exertion, Champaign, IL, Human Kinetics. 
O'Connor, C. M., Whellan, D. J., Lee, K. L., Keteyian, S. J., Cooper, L. S., et al. (2009) 
Efficacy and Safety of Exercise Training in Patients with Chronic Heart Failure: Hf-
Action Randomized Controlled Trial. JAMA, 301: 1439-1450. 
O'Donovan, G., Blazevich, A. J., Boreham, C., Cooper, A. R., Crank, H., et al. (2010) The Abc 
of Physical Activity for Health: A Consensus Statement from the British Association of 
Sport and Exercise Sciences. Journal of Sports Sciences, 28: 573 - 591. 
Oja, P. (2001) Dose Response between Total Volume of Physical Activity and Health and 
Fitness. Med Sci Sports Exerc, 33: S428-S437. 
Owen, A. & Croucher, L. (2000) Effect of an Exercise Programme for Elderly Patients with 
Heart Failure. Eur J Heart Fail, 2: 65-70. 
Packer, M. (1992) The Neurohormonal Hypothesis: A Theory to Explain the Mechanism of 
Disease Progression in Heart Failure. J Am Coll Cardiol, 20: 248. 
Packer, M. (2003) Should B-Type Natriuretic Peptide Be Measured Routinely to Guide the 
Diagnosis and Management of Chronic Heart Failure? Circulation, 108: 2950-2953. 
Page, E., Cohen-Solal, A., Jondeau, G., Douard, H., Roul, G., et al. (1994) Comparison of 
Treadmill and Bicycle Exercise in Patients with Chronic Heart Failure. Chest, 106: 
1002-1006. 
Palmer, G. S., Borghouts, L. B., Noakes, T. D. & Hawley, J. A. (1999) Metabolic and 
Performance Responses to Constant-Load Vs. Variable-Intensity Exercise in Trained 
Cyclists. J Appl Physiol, 87: 1186-1196. 
Panton, L., Graves, J., Pollock, M., Garzarella, L., Carroll, J., et al. (1996) Relative Heart Rate, 
Heart Rate Reserve, and Vo2 During Submaximal Exercise in the Elderly. J Gerontol A 
Biol Sci Med Sci., 51: M165-71. 
Parnell, M. M., Holst, D. P. & Kaye, D. (2005) Augmentation of Endothelial Function 
Following Exercise Training Is Associated with Increased L-Arginine Transport in 
Human Heart Failure. Clin Sci, 109: 523-30. 
Parnell, M. M., Holst, D. P. & Kaye, D. M. (2002) Exercise Training Increases Arterial 
Compliance in Patients with Congestive Heart Failure. Clin. Sci., 102: 1-7. 
Pascual-Figal, D., Peñafiel, P., Nicolas, F., de la Morena, G., Ansaldo, P., et al. (2008) 
Prognostic Value of Bnp and Cardiopulmonary Exercise Testing in Patients with 
Systolic Heart Failure on Beta-Blocker Therapy Rev Esp Cardiol, 61: 260-268. 
Passino, C., Poletti, R., Bramanti, F., Prontera, C., Clerico, A., et al. (2006a) Neuro-Hormonal 
Activation Predicts Ventilatory Response to Exercise and Functional Capacity in 
Patients with Heart Failure. Eur J Heart Fail, 8: 46. 
Passino, C., Severino, S., Poletti, R., Piepoli, M. F., Mammini, C., et al. (2006b) Aerobic 
Training Decreases B-Type Natriuretic Peptide Expression and Adrenergic Activation 
in Patients with Heart Failure. J Am Coll Cardiol, 47: 1835-39. 
Patwala, A. Y., Woods, P. R., Sharp, L., Goldspink, D. F., Tan, L. B., et al. (2009) Maximizing 
Patient Benefit from Cardiac Resynchronization Therapy with the Addition of 
Structured Exercise Training: A Randomized Controlled Study. J Am Coll Cardiol, 53: 
2332-2339. 
Philp, A., Macdonald, A. L. & Watt, P. W. (2005) Lactate - a Signal Coordinating Cell and 
Systemic Function. J Exp Biol, 208: 4561-4575. 
Picozzi, N. M., Clark, A. L., Lindsay, K. A., McCann, G. P. & Hillis, W. S. (1999) Responses 
to Constant Work Exercise in Patients with Chronic Heart Failure. Heart, 82: 482-485. 
239 
 
 
 
Piepoli, M., Clark, A. L., Volterrani, M., Adamopoulos, S., Sleight, P., et al. (1996) 
Contribution of Muscle Afferents to the Hemodynamic, Autonomic, and Ventilatory 
Responses to Exercise in Patients with Chronic Heart Failure : Effects of Physical 
Training. Circulation, 93: 940-952. 
Piepoli, M. F., Davos, C., Francis, D. P. & Coats, A. J. (2004) Exercise Training Meta-Analysis 
of Trials in Patients with Chronic Heart Failure (Extramatch Collaborative). BMJ, 328: 
189-192. 
Piepoli, M. F., Scott, A. C., Capucci, A. & Coats, A. J. S. (2001) Skeletal Muscle Training in 
Chronic Heart Failure. Acta Physiologica Scandinavica, 171: 295-303. 
Pina, I. L., Apstein, C. S., Balady, G. J., Belardinelli, R., Chaitman, B. R., et al. (2003) 
Exercise and Heart Failure: A Statement from the American Heart Association 
Committee on Exercise, Rehabilitation, and Prevention. Circulation, 107: 1210-1225. 
Poole, D. C. & Gaesser, G. A. (1985) Response of Ventilatory and Lactate Thresholds to 
Continuous and Interval Training. J Appl Physiol, 58: 1115-1121. 
Prescott, E., Hjardem-Hansen, R., Dela, F., Teisner, A. S. & Nielsen, H. (2009) Exercise 
Training in Older Patients with Systolic Heart Failure: Adherence, Exercise Capacity, 
Inflammation and Glycemic Control Scand Cardiovasc J, 43: 249-255. 
Puhan, M., Busching, G., Schunemann, H., vanOort, E., Zaugg, C., et al. (2006) Interval Versus 
Continuous High-Intensity Exercise in Chronic Obstructive Pulmonary Disease: A 
Randomized Trial Ann Intern Med, 145: 816-825. 
Puhan, M., Busching, G., vanOort, E., Zaugg, C., Schunemann, H., et al. (2004) Interval 
Exercise Versus Continuous Exercise in Patients with Moderate to Severe Chronic 
Obstructive Pulmonary Disease. Study Protocol for a Randomised Controlled Trial. 
BMC Pulmonary Medicine, 4: 5. 
Quittan, M., Sturm, B., Wiesinger, G. F., Pacher, R. & Fialka-Moser, V. (1999) Quality of Life 
in Patients with Chronic Heart Failure: A Randomised Controlled Trial of Changes 
Induced by a Regular Exercise Program J Rehabil. Med, 31: 223 - 228. 
Rajappan, K., Bellenger, N. G., Anderson, L. & Pennell, D. J. (2000) The Role of 
Cardiovascular Magnetic Resonance in Heart Failure. Eur J Heart Fail, 2: 241-252. 
Rector, T. & Cohn, J. (2004) Minnesota Living with Heart Failure Questionnaire.  Instructions 
for Data Collection and Scoring. Www.Mlfhq.Org/. 
Rector, T. S. (2005) The Minnesota Living with Heart Failure Questionnaire. 
Rector, T. S. & Cohn, J. N. (1992) Assessment of Patient Outcome with the Minnesota Living 
with Heart Failure Questionnaire: Reliability and Validity During a Randomized, 
Double-Blind, Placebo-Controlled Trial of Pimobendan. American Heart Journal, 124: 
1017-1025. 
Rector, T. S., Francis, G. S. & Cohn, J. N. (1987a) Patients' Self-Assessment of Their 
Congestive Heart Failure. Part 1 Patient Preceived Dysfunction and Its Poor 
Correlation with Maximal Exercise Tests. Heart Failure, Oct/Nov: 192-6. 
Rector, T. S., Kubo, S. H. & Cohn, J. N. (1987b) Patients' Self-Assessment of Their Congestive 
Heart Failure. Part 2 Content Reliability and Validity of the New Measure, the 
Minnesota Living with Heart Failure Quesionnaire. Heart Failure, Oct/Nov: 198-209. 
Rees, K., Taylor, R., Singh, S., Coats, A. & Ebrahim, S. (2004) Exercise Based Rehabilitation 
for Heart Failure. Cochrane Database Syst Rev. 2004;(3), 2004: CD003331. 
Reilly, T. (2007) Circadian Rhythms. IN Winter, E. M., Jones, A. M., Davison, R. C., Bromley, 
P. D. & Mercer, T. H. (Eds.) Sport and Exercise Physiology Testing Guidelines.  The 
British Associaton of Sport and Exercise Sciences Guide.  Volume 2: Exercise and 
Clinical Testing. London, Routledge. 
Roditis, P., Dimopoulos, S., Sakellariou, D., Sarafoglou, S., Kaldara, E., et al. (2007) The 
Effects of Exercise Training on the Kinetics of Oxygen Uptake in Patients with 
Chronic Heart Failure. Eur J Cardiovasc Prev Rehabil, 14: 304-311. 
Roveda, F., Middlekauff, H. R., Rondon, M. U. P. B., Reis, S. F., Souza, M., et al. (2003) The 
Effects of Exercise Training on Sympathetic Neural Activation in Advanced Heart 
Failure: A Randomized Controlled Trial. J Am Coll Cardiol, 42: 854. 
240 
 
 
 
Rozanski, A., Qureshi, E. A. & Bornstein, A. (2001) Postexercise Left Ventricular Function: A 
Comparative Assessment by Different Noninvasive Imaging Modalities. Prog 
Cardiovasc Dis., 43: 335-350. 
Sabelis, L. W. E., Senden, P. J., Te Boekhorst, B. C. M., Hulzebos, H. J., Van De Wiel, A., et 
al. (2004) Does Physical Training Increase Insulin Sensitivity in Chronic Heart Failure 
Patients? Clin. Sci., 106: 459-466. 
Savage, P. D., Brochu, M., Scott, P. & Ades, P. A. (2000) Low Caloric Expenditure in Cardiac 
Rehabilitation. Am Heart J, 140: 527-533. 
Schairer, J. R., Kostelnik, T., Proffitt, S. M., Faitel, K. I., Windeler, S., et al. (1998) Caloric 
Expenditure During Cardiac Rehabilitation. J Cardiopulm Rehabil Prev., 18: 290-294. 
Scott, A., Antonishen, K., Johnston, C., Pearce, T., Ryan, M., et al. (2006) Effect of 
Semirecumbent and Upright Body Position on Maximal and Submaximal Exercise 
Testing. Measurement in Physical Education and Exercise Science, 10: 41 - 50. 
Scott, A. C., Francis, D., Davies, L. C., Ponikowski, P., Coats, A., et al. (2000) Contribution of 
Skeletal Muscle ‘Ergoreceptors’ in the Human Leg to Respiratory Control in Chronic 
Heart Failure J. Physiol., 529: 863-870. 
Senden, P. J., Sabelis, L. W., Zonderland, M. L., van de Kolk, R., Meiss, L., et al. (2004) 
Determinants of Maximal Exercise Performance in Chronic Heart Failure. Eur J 
Cardiovasc Prev Rehabil, 11: 41-7. 
Seta, Y., Shan, K., Bozkurt, B., Oral, H. & Mann, D. L. (1996) Basic Mechanisms in Heart 
Failure: The Cytokine Hypothesis. Journal of Cardiac Failure, 2: 243. 
Sietsema, K. E., Ben-Dov, I., Zhang, Y. Y., Sullivan, C. & Wasserman, K. (1994) Dynamics of 
Oxygen Uptake for Submaximal Exercise and Recovery in Patients with Chronic Heart 
Failure. Chest, 105: 1693-1700. 
Simonton, C. A., Higginbotham, M. B. & Cobb, F. R. (1988) The Ventilatory Threshold: 
Quantitative Analysis of Reproducibility and Relation to Arterial Lactate Concentration 
in Normal Subjects and in Patients with Chronic Congestive Heart Failure. Am J 
Cardiol, 62: 100. 
Smart, N., Haluska, B., Jeffriess, L., Case, C. & Marwick, T. H. (2006) Cardiac Contributions 
to Exercise Training Responses in Patients with Chronic Heart Failure: A Strain 
Imaging Study. Echocardiography, 23: 376-382. 
Smart, N. & Steele, M. (2009) Systematic Review of the Effect of Aerobic and Resistance 
Exercise Training on Systemic Brain Natriuretic Peptide (Bnp) and N-Terminal Bnp 
Expression in Heart Failure Patients Int J Cardiol, 140: 260-65. 
Spertus, J. A., Peterson, E. v., Breda, Conard, M., W., Heidenreich, P., A., Krumholz, H., M., et 
al. (2005) Monitoring Clinical Changes in Patients with Heart Failure: A Comparison 
of Methods. American Heart Journal, 150: 707-715. 
Stolen, K. Q., Kemppainen, J., Ukkonen, H., Kalliokoski, K. K., Luotolahti, M., et al. (2003) 
Exercise Training Improves Biventricular Oxidative Metabolism and Left Ventricular 
Efficiency in Patients with Dilated Cardiomyopathy. J Am Coll Cardiol, 41: 460-467. 
Strzelczyk, T. A., Quigg, R. J., Pfeifer, P. B., Parker, M. A. & Greenland, P. (2001) Accuracy 
of Estimating Exercise Prescription Intensity in Patients with Left Ventricular Systolic 
Dysfunction. J Cardiopulmonary Rehabil, 21: 158-163  
Sullivan, M. J., Higginbotham, M. B. & Cobb, F. R. (1988) Exercise Training in Patients with 
Severe Left Ventricular Dysfunction. Hemodynamic and Metabolic Effects. 
Circulation, 78: 506-515. 
Swedberg, K., Cleland, J., Dargie, H., Drexler, H., Follath, F., et al. (2005) Guidelines for the 
Diagnosis and Treatment of Chronic Heart Failure: Executive Summary (Update 
2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the 
European Society of Cardiology. Eur Heart J, 26: 1115-1140. 
Tabata, I., Nishimura, K., Kouzaki, M., Hirai, Y., Ogita, F., et al. (1996) Effects of Moderate-
Intensity Endurance and High-Intensity Intermittent Training on Anaerobic Capacity 
and Vo2max. Med Sci Sports Exerc, 28: 1327-30. 
241 
 
 
 
Tabet, J.-Y., Meurin, P., Beauvais, F., Weber, H., Renaud, N., et al. (2008) Absence of 
Exercise Capacity Improvement after Exercise Training Program: A Strong Prognostic 
Factor in Patients with Chronic Heart Failure. Circ Heart Fail, 1: 220-226. 
Tabet, J.-Y. B., Florence; Thabut, Gabriel; Tartiere, Jean-Michel; Logeart, Damien; Cohen-
Solal, Alain (2003) A Critical Appraisal of the Prognostic Value of the Ve/Vco2 Slope 
in Chronic Heart Failure. Eur J Cardiovasc Prev Rehabil, 10: 267-272. 
Tanehata, M., Adachi, H., Oshima, S., Taniguchi, K., Itoh, H., et al. (1999) The Time from 
Anaerobic Threshold (at) to Respiratory Compensation Point Reflects the Rate of 
Aerobic and Anaerobic Metabolism after the at in Chronic Heart Failure Patients. Jpn 
Circ J, 63: Vol. 63. 274-277. 
Tavazzi, L., Giannuzzi, P., Dubach, P., Opasich, C., Myers, J., et al. (2001) Recommendations 
for Exercise Testing in Chronic Heart Failure Patients. Working Group on Cardiac 
Rehabilitation & Excercise Physiology and Working Group on Heart Failure of the 
European Society of Cardiology. Eur Heart J, 22: 37-45. 
Taylor, A. (1999) Physiological Response to a Short Period of Exercise Training in Patients 
with Chronic Heart Failure. Physiotherapy Research International, 4: 237-249. 
Taylor, R. S., Bethell, H. J. & Brodie, D. A. (2007) Clinical Trials Versus the Real World: The 
Example of Cardiac Rehabilitation Brit J Cardiol, 14: 175-178. 
Thompson, P. D., Franklin, B. A., Balady, G. J., Blair, S. N., Corrado, D., et al. (2007) Exercise 
and Acute Cardiovascular Events: Placing the Risks into Perspective: A Scientific 
Statement from the American Heart Association Council on Nutrition, Physical 
Activity, and Metabolism and the Council on Clinical Cardiology (in Collaboration 
with the American College of Sports, Medicine). Circulation, 115: 2358-2368. 
Trohman, R. G., Kim, M. H. & Pinski, S. L. (2004) Cardiac Pacing: The State of the Art. The 
Lancet, 364: 1701-1719. 
Tyni-Lenné, R., Gordon, A., Jansson, E., Bermann, G. & Sylvén, C. (1997) Skeletal Muscle 
Endurance Training Improves Peripheral Oxidative Capacity, Exercise Tolerance, and 
Health-Related Quality of Life in Women with Chronic Congestive Heart Failure 
Secondary to Either Ischemic Cardiomyopathy or Idiopathic Dilated Cardiomyopathy. 
Am J Cardiol, 80: 1025-1029. 
Tyni-Lenné, R., Gordon, A. & Sylvén, C. (1996) Improved Quality of Life Inchronic Heart 
Failure Patients Following Local Endurance Training with Leg Muscles. Journal of 
Cardiac Failure, 2: 111-117. 
Vallebona, A., Gigli, G., Orlandi, S. & Reggiardo, G. (2005) Heart Rate Response to Graded 
Exercise Correlates with Aerobic and Ventilatory Capacity in Patients with Heart 
Failure. Clin Cardiol., 28: 25-9. 
van den Berg-Emons, R., Balk, A., Bussmann, H. & Stam, H. (2004) Does Aerobic Training 
Lead to a More Active Lifestyle and Improved Quality of Life in Patients with Chronic 
Heart Failure? Eur J Heart Fail, 6: 95-100. 
Van Laethem, C., Van De Veire, N., Backer, G. D., Bihija, S., Seghers, T., et al. (2007) 
Response of the Oxygen Uptake Efficiency Slope to Exercise Training in Patients with 
Chronic Heart Failure. Eur J Heart Fail, 9: 625. 
van Tol, B. A. F., Huijsmans, R. J., Kroon, D. W., Schothorst, M. & Kwakkel, G. (2006) 
Effects of Exercise Training on Cardiac Performance, Exercise Capacity and Quality of 
Life in Patients with Heart Failure: A Meta-Analysis. Eur J Heart Fail, 8: 841-850. 
Vanhees, L., Kornaat, M., Defoor, J., Aufdemkampe, G., Schepers, D., et al. (2004) Effect of 
Exercise Training in Patients with an Implantable Cardioverter Defibrillator. Eur Heart 
J, 25: 1120-1126. 
Ventura-Clapier, R. (2009) Exercise Training, Energy Metabolism, and Heart Failure. Appl 
Physiol Nutr Metab., 34: 336-9. 
Ventura-Clapier, R., Mettauer, B. & Bigard, X. (2007) Beneficial Effects of Endurance 
Training on Cardiac and Skeletal Muscle Energy Metabolism in Heart Failure. 
Cardiovascular Research, 73: 10. 
Vogeser, M. & Jacob, K. (2001) B-Type Natriuretic Peptide (Bnp): Validation of an Immediate 
Response Assay. Clin Lab., 47: 29-33. 
242 
 
 
 
Vogiatzis, I., Nanas, S. & Roussos, C. (2002) Interval Training as an Alternative Modality to 
Continuous Exercise in Patients with Copd. Eur Respir J, 20: 12-19. 
Walsh-Riddle, M. & Blumenthal, J. A. (1989) Cardiovascular Responses During Upright and 
Semi-Recumbent Cycle Ergometry Testing. Med Sci Sports Exerc, 21: 581-585. 
Walther, C., Gielen, S. & Hambrecht, R. (2004) The Effect of Exercise Training on Endothelial 
Function in Cardiovascular Disease in Humans. Exerc Sport Sci Rev., 32: 129-134. 
Warburton, D., Taylor, A., Bredin, S., Esch, B., Scott, J., et al. (2007) Central Haemodynamics 
and Peripheral Muscle Function During Exercise in Patients with Chronic Heart 
Failure. Appl. Physiol. Nutr. Metab. , 32: 318–331. 
Ware, J., Snow, K., Kosisnki, M. & Gandek, B. (1993) Sf-36 Health Survey. Manaul and 
Interpretation Guide. 
Ware, J. E. & Sherbourne, C. D. (1992) The Mos 36-Item Short-Form Health Survey (Sf-36): I. 
Conceptual Framework and Item Selection Medical Care, 30: 473-483. 
Wasserman, K., Hansen, J. E., Sue, D. Y., Stringer, W. W. & Whipp, B. J. (2005) Principles of 
Exercise Testing and Interpretation  Including Pathophysiology and Clinical 
Applications, Philadelphia, Lippincott Williams and Wilkins. 
Weber, K. T., Kinasewitz, G. T., Janicki, J. S. & Fishman, A. P. (1982) Oxygen Utilization and 
Ventilation During Exercise in Patients with Chronic Cardiac Failure. Circulation, 65: 
1213-1223. 
Whaley, M. H., Brubaker, P. H., Kaminsky, L. A. & Miller, C. R. (1997) Validity of Rating of 
Perceived Exertion During Graded Exercise Testing in Apparently Healthy Adults and 
Cardiac Patients. J Cardiopulm Rehabil Prev, 17: 261-267. 
Whellan, D. J., O'Connor, C. M., Lee, K. L., Keteyian, S. J., Cooper, L. S., et al. (2007) Heart 
Failure and a Controlled Trial Investigating Outcomes of Exercise Training (Hf-
Action): Design and Rationale. Am Heart J, 153: 201. 
Whipp, B. J., Davis, J. A., Torres, F. & Wasserman, K. (1981) A Test to Determine Parameters 
of Aerobic Function During Exercise. J Appl Physiol, 50: 217-221. 
Wielenga, R. P., Huisveld, I. A., Bol, E., Dunselman, P. H. J. M., Erdman, R. A. M., et al. 
(1998) Exercise Training in Elderly Patients with Chronic Heart Failure. Coronary 
Artery Disease, 9: 765-770. 
Wielenga, R. P., Huisveld, I. A., Bol, E., Dunselman, P. H. J. M., Erdman, R. A. M., et al. 
(1999) Safety and Effects of Physical Training in Chronic Heart Failure. Results of the 
Chronic Heart Failure and Graded Exercise Study (Change). Eur Heart J, 20: 872-879. 
Willenheimer, R., Erhardt, L., Cline, C., Rydberg, E. & Israelsson, B. (1998) Exercise Training 
in Heart Failure Improves Quality of Life and Exercise Capacity. Eur Heart J, 19: 774-
781. 
Willenheimer, R., Rydberg, E., Cline, C., Broms, K., Hillberger, B., et al. (2001) Effects on 
Quality of Life, Symptoms and Daily Activity 6 Months after Termination of an 
Exercise Training Programme in Heart Failure Patients. Int J Cardiol, 77: 25-31. 
Williams, A. D., Selig, S., Hare, D. L., Hayes, A., Krum, H., et al. (2004) Reduced Exercise 
Tolerance in Chf May Be Related to Factors Other Than Impaired Skeletal Muscle 
Oxidative Capacity. Journal of Cardiac Failure, 10: 141. 
Wilson, J. R., Groves, J. & Rayos, G. (1996) Circulatory Status and Response to Cardiac 
Rehabilitation in Patients with Heart Failure. Circulation, 94: 1567-1572. 
Wisloff, U., Stoylen, A., Loennechen, J. P., Bruvold, M., Rognmo, O., et al. (2007) Superior 
Cardiovascular Effect of Aerobic Interval Training Versus Moderate Continuous 
Training in Heart Failure Patients: A Randomized Study. Circulation, 115: 3086-3094. 
Witham, M. D., Argo, I. S., Johnston, D. W., Struthers, A. D. & McMurdo, M. E. T. (2007) 
Long-Term Follow-up of Very Old Heart Failure Patients Enrolled in a Trial of 
Exercise Training. The American Journal of Geriatric Cardiology, 16: 243-248. 
Witham, M. D., Gray, J. M., Argo, I. S., Johnston, D. W., Struthers, A. D., et al. (2005) Effect 
of a Seated Exercise Program to Improve Physical Function and Health Status in Frail 
Patients > 70 Years of Age with Heart Failure. Am J Cardiol, 95: 1120-1124. 
Witte, K. K. & Clark, A. L. (2007) Why Does Chronic Heart Failure Cause Breathlessness and 
Fatigue? Progress in Cardiovascular Diseases, 49: 366-384. 
243 
 
 
 
Witte, K. K. A. & Clark, A. L. (2005) Cycle Exercise Causes a Lower Ventilatory Response to 
Exercise in Chronic Heart Failure. Heart, 91: 225-226. 
Witte, K. K. A., Cleland, J. G. F. & Clark, A. L. (2006) Chronic Heart Failure, Chronotropic 
Incompetence, and the Effects of {Beta} Blockade. Heart, 92: 481-486. 
Witte, K. K. A., Thackray, S., Nikitin, N. P., Cleland, J. G. F. & Clark, A. L. (2005) The 
Effects of Long-Term [Beta]-Blockade on the Ventilatory Responses to Exercise in 
Chronic Heart Failure. Eur J Heart Failure, 7: 612. 
Wolk, R., Johnson, B. D., Somers, V. K., Allison, T. G., Squires, R. W., et al. (2005) Effects of 
[Beta]-Blocker Therapy on Ventilatory Responses to Exercise in Patients with Heart 
Failure. Journal of Cardiac Failure, 11: 333. 
Wu, A. H. B. & Smith, A. (2004) Biological Variation of the Natriuretic Peptides and Their 
Role in Monitoring Patients with Heart Failure. Eur J Heart Fail, 6: 355. 
Yoshida, T., Takeuchi, N. & Suda, Y. (1982) Arterial Versus Venous Blood Lactate Increase in 
the Forearm During Incremental Bicycle Exercise Eur J Appl Physiol Occup Physiol., 
50: 87-93. 
Zwisler, A.-D. O., Soja, A. M. B., Rasmussen, S., Frederiksen, M., Abadini, S., et al. (2008) 
Hospital-Based Comprehensive Cardiac Rehabilitation Versus Usual Care among 
Patients with Congestive Heart Failure, Ischemic Heart Disease, or High Risk of 
Ischemic Heart Disease: 12-Month Results of a Randomized Clinical Trial. Am Heart 
J, 155: 1106. 
 
 
 
244 
 
 
APPENDICES 
 
List of Appendices 
APPENDIX 1: Table of exercise training studies in chronic heart failure ...............................................245 
 Table A1: Summary of aerobic exercise training studies in CHF .................................................225 
 Table A2: Summary of combined aerobic and resistance exercise training studies in CHF ........268 
APPENDIX 2: Outcome measures not used in this study ........................................................................271 
APPENDIX 3: Local Research Ethics Committee approval.....................................................................273 
APPENDIX 4: Participant information sheets .........................................................................................276 
APPENDIX 5: Statistical results ..............................................................................................................287 
 Statistical results tables for Study 2 (Chapter 5) ...........................................................................288 
 Statistical results tables for Study 3 (Chapter 6) ...........................................................................290 
 Statistical results tables for Study 4 (Chapter 7) ...........................................................................293 
APPENDIX 6: Quality of life questionnaires ...........................................................................................295 
 Minnesota Living with Heart Failure Questionnaire .....................................................................296 
 SF-36 Questionnaire ......................................................................................................................297 
APPENDIX 7: Publications ......................................................................................................................298 
 Beale et al (2010). Brit. J. Cardiol. 17: 133-7 ...............................................................................299 
 Beale et al (in press). Eur. J. Cardiovasc. Nursing  ......................................................................320 
 
 
245 
 
 
 
APPENDIX 1: TABLE OF EXERCISE TRAINING 
STUDIES IN CHRONIC HEART FAILURE
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Abbreviations: ACE angiotensin converting enzyme; BMI body mass index; BNP B-type natriuretic peptide; CPET cardiopulmonary exercise test; C control group; E 
exercise group; DCM dilated cardiomyopathy; EDV end diastolic volume; ESV end systolic volume; HR heart rate; LVEF left ventricular ejection fraction; M/F male/female 
MLHFQ Minnesota Living with Heart Failure Questionnaire; NT-BNP N terminal b-type natriuretic peptide; NYHA New York Heart Association; QoL quality of life; RCT 
randomised controlled trial; RV right ventricular; SF-36 Short-Form 36 Questionnaire; VO2peak  peak oxygen uptake; VT ventilatory threshold, 1RM 1 repetition maximum  
 
 
Table A1: Summary of aerobic exercise training studies in CHF 
Study Setting Design Sample Exercise Intervention Outcome Variables Results 
Adamopoulos 
et al (2001) 
 
 
 
 
Adamopoulos 
et al (2002) 
Home-based 
setting, 
Athens, 
Greece 
Randomised 
cross-over study 
of CHF after 12 
weeks' home-
based training 
/detraining 
 
 
 
n=12 CHF and 10 healthy 
controls. CHF:  Age 60 ± 2 
yrs; NYHA II-III;  LVEF 24 
± 2%; ischaemic aetiology 
n=6, DCM n=6   
 
n=24 CHF and 20 healthy 
controls. CHF:  Age 55 ± 2 
yrs; NYHA II-III;  LVEF 23 
± 1%; ischaemic aetiology 
46%, DCM 54% 
5 x 30 min per week 
home-based cycling @ 
70-80% HRmax
CPET on cycle 
ergometer, peripheral 
inflammatory 
markers  
 
 
proinflammatory 
cytokines (TNF-
alpha, IL-6, sTNF-RI, 
sTNF-RII, sIL-6R 
and sFas) 
 for 12 
weeks 
Significant increase in 
VO2peak (15%) and correlated 
reduction in inflammatory 
markers after training. 
Significant reduction in 
plasma pro-inflammatory 
cytokines and soluble aptosis 
mediators (correlated with 
increase in VO2peak ) in CHF 
after training vs no training, 
but not in controls 
Arad et al 
(2008)  
 
 
 
 
 
 
Freimark et al 
(2007) 
 
 
 
 
 
Tenenbaum et 
al (2006) 
Hospital 
outpatient 
setting, Israel 
Prospective study 
following 
consecutive 
patients enrolled 
in a cardiac 
rehabilitation 
programme (E) 
 
Patients unable to 
attend acting as 
control group (C) 
 
 
 
 
Follow-up of  
long-term (E1) vs 
intermediate term 
(E2) attendees 
n=30  NYHA III  CHF, M/F 
24/6, Age 61 ± 13 yrs;  
LVEF 27 ± 4%; ischaemic 
aetiology 77%, medication:  
ACE inhibitors/ARB 97%, 
diuretics 100%, digoxin 
67%, β-blockers 77% 
 
n=66  NYHA III  CHF (E/C) 
n=44/12, M/F (EvsC) 35/9 
vs 8/4, Age 62±13/61±12 
yrs;  LVEF (E/C) 25±5/22 ± 
4%; ischaemic aetiology 
43/17%, medication:  ACE 
inhibitors 44/12%, diuretics 
100/100%, digoxin 61/67%, 
β-blockers 64/91% 
 
n=42  CHF (E1/E2) n=22/20 
2 x 60 min sessions (45 
min treadmill, stair 
climbing, cycle @ 60-
70% HRR) per week 
for 18 weeks 
 
 
 
 
 
 
 
 
 
 
 
2 x 60 min sessions per 
week for 3 years (E1) 
or 1.6 years (E2) 
CPET on treadmill 
(modified Bruce), 6-
min walk distance, 
tissue doppler 
echocardiography, 
impedance 
cardiography, 
MLHFQ, serum NT-
proBNP 
 
 
 
 
 
 
 
Survival, modified 
Bruce protocol, 6 min 
walk distance 
Significant improvement in 
VO2max (13%), 6-min walk 
distance (39%), cardiac index 
(15%), peripheral vascular 
resistance (11%), LVEF 
(11%), pulmonary artery 
pressure (12%), but  no 
change in NT-proBNP in C.  
 
Significant improvement in 
functional and hemodynamic 
parameters in E vs C. 
 
 
 
Significant improvement at 3 
year follow-up in survival, 
and exercise tolerance (13%) 
in E1 vs E2 
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Abbreviations: ACE angiotensin converting enzyme; BMI body mass index; BNP B-type natriuretic peptide; CPET cardiopulmonary exercise test; C control group; E 
exercise group; DCM dilated cardiomyopathy; EDV end diastolic volume; ESV end systolic volume; HR heart rate; LVEF left ventricular ejection fraction; M/F male/female 
MLHFQ Minnesota Living with Heart Failure Questionnaire; NT-BNP N terminal b-type natriuretic peptide; NYHA New York Heart Association; QoL quality of life; RCT 
randomised controlled trial; RV right ventricular; SF-36 Short-Form 36 Questionnaire; VO2peak  peak oxygen uptake; VT ventilatory threshold, 1RM 1 repetition maximum  
 
 
Study Setting Design Sample Exercise Intervention Outcome Variables Results 
Austin et al 
(2005) 
 
 
 
 
 
Austin et al 
(2008) 
Hospital 
outpatient then 
community 
setting, 
Abergavenny, 
UK 
RCT comparing 
cardiac 
rehabilitation with 
usual care.    
 
  
 
Follow-up at 5 
years 
Randomised, n=200 CHF  
LVEF < 40% (E/C) 100/100; 
Age (E/C) 72 ± 6/ 72 ± 7yrs; 
M/F (E vs C) 44/56 vs 
42/58; NYHA II/III 56/44 vs 
47/53 ; aetiology: ischaemic 
cardiomyopathy 75/79, 
DCM 6/5, hypertension 
17/14, unknown 2/2; atrial 
fibrillation 23/35; 
medication ACE inhibitors 
84/79,  diuretics 88/87, β-
blockers 34/26, angiotensin 
II antagonists 13/8 
8 week cardiac 
rehabilitation 
programme: 2 x 
exercise sessions per 
week for 8 weeks, then 
1 x per week 
community-based for 
16 weeks according to 
BACR guidelines, plus 
guidelines for 3 x per 
week home-based 
sessions 
6-min walk distance, 
QoL via MLHFQ and 
EuroQoL, number 
and length of stay of 
hospital admissions 
Significant improvement in 
6-min walk distance (16%), 
MLFHQ and EuroQoL plus 
fewer admissions and days in 
hospital in exercise vs control 
 
 At 5 yrs walk distance 
deteriorated significantly 
more in controls vs than 
exercise (-11% vs -5%). 
Improved MLFHQ score was 
sustained in both groups. No 
significant difference in 
survival or hospital admission 
Beer et al 
(2008) 
Hospital 
outpatient 
setting, 
Germany 
RCT comparing 
exercise training 
with usual care 
Randomised, n=24 CHF  
(E/C) 12/12; Age (E/C) 53 ± 
12/58 ± 6  yrs; LVEF (E/C) 
29 ± 10/25 ± 10%; 
aetiology: 100% DCM; 
medication (E/C) ACE 
inhibitors 12/11, digoxin 5/6, 
diuretics 10/10, β-blockers 9/9 
5 x 45 min sessions per 
week for 2 months: 
cycle ergometer plus 
dynamic exercises @ 
60-80% VO2peak
CPET on cycle 
ergometer, magnetic 
resonance imaging 
(MRI), phosphorous-
31 magnetic 
resonance 
spectroscopy (P-
MRS) 
, RPE 
13-15. Counselling to 
maintain activity in 6 
month follow-up  
Significant increase in 
VO2peak (17%), VO2 at VT 
(46%) at 8 months. LVESV 
and LVEF unchanged at 2 but 
improved at 8 months vs C. 
No change in RV parameters 
or LV energy metabolism 
Braith et al 
(1999) 
USA RCT comparing 
exercise training 
with usual care 
Randomised, n=69 CHF  
(E/C) 30/39; Age (E/C) 70 ± 
5/70 ± 6  yrs; LVEF (E/C) 
32 ± 9/30 ± 9 %; NYHA 
II/III/IV (E vs C) 15/15/0 vs 
16/12/1; medication (E/C) 
ACE inhibitors 80/86 %, 
digoxin 70/72 %, diuretics 
87/86 %, β-blockers 20/13 
%, calcium channel blockers 
30/21 % 
 
3 x 60 min supervised 
sessions per week for 
16 weeks.  Walking & 
cycling 20-30 min @ 
40-50% HRR,  
progressing to 30-40 
min @ 60-70% HRR  
 Resting and peak 
exercise 
neurohormones 
(angiotensin II, 
aldosterone, 
vasopressin, atrial 
natriuretic peptide) 
No change in resting or peak 
hormone levels in controls. 
No change in peak hormone 
levels in exercise group, but 
significant reduction in 
resting levels of angiotensin 
(-26%), aldosterone (-32%), 
vasopressin (-30%) and atrial 
natriuretic peptide (-27%) 
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Abbreviations: ACE angiotensin converting enzyme; BMI body mass index; BNP B-type natriuretic peptide; CPET cardiopulmonary exercise test; C control group; E 
exercise group; DCM dilated cardiomyopathy; EDV end diastolic volume; ESV end systolic volume; HR heart rate; LVEF left ventricular ejection fraction; M/F male/female 
MLHFQ Minnesota Living with Heart Failure Questionnaire; NT-BNP N terminal b-type natriuretic peptide; NYHA New York Heart Association; QoL quality of life; RCT 
randomised controlled trial; RV right ventricular; SF-36 Short-Form 36 Questionnaire; VO2peak  peak oxygen uptake; VT ventilatory threshold, 1RM 1 repetition maximum  
 
 
Study Setting Design Sample Exercise Intervention Outcome Variables Results 
Bellardinelli et 
al (1995) 
 
 
 
 
 
Bellardinelli et 
al (1999) 
Hopsital 
outpatient 
setting, Italy 
RCT comparing 
exercise training 
with usual care 
Randomised, n=55 CHF  
(E/C) 36/19; Age 55 ± 7 yrs; 
M/F 47/8; NYHA II/III 
38/17, LVEF 27 ± 7%; 
aetiology: ischaemic 67%, 
DCM 33% ; medication 
ACE inhibitors 52, digitalis 
18, diuretics 46, aspirin 18, 
warfarin 31 
Randomised, n=99 CHF, 
completed n=94   (E/C) 
48/46, Age (E/C) 56 ± 7/ 53 
± 9 yrs; M/F (E/C) 45/5 vs 
43/6; NYHA II/III/IV (E/C) 
22/18/10 vs 25/16/9, LVEF 
(E/C) 29 ± 6/ 28 ± 5 %; 
aetiology (E/C) ischaemic  
43/41, DCM 7/8, 
hypertension 5/3, diabetes 
2/3; medication  (E/C)  ACE 
inhibitors 90/88 %, digitalis 
35/30 %, diuretics 92/90 %, 
warfarin 68/65 % 
3 x 40 min sessions per 
week for 8 weeks on 
cycle ergometer @ 
60% VO2peak 
CPET on cycle 
ergometer (5W every 
20 sec), echocardio-
grpahy and radio-
nuclide angiography  
 
 
Echocardiography 
(LV diameter, 
fractional shortening, 
EF), thallium activity 
score, QoL via 
MLHFQ 
(preceded 
by 15-20 min warm up)  
 
Maintenance 
programme of 2 x 60 
min sessions per week 
for 12 months 
Significant improvements in 
functional capacity only in DCM 
patients with abnormal left 
ventricular relaxation. 
Improvement in VO2peak 
significantly correlated with  
increase in peak early filling 
rate,  peak filling rate and 
decrease in atrial filling rate.  
 
Improvements in VO2peak (18%), 
VT (30%) thallium activity score 
(24%) and QoL in E vs C at 8 
weeks and maintained at 12 
months.  Training associated 
with lower mortality and 
hospital admissions.  
Brubaker et al 
(2009) 
USA Retrospective 
RCT comparing 
exercise training 
with usual care 
Randomised, n=59 CHF  
(E/C) 30/29; Age (E/C) 61 ± 
6/62 ± 7  yrs; LVEF (E/C) 
30 ± 7/30 ± 7%; aetiology: 
100% ischaemic; medication 
(E/C) ACE inhibitors 7/6, 
digitalis 8/8, diuretics 8/8, β-
blockers 2/2 
 3 x 30-40 min sessions 
per week for 16 weeks 
(walking and cycling) 
CPET (25W every 3 
min), 6 min walk 
distance, echocardio-
graphy (LV volumes, 
EF, diastolic filling), 
neurohormones, QoL 
via SF-36 and MLHFQ 
Improvements in peak workload 
(12%), exercise duration (13%) 
and aldosterone in E vs C, but 
not VO2peak, VT or VE/VCO2 
slope, QoL, echocardiographic 
measures or other 
neurohormones (inc BNP).   
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Study Setting Design Sample Exercise Intervention Outcome Variables Results 
Coats et al 
(1990) 
 
Coats et al 
(1992) 
Home-based, 
UK 
Cross over RCT 
comparing 
exercise training 
with exercise 
restriction 
Randomised, n=11 male 
CHF ischaemic aetiology, 
age 63 ± 7 yrs; LVEF 19 ± 8 
%  Randomised, n=19 
(completed n=17) male CHF 
ischaemic aetiology, NYHA 
II-III, age 62±2 yrs; LVEF 
19±2%   
5 x 20 min sessions per 
week for 8 weeks on 
cycle ergometer @ 60-
80% HRmax
CPET on cycle 
ergometer  (25W 
increments every 4 
min). Haemodynamic 
measurements (2nd 
exercise test after 1 
hour's rest), heart rate 
variability, nor-
epinephrine spillover. 
  
 
Improvement in VO2peak and 
exercise duration (18%), 
VE/VCO2 slope, 
haemodynamics, autonomic 
function and symptomatic 
status 
Conraads et al 
(2007) 
Hospital 
Outpatient 
setting, 
Antwerp, 
Belgium 
RCT comparing 
exercise training 
with usual care 
Randomised, n=17 CRT 
CHF, (E/C) 8/9 (plus age-
matched non-CRT CHF 
random-ised to E or C), male 
/female 8/9, age 59 ± 9 yrs 
  CPET on cycle 
ergometer, and 
circulatory power 
Increase in VO2peak and 
circulatory power 
significantly higher in E than 
C (40% vs 16% and 74% vs 
32% respectively)  
Demopoulos et 
al (1997) 
New York, 
USA 
Observational 
study of CHF pre 
and post exercise 
training  
n=16 CHF,  age  61 ±  2 yrs; 
M/F 9/7; NYHA II/III/IV  
6/7/3, LVEF 21 ± 2%; 
aetiology (C/I) ischaemic/ 
DCM  7 /9, medication: 
ACE inhibitors 100%, 
diuretics 100%, digoxin=12 
4 x 15-60 min sessions 
per week for 12 weeks 
(cycle @ 50% 
VO2peak
CPET on cycle 
ergometer (10W.min
).  
-1
Improvement in VO
) 
peak reactive 
hyperaemic calf/ 
forearm blood flow, 
LVEDV via 
echocardiography 
2peak 
(22% after 6 weeks, further 
7% at 12 weeks) and calf, but 
not forearm, reactive 
hyperaemia after training. No 
change in LVEDV  
Dimopoulos et 
al (2006) 
 
 
 
 
 
Roditis et al 
(2006) 
Athens, 
Greece 
RCT parallel two-
group study 
comparing 
continuous (C) to 
interval (I) 
training 
Randomised, n=29 CHF, 
completed n=24  (C/I) 14/11, 
Age (C/I) 61 ± 10/62 ± 7 
yrs; M/F (C vs I)14/0 vs 9/1; 
NYHA I/II/III 4/9/1 vs 
3/6/1, LVEF (C/I) 31 ± 10/ 
35 ± 11 %; aetiology (C/I) 
ischaemic  5/14, DCM 8/6, 
valvular 1/1; medication 
(C/I): ACE inhibitors 13/10, 
diuretics 11/10, digitalis 6/4, 
β-blockers 12/8 
 
3 x 40 min sessions per 
week for 12 weeks. C: 
50% peak work rate, 
increased by 5% every 
4 weeks; I:30s @ 100% 
peak work rate, 
increased by 10% every 
4 weeks, alternated 
with 30s rest 
CPET on cycle 
ergometer, 
chronotropic 
response, heart rate 
recovery at 1 min 
 
 
VO2
Improvement in VO
 kinetics 
2peak (C 
6% ,I: 8%) and VT (C 10% 
,I: 6%). Only C showed 
significant improvements in 
chronotropic response (26%) 
and heart rate recovery (61%) 
at 1 min.  
Significant increase in 
VO2peak (C 9% I: 9%), phase 
I  VO2 kinetics in both C and 
I. Improvements in phase II 
kinetics in C only 
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Dubach et al 
(1997) 
Residential 
rehabilitation 
in the Alps, 
Switzerland 
RCT comparing 
intensive exercise 
training with 
usual care 
 
 
 
 
 
 
6 year follow-up  
Randomised, n=25 male 
CHF  NYHA II/III  (E/C) 
12/13; Age (E/C) 56 ± 5/ 55 
± 7 yrs;  LVEF (E/C) 32 ± 
7/33 ± 8 %;  ischaemic 
aetiology 100%; medication 
(E/C) : ACE inhibitors 
12/13, digoxin 8/7, diuretics 
6/7 
 
 (E/C) 8/8 
2 x 60 min supervised 
walking sessions per 
day plus 4 x 45 min 
sessions per week on 
cycle ergometer @ 70-
80% HRmax
VO
 for 8 weeks 
2peak Improvement in VO, VT, 
haemodynamic 
measurements 
(measured during a 
2nd exercise test on a 
seperate day), LV 
volume and mass via 
MRI 
 
 
2peak 
(23%), exercise duration, 
peak workload and VT at 1 
month. Further increase 
(VO2peak 6%) at 2 months, 
increase in maximal cardiac 
output (14%) and a-vO2 
difference (13%) in E vs C. 
VO2peak was 12% higher than 
pre-training at 6 year follow 
up in E vs no change in C. 
LV mass and volumes tended 
to decrease in E, but tended 
to increase in C after 6 years 
Ennezat et al 
(2001) 
New York Parallel design 
with control 
group  
n=14 CHF NYHA III (E/C) 
10/4; age (E/C) 62 ± 6/66 ± 
6 aetiology (E/C): ischaemic 
6/4; DCM 4/2; LVEF 34 ± 
9/27 ± 5 %; medication 
(E/C) : ACE inhibitors 
100%, digoxin 35%, diuretics 
100 %, β-blocker 57% 
4 x 45 min cycle 
ergometer sessions per 
week for 12 weeks @ 
50% VO
CPET on treadmill 
(modified Naughton 
protocol), muscle 
biopsies for analysis 
of endothelial nitric 
oxide synthase gene 
and shear stress 
regulated genes 
2peak 
No significant change in 
endothelial nitric oxide 
synthase gene expression. 
Significant increase in genes 
encoding antioxidant 
enzymes 
Giannuzzi et al 
(2003) (ELVD-
CHF) 
Multicentre 
oupatient 
setting, Italy 
Multicentre RCT 
comparing 
exercise training 
with usual care 
n=90  CHF (E/C) 45/45, Age 
(E/C) 60 ± 7/ 61 ± 7 yrs; 
NYHA II/III (E/C) 28/17 vs 
33/12, LVEF (E/C) 25 ± 4/ 
25 ± 5%; aetiology (E/C) 
ischaemic  30/30, DCM 12/13, 
valvular heart disease 3/2, 
hypertension 30/27; 
medication (E/C): ACE 
inhibitors 41/42, diuretics 
41/41, digitalis 30/31, β-
blockers 10/9 
3-5 x supervised cycle 
ergometer sessions @ 
60% VO2peak
CPET (10W.min
, plus 
home-based brisk daily 
walk > 30 min and 
intermittent 30 min 
calisthenics sessions for 
6 months 
-1 Significant decrease in EDV 
(5%) and ESV (9%) in E 
compared with increases of 
6% and 7% respectively in C. 
Significant improvement in 
LVEF (16%), VT (17%) and 
VO
 
increments), 6 min 
walk distance, 2D 
resting 
echocardiography, 
QoL 
2peak (19%), 6 min walk 
distance (20%) and QoL in E, 
vs no change in C.  
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Gottlieb et al 
(1999) 
Medical 
Centre, 
Baltimore, 
USA 
RCT comparing 
exercise training 
with usual care 
Randomised, n=33 CHF, 
completed n=25   (E/C) 14/11 
(plus 5 C who crossed over to 
exercise group), Age (E/C) 67 ± 
7/64 ± 10 yrs; M/F (E/C) 11/0 
vs 3/11; NYHA II/III (E/C) 5/6 
vs 4/10, LVEF (E/C) 22 ± 8/ 25 
± 10 %; aetiology (E/C) 
ischaemic  7/11; medication: 
ACE inhibitors, diuretics, 
digoxin, β-blockers 
 
3 sessions per week for 
6 months on cycle 
ergometer and treadmill 
@ RPE 12-13 
VO2peak Improvement in VO, 6 min walk 
distance, QoL via 
MLHFQ, Medical 
Outcomes Study and 
Functional Status 
Assessment 
2peak 
(17%) and 6 min walk 
distance (15%) in exercise vs 
control.  No change in QoL. 6 
patients did not tolerate 
exercise training. 
Hagerman et al 
(2005) 
University 
outpatient 
setting, 
Stockholm, 
Sweden 
Retrospecive 
long-term follow-
up comparing 
exercise training 
with usual care 
n=97  CHF (E/C) 48/49, 
M/F (E vs C) 28/20 vs 29/20; 
Age (E/C) 61 ± 9/ 61 ± 5 yrs 
NYHA II/III (E/C) 26/22 vs 
28/21, LVEF (E/C) 28±9/30 
± 17%; aetiology ischaemic 
20/28, DCM 27/14, valvular 
1/5, hypertension 0/2; medic- 
ation (E/C): ACE inhibitors 
39/29, diuretics 44/45, digitalis 
17/14, β-blockers 19/30 
 
3 sessions per week for 
8 weeks. 6 & 3 min 
walk to warm up and 
cool down, plus 2 leg: 
15 min simulataneous 
knee extensor exercise 
@ 70% peak; 1 leg: 1 
leg at a time for 15 min 
each @ 35% 2 leg 
peak.  
Mortality, 
hospitalisation events 
and days 
Significantly fewer 
hospitalisation events and 
days due to cardiac events in 
training vs control at 5 year 
follow-up.  No difference 
between groups in mortality.  
Harris et al 
(2003) 
Home-based, 
UK 
RCT comparing 
cycle training 
with functional 
electrical 
stimulation 
Randomised E1 (cycle) E2 
(stimulation), n=49 CHF 
NYHA II-III  (E1/E2) n=24/22; 
M/F (E1 vs E2) 21/3 vs 17/5, 
Age 62 ± 11/63 ± 10 yrs;  
LVEF (E1/E2) 32 ± 9/28 ± 6%; 
aetiology: ischaemic/DCM  
(E1 vs E2) 67/33 vs 59/41%; 
medication (E1/E2): ACE 
inhibitors 92/100%, diuretics 
71/91%, digoxin 38/45%, β-
blocker 38/41% 
E1: home-based 5 x 30 
min cycle ergometer 
sessions @ 70% HRmax
CPET on treadmill 
(modified Bruce), 6-
min walk distance, 
maximum leg 
strength and 
quadriceps fatigue 
index, LVEF via 
echocardiography, 
QoL via MLHFQ,  
 
for 6 weeks; E2: home-
based 5 x 30 min 
functional electrical 
stimulation for 6 weeks  
Significant improvements in 
E1 and E2 (no difference 
between groups) in 6-min 
walk distance, treadmill 
exercise time, maximum leg 
strength, quadriceps fatigue 
index and QoL, but not 
VO2peak.  
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Study Setting Design Sample Exercise Intervention Outcome Variables Results 
Hambrecht et al 
(1995) 
 
 
 
 
 
 
 
 
 
 
 
 
Hambrecht et al 
(1997) 
 
 
 
 
 
 
 
Hambrecht et al 
(1998) 
University 
Cardiology 
inpatient 
setting 
followed by 
home-based 
training for 6 
months, 
Germany 
RCT comparing 
exercise training 
with usual care 
Randomised, n=22  M CHF, 
completed n=18   (E/C) 
12/10, Age (E/C) 50 ± 12/ 
52 ± 8 yrs; NYHA II/III 
(E/C) 6/6 vs 6/4, LVEF 
(E/C) 26 ± 9/ 27 ± 10 %; 
aetiology (E/C) ischaemic  
1/2, DCM 11/8; medication 
(E/C): ACE inhibitors 12/10, 
diuretics 10/9, digoxin 10/8, 
anti-arrhythmic 1/0, nitrates 
2/3, calcium channel 
blockers 1/1 
 
                 “ 
 
 
 
 
 
 
 
 
Randomised, n=20 M CHF, 
completed n=18   (E/C) 
10/10, Age (E/C) 54 ± 4/ 56 
± 3 yrs; NYHA II/III (E/C) 
7/6 vs 3/4, LVEF (E/C) 24 ± 
4/ 23 ± 3 %; aetiology (E/C) 
ischaemic 3/4, DCM 7/6; 
medication (E/C): ACE 
inhibitors 100/100%, 
diuretics 82/70 %, digoxin 
73/70% 
 
4-6 x 10 min sessions 
per day @ 70% VO2max 
(cycle ergometer) for 2 
weeks, then 20 min per 
day  (home-based, 
cycle ergometer @ 
70% VO2max
CPET on cycle 
ergometer (50W 
initially, then 25W 
every 3 min), 
haemodynamic 
measurement via 
thermodilution, 
muscle biopsy (vastus 
lateralis), 2-D 
echocardiography 
(LV volumes), 
Minnesota Leisure 
Time Physical 
Activity Questionnaire 
 
Ultrastructural 
morphometry 
 
 
 
 
 
 
Peripheral blood flow 
(endothelium-
dependent and 
independent arteriolar 
vasodilation, basal 
nitric oxide 
formation) 
) plus 1 x 
60 min supervised 
group sessions per 
week for 6 months 
Increase in VO2peak (31%), 
VT (23%), oxidative capacity 
(19 & 41%), maximal cardiac 
output (19%), peak leg 
oxygen consumption (45%) 
and  leisure time energy 
expenditure in E vs C. 
Compliance = 70% (~ 3 hrs 
training per week) 
 
 
 
 
 
Significant improvements in 
surface density of 
cytochrome c oxidase-
positive mitochondria, 
mitochondrial cristae (41%) 
and inner border membrane 
(92%), and increase in type 1 
fibres (8%) in E vs C 
 
Increase in VO2peak (26%) 
and endothelium dependent 
peripheral blood flow (187%) 
(with significant correlation 
between the two) in E vs C 
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Hambrecht et al 
(2000) 
 
 
 
 
 
 
 
 
 
 
 
Gielen et al 
(2003)  
 
 
 
 
 
 
 
 
 
 
 
Linke et al 
(2001)     
University 
Cardiology 
inpatient 
setting 
followed by 
home-based 
training for 6 
months, 
Germany 
RCT comparing 
exercise training 
with usual care 
Randomised, n=73 M CHF, 
completed n=64  (E/C) 
36/37, Age (E/C) 54 ± 9/ 55 
± 8 yrs; NYHA I-II/III (E/C) 
26/10 vs 28/9, LVEF (E/C) 
27 ± 9/ 27 ± 9 %; aetiology 
(E/C) ischaemic 5/7, DCM 
31/30; medication (E/C): 
ACE inhibitors 94/95%, 
diuretics  78/78 %, digoxin 
76/62%, β-blocker 8/13%, 
calcium channel blocker 
17/14%, anti-arrhythmic 6/8% 
 
Randomised, n=20 M CHF   
(E/C) 10/10, plus 10 age-
matched healthy controls; Age 
(E/C) 55 ± 2/ 53 ± 3 yrs; 
NYHA II/III (E/C) 9/1 vs 9/1, 
LVEF (E/C) 26 ± 3/ 25 ± 2 %; 
aetiology (E/C) ischaemic  and 
DCM; medication (E/C): 
ACE inhibitors 100/90%, 
diuretics  40/90 %, digitalis 
50/50%, β-blockers 
40%/40% 
 
Randomised, n=22 M CHF 
(E/C) 11/11, NYHA II/III  
(E vs C) 8/3 vs 8/3; Age 
(E/C) 58 ± 2/ 59 ± 3 yrs;  
LVEF (E/C) 26 ± 3/24 ± 2 
%; medication (E/C): ACE 
inhibitors 11/11, diuretics 
9/7, digoxin 7/5, β-blockers 
5/8  
4-6 x 10 min sessions 
per day @ 70% VO2max 
(cycle ergometer) for 2 
weeks, then 20 min per 
day  (home-based, 
cycle ergometer @ 
70% VO2max) plus 1 x 
60 min supervised 
group sessions per 
week for 6 months 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 x 10 min sessions per 
day @ 70% VO2max
CPET on cycle 
ergometer (25W 
increments every 3 
min), total peripheral 
resistance at rest and 
LV diameter (via 
thermodilution) and 
stroke volume during 
exercise 
 
 
 
 
 
Serum markers of 
inflammation (TNF-
α, IL-6, IL-1-β), local 
markers of 
inflammation via 
muscle biopsy (TNF-
α, IL-6, IL-1-β and 
inducible nitric oxide 
synthase ( iNOS). 
 
 
 
Endothelial function 
(arterial diameter, 
flow-dependent 
vasodilation, 
endothelium-
independent 
vasodilation) 
 
(cycle ergometer) for 4 
weeks 
Increase in VO2peak (26%), 
VT (33%), decrease in resting 
heart rate, increase in 
maximal heart rate, stroke 
volume (15%) and cardiac 
output (19%), small but 
significant decrease in LV 
diameters and volumes, 
decrease in total peripheral 
resistance at rest and peak 
exercise in E vs C 
 
 
 
Increase in VO2peak (29%) & 
decrease in local TNF-α, IL-
1-β and IL-6 (while no 
change in serum values), and 
iNOS in E vs C.  
 
 
 
 
 
 
 
Significant increase in 
endothelium-dependent 
vasodilation correlated with 
improvements in functional 
capacity in E vs C.  No 
change in endothelium-
independent vasodilation  
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Study Setting Design Sample Exercise Intervention Outcome Variables Results 
HF-ACTION:   
O'Connor et al 
(2009)       
Flynn et al 
(2009)       
Whellan (2007) 
Multicentre 
outpatient 
setting (USA, 
Canada, 
France) 
RCT comparing 
exercise training 
with usual care 
with intention-to-
treat analysis 
Randomised n=2331 CHF 
(E/C) n=1172/1159. Median 
age: 59 yrs; M/F 72/28%; 
ischaemic aetiology 51%; 
mean LVEF 25% 
~ 3 supervised sessions 
per week (36 sessions 
total) within 6 months. 
Home-based training 
starting from session 
18, and after session 36 
comprising the primary 
setting 5 x per week. 
Walking or cycling @ 
60% HRR for 15-30 
min, increasing to 40 
min @ 70% HRR, RPE 
12-14 
Primary endpoints: 
all-cause mortality 
and all-cause 
hospitalisation. 
Exercise tolerance 
(VO2peak
At 30 months: non-significant 
reductions in all-cause 
mortality, hospitalisation & 
key secondary endpoints in E 
vs C. After adjustment for 
highly prognostic predictors 
of the primary end point (e.g. 
LVEF), training was 
associated with modest 
significant reductions for 
mortality & hospitalisation. 
Modest but significant 
improvements in self-
reported health status in E vs 
C 
 (treadmill: 
modified Naughton 
protocol, or cycle 
ergometer), heart rate 
at sub-maximal 
workload, 6-min 
walk distance), LVEF 
via echocardiography, 
QoL, cost-effective-
ness, biomarkers 
(BNP, TNF, C-
reactive protein) 
Jetté et al 
(1991) 
Hospital 
inpatient 
setting, 
Germany 
RCT comparing 
exercise training 
with minimal 
activity 
Randomised, n=39  male 
post anterior MI (< 10 
weeks) CHF (NYHA I-III). 
E1 or C1: LVEF < 30% 
(10/8), E2 or C2: LVEF 31-
50% (11/10), Age (E1/C1) 54 
± 6/ 51 ± 7 yrs (E2/C2) 46 ± 
11/ 52 ± 7 yrs; medication 
(E1/C1/E2/C2) ACE 
inhibitors 2/2/0/1, diuretics 
6/7/8/4, digitalis 7/6/5/4, β-
blocker 3/3/8/5, calcium 
channel blocker 2/4/2/4, 
anti-arrhythmic 2/3/1/2 
2 x 5 min jog 3 x per 
week, 30 min 
calisthenics, 20 min 
relaxation, 15 min 
cycle ergometry, 
walking 30-60 min @ 
70-80% HRmax 
Supine cycle 
ergometer maximal 
exercise test (40W 
followed by 40W 
every 4 min), 
radionuclide 
ventriculography,  5 days  
per week for 4 weeks 
Increase in VO2peak (22%) in 
LVEF < 30% in E vs C, but 
no difference in LVEF > 30% 
group.  Associated increase in 
pulmonary wedge pressure in 
< 30% E group. 
Improvements in both < 30% 
groups in resting LVEF, not 
associated with exercise 
capacity. 
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Study Setting Design Sample Exercise Intervention Outcome Variables Results 
Jonsdottir et al 
(2006) 
Hospital 
outpatient 
setting, 
Reykjavik, 
Iceland 
RCT comparing 
exercise training 
with usual care 
Randomised, n=43 NYHA 
II-III CHF (E/C) 15/14, M/F 
(E vs C)  18/4 vs 16/5, Age 
(E/C) 69 ± 5/ 68 ± 7 yrs; 
LVEF (E/C) 41 ± 14/ 42 ± 
14 %; aetiology (E/C) 
ischaemic 16/18, AF 4/1, 
valvular 2/1, hypertension 
0/1; medication (E/C): ACE 
inhibitors 5/8, diuretics 
19/17, anti-arrhythmics 
14/10, β-blockers 14/11, 
angiotensin II receptor 
blockers 10/13 
2 x 50 min sessions per 
week for 5 months. 15 
min cycling @ 50% 
peak work rate plus 20 
min circuit resistance 
exercises @ 20-25% 
1RM, increasing in 
intensity as appropriate.  
CPET  on cycle 
ergometer, muscle 
strength (1RM), 
plasma ANP & BNP, 
LVEF via echo-
cardiography, QoL 
(country-specific 
questionnaire), 
hospitalisation @ 12 
& 28 months' follow-
up 
Significant improvement in 
exercise duration and peak 
work rate (but not VO2peak), 
and in 6-min walk distance 
and muscle strength in E vs 
C. No change or difference 
between groups in ANP, 
BNP, LVEF or QoL.  
Karapolat et al 
(2009) 
Turkey RCT comparing 
hospital-based 
exercise training 
with home-based 
exercise training 
Randomised n=74 CHF  E1: hospital-based 
exercise; E2 home-
based exercise for 8 
weeks 
CPET, 6-min walk 
distance, QoL via 
Medical Outcomes 
Study and SF-36, 
haemodynamic 
parameters via 
echocardiography  
Significant improvement in 
VO2peak, 6-min walk distance, 
SF-36 subscale scores and 
LVEF, but no difference 
between groups 
Kavanagh et al 
(1996) 
Toronto, 
Canada 
Non-randomised 
controlled trial 
with 12 month 
follow up 
30 CHF (E/C) 21/9, 
completed (E) n=15, Age 
(E/C) 62 ± 6/ 65 ± 6 yrs, 
M/F (E vs C) 17/4 vs 8/1;  
NYHA II/III (E) 2/19; LVEF 
(E) 21 ± 2 %; aetiology (E) 
ischaemic 15, idiopathic 
cardiomyopathy 2, valvular 
3, ethanol-related 1 
5 x weekly supervised 
sessions (50-60% 
VO2peak
CPET on cycle 
ergometer (17 W.min
) for 16 weeks; 
then twice weekly for 
20 weeks, once 
monthly for 16 weeks 
plus home based 
exercise to complete 
required 5 weekly 
sessions 
-1
No changes in C. Significant 
increase in E in LVEF (28%), 
6 min walk distance (18% at 
16 weeks and 52 weeks), 
VO
 
increments), 6-min 
walk distance, resting 
LVEF via 
radionuclide 
ventriculography, 
QoL at 4, 8, 12 , 16, 
26 and 52 weeks. 
2peak (17% at 16 weeks, 
and at 52 weeks), VT (14% at 
52 weeks), and improved 
QoL at 4 weeks, and further 
improvement up to 26 wks 
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Keteyian et al 
(1996) 
 
 
 
 
 
 
 
 
 
Keteyian et al 
(1999) 
Outpatient 
clinic, Detroit, 
USA 
RCT comparing 
exercise training 
with usual care 
Randomised, n=40 M CHF, 
completed n=29 (E/C) 15/14, 
Age (E/C) 56 ± 12/ 52 ± 11 
yrs; NYHA II/III (E/C) 9/5 
vs 12/3, LVEF (E/C) 22 ± 6/ 
23 ± 10 %; aetiology (E/C) 
ischaemic  3/6, DCM 11/9; 
medication (E/C): ACE 
inhibitors 14/14, diuretics 
12/14, digoxin 13/14, β-
blockers 2/0 
Randomised, n=51 male 
CHF, completed n=43   
(E/C) 22/21, Age (E/C) 57 ± 
12/ 55 ± 11 yrs; NYHA II/III 
(E/C) 16/6 vs 18/3, LVEF 
(E/C) 22 ± 7/ 22 ± 8 %; 
aetiology (E/C) ischaemic  
n=9/7, cardiomyopathy 
n=13/14; medication (E/C): 
ACE inhibitors n=21/20, 
diuretics n=18/19, digoxin 
n=20/19, β-blockers n=2/1 
3 x 33 min sessions per 
week for 24 weeks. 5 
min warm-up and cool-
down, 3 x 11 min 
treadmill, cycle/arm 
ergometer, rower @ 
60-80% HRR, RPE 12-
14. 
CPET on cycle 
ergometer (25W 
every 3 min). 
 
 
 
 
 
 
 
 
Chronotropic 
incompetence, 
plasma noradrenaline, 
QoL via MLHFQ 
Improvement in VO2peak 
(16%), exercise duration and 
peak power output and peak 
HR in exercise vs control.  
No change in VT or 
VE/VCO2 slope.  
 
 
 
 
 
Improvement in VO2peak 
(14%), exercise duration 
(24%), peak power output 
(21%) and peak HR (7%) inE 
vs C.  No change in plasma 
norepinephrine at rest, 
submaximal or peak exercise, 
or in QoL 
Klecha et al  
(2007) 
Outpatient 
rehabilitation 
setting, 
Krakow, 
Poland 
RCT comparing 
exercise training 
with usual care  
Randomised, n=50 CHF (38 
M/18 F) NYHA I/II/III, 
LVEF < 35%  (E/C) 25/25; 
Age (E/C) 60 ± 10/ 61 ± 10 
yrs;  ischaemic aetiology 
(E/C) 96/92%; medication 
(E/C) : ACE inhibitors 
100/100%, digitalis 36/32%, 
anti-arrhythmic 16/20%, 
diuretics 64%/68%, β-blocker 
100/100% 
 
3 x 60 min sessions per 
week for 6 months (20 
min warm up, 25 min 
cycle ergometer @ 
80% HRmax
CPET on treadmill 
(modified Bruce 
protocol), MRI of left 
ventricle 
, including 
4 x 3-min intervals, 15 
min relaxation) 
Significant increase in 
VO2peak (32%) and VT (24%) 
VE/VCO2 slope in E vs C. 
No significant changes in LV 
parameters over time, but a 
tendency towards improved 
LVEF, EDV and wall motion 
score index in E whereas 
opposite trend in C 
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Killavuori et al 
(1995) 
 
 
 
 
 
 
 
 
 
 
Killavuori et al 
(1996) and 
(2000) 
 
 
 
 
 
 
Helsinki, 
Finland 
RCT comparing 
exercise training 
with usual care 
Randomised, n=20  CHF 
NYHA II-III  (E/C) 8/12, 
M/F (E vs C) 8/0 vs 11/1, 
Age (E/C) 52 ± 8/ 52 ± 10 
yrs;  LVEF (E/C) 24 ± 6/24 
± 76%; aetiology (E/C) 
ischaemic  3/4, DCM 5/8; 
medication (E/C): ACE 
inhibitors 8/12, diuretics 
7/10, digitalis 8/9, β-
blockers 1/2 
 
Randomised, n=27  CHF 
NYHA II-III  (E/C) 12/15, 
M/F (E vs C) 12/0 vs 14/1, 
Age (E/C) 52 ± 7/ 52 ± 9 
yrs;  LVEF (E/C) 24 ± 5/25 
± 7 %; aetiology (E/C) 
ischaemic  4/5, DCM 8/10; 
medication (E/C): ACE 
inhibitors 11/14, diuretics 
11/11, digoxin 12/12, β-
blockers 4/2 
3 x 30 min per week 
supervised cycle 
ergometer sessions @ 
50-60% VO2peak
CPET on cycle 
ergometer (20W 
every 3 min) and 
constant load 
endurance test @ 
85% VO
 for 3 
months. 
 
 
 
 
 
 
 
As above, plus 
supervised, plus home 
based exercise for a 
further 3 months 
2peak
Significant increase in para-
sympathetically mediated 
component of heart rate 
variability and in exercise 
endurance at 3 (88%) and 6 
months (84%) in E vs C. 
Non-significant increase in 
VO
 , heart 
rate variability via 20 
hr ambulatory ECG 
and frequency 
domain analysis  
 
 
Haemodynamic 
measurements, 
muscle biopsy 
(muscle fibre 
distribution,  
glycolysis & fatty 
acid oxidation 
enzymes) 
2peak (12%), significant 
increase in VT (21% and 
17%), ventilatory response to 
exercise and maximum 
workload (18% and 16%) at 3 
and 6 months. No change in 
central haemodynamic 
parameters. Increase in 
anaerobic glycolysis enzymes 
(PFK) (55%) in E vs C, but 
no change in citric acid cycle, 
fatty acid oxidation enzymes. 
or muscle fibre type 
distribution or size. 
Klecha et al  
(2007) 
Outpatient 
rehabilitation 
setting, 
Krakow, 
Poland 
RCT comparing 
exercise training 
with usual care  
Randomised, n=50 CHF (38 
M/18 F) NYHA I/II/III, 
LVEF < 35%  (E/C) 25/25; 
Age (E/C) 60 ± 10/ 61 ± 10 
yrs;  ischaemic aetiology 
(E/C) 96/92%; medication 
(E/C) : ACE inhibitors 
100/100%, digitalis 
36/32%, anti-arrhythmic 
16/20%, diuretics 64%/68%, 
β-blocker 100/100% 
3 x 60 min sessions per 
week for 6 months (20 
min warm up, 25 min 
cycle ergometer @ 
80% HRmax
CPET on treadmill 
(modified Bruce 
protocol), MRI of left 
ventricle 
, including 
4 x 3-min intervals, 15 
min relaxation) 
Significant increase in 
VO2peak (32%) and VT (24%) 
VE/VCO2 slope in E vs C. 
No significant changes in LV 
parameters over time, but a 
tendency towards improved 
LVEF, EDV and wall motion 
score index in E whereas 
opposite trend in C 
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Study Setting Design Sample Exercise Intervention Outcome Variables Results 
Kobayashi et al 
(2003) 
Saitama, Japan RCT comparing 
exercise training 
with usual care 
Randomised, n=28  CHF 
NYHA II-III  (E/C) 14/14, 
M/F (E vs C) 12/2 vs 8/6, 
Age (E/C) 55 ± 2/ 62 ± 2 
yrs;  LVEF (E/C) 29 ± 2/33 
± 2%; aetiology (E/C) 
ischaemic 8/5, DCM 9/6; 
medication (E/C): ACE 
inhibitor 13/10, β-blocker 10/7 
2 x 15 min cycle 
ergometer sessions per 
day 2-3 x per week for 
3 months @ VT HR 
6-min walk distance, 
humoral factors 
(noradrenaline, 
endothelin-1, 
interleukin-6), 
endothelial function 
via flow-mediated 
vasodilation in upper 
and lower extremities 
Significant increase in 6 min 
walk distance (14%) and 
lower limb (but not upper 
limb) flow-mediated 
vasodilation in E vs C. No 
change in humoral factors.  
Larsen et al 
(2002) 
Rehabilitation 
Centre, 
Norway 
Prospective study 
to evaluate the 
effects of exercise 
training 
n=15 CHF NYHA II-III; 
Age 69 ± 8 yrs;  LVEF 33 ± 
5 %; medication (E/C): ACE 
inhibitors 13, diuretics 13, 
digitalis 11  
3 x 45 min sessions per 
week for 3 months, 
including 25 min 
aerobic exercise @ 
80% max 
CPET on cycle 
ergometer, 6-min 
walk distance, muscle 
biopsy, plasma 
cytokines (TNF-α, 
IL-8, IL-1) 
Significant improvements in 
VO2peak (11%) and 6 min 
walk distance (7%) from pre 
to post exercise, no change in 
LVEF, IL-6 or IL-8, and 
small non-significant 
decrease in TNF-α 
Maiorana et al 
(2000) 
Hospital 
outpatient 
setting, Perth, 
Australia 
Crossover RCT 
comparing 
combined aerobic 
and resistance 
training with no 
formal exercise 
Randomised, n=13  male 
CHF NYHA I-III, Age 
(mean ± SEM) 60 ± 2 yrs;  
LVEF 26 ± 3 %; aetiology: 
ischaemic 7, DCM 6; 
medication: ACE inhibitors 
12, diuretics 6, digoxin 3, β-
blockers 2, anti-arrhythmic 2 
3 x 60 min sessions per 
week for 8 weeks. Circuit 
training (45s work): 7 
resistance (55-65% 
MVC) and 8 aerobic 
cycle/tread- mill stations 
(70-85% HRpeak
CPET on cycle 
ergometer (20W 
every 32 min) and 
muscular strength 
(maximum voluntary 
contraction) 
) 
Significant improvements in 
maximum voluntary 
contraction, VO2peak (13%), 
VT after exercise training 
compared to activity 
restriction  
Malfatto et al 
(2002) 
Hospital 
outpatient 
setting, Milan, 
Italy 
Non-randomised 
controlled trial 
with 9 month 
follow up of sub-
group 
n=45 CHF (E/C 30/15) 
NYHA II/III. (11E completed 
further 6 months). M/F (E vs 
C) 26/4 vs 12/3 %, Age 
(E/C) 62 ± 7/ 60 ± 16 yrs;  
LVEF (E/C) 29 ± 7/31 ± 8 %; 
aetiology (E/C) ischaemic 16/8,  
idiopathic 14/7; medication 
ACE inhibitors 100/100%, 
digitalis 0/0 %, β-blockers 
8/51% 
5 x 60 min sessions per 
week for 3 months 
(calisthenics, treadmill, 
bike @ 40-50% 
VO2peak
HR variability at rest 
(autoregressive 
power spectral 
density of RR 
intervals variability), 
CPET 
).  6 months 
further home-based 
training 2-3 x per week 
Significant improvement in 
autonomic tone and reactivity 
to vagal  and sympathetic 
stimuli after 3 months, with a 
further improvement at 9 
months, accompanied by 
significant improvement in 
NYHA class and improved 
VO2peak  (20%) 
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Malfatto et al 
(2009) 
Hospital 
outpatient 
setting, Milan, 
Italy 
RCT comparing 
exercise and usual 
care 
n=54 CHF (E/C 27/27), 
NYHA II/III (E vs C) 18/9 
vs 20/7;  M/F 39/15; Age 65 
± 10 yrs;  LVEF 32 ± 5 %; 
medication (E/C): ACE 
inhibitors 88/82%, β-blockers 
81/79%, diuretics 67/71% 
3 x 40 min sessions per 
week for 12 weeks 
(cycling/walking @ 
60% VO2peak
LV diastolic stiffness 
assessed by Doppler 
echocardiography, 
CPET, BNP ).   
Significant improvement in 
LV compliance (27%), 
reduction in BNP and  
improvement in exercise 
performance in E vs C 
McKelvie et al 
(2002) EXERT 
Trial 
Hospital and 
home-based 
training, 
Hamilton & 
Edmonton, 
Canada 
RCT comparing 
exercise training 
with usual care 
Randomised, n=181  CHF 
(E/C 90/91), completed 3 
months n= 83, 12 months 
n=75, NYHA 1/II/III  
(EvsC) 2/67/31 vs 1/66/33, 
M/F (E vs C) 82/18 % vs 
80/20 %, Age (E/C) 65 ± 1/ 
66 ± 1 yrs;  LVEF (E/C) 28 
± 1/28 ± 1 %; aetiology 
(E/C) ischaemic 79/73, 
hypertensive 7/6, valvular 
5/4, idiopathic 6/13, other 
6/4; medication (E/C): ACE 
inhibitors 91/92, diuretics 
81/86, digoxin 62/66, β-
blockers 23/20, calcium 
channel blocker 13/9 
2 x 60 min supervised 
sessions per week (30 
min cycle, treadmill, 
arm ergometry @ 60-
70% HRmax
6-min walk distance, 
CPET on cycle 
ergometer (17W 
every 2 min), 
dynamic muscle 
strength, cardiac 
funtion via 
radionuclide 
ventriculography, 
QoL via MLHFQ 
 and 30 min 
resistance @ 40-60% 
1RM) plus 1 x 30 min 
home-based walk for 3 
months; followed by 9 
months’ home-based 
training on cycle 
ergometer & free 
weights 
Significant increase in 6-min 
walk distance in E and C at 3 
and 12 months, but no 
between-group differences.  
Significant increase in 
VO2peak at 3 months (10%) 
and 12 months (14%), and in 
strength (14-16% at 3 
months, no further 
improvement at 12 months) 
in E vs C. No significant 
change in cardiac function or 
QoL.  
Meyer et al 
(1996) 
Hospital 
inpatient 
setting, 
Germany 
Crossover RCT 
comparing 
combined aerobic 
and resistance 
training with 
usual care 
Randomised, n=18  male 
CHF NYHA II/III (8/10), 
Age (mean  ± SEM) 52 ± 2 
yrs;  LVEF 21 ± 2 %; 
aetiology: ischaemic 9, 
DCM; medication (E/C): 
ACE inhibitors 16, diuretics 
16, digoxin/digitalis 14, β-
blockers 7 
 
5 x 15 min cycle 
ergometer (30s work @ 
50% MSEC:60s @ 
15W) 3 x 10 min 
treadmill (60s work: 
60s low speed) 3 x 20 
min flexibility/strength/ 
inspiratory exercises per 
week for 3 weeks 
CPET on cycle 
ergometer (12.5 
W.min-1
Significant improvement in 
VO
) 
2peak (20%) & VT (24%) 
after exercise compared with 
activity restriction 
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Meyer et al 
(2003) (a) 
 
 
 
 
 
 
 
 
 
 
Meyer et al 
(2003) (b) 
Hospital 
outpatient 
setting, 
Germany 
RCT comparing 
exercise training 
with usual care 
 
 
 
 
 
 
 
 
 
Observational 
study of cardiac 
rehabilitation 
Randomised, n=54  CHF 
(E/C 26/28), NYHA II/III  
(E vs C) 19/7 vs 21/7, M/F 
(E vs C) 21/5 vs 23/5, Age 
(E/C) 59 ± 10/ 55 ± 9 yrs;  
LVEF (E/C) 30 ± 13/32 ± 15 
%; aetiology (E/C) 
ischaemic 16/10, DCM 
14/14; medication (E/C): 
ACE inhibitors 24/26, 
diuretics 24/24, digitalis 
20/20, β-blockers 24/24 
n=51  CHF, NYHA I/II/III  
3/26/22, M/F 43/8, Age 59 ± 
11 yrs;  LVEF (E/C) 30 ± 
13/32 ± 15 %; aetiology: 
ischaemic 28, DCM 19, 
valvular heart disease 4; 
medication:  ACE inhibitors, 
diuretics, β-blockers, 
angiotensin II inhibitors 
4 x 45 min cycle 
ergometer sessions per 
week for 12 weeks @ 
VT work rate   
 
 
 
 
 
 
 
 
3 sessions per week (30 
min cycle ergometer 
interval training, 30-45 
min 
calishenics/resitance 
plus respiratory training  
and 1 hour per week 
multidisciplinary 
education for 12 weeks 
CPET on cycle 
ergometer (5-15 
W.min-1)  
 
 
 
 
 
 
 
 
 
CPET on cycle 
ergometer (12.5 
W.min-1
Significant improvement in 
VT (11.6%) and rightward 
shift in HR curve at same 
exercise workload in E vs C 
 
 
 
 
 
 
 
 
Significant improvement in 
VT (12%), VO
), 6 min walk 
distance, and QoL via 
SF-36 and MLHFQ 
2peak (11%), 
SF-36 physical functioning, 
role physical and mental 
health and MLHFQ sum 
(29%) and physical scores 
(37%) 
Myers et al 
(2007) 
Residential 
rehabilitation 
in Switzerland 
RCT comparing 
exercise training 
with usual care 
Randomised, n=24  male 
post-MI CHF. Age (E/C) 56 
± 5/ 55 ± 7 yrs;  LVEF (E/C) 
32 ± 7/35 ± 4%; medication 
(E/C): ACE inhibitors 12/11, 
diuretics 6/6, digoxin 8/6 
2 x 60 min supervised 
walking sessions per 
day plus 4 x 45 min on 
cycle ergometer per 
week @ 60-80% HRR 
for 8 weeks 
CPET on cycle 
ergometer, lactate 
threshold, heart rate 
recovery 
Improvement in VO2peak 
(29%), lactate threshold 
(39%) and heart rate recovery 
in E vs C 
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Nechwatal et al 
(2002) 
Germany RCT comparing 
interval and 
continuous 
training 
Randomised E1 (continuous: 
n=20) E2 (interval n=20) E3 
(control: n=10) CHF NYHA 
I-III ;  LVEF (E1/E2/C) 
27/29/27 %; aetiology: 
ischaemic/DCM, 9 evaluated 
for heart transplant 
E1: 6 x 15 min cycle 
ergometer sessions @ 
75% HRmax
CPET on cycle 
ergometer, 
haemodynamic 
measurements and 
QoL via SF-36 
 for 3 
weeks; E2: 6 x 15 min 
cycle ergometer 
sessions with intervals 
@ 50% steep ramp 
workload for 3 weeks 
Significant increase in 
VO2peak (E1: 14%; E2: 14%) 
and VT (E1: 9%; E2: 8%), 
but no difference between 
groups. No change in central 
haemodynamics in E1, but 
significant improvement in 
cardiac index, stroke volume 
index, and peripheral 
resistance. QoL improved 
significantly in both groups, 
but psychological sum factor 
improved more in E1.   
Nilsson et al 
(2008) (a) 
 
 
 
 
 
 
 
 
Nilsson et al 
(2008) (b) 
Hospital 
outpatient 
setting, 
Ullevaal, 
Norway 
RCT comparing 
high intensity 
aerobic interval 
training with 
usual care 
 
 
 
 
 
Long-term 
follow-up 
Randomised, n=80 CHF, 
completed n=76   (E/C) 
38/38, Age (E/C) 69 ± 8/ 72 
± 8 yrs; M/F (E/C) 31/9 vs 
32/8; NYHA II/III (E/C) 
21/19 vs 26/16, LVEF (E/C) 
31 ± 8/ 31 ± 9 %; aetiology 
(E/C) ischaemic  68/70%, 
cardiomyopathy 20/18%, 
hypertension 13/13% 
n=72 completed  follow-up  
2 x 50 min per week 
(32 sessions) for 24 
weeks.  Upper/lower 
body endurance and  
strength exercises 
including 3 x 5-10 min 
high intensity intervals 
@ RPE 15-18.  After 
supervised programme, 
encouragement to 
follow local exercise 
classes and brisk 
walking 
6-min walk distance, 
peak work rate on 
incremental cycle 
ergometer test (10 
W.min-1
Significant improvements in 
E vs C for 6-min walk 
distance (+ 58 vs -15 m), 
peak work rate (+10 vs -1 W), 
exercise duration (+57 vs -8 s) 
and MLHFQ improvement (-
11 vs +1  points). Significant 
inverse correlation between 
QoL and functional capacity. 
Significant improvements 
persisted in E vs C for 6-min 
walk distance, peak work rate 
exercise duration and MLHFQ  
), QoL via 
MLHFQ 
Owen and 
Croucher 
(2000) 
Hospital 
outpatient 
setting, 
Canterbury, 
UK 
Crossover RCT 
comparing 
exercise with 
usual care 
Randomised, n=22 CHF, 
completed (E/C) n=15/9, 
Age  81 ± 4 yrs; M/F 75/25 
%; LVEF < 40%; aetiology 
ischaemic  67%, DCM 33%, 
atrial fibrillation  
1 x 60 min exercise 
class (circuit training 
alternating aerobic and 
resistance work @ ≤ 
75% HRmax
6-min walk distance, 
QoL via MLHFQ 
) per week 
for 12 weeks.  
Significant improvement in 6 
min walk distance (20%), no 
change in MLHFQ following 
training 
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Study Setting Design Sample Exercise Intervention Outcome Variables Results 
Oka et al (2000) Home-based 
setting, USA 
RCT comparing 
home-based 
combined aerobic 
and resistance 
training with 
usual care 
Randomised, n=40 CHF 
(E/C 20/20), aged 30-76 
years, NYHA II/III  (EvsC) 
9/11 vs 16/4, M/F (E vs C) 
17/3 vs 14/6,  LVEF (E/C) 
25 ± 9/22 ± 6 %; aetiology 
(E/C) ischaemic 8/6, DCM 
6/7, hypertension 2/1, other 
4/6; medication: ACE 
inhibitors 14/12, diuretics 19/19 
digoxin 18/15, β-blockers 
1/4, anti-arrhythmic 13/8 
3 x 40-60 min walking 
at ≤ 70% peak HR plus 
2 sessions total body 
unilateral resistance 
exercises @ 75% 1RM 
per week for 3 months 
CPET on treadmill 
(modified Naughton 
protocol), QoL via 
Chronic Heart Failure 
Questionnaire 
No change in exercise 
capacity. Significant 
improvement in fatigue, 
emotional functioning and 
sense of mastery in E vs C. 
Adherence to aerobic 
exercise was higher than to 
resistance, but adherence 
decreased to 75% at 3 months 
Parnell et al 
(2002) 
 
 
 
 
 
 
 
Parnell et al 
(2005) 
Melbourne, 
Australia 
RCT comparing 
exercise training 
with usual care 
Randomised, 21  CHF (E/C) 
11/10, NYHA II/III  (EvsC) 
7/4 vs 7/3, M/F (E vs C) 
10/1 vs 9/1, Age (E/C) 57 ± 
15/ 53± 11 yrs;  LVEF (E/C) 
25 ± 2/24 ± 3 %; aetiology 
(E/C) ischaemic  2/4, DCM 
9/6; medication (E/C): ACE 
inhibitors & diuretics 
100/100 %, digoxin 45/90% 
β-blockers 72/80% 
3 x 30 min sessions 
(walking, cycling, 
strength exercises) per 
week @ 50-60% 
HRmax
6-min walk distance, 
QoL via MLHFQ, 
systemic arterial 
compliance (non-
invasive applanation 
tonometry), LV 
function (2-D 
echocardiography) 
Forearm blood flow, 
endothelial function, 
L-arginine transport 
, progressing to 
5-7 x 60 min sessions 
for 8 weeks 
Significant improvement in 6 
min walk distance (15%), 
systemic arterial compliance 
(35%) and  MLHFQ (-22 
points) in E vs C. No change 
in LV dimensions/function. 
 
Significant increase in 
forearm blood flow, 
endothelial function,  
L-arginine transport 
Passino et al 
(2006) 
Hospital 
outpatient 
setting, Pisa, 
Italy, followed 
by home-
based exercise 
RCT comparing 
exercise with 
usual care 
n=95 CHF (E/C) 47/48 
completed 44/41.  NYHA 
I/II/III (E vs C) 6/28/10 vs 
8/23/10, M/F  39/5 vs 35/6, Age 
60 ± 2/61± 2 yrs; LVEF (E/C) 
35 ± 2/32 ± 2 %; aetiology 
(E/C): ischaemic 27/23, 
idiopathic DCM 27/23, atrial 
fibrillation 3/2; medication 
(E/C): ACE inhibitors 78/79 %, 
diuretics 82/85 %, β-blockers 
72/73 %, angiotensin receptor 
blockers 7/5% 
30 min cycling @ 60% 
HRpeak
CPET on cycle 
ergometer (10.W.min at least 3 days 
per week for 9 months 
-1
Significant improvement in 
VO ) 
QoL via MLHFQ, 
BNP, NT-pro BNP, 
catecholamines, 
plasma renin activity, 
aldosterone 
2peak (13%), peak work 
rate (14%), LVEF (9%), QoL 
(-22 points), BNP (-34%), 
NT-pro BNP (-32%), 
noradrenaline (-26%) inE vs 
C. No change in plasma renin 
activity, aldosterone or 
VE/VCO2 slope.  
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Study Setting Design Sample Exercise Intervention Outcome Variables Results 
Patwala et al 
(2009) 
University 
exercise 
setting, 
Liverpool, UK 
RCT comparing 
exercise with 
usual care in CRT 
CHF 
n=50 CHF (E/C) 25/25, 
NYHA III-IV, male/female 
92/8%, Age 64.4 yrs, LVEF 
24 %,  atrial fibrillation 
34%; medication (E/C): 
ACE inhibitors  or 
angiotensin receptor 
blockers 98%, diuretics 96 
%, β-blockers 60% 
Exercise training 
commenced 3 months 
post CRT. 3 x 30 min 
sessions per week. 10 
min treadmill, 10 min 
cycle, 10 min treadmill 
@ 80%-90% HR
Measurements taken 
at pre-CRT, 3 and 6 
months post CRT. 
CPET (modified 
Bruce treadmill 
protocol), resting/peak 
cardiac output via 
rebreathing, resting 
echochardiography, 
isokinetic dynamometry 
QoL via MLHFQ 
peak 
Significantly greater further 
improvements in VO2peak 
(7%), MLHFQ (-9 points), 
peak skeletal muscle torque, 
peak cardiac power output 
and reserve, and ejection 
fraction (14%) in E vs C 
Prescott et al 
(2009) 
Copenhagen, 
Denmark 
Observational 
study measuring 
effect of exercise 
training in older 
CHF  
n=52 CHF, 41 M, 11 F, 
mean age 68 ± 11 yrs, LVEF 
31 ±  9% ,  NYHA II/III, 
medication: ACE inhibitor 
or angiotensin receptor 
blocker 98%, β-blocker 88% 
2 x 60-90 min sessions 
(15-20 min warm up, 4 
x 6 min walking, 
cycling, stepping @ 70-
80% VO2peak
6-min walk distance, 
incremental shuttle 
walk test, glycemic 
control, inflammatory/ 
endothelial function, 
NT-proBNP, QoL via 
MLHFQ 
, 3 x 20 
arm/leg resistance 
exercises) per week for 
8 weeks   
Significant improvement in 
measures of physical fitness 
(5-7%), but no change in any 
other measures.  
Quittan et al 
(1999) 
Austria RCT comparing 
exercise with 
usual care 
Randomised, n=25 CHF, 
mean age 55 yrs; M/F 23/2 
vs 32/8; NYHA II/III, LVEF 
18.1 ±8.0%  %; aetiology: 
100% DCM 
2-3 x 60 min sessions 
(cycling, stepping @ 
50% VO2max
CPET & QoL via SF-
36 
) per week 
for 12 weeks   
Significant improvement in 
QoL (physical and social 
functioning, role-physical, 
vitality) and  VO2peak. 
Improvements not correlated  
Roveda et al 
(2003) 
 
 
 
 
 
 
 
 
Hospital 
Outpatient 
Setting, Sao 
Paulo, Brazil 
RCT comparing 
exercise with 
usual care 
 
 
 
 
 
 
 
n=16 CHF NYHA II-III (53 
± 9 yrs)  (E/C) 7/9 plus 8 
healthy controls (46 ± 5 yrs).  
M/F (E vs C) 5/2 vs 6/3; 
LVEF (E/C) 35 ± 3/35 ± 3 
%; aetiology (E/C): 
ischaemic 1/0, idiopathic 
DCM 5/5, chagas disease 
1/4; medication (E/C): ACE 
inhibitors 7/9, diuretics 5/5, 
digoxin 7/9 
3 x 60 min sessions per 
week for 4 months, 
including 25-40 cycling 
@ 10% below 
respiratory 
compensation point 
plus 10 min strength 
exercises.  
CPET on cycle 
ergometer, forearm 
blood flow via 
venous plethys-
mography, muscle 
sympathetic nerve 
activity, LVEF via 2-
D echocardiography 
Significant increase in 
VO2peak (39%) and forearm 
blood flow (76%), but not 
LVEF in E vs C. Significant 
decrease (35%) in muscle 
sympathetic nerve activity, to 
levels comparable to healthy 
controls. 
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Study Setting Design Sample Exercise Intervention Outcome Variables Results 
Roveda group 
 
de Mello 
Franco et al 
(2006)   
(follow-up to 
Roveda et al,  
2003) 
 
 
 
 
 
Fraga et al 
(2007)   
Hospital 
Outpatient 
Setting, Sao 
Paulo, Brazil 
RCT comparing 
home-based 
exercise 
(following 
supervised 
exercise training) 
with usual care 
 
 
 
 
 
 
sub-study on CHF 
taking β-blockers 
n=29 NYHA II - III CHF 
(E/C) 17/12 (E only 
followed up at 8 months 
n=12); Age 56 ± 3/52 ± 2 
yrs; M/F 13/4 vs 9/3; LVEF 
29 ± 2/37 ± 3 %; aetiology: 
ischaemic 5/1, idiopathic 
DCM 3/5, chagas disease 
4/2, hypertensive 5/4; 
medication (E/C): ACE 
inhibitors/angiotensin 
receptor blockers 17/12, 
diuretics 14/1, digoxin 8/9, 
β-blockers 15/11 
n=27  (carvedilol 15/12) 
3 x 60 min supervised 
sessions per week for 4 
months, including 25-
40 min cycling @ 10% 
below respiratory 
compensation point 
plus 10 min strength 
exercises, followed by 
4 months' home-based 
training of equal 
frequency and intensity 
(HR)  
 
Supervised training for 
4 months only 
CPET on cycle 
ergometer, forearm 
blood flow via 
venous plethysmo-
graphy, muscle 
sympathetic nerve 
activity (MSNA), 
LVEF via 2-D 
echocardiography, 
QoL via MLFHQ 
After home-based training 
reduction in forearm vascular 
resistance and QoL were 
maintained. Improvements in 
VO2peak and muscle 
sympathetic nerve activity 
were not 
 
 
 
 
 
Significant improvement in 
VO2peak (21%), forearm 
blood flow and MSNA in E 
vs C 
Smart et al 
(2006) 
Brisbane, 
Australia 
Prospective study 
following a single 
group pre and 
post training 
n=37 CHF; M/F 35/2; age 
63 ± 9 yrs; NYHA II/III  
8/29; LVEF 29 ± 9%; ischaemic 
25, DCM 8, viral/alcoholic 
DCM 4; medication: ACE 
inhibitors 36, diuretics 31, 
digoxin 13, β-blocker 34  
3 x sessions per week 
(cycle ergometer @ 60-
70% VO2peak
CPET on cycle 
ergometer (10.W.min
, plus 
strength exercises from 
weeks 8-16) for 16 
weeks 
-1
VO
) 
resting/peak LVEF 
via tissue doppler 
echocardiography 
2peak increased at 8 (8%) 
and 16 weeks (21%), and this 
improvement was related to 
myocardial function at 
baseline.  
Stolen et al 
(2003) 
Finland Non RCT 
comparing 
exercise with 
usual care 
n=20 CHF (E/C) 9/11 
NYHA (E/C) 1.6/1.2, M/F 
(E vs C) 7/2 vs 7/0, Age 55 
± 8/ 55 ± 8 yrs;  LVEF (E/C) 
33 ± 8/35 ± 7 %; aetiology: 
idiopathic DCM; medication: 
ACE inhibitors 78/86 %, 
diuretics 33/14 %, digoxin 
33/29% , β-blockers 78/100 % 
3 x 45 min sessions per 
week for 5 months @ 
50-70% VO2peak
CPET (cycle), LV 
function via 2-D 
echocardiography, 
myocardial perfusion 
and oxidative 
metabolism via 
positron emission 
tomography 
, plus 
twice weekly resistance 
training starting after 4 
weeks. 
Significant increase in 
VO2peak (27%), and stroke 
volume (11%), LVEF (16%), 
LVESD and myocardial work 
efficiency, plus reduction in 
basal myocardial perfusion, 
RV and LV oxidative 
metabolism (10%) in E vs C 
  
265 
 
Abbreviations: ACE angiotensin converting enzyme; BMI body mass index; BNP B-type natriuretic peptide; CPET cardiopulmonary exercise test; C control group; E 
exercise group; DCM dilated cardiomyopathy; EDV end diastolic volume; ESV end systolic volume; HR heart rate; LVEF left ventricular ejection fraction; M/F male/female 
MLHFQ Minnesota Living with Heart Failure Questionnaire; NT-BNP N terminal b-type natriuretic peptide; NYHA New York Heart Association; QoL quality of life; RCT 
randomised controlled trial; RV right ventricular; SF-36 Short-Form 36 Questionnaire; VO2peak  peak oxygen uptake; VT ventilatory threshold, 1RM 1 repetition maximum  
 
 
Study Setting Design Sample Exercise Intervention Outcome Variables Results 
Sullivan et al 
(1988 & 1989) 
Outpatient 
rehabilitation 
clinic, The 
Netherlands 
Prospective study 
following a single 
group pre and 
post training 
n=16 CHF, completed n=12, 
age 57 ± 10  yrs; NYHA I-
III (mean 2.4 ± 0.6), LVEF 
24 ± 10%; medication: ACE 
inhibitors 4, diuretics 12, 
digoxin 11 
3-5 hr per week 
supervised training @ 
75% VO2peak
CPET on cycle 
ergometer, constant 
load test @ ~ 80% 
peak workload, 
haemodynamic 
measurements 
 (cycling, 
stair climbing, 
walking/jogging) for 
16-24 weeks 
Significant increase in 
VO2peak (23%), VT (20%), 
peak leg blood flow (20%), 
peak central aterio-venous 
oxygen difference (11%), and 
submaximal exercise 
performance, but not central 
haemodynamic measures 
Taylor et al 
(1999) 
Hospital 
outpatient 
setting, 
London 
Randomised 
crossover study 
comparing 
exercise with a 
control period 
n=8  M CHF, NYHA II-III, 
ischaemic aetiology n=6 
3 sessions per week for 
8 weeks. Warm up, ≤ 
30 min cycling @ 45-
70% VO2peak
Treadmill exercise 
tolerance test, blood 
flow via venous 
occlusion 
plethysmography 
) 
Significant increase in 
exercise capacity from 3.4 to 
4 METS, non-significant 
improvements in blood flow, 
but benefits lost after 2 
months' cessation of exercise 
Tyni-Lenné et 
al (1996) and 
Gordon et al 
(1996) 
 
 
 
 
 
 
Tyni-Lenné et 
al (1997) 
Hospital 
outpatient 
setting, 
Huddinge, 
Sweden 
RCT comparing 
one and two 
legged exercise 
with usual care 
 
 
 
 
 
 
Crossover RCT 
comparing 
exercise with 
usual care 
Randomised, n=21 M CHF,  
NYHA II/III, mean age 60 
yrs (range 43-73), LVEF 28 
± 11 %, aetiology: ischaemic 
12, DCM 9, medication: 
ACE inhibitors 19, diuretics 
21, digoxin 9, β-blockers 10 
 
 
 
Randomised, n=16 female 
CHF,  NYHA II/III, mean 
age 63 ± 10 yrs , LVEF 28-
30 %, aetiology: ischaemic 
11, DCM 5, medication: 
ACE inhibitors 12, diuretics 
13, digoxin 4, β-blockers 8, 
calcium antagonists 2 
3 sessions per week for 
8 weeks. 6 & 3 min 
walk to warm up and 
cool down, plus 2 leg: 
15 min simultaneous 
knee extensor exercise 
@ 70% peak; 1 leg: 1 
leg at a time for 15 min 
each @ 35% 2 leg 
peak.  
3 x 15 min  knee 
extensor exercise (@ 
65-75% peak) sessions 
per week for 8 weeks. 6 
& 3 min walk to warm 
up and cool down 
CPET on cycle 
ergometer (10 W.min-1
Significant increase in 6-min 
walk distance in 2 and 1 
legged (12% and 5%) 
compared with C, and in QoL 
(improvements in 2 legged > 
1 legged), but not in VO
), 
6-min walk distance, 
QoL via Sickness 
Impact Profile and 
Sense of Coherence 
Scale, muscle 
strength and muscle 
biopsy for citrate 
synthase 
2peak 
(+3-4%).  Significant 
increase in strength (16%) in 
2 legged, and  in citrate 
synthase activity (35%) in 1/2 
leg vs C. 
Significant increase in citrate 
synthase (44%), lactate 
dehydrogenase (23%), 
oxidative vs glycolytic 
capacity (23%), and in 
VO2peak (14%), 6-min walk 
distance and QoL 
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Study Setting Design Sample Exercise Intervention Outcome Variables Results 
Van den Berg-
Emons et al 
(2004) 
Rotterdam, 
The 
Netherlands 
RCT comparing 
exercise training 
with usual care 
Randomised, n=34 CHF 
(E/C) 18/16; Age 59±12/59± 
11 yrs; M/F (E/C) 12/6 vs 
13/3; NYHA II/III (E/C) 
10/8 vs 10/6; LVEF 24 ± 
9/28 ± 6 %; aetiology (E/C) 
ischaemic  6/8, idiopathic 
DCM 11/6, hypertension 
0/1, valvular disease 1/1 
2 x 1 hour exercise 
classes per week for 3 
months (cycling, 
walking and games @ 
60% HRR) 
 CPET on cycle ergo-
meter (10 W.min-1
No significant difference in 
changes between E and C for 
daily activity or QoL. Mean 
improvements in peak power, 
6-min walk distance, 
extension and flexion peak 
torque and depression > in E 
vs C. Significant correlation 
between VO
), 
6-min walk distance, 
muscle strength, daily 
activity (accelerometry) 
QoL via MLHFQ, 
Medical Psychological 
Questionnaire for heart 
patients, Hospital 
Anxiety and Depression 
Scale. 
2peak and daily 
activity.  
Van Laetham 
(2007) 
Belgium Observational 
study measuring 
changes after 
cardiac 
rehabilitation 
n=35  CHF, NYHA II-III,  
M/F  26/9, Age 54 ± 9 yrs;  
LVEF 31 ± 10%; aetiology: 
ischaemic 23, DCM 12; 
medication:  ACE inhibitor 
33, diuretics 15, digoxin 7, 
β-blocker 32;  ICD  3, atrial 
fibrillation/flutter 2 
2 x 1 hour circuit 
training sessions 
(including 25 min total 
time on aerobic 
exercises @ 70-85% 
HRpeak
CPET on cycle 
ergometer (25 W 
initial load, 10 
W.min
, alternated with 
muscles strengthening 
exercises) per week for 
6 months (40 sessions)  
-1
Significant increase in 
VO
 increments), 
oxygen uptake 
efficiency slope 
(OUES), 6 min walk 
distance 
2peak (18%), peak work 
rate (24%), VT (20%), OUES 
(14%), 6 min walk distance 
and decrease in VE/VCO2 
slope (6%) after 3 months.  
Improvements in OUES best 
correlated with improvements 
in VO2peak. At 6 months 
further improvement in VT, 
peak work rate & 6 min walk.  
Wielenga et al 
(1998) 
 
 
 
Wielenga et al 
(1999) 
Outpatient 
rehabilitation 
clinic, The 
Netherlands 
RCT comparing 
exercise training 
with usual care 
n=67 M ischaemic and DCM 
CHF  NYHA II-III,  mean 
age 64 yrs, LVEF < 40%  
Randomised, n=80 CHF, 
completed n= 67 (E/C) 
35/32; Age 63±2/65±1 yrs; 
NYHA II/III (E/C) 26/9 vs 
19/13; LVEF 30±2/25±2 %; 
aetiology ischaemic 14/13, 
DCM 21/19; ACE inhibitors 
26/25, diuretics 30/27, 
digoxin 27/23, β-blockers 
2/1 
3 x 45 min sessions per 
week for 12 weeks (10 
min walking, cycling, 
ball games @ 60% 
HRR, separated by 5 
min rest) 
CPET (modified 
Naughton protocol) 
QoL via Heart Patients 
Psychological 
Questionnaire/Self-
awareness of general 
well-being test 
Significant improvements in 
exercise capacity and QoL in 
both older (> 65 yrs) and 
younger (< 65 yrs) CHF 
 
No significant improvement 
in VO2peak in E (10%) vs C 
(5%), despite increase in 
exercise duration (24% vs 
1%), VT (15% vs 5%), 
submaximal VE/VCO2 & 
QoL 
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Study Setting Design Sample Exercise Intervention Outcome Variables Results 
Willenheimer et 
al (1998) 
Malmo, 
Sweden 
RCT comparing 
exercise training 
with usual care 
Randomised, n=54 CHF, 
completed n= 49 (E/C) 
26/23 ; Age (E/C) 64 ± 9/ 64 
± 5 yrs; NYHA I/ II/III 
(E/C) 3/8/16 vs 3/11/8; 
LVEF (E/C) 36 ±11/35 ±11 %; 
ischaemic aetiology 78/73; 
medication: ACE inhibitors 
100/100 %, diuretics 93/95 
%, digitalis 30/50% 
3 x 15-45 min sessions 
per week interval 
training (90s @ 80% 
VO2peak HR ± 5 
beats.min-1,
CPET on cycle 
ergometer (30W start, 
10 W.min
 or RPE 15, 
for as long as possible, 
30s rest) for 16 weeks 
-1
No significant improvement 
in VO
 
increments), LV 
function via 
echocardiography, 
dyspnea-fatigue 
index, QoL and 
habitual physical 
activity 
2peak or VT  in E (5%) 
vs C, despite significant 
increase in exercise duration 
(7W, 6%) and global QoL. 
Greater improvement in M 
(n=11)  with ischaemic vs 
non-ischaemic aetiology and 
F.    
Wisloff et al 
(2007) 
Hospital 
outpatient 
setting, 
Trondheim, 
Norway 
RCT comparing 
aerobic interval 
training (E1) with 
moderate 
continuous 
training (E2) and 
usual care (C) 
Randomised, n=27 post-
infarction CHF LVEF < 
40%, (E1/E2/C) n=9/9/9; 
Age (E1/E2/C) 76 ± 13/ 74 ± 
12/77 ± 9 yrs; M/F 
(E1/E2/C) 6/3 vs 7/2 vs 7/2;  
BMI (E1/E2/C) 26 ± 2/25 ± 
3/25 ± 3 kg/m2
2 x supervised 
treadmill sessions plus 
1 home-based session 
per week for 12 weeks. 
E1: 4 x 4 min intervals 
@ 90-95% HR
; medication: 
ACE inhibitors 100% 
patients, diuretics n=5/4/5, 
β-blockers 100%  
max 
interspersed with 3 min 
recovery @ 50-70% 
HRmax: total 38 min. 
E2: 47 min @ 70-75% 
HRmax
CPET on treadmill, 
endothelial function 
via ultrasound, LV 
function via 
echocardiography, 
skeletal muscle 
function via muscle 
biopsy, QoL via 
MacNew 
Questionnaire 
. Isocaloric.  
Significantly greater 
improvement in endothelial 
function  and VO2peak in E1 
interval (46%) vs E2 
continuous group (14%). 
Decreased LVESV (18%) 
and EDV (25%), increased 
LVEF (35%), decreased BNP 
(40%) and improved 
mitochondrial function in E1 
only. QoL improved in E1 
and E2. No changes in C 
Witham et al 
(2005) and 
(2007) 
Hospital 
outpatient 
setting, 
Dundee, 
Scotland 
RCT comparing 
seated exercise 
with usual care 
(plus long-term 
follow-up) 
Randomised, n=82 CHF, 
completed n=68 (E/C) 
36/32. Age (E/C) 80 ± 6 /81 
± 4 yrs; M (E/C) 63%/46%; 
NYHA II/III (E/C) 25 vs 16/ 
21 vs 20; ischaemic 
aetiology (E/C) 76%/56%; 
BMI (E/C) 26±4/26±5 kg/m2
0-3 months:  twice 
weekly supervised  
sessions. Warm-up, 20 
min upper/lower limb 
exercise, whole body 
aerobic movements 
RPE 11-13, cool-down. 
Wrist/ankle weights for 
progression. 3-6 month 
home-based: same 
exercises 2-3 x per week 
; 
sinus rhythm/atrial fibrillation 
(E/C) 36 vs 5/33 vs 8 
6-min walk distance,  
physical activity via 
accelerometry, Guyatt 
CHF questionnaire, 
Hospital Anxiety and 
Depression score, 
Philadelphia Geriatric 
Morale Scale at 3 & 6 
months and follow-up 
(mean 19 months) 
No improvement in 6-min 
walk distance (or difference 
between E and C). Significant 
increase in physical activity 
in E vs C at 6 months only. 
No significant differences in 
health-related QoL or 
psychological status. No 
significant differences 
between E and C at long-term 
follow-up. 
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Table A2: Summary of combined aerobic and resistance exercise training studies in CHF 
Study Setting Design Sample Exercise Intervention Outcome Variables Results 
Beckers et al 
(2008)   
 
 
 
 
 
 
 
 
 
 
 
Conraads et al 
(2004) 
Hospital 
outpatient 
setting, 
Antwerp, 
Belgium 
RCT comparing 
combined aerobic 
(CT) and 
resistance training  
with endurance 
training (ET) 
 
 
 
 
 
 
 
Non-randomised 
combined 
endurance & 
resistance training 
with untrained 
control group 
Randomised, n=58 CHF 
(CT/ET) 28/30. Age 58±11 
/59±11 yrs; M/F (CT vs ET) 
18/10 vs 24/6; NYHA II/III 
(CT/ET) 9/19 vs 12/18; 
LVEF 26±7%/23±9% 
ischaemic aetiology (CT/ET) 
16/18, idiopathic DCM 
18/12; medication (CT/ET): 
ACE inhibitors 96/100%, 
diuretics 85/70%, digoxin 
39/30%, β-blockers 57/90%  
 
n=49 CHF (controls unable 
to attend exercise)  (E/C) 
27/22. Age (E/C) 59 ± 2 /59 
± 2 yrs; male/female (E vs 
C) 21/6 vs 15/7; NYHA 
II/III (E/C) 6/21 vs 10/12; 
LVEF (E/C) 26 ± 1%/ 26 ± 
1%; aetiology (E/C) 
ischaemic 19/6, idiopathic 
8/6; medication: ACE 
inhibitors 26/21, diuretics 
20/17, digoxin 10/9, β-
blockers 16/14 
3 x 1 hour sessions per 
week for 6 months. CT: 
month 0-2: 10 min 
endurance (90% HR   @ 
respiratory compensation 
point) plus 40 min 
resistance work @ 50-
60% 1RM; month 2-4: 
2 x 8 min endurance,  
30 min resistance. 
month 4-6
CPET on cycle ergo-
meter (10-20 W.min
: 3 x 15 min 
endurance/10 min 
resistance.   ET: 5 x 8 
min treadmill, cycle, 
stair, step, arm 
ergometer, increasing 
to 3 x 15 min, with 2 
min recovery  
 
3 x 1 hour sessions per 
week (10 min 
endurance  plus 40 min 
resistance for 2 months, 
then 25 min endurance 
plus 25 min resistance  
for 2 months) 
-1
CT more effective than ET at 
improving strength, 
submaximal exercise 
performance and QoL, 
whereas maximal exercise 
capacity improved to the 
same extent  in CT and ET 
(5-11%), as did LVEF (10-
25%). No change in LV 
volumes or BNP. 
 
 
 
 
Significant improvement      
(-23%) in NT-proBNP, LV 
end systolic diameter (-9%), 
A wave and E/A ratio 
(reflecting LVED pressure 
and filling pressures), and 
VO
), 
LV dimensions via 2-
D echocardiography, 
LVEF via radionuclide 
ventriculography, 
muscular strength and 
endurance via1RM 
and linear isokinetic 
measurements, QoL 
via Health 
Complaints Scale  
 
 
CPET on treadmill, 
NT-pro BNP, resting 
echocardiography (M 
mode and tissue 
doppler) 
2peak (11%), VT (13%) 
and Wattmax/VO2peak (27%) in 
E vs C 
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MLHFQ Minnesota Living with Heart Failure Questionnaire; NT-BNP N terminal b-type natriuretic peptide; NYHA New York Heart Association; QoL quality of life; RCT 
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Study Setting Design Sample Exercise Intervention Outcome Variables Results 
Feiereisen et al 
(2007) 
  RCT comparing 
exclusive strength 
training (ST) with 
traditional 
endurance 
training (ET) and 
combined 
endurance and 
resistance training 
(CT) 
Randomised, n=45 CHF 
NYHA II-III, (ST/ET/CT) 
n=15/15/15, plus control 
group (con) n=15; Age 
(ST/ET/CT/con) 59 ± 7/ 61 
± 6/58 ± 6/56 ± 8 yrs; M/F 
(ST/ET/CT/con) 11/4 vs 
13/2 vs 14/1 vs 13/2;  
ischaemic/non-ischaemic 
aetiology (ST/ET/CT/con) 
7/8 vs 7/8 vs 8/7 vs 9/6 
3 sessions per week for 
3 months. ST: 10 
resistance machine 
exercises @ 60-70% 
1RM, 2 min recovery 
phases; ET: 20 cycle 
and 20 min treadmill 
60% - 75% VO2peak; 
CT 20 min cycle (60-
75% VO2peak
CPET on cycle 
ergometer, isokinetic 
strength test, thigh 
muscle volume via 
CT scan, LV function 
via radionuclide 
ventriculography, 
QoL via MLHFQ 
) , 5 
resistance machine 
exercises (60-70% 
1RM ) 
Significant improvement in 
VO2peak,  peak workload, 
thigh muscle volume and 
knee extensor endurance in 
the ST, EC and CT compared 
to control.  No differences 
between training modalities.  
Knee extensor strength, 
LVEF and cardiac function 
improved in ST, EC and CT 
more than control, but not 
statistical ly significant 
Haykowsky et 
al (2005) 
Edmonton, 
Canada 
RCT comparing 
aerobic training 
(E1) with 
combined aerobic 
and strength 
training (E2) for 3 
months 
supervised and 3 
months 
unsupervised 
Randomised, n=20 female 
CHF (E/C) 10/10. Age 72 ± 
8 yrs 
E1: 2 aerobic sessions 
(@ 60-70%) HRR per 
week for 3 months, 
then 3 months 
unsupervised sessions 
@ RPE 12-14. E2: 
Same as E1 plus 
additional 1-2 sets low-
moderate strength 
training 2 x per week. 
CPET, muscle 
strength, QoL 
Significant increase in 
VO2peak (12%) and leg 
strength (13%) in E1 and E2 
after supervised training, but 
this returned to baseline after 
unsupervised training period. 
Upper body strength 
increased (23%) after 
supervised training in E2 
only.  No change in QoL 
Mandic et al 
(2009) 
Cardiac 
rehabilitation 
centre, 
Alberta, 
Canada 
RCT comparing 
combined aerobic 
and resistance 
training (E1) with 
aerobic training 
(E2) and usual 
care (C) 
Randomised, n=42 CHF, 
(E1/E2/C) n=14/15/13; Age 
63±1/59 ±11/62±13 yrs; M/F 
(E1/E2/C) 11/3 vs 11/4 vs 
10/3;   LVEF (E1/E2/C) 30 
±  11/34 ± 14/29 ± 11 %; 
ischaemic/non-ischaemic 
aetiology (E1/E2/C) 7/7 vs 
8/7 vs 4/9 
E1: 15 min treadmill + 
15 min arm/leg 
ergometer @ 50-70% 
HRR plus 1-2 sets 10-
15 reps of 6 upper and 
lower body resistance 
exercises @50-70% 
1RM  E2: 15 min 
treadmill + 15 min 
cycle ergometer @ 50-
70% HRR  
CPET on cycle 
ergometer (increments 
15W every 2 min), LV 
systolic function via 
2-D echocardiography, 
muscular strength/ 
endurance using 
1RM, QoL via 
MLHFQ and MacNew 
Heart Disease 
Questionnisaire 
Intention-to-treat analysis: no 
change in VO2peak, systolic 
function or QoL in E1 or E2 
vs C.  Combined training 
(E1) improved upper 
extremity muscular strength 
and endurance vs aerobic 
training (E2) or C. In 
compliant participants (> 
80% sessions) VO2peak & QoL 
increased in E2 vs E1 and C. 
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Study Setting Design Sample Exercise Intervention Outcome Variables Results 
Miche et al 
(2009) 
Hospital 
inpatient 
setting, 
Germany 
Longitudinal 
study measuring 
improvements in 
quality of life 
after cardiac 
rehabilitation 
n=116 CHF, NYHA I-III, 
Group 1 > 70 yrs; Group 2 < 
70 yrs;  Age (1/2) 74 ± 3/ 61 
± 6 yrs;  LVEF (1/2) 34 ± 
6/33 ± 8%; aetiology (1/2): 
ischaemic 76/77 %, DCM 
11/20%, valvular 13/3%; 
medication (1/2): ACE 
inhibitors 65/73%, diuretics 
67/54%, digoxin 13/31%, β-
blockers 72/70% 
3 x 15-20 min 
supervised cycle 
ergometer sessions (60-
80% VO2peak
CPET on cycle 
ergometer (25W, then 
10W every 1-2 min), 
6 min walk test, QoL 
via SF-36, Hospital 
Anxiety & 
Depression Scale 
(HADS) @ 4 weeks 
and 6 months'  
follow-up 
) 2-3 
strength training 
sessions per week for 4 
weeks 
Improvement in VO2peak in 
both groups at 4 weeks (> 70 
yrs: 10%, < 70 yrs: 17%), 
further improvement at 6 
months in  > 70 yrs only 
(13%).  Improved LVEF, 
LVESV and LVEDV, 6-min 
walk distance and  QoL. In > 
70 yrs QoL improvements 
not maintained at 6 months.   
Sabelis et al 
(2004) 
Hospital 
outpatient 
setting, The 
Netherlands 
RCT comparing 
exercise with 
usual care 
Randomised n=77 CHF 
NYHA II-III LVEF < 35%  
age 40-70 years, completed 
n=61 (E/C) 36/25; 
male/female (E vs C) 25/11 
vs 20/5 ;  aetiology (E/C): 
ischaemic 53/52 %, dilated 
47/48%; medication (E/C): 
ACE inhibitors 75/84%, 
diuretics 53/60%, digoxin 
13/31%, β-blockers 50/52% 
2 x 60 min supervised 
sessions per week 
(warm-up, interval 
training 30s work @ 
50% steep test max/60s 
recovery plus strength 
and endurance 
exercises @ 70% steep 
test HRmax
CPET on cycle 
ergometer (20W 
every 3 min), insulin 
sensitivity 
(euglycaemic 
hyperinsulinaemic 
clamp) 
) and 2 x 11 
min home-based 
strength and endurance 
sessions for 6 months 
Significant increase in 
VO2peak (6%) in E vs C. No 
significant effect of training 
on insulin sensitivity, 
although change in insulin 
sensitivity correlated 
positively with change in 
VO2peak 
 
271 
 
APPENDIX 2: OUTCOME MEASURES NOT USED 
IN THIS THESIS 
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6 minute walk test (6MWT)  
 
The 6MWT is widely used as a measure of functional capacity in elderly patients with 
CHF, and is useful for prognosis, when the “gold standard” cardiopulmonary exercise 
test is not feasible (Ingle et al., 2007).  Although it is simple to administer and does not 
require expensive equipment, it does take 6 minutes to administer.  It is not appropriate 
for patients with orthopaedic limitation, and  is influenced by patient motivation. 
Furthermore, the validity of this test to determine functional capacity in older CHF has 
been  questioned  (Maldonado-Martin et al., 2006). In the experiments in this thesis, 
cardiopulmonary exercise testing was the main outcome measure.  It was not considered 
appropriate to burden the experimenter or participants  with this extra test.   
 
Oxygen uptake efficiency slope  
 
The oxygen uptake efficiency slope (OUES) is a non-linear description of the 
ventilatory response to incremental exercise. It describes the relationship between VO2 
and VE via a logarithmic transformation of VE, thus representing the absolute rate of 
increase in VO2 per 10-fold increase in VE. It is reduced in CHF due to a combination 
of gas exchange, metabolic and ergoreflex abnormalities.  Lower values are associated 
with worsening symptoms, and it is a good prognostic indicator (Davies et al., 2006).  
The authors speculate that its prognostic value is improved as its calculation separates 
the exercise-induced changes in ventilation from any hyperventilation at rest.  The 
OUES from the first 50% or maximal cardiopulmonary exercise test data does not vary 
(< 1%) from data from whole test.  This measurement  is therefore considered most 
useful for risk assessment in patients who are unable to perform  maximal 
cardiopulmonary exercise testing.  In the experiments in this thesis,  maximal 
cardiopulmonary exercise data collection was achieved for the majority of patients, and 
VE/VCO2
  
 slope was used as a measure of ventilatory efficiency.  
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APPENDIX 4: PARTICIPANT INFORMATION 
SHEETS 
 
 
January 2006 
1 
 
 
 
Chelsea School East Sussex Health Authority 
University of Brighton Eastbourne District General Hospital 
Hillbrow Cardiology Department 
Denton Road King’s Drive 
Eastbourne BN20 7SP Eastbourne BN21 2UD  
Telephone: 01435 813759 or 07780 601005  Telephone: 01323 417400 bleep 0762 
e-mail: lb33@brighton.ac.uk e-mail: johnsilberbauer@lycos.com 
 
Investigators:   
Louisa Beale & Dr Gary Brickley  Dr John Silberbauer & 
 
Dr Guy Lloyd 
 
Participant Information Sheet 
 
Intermittent Exercise Training in Heart Failure Rehabilitation:  
Study Title 
INTEXT Heart Failure Study: Phase 1 
 
Invitation paragraph 
 
Before you decide if you would like to participate in this research study, it is important that you 
understand why the research is being done, and what it will involve.  Please take time to read the 
following information carefully.  Ask us if there is anything that is not clear, or if you would like 
more information. Take time to decide whether or not you wish to participate. 
   
What is the purpose of the study? 
 
Heart failure is now recognised as a major public health problem in the UK. There are currently 
about 900,000 individuals with this condition, many of whom suffer disabling symptoms which 
severely reduce their quality of life. Heart failure patients require continual care and support, 
drawing upon the limited resources of the National Health Service. Previous studies show that 
exercise training for heart failure patients improves their ability to perform daily activities, 
enables a better quality of life, reduces time spent in hospital and may prolong their lives.  
Supervised medical exercise training is safe, and is recommended as part of the standard 
treatment of heart failure.   
 
It is not yet clear what the best amount and type of physical activity is for this population, but 
intermittent exercise (i.e. short intervals of harder exercise with regular rest periods in between) 
may be a better way of training than continuous exercise (i.e. a longer bout of moderate 
exercise).  
 
This study aims to compare the short-term effects of different bouts of intermittent exercise with 
a continuous exercise bout.  The study duration is 4-6 weeks. 
January 2006 
2 
Why have I been chosen? 
 
12 heart failure patients, and 12 healthy participants will be studied. Heart failure patients will be 
identified by the Cardiology Department at Eastbourne DGH or by the Community Heart Failure 
Nurse, and invited to participate in the study. Healthy participants will be invited to participate in 
the study via advertisements in local clubs, libraries, newspapers etc.  
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you do decide to take part, the cardiologist 
will study your medical notes to ensure that you are suitable to participate in the study. You will 
be given this information sheet to keep, and be asked to sign a consent form. We will then send 
your GP a letter advising him/her that you are participating in the study. If you decide to take 
part, you are still free to withdraw at any time, and without giving a reason. A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of care you 
receive.  
 
The tests will be carried out at the Coronary Care Unit (CCU) at Eastbourne District General 
Hospital, Kings Drive, Eastbourne, BN21 2UD. The testing area is on a ward, and is curtained 
off to allow full privacy. All the sessions will be conducted under the direct supervision of a 
cardiologist and an exercise physiologist. 
What will happen to me if I take part? 
Number of hospital visits: There are a total of 6 hospital visits, one a week. The first 2 visits 
will last about 3 hours, and the next 4 will last about one hour.  
Exercise Tests  
On the first visit, you will perform 2 exercise tests (described below) on an exercise bike.   
Peak oxygen uptake test: this will involve you pedalling for about 10 minutes, starting off easy 
and becoming progressively harder until you cannot continue.   
You will then have 1 hour’s rest before the next test, which is: 
Short-term exercise capacity test:  this will involve you pedalling for about 60-90 seconds, also 
starting off easy then becoming progressively harder.  
Your second visit will take place one week later, when these two tests will be repeated. 
Continuous and Intermittent Exercise Bouts: the next 4 weeks will involve 1 visit each week to 
the hospital. During each visit you will perform a different exercise protocol, lasting 
approximately 15-20 minutes, on the exercise bike.  For example, one protocol requires you to 
pedal at a constant moderate work rate for 15-20 minutes; another requires you to pedal at a 
harder work rate for 30 seconds and then pedal at an easy work rate for 60 seconds before 
repeating the 30 seconds harder pedalling, and repeating this sequence about 10 times.   
It is possible that it will only be necessary for you to complete 2 of these 4 protocols, meaning 
that you will only need to make 4 visits, rather than 6, to complete the study.  
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Measurements involved: 
 
On the initial visit, your height and weight will be recorded.   
 
During all of the visits we will measure your heart rate and take an electrical recording of you 
heart’s activity with an electrocardiogram (ECG).  We will also measure your blood pressure, 
oxygen saturation and the air you breathe out, both at rest and during exercise.  You will 
therefore be fitted with electrodes on your chest, a blood pressure cuff on your arm, an oxygen 
pulse monitor on your finger, and a face mask around your mouth and nose. None of these 
should cause you any discomfort. The face mask will not restrict your breathing, but your voice 
will be muffled when you have this on so, before the testing starts, we will discuss hand signals 
with you so that you can communicate with us during the test.  We will also ask you to tell us 
how hard you feel you are working, by pointing to a chart (called a rating of perceived exertion 
(RPE) scale) at regular intervals during the test. 
  
We will also take a sound wave picture of your heart with an echocardiogram, at rest and 
immediately after exercise. For this the cardiologist will require you to remove clothing on the 
top part of your body. 
A small tube will be inserted into a vein in your arm before the testing. Blood samples will be 
taken from this before, during and after exercise in order to measure hormones, by-products of 
energy release and heart failure markers in the blood.   
What do I have to do? 
During the period between the testing sessions you may continue your normal lifestyle. 
However, we ask that you do not do any exhausting exercise for 48 hours before the visit, and 
you should not drink any alcohol for 24 hours before each testing session.  
You should have a light meal 2-3 hours before testing.   It is best to avoid eating for at least an 
hour before exercising, and avoid caffeinated drinks for 3-4 hours beforehand.   
You should wear light clothes and shoes that are comfortable for cycling. 
 
 
Exercise can provide many cardiovascular benefits, but it also carries risks.  The incidence of 
sudden death during exercise for healthy individuals is estimated to be 1 death per 18,000. 
Exercise complications and death are more frequent in older populations and those with cardiac 
disease, but are still rare.  It is estimated that there are approximately 6 major complications for 
every 10,000 exercise tests.  Previous research in heart failure patients reports no increase in 
adverse events or death due to exercise testing or training.   
 
You may experience some discomfort during the testing. The exercise tests will require you to 
keep pedalling for as long as you can, and you are likely to feel your heart rate and breathing 
increase (you may feel breathless), and to feel fatigued, particularly in the legs. Although we will 
encourage you to keep going for as long as you can, you are free to stop the tests at any time.  
During the 4 continuous and intermittent exercise bouts the exercise will range from easy to 
hard, and you should not experience any discomfort other than the increase in heart rate, 
breathing, body temperature and muscle fatigue which is normal during physical activity. 
 
What are the possible disadvantages and risks of taking part?  
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The insertion of the tube into a vein in your arm involves a moment of slight discomfort, and 
may cause minor bruising, but drawing the blood samples should not cause further discomfort. 
Standard hygiene procedures will be put in place at all times.   
 
What are the possible benefits of taking part? 
 
Exercise training is recommended for heart failure patients.  It improves fitness and the ability to 
perform daily activities, thus enabling a better quality of life, and a reduction in time spent in 
hospital.  This study will give you the opportunity to exercise in a supervised medical setting, 
and will help us to set up a new exercise rehabilitation programme which may benefit you and 
other heart failure patients in the community. 
 
What if new information becomes available? 
 
If new information relevant to the research becomes available during the study, you will be 
informed. 
 
What happens when the research study stops? 
 
You will be informed whether or not there is a suitable exercise rehabilitation programme for 
you to join (on a voluntary basis) at Eastbourne DGH.   
 
What if something goes wrong? 
 
It is extremely unlikely that you will be harmed as a result of this research.  In the unlikely event 
that you are harmed by taking part in this research, the Trust compensation procedure will be 
followed.  If you wish to complain, or have any concerns about any aspect of the way you have 
been approached or treated during the course of the study, the National Health Service 
complaints mechanism will be available to you.   
 
 
If you consent to take part in the study, your medical records will be inspected by the 
Cardiologist, and your GP will be notified of your participation in the trial. All information 
which is collected about you during the study will be kept strictly confidential.  Any information 
about you which leaves the hospital will have your name and address removed so that you cannot 
be recognised from it.   
 
Will my taking part in this study be kept confidential? 
What will happen to the results of the research study? 
 
The results of the study will be published in journals, presented at conferences, and reported to 
local and national organisations.  This is likely to occur from 1 to 5 years after the study 
completion.  You will be provided with a copy of the published results on request.   
 
The blood samples will be analysed for the purposes of this study only. In the unlikely event that 
any abnormality is found in the blood tests, full information will be provided to you (unless you 
choose not to receive this information), and you will be directed to the cardiologist and/or your 
GP, as appropriate, to discuss these. 
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Who is organising and funding the research? 
 
The study is being organised by researchers at University of Brighton and Eastbourne District 
General Hospital.  East Sussex Hospitals NHS Trust and the Peel Medical Research Trust have 
provided funding to cover expenses for the testing.  
 
Who has reviewed the study? 
  
The study has been reviewed by the East Sussex Local Research Ethics Committee. 
 
who will be happy to address any questions or concerns that you may have. 
Contact for further information 
 
If you would like any further information, please contact 
Louisa Beale 
Chelsea School (Eastbourne campus) 
University of Brighton 
Hillbrow 
Denton Road 
Eastbourne BN20 7SP 
 01435 813759 or 07780 601005  
lb33@bton.ac.uk 
 
If you decide to voluntarily participate in this study, you will be given a copy of this information 
sheet and a signed consent form to keep. 
 
Thank you for your participation in the study. 
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Chelsea School East Sussex Health Authority 
University of Brighton Eastbourne District General Hospital 
Telephone: 01273 643759 or 07780 601005  Telephone: 01323 417 400, Bleep 0437 
e-mail: lb33@brighton.ac.uk e-mail: Robert.McIntosh@esht.nhs.uk 
 
Investigators:   
Louisa Beale & Dr Gary Brickley  Dr Robert McIntosh & 
 
 
Dr Guy Lloyd 
Participant Information Sheet 
 
 
Study title 
Intermittent Exercise Training in Heart Failure Rehabilitation:  
INTEXT Heart Failure Study: Phase 2 
 
Invitation paragraph 
 
Before you decide if you would like to participate in this research study, it is important that you 
understand why the research is being done, and what it will involve.  Please take time to read the 
following information carefully.  Ask us if there is anything that is not clear, or if you would like 
more information. Take time to decide whether or not you wish to participate. 
 
What is the purpose of the study? 
 
Heart failure is now recognised as a major public health problem in the UK. There are currently 
about 900,000 individuals with this condition, many of whom suffer disabling symptoms which 
severely reduce their quality of life. Heart failure patients require continual care and support, 
drawing upon the limited resources of the National Health Service. Previous studies show that 
exercise training for heart failure patients improves their ability to perform daily activities, enables a 
better quality of life, reduces time spent in hospital and may prolong their lives.  Supervised medical 
exercise training is safe, and is recommended as part of the standard treatment of heart failure.   
 
It is not yet clear what the best amount and type of physical activity is for this population, but 
intermittent exercise (i.e. short intervals of harder exercise with regular rest periods in between) may 
be a better way of training than continuous exercise (i.e. a longer bout of moderate exercise).  
 
This study aims to compare the effects of an intermittent exercise training programme and a 
continuous exercise training programme on cardio-respiratory fitness and quality of life in heart 
failure patients.  The study duration is 8 weeks. 
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Why have I been chosen? 
 
40 heart failure patients will be identified by the Heart Failure Nurse at Eastbourne DGH and invited 
to participate in the study.  
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you do decide to take part, the cardiologist 
will study your medical notes to ensure that you are suitable to participate in the study. You will be 
given this information sheet to keep, and be asked to sign a consent form. We will then send your 
GP a letter advising him/her that you are participating in the study. If you decide to take part, you are 
still free to withdraw at any time, and without giving a reason. A decision to withdraw at any time, 
or a decision not to take part, will not affect the standard of care you receive.  
 
The tests will be carried out in an exercise testing room at the Cardiology Department at Eastbourne 
District General Hospital, Kings Drive, Eastbourne, BN21 2UD. All the sessions will be conducted 
under the direct supervision of a cardiologist and an exercise physiologist. 
What will happen to me if I take part? 
The exercise training will be carried out in the Physiotherapy Department at Eastbourne District 
General Hospital for 6 weeks. During the training sessions you will be exercising with other 
participants and patients on the cardiac rehabilitation programme and will be supervised by trained 
cardiac nurses and exercise physiologists, with at least one member of staff for every three 
participants.  
Number of hospital visits: There will be 2 testing sessions, and 12 training sessions over a period of 
8 weeks. You will need to attend at least 10 out of the 12 training sessions in order to complete the 
study.  Each testing and training session will last approximately one hour.  The timetable below 
shows which sessions will take place in each week. 
Week 
 
Visits 
1 Testing session  
2 Exercise training programme starts 
 2 x training sessions per week at Eastbourne DGH for 6 weeks 
8 Testing session 
 
Exercise Tests 
During the testing sessions, you will perform a “peak oxygen uptake test” on an exercise bike. This 
will involve you pedalling for about 10 minutes, starting off easy and becoming progressively harder 
until you cannot continue.   
Measurements involved: 
 
On the initial visit, your height and weight will be recorded.   
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During the testing sessions in weeks 1 and 8 we will measure your heart rate and take an electrical 
recording of you heart’s activity with an electrocardiogram (ECG).  We will also measure your 
blood pressure and the air you breathe out, both at rest and during exercise.  You will therefore be 
fitted with electrodes on your chest, a blood pressure cuff on your arm, and a face mask around 
your mouth and nose. The face mask will not restrict your breathing, but your voice will be 
muffled when you have this on so, before the testing starts, we will discuss hand signals with you 
so that you can communicate with us during the test.  We will also ask you to tell us how hard you 
feel you are working, by pointing to a chart (called a rating of perceived exertion (RPE) scale) at 
regular intervals during the test.  We will also take a sound wave picture of your heart with an 
echocardiogram, at rest and immediately after exercise. For this the cardiologist will require you to 
remove clothing on the top part of your body.  None of these procedures should cause you any 
discomfort.   
 
A small blood sample will be taken from a vein in your arm before the testing in order to measure 
heart failure markers in the blood.   
 
Exercise training programme 
After your first exercise testing session, you will begin your twice weekly exercise training 
programme. At each session you will first warm up gradually by walking and performing arm and 
leg movements and stretches for 15 minutes.  For the next 20 minutes you will either do a 
combination of aerobic exercises (walking, stepping up and down, cycling) and strength exercises 
(lifting small weights) or do interval training on an exercise bike (pedalling for short periods at a 
harder work rate with recovery periods of easier pedalling in between). As you get fitter, this 20 
minutes of exercise may be increased gradually to 30 minutes if appropriate. We will be comparing 
the two different types of exercise training, so at the beginning of the study you will be randomly 
assigned to one of these two different training groups.  This means that the groups are selected by a 
computer, which has no information about the individual, i.e. by chance. The exercise session will 
then finish with a 10 minute cool down of gentle movements and stretching.  
You will repeat the exercise testing sessions at the end of the training programme.   
What do I have to do? 
During the period between the testing and training sessions you may continue your normal 
lifestyle. However, we ask that you do not do any exhausting exercise for 48 hours before or drink 
any alcohol for 24 hours before the testing sessions.  
 
 
Exercise can provide many cardiovascular benefits, but it also carries risks.  The incidence of 
sudden death during exercise for healthy individuals is estimated to be 1 death per 18,000. 
Exercise complications and death are more frequent in older populations and those with cardiac 
disease, but are still rare.  It is estimated that there are approximately 6 major complications for 
every 10,000 exercise tests.  Previous research in heart failure patients reports no increase in 
adverse events or death due to exercise testing or training.   
 
What are the possible disadvantages and risks of taking part?  
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You may experience some discomfort during the exercise tests.  These tests will require you to 
keep pedalling for as long as you can, and you are likely to feel your heart rate and breathing 
increase (you may feel breathless), and to feel fatigued, particularly in the legs. Although we will 
encourage you to keep going for as long as you can, you are free to stop the tests at any time.  
During the exercise training sessions you should not experience any discomfort other than the 
increase in heart rate, breathing, body temperature and muscle fatigue which is normal during 
physical activity. 
 
The blood sampling from the vein in your arm involves a moment of slight discomfort, and may 
cause minor bruising. Standard hygiene procedures will be put in place at all times.   
 
What are the possible benefits of taking part? 
 
Exercise training is recommended for heart failure patients.  It improves fitness and the ability to 
perform daily activities, thus enabling a better quality of life, and a reduction in the time spend in 
hospital.  This study will give you the opportunity to participate in a medically supervised, structured 
exercise training programme, and will help us to set up a new exercise rehabilitation programme 
which may benefit you and other heart failure patients in the community. 
 
What if new information becomes available? 
 
If new information relevant to the research becomes available during the study, you will be 
informed. 
 
What happens when the research study stops? 
 
You will be informed whether or not there is a suitable exercise rehabilitation programme for you to 
join (on a voluntary basis).   
 
What if something goes wrong? 
 
It is extremely unlikely that you will be harmed as a result of this research.  In the unlikely event that 
you are harmed by taking part in this research, the Trust compensation procedure will be followed.  
If you wish to complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of the study, the National Health Service complaints 
mechanism will be available to you.   
 
 
If you consent to take part in the study, your medical records will be inspected by the Cardiologist, 
and your GP will be notified of your participation in the trial. All information which is collected 
about you during the study will be kept strictly confidential.  Any information about you which 
leaves the hospital will have your name and address removed so that you cannot be recognised from 
it.   
 
Will my taking part in this study be kept confidential? 
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What will happen to the results of the research study? 
 
The results of the study will be published in journals, presented at conferences, and reported to local 
and national organisations.  This is likely to occur from 1 to 5 years after the study completion.  You 
will be provided with a copy of the published results on request.   
 
The blood samples will be analysed for the purposes of this study only. In the unlikely event that 
any abnormality is found in the blood tests, full information will be provided to you (unless you 
choose not to receive this information), and you will be directed to the cardiologist and/or your 
GP, as appropriate, to discuss these. 
 
Who is organising and funding the research? 
 
The study is being organised by researchers at University of Brighton and Eastbourne District 
General Hospital.  Funding to cover expenses for the testing is currently being sought from grant-
making organisations.   
 
Who has reviewed the study? 
  
The study has been reviewed by the East Sussex Local Research Ethics Committee. 
 
who will be happy to address any questions or concerns that you may have. 
Contact for further information 
 
If you would like any further information, please contact 
Louisa Beale 
Welkin Laboratories, Chelsea School (Eastbourne campus) 
University of Brighton, Carlisle Road, Eastbourne BN20 7SP 
 Tel: 01273 643759 or 07780 601005   email: lb33@bton.ac.uk 
 
If you decide to voluntarily participate in this study, you will be given a copy of this information 
sheet and a signed consent form to keep. 
 
Thank you for your participation in the study. 
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Statistical Results: Study 2 (Chapter 5)  
 
2-way mixed design ANOVA (difference between CON and MED and Controls and CHF) 
Dependent variable  
degrees 
of 
freedom 
(df) 
F value significance (P value) 
effect 
size 
(partia
l η2) 
observe
d power 
Resting VO2 (ml.min-1
exercise protocol 
) 
1 0.006 0.937 0.000 0.051 
protocol*group 1 0.238 0.632 0.016 0.074 
group 1 2.927 0.108 0.163 0.360 
Unloaded VO2
(ml.min
  
-1
exercise protocol 
) 
1 0.724 0.408 0.046 0.125 
protocol*group 1 0.264 0.615 0.017 0.077 
group 1 8.245 0.012* 0.355 0.765 
Total exercise VO2
exercise protocol 
 
(work-rest) (ml) 
1 0.299 0.533 0.020 0.081 
protocol*group 1 0.036 0.852 0.002 0.054 
group 1 5.656 0.031* 0.274 0.604 
Average 15-20 min net 
work VO2  (ml min-1
exercise protocol 
) 
1 0.002 0.096 0.000 0.050 
protocol*group 1 0.134 0.719 0.009 0.064 
group 1 4.198 0.050* 0.219 0.483 
Work economy 
(VO2
exercise protocol 
/W) 
1 0.005 0.944 0.000 0.051 
protocol*group 1 0.680 0.422 0.043 0.121 
group 1 5.108 0.039* 0.254 0.561 
Recovery VO2
exercise protocol 
 (3 min) 
(ml) 
1 0.991 0.335 0.062 0.154 
protocol*group 1 3.977 0.065 0.210 0.463 
group 1 0.080 0.781 0.005 0.058 
Ventilation  (L.min-1
exercise protocol 
) 
1 5.422 0.034* 0.266 0.586 
protocol*group 1 0.251 0.624 0.016 0.076 
group 1 1.964 0.181 0.116 0.259 
RER 
exercise protocol 1 1.956 0.182 0.115 0.258 
protocol*group 1 0.122 0.731 0.008 0.062 
group 1 0.000 1.000 0.000 0.050 
Heart Rate (beats.min-1
exercise protocol 
) 
1 0.092 0.765 0.006 0.059 
protocol*group 1 1.011 0.331 0.063 0.156 
group 1 24.981 0.000* 0.625 0.997 
Blood Pressure 
(systolic) (mm.Hg-1
exercise protocol 
) 
1 0.099 0.757 0.007 0.060 
protocol*group 1 0.241 0.630 0.016 0.075 
group 1 12.78 0.003* 0.460 0.916 
Blood Lactate 
 (mmol.L-1
exercise protocol 
) 
1 3.534 0.080 0.191 0.421 
protocol*group 1 0.204 0.658 0.013 0.071 
group 1 0.411 0.531 0.027 0.092 
* P ≤ 0.05.   
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Non-parametric tests 
Wilcoxon Signed Ranks (difference between CON & MED) 
Dependent variable  df Z score P value 
Rating of Perceived Exertion exercise protocol 1 -0.818 0.414 
 
Mann Whitney U Test (difference between Controls and CHF in CON & MED) 
Dependent variable   df Z score P value 
Rating of Perceived Exertion 
CON group 1 -2.001 0.045* 
MED group 1 -3.424 0.001* 
* P ≤ 0.05.   
3-way mixed design ANOVA (difference between CON and MED and Controls and CHF over time) 
Dependent variable   df F value 
significanc
e (P value) 
 
partial 
η2 
observe
d power 
Average VO2
(ml.min
  
-1
exercise protocol 
) 
1 0.673 0.425 0.043 0.120 
protocol*group 1 0.400 0.537 0.026 0.091 
time 1.836 65.437 ‡ 0.000* 0.814 1.000 
time*group 1.836 2.406 ‡ 0.113 0.138 0.416 
time*protocol 1.836 8.465 ‡ 0.002*§ 0.361 0.930 
time*protocol*gro
up 1.836 5.381 
‡ 0.013* 0.264 0.772 
group 1 3.258 0.091 0.178 0.394 
Blood lactate 
concentration   
(mmol.L-1
exercise protocol 
) 
1 0.807 0.383 0.051 0.134 
protocol*group 1 0.115 0.739 0.008 0.062 
time 1.836 19.076 ‡ 0.000* 0.560 0.991 
time*group 1.836 2.079 ‡ 0.143 0.122 0.393 
time*protocol 1.836 4.085 ‡ 0.030*§ 0.214 0.660 
time*protocol*gro
up 
1.836 0.171 ‡ 0.832 0.011 0.073 
group 1 0.031 0.863 0.002 0.053 
Heart rate (beats.min-1
exercise protocol 
) 
1 0.013 0.913 0.001 0.051 
protocol*group 1 0.462 0.510 0.037 0.096 
time 1.589 29.797 ‡ 0.000* 0.713 1.000 
time*group 1.589 12.164 ‡ 0.001* 0.503 0.972 
time*protocol 1.824 0.347 ‡ 0.692 0.028 0.097 
time*protocol*gro
up 
3 0.368 0.776 0.030 0.100 
group 1 17.109 0.001* 0.588 0.966 
* P ≤ 0.05.  ‡Greenhouse Gaesser correction applied for non-spherical data. § Follow-up t-tests with 
Bonferroni adjustment were not significant 
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Statistical Results: Study 3 (Chapter 6) 
 2-way mixed design ANOVA (difference between CON, LOW and HIGH and Controls and CHF) 
Dependent variable  
degrees 
of 
freedom 
(df) 
F value significance (P value) 
effect 
size 
(partia
l η2) 
observe
d power 
Resting VO2 (ml.min-1
exercise protocol 
) 
2 0.482 0.624 0.042 0.119 
protocol*group 2 2.392 0.115 0.179 0.431 
group 1 1.513 0.244 0.121 0.203 
Unloaded VO2
(ml.min
  
-1
exercise protocol 
) 
2 0.413 0.666 0.036 0.108 
protocol*group 2 0.165 0.849 0.015 0.072 
group 1 3.188 0.102 0.225 0.371 
Total exercise VO2
exercise protocol 
 
(work-rest) (ml) 
2 0.068 0.934 0.006 0.059 
protocol*group 2 0.264 0.770 0.023 0.086 
group 1 6.510 0.027* 0.372 0.642 
Average 15-20 min net 
work VO2  (ml min-1
exercise protocol 
) 
2 0.463 0.636 0.044 0.115 
protocol*group 2 0.818 0.456 0.076 0.170 
group 1 5.456 0.042* 0.353 0.559 
Work economy 
(VO2
exercise protocol 
/W) 
2 0.420 0.662 0.037 0.109 
protocol*group 2 0.290 0.751 0.026 0.090 
group 1 0.319 0.548 0.028 0.081 
Recovery VO2
exercise protocol 
 (3 min) 
(ml) 
2 0.656 0.529 0.056 0.146 
protocol*group 2 0.743 0.487 0.063 0.160 
group 1 0.003 0.959 0.000 0.050 
Ventilation  (L.min-1
exercise protocol 
) 
2 3.887 0.034*§ 0.245 0.645 
protocol*group 2 2.847 0.078 0.192 0.505 
group 1 4.900 0.047* 0.290 0.530 
RER 
exercise protocol 1.198‡ 3.402 0.088 0.274 0.419 
protocol*group 1.198‡ 8.689 0.011* 0.491 0.805 
group 1 1.110 0.320 0.110 0.157 
Heart Rate (beats.min-1
exercise protocol 
) 
2 0.035 0.966 0.003 0.055 
protocol*group 2 1.52 0.860 0.012 0.071 
group 1 27.722 0.000* 0.681 0.998 
Blood Pressure 
(systolic) (mm.Hg-1
exercise protocol 
) 
2 1.759 0.192 0.119 0.334 
protocol*group 2 1.772 0.190 0.120 0.337 
group 1 14.966 0.002* 0.535 0.946 
Blood Lactate  
(mmol.L-1
exercise protocol 
) 
2 11.831 0.000* 0.476 0.989 
protocol*group 2 0.515 0.603 0.038 0.126 
group 1 1.872 0.194 0.126 0.245 
* P ≤ 0.05.  § Follow-up t-tests with Bonferroni adjustment were not significant ‡Greenhouse Gaesser 
correction applied for non-spherical data 
  
291 
 
Follow-up t-tests with Bonferroni adjustment (3 comparisons; α level P ≤ 0.0167 = significant) 
Dependent variable 
 t statistic df 
Significance 
(P value) 
Blood Lactate (mmol.L-1
CON vs LOW 
) 
-1.297 13 0.216 
CON vs HIGH -4.487 13 0.001* 
LOW vs HIGH -3.292 13 0.005* 
* P ≤ 0.0167   
Non-parametric tests 
Friedman’s Test (difference between CON, LOW & HIGH) 
Dependent variable  df Chi-Square P value Rating of Perceived Exertion exercise protocol 2 4.863 0.088 
 
Mann Whitney U Test (difference between Controls and CHF in CON, LOW & HIGH) 
Dependent variable   df Z score P value 
Rating of Perceived Exertion 
CON group 1 -2.525 0.012* 
LOW group 1 -2.577 0.011* 
HIGH group 1 -1.415 0.157 
* P ≤ 0.05.   
 
3-way mixed design ANOVA (difference between CON, LOW and HIGH and Controls and CHF 
over time) 
Dependent variable   df F value 
significanc
e (P value) 
 
partial 
η2 
observe
d power 
Average VO2 (ml.min-
1
exercise protocol 
) 
2 0.189 0.830 0.019 0.075 
protocol*group 2 0.854 0.441 0.079 0.176 
time 1.593 86.611 ‡ 0.000* 0.896 1.000 
time*group 3 6.178 0.002 0.382 0.938 
time*protocol 6 7.403 0.000*§ 0.425 1.000 
time*protocol*gro
up 6 0.844 0.541 0.078 0.308 
group 1 4.676 0.056 0.319 0.498 
Blood lactate 
concentration  (mmol.L-
1
exercise protocol 
) 
2 6.737 0.004* 0.341 0.882 
protocol*group 2 0.913 0.414 0.066 0.190 
time 1.207 32.352 ‡ 0.000* 0.713 1.000 
time*group 2 3.779 0.064 0.225 0.484 
time*protocol 4 7.488 ‡ 0.001* 0.364 0.971 
time*protocol*gro
up 
4 0.608 ‡ 0.606 0.045 0.161 
group 1 1.237 0.286 0.087 0.178 
* P ≤ 0.05.  ‡Greenhouse Gaesser correction applied for non-spherical data.  § Follow-up tests with 
Bonferroni adjustment (4 comparisons; α level P ≤ 0.0125 = significant) showed that average VO2
  
 at 0-5 
min was significantly lower in HIGH than CON (t = 4.158, P = .006). No other significant differences 
were found.  
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Follow-up t-tests with Bonferroni adjustment (3 comparisons; α level P ≤ 0.01667 = significant) 
Dependent variable 
 t statistic df 
significance 
(P value) 
Blood Lactate (mmol.L-1
 
) 
Controls: values @ 10 min  
   CON vs LOW -1.062 4 0.337 
CON vs HIGH -1.798 4 0.132 
LOW vs HIGH -1.064 4 0.336 
Controls: values @ 20 min  
   CON vs LOW -1.549 4 0.182 
CON vs HIGH -3.978 4 0.011* 
LOW vs HIGH -1.616 4 0.167 
CHF: values @ 10 min  
   CON vs LOW 0.573 8 0.582 
CON vs HIGH -2.377 8 0.132 
LOW vs HIGH -6.194 8 0.000* 
CHF: values @ 20 min  
   CON vs LOW -0.429 8 0.680 
CON vs HIGH -2.701 8 0.027 
LOW vs HIGH -3.257 8 0.012* 
* P ≤ 0.01667 
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Statistical Results: Study 4 (Chapter 7) 
 
Dependent variable  df F value 
significance 
(P value) 
effect size 
(partial η2) 
observed 
power 
Test duration (s) 
training 1 3.340 0.084 0.157 0.409 
training*group 1 0.454 0.509 0.025 0.098 
group 1 0.004 0.950 0.000 0.050 
Peak work rate (W) 
training 1 6.194 0.023* 0.256 0.653 
training*group 1 0.854 0.368 0.045 0.141 
group 1 0.135 0.717 0.007 0.135 
VO2peak (L.min-1
training 
) 
1 3.416 0.081 0.159 0.417 
training*group 1 0.687 0.418 0.037 0.123 
group 1 0.337 0.569 0.018 0.085 
VO2peak (ml.kg-1.min-1
training 
) 
1 3.880 0.064 0.177 0.462 
training*group 1 1.726 0.205 0.088 0.238 
group 1 0.001 0.976 0.000 0.050 
VO2 at VT  (L.min-1
training 
) 
1 11.564 0.008* 0.562 0.856 
training*group 1 0.019 0.893 0.002 0.052 
group 1 0.111 0.747 0.012 0.060 
VO2 at VT  (ml.kg-1.min-
1
training 
) 
1 10.769 0.010* 0.545 0.831 
training*group 1 0.342 0.573 0.037 0.082 
group 1 0.406 0.540 0.043 0.088 
VE/VCO2
training 
 slope 
1 0.273 0.614 0.029 0.076 
training*group 1 0.024 0.880 0.003 0.052 
group 1 2.174 0.174 0.195 0.262 
BNP (pg.ml-1
training 
) 
1 0.119 0.738 0.013 0.061 
training*group 1 0.950 0.355 0.096 0.141 
group 1 0.357 0.565 0.038 0.084 
*P ≤ 0.05 
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Non-parametric tests 
Wilcoxon Signed Ranks (difference between pre- and post-training) 
Dependent variable  df Z score P value 
MLHFQ total score 
Circuit group  
1 -2.383 0.017* 
MLHFQ physical component 1 -2.077 0.038* 
MLHFQ emotional component 1 -1.278 0.201 
MLHFQ total score 
Intermittent 
group  
1 -1.947 0.050* 
MLHFQ physical component 1 -1.101 0.271 
MLHFQ emotional component 1 -0.496 0.024* 
SF-36 Physical Functioning 
Circuit group 
1 -.949 0.343 
SF-36 Role-Physical 1 -1.414 0.157 
SF-36 Bodily Pain 1 -0.000 1.000 
SF-36 General Health 1 -0.355 0.723 
SF-36 Vitality 1 -0.691 0.091 
SF-36 Social Functioning 1 -0.136 0.892 
SF-36 Role-Emotional 1 -1.604 0.109 
SF-36 Mental health 1 0.736 0.461 
SF-36 Physical Functioning 
Intermittent 
Group 
1 -1.219 0.233 
SF-36 Role-Physical 1 -1.633 0.102 
SF-36 Bodily Pain 1 -1.633 0.102 
SF-36 General Health 1 -1.604 0.109 
SF-36 Vitality 1 -1.802 0.072 
SF-36 Social Functioning 1 -.318 0.750 
SF-36 Role-Emotional 1 -1.134 0.257 
SF-36 Mental health 1 -.848 0.396 
* P ≤ 0.05.   
Mann Whitney U Test (difference in change post-training between Circuit and Intermittent 
Groups) 
Dependent variable df Z score P value 
MLHFQ total score 1 -0.822 0.411 
MLHFQ physical component 1 -1.107 0.268 
MLHFQ emotional component 1 -0.496 0.620 
SF-36 Physical Functioning 1 0.000 1.000 
SF-36 Role-Physical 1 -0.791 0.429 
SF-36 General Health 1 -0.526 0.599 
SF-36 Vitality 1 -0.773 0.440 
SF-36 Social Functioning 1 -0.589 0.556 
SF-36 Role-Emotional 1 -1.394 0.163 
SF-36 Mental health 1 -0.366 0.737 
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APPENDIX 6: QUALITY OF LIFE 
QUESTIONNAIRES 
 
 
11/10/04 
 
MINNESOTA LIVING WITH HEART FAILURE 
 
QUESTIONNAIRE 
 
The following questions ask how much your heart failure (heart condition) affected your 
life during the past month (4 weeks).  After each question, circle the 0, 1, 2, 3, 4 or 5 to 
show how much your life was affected.  If a question does not apply to you, circle the 0 
after that question. 
Did your heart failure prevent  
you from living as you wanted during                        Very                            Very 
       
1.  causing swelling in your ankles or legs?           0            1        2        3        4        5 
2.  making you sit or lie down to rest during    
     the day?                    0            1        2        3        4        5 
3.  making your walking about or climbing      
     stairs difficult?                   0            1        2        3        4        5 
4.  making your working around the house    
     or yard difficult?                   0            1        2        3        4        5 
5.  making your going places away from           
     home difficult?                   0            1        2        3        4        5 
6.  making your sleeping well at night 
     difficult?                    0            1        2        3        4        5 
7.  making your relating to or doing things 
     with your friends or family difficult?                0            1        2        3        4        5 
8.  making your working to earn a living 
     difficult?                    0            1        2        3        4        5                                                               
9.  making your recreational pastimes, sports 
     or hobbies difficult?                  0            1        2        3        4        5 
10.  making your sexual activities difficult?    0            1        2        3        4        5 
11.  making you eat less of the foods you  
        like?                    0            1        2        3        4        5 
12.  making you short of breath?                 0            1        2        3        4        5 
13.  making you tired, fatigued, or low on 
       energy?                    0            1        2        3        4        5 
14.  making you stay in a hospital?     0            1        2        3        4        5 
15.  costing you money for medical care?    0            1        2        3        4        5 
16.  giving you side effects from treatments?    0            1        2        3        4        5   
17.  making you feel you are a burden to your  
       family or friends?          0            1        2        3        4        5 
18.  making you feel a loss of self-control 
        in your life?                   0            1        2        3        4        5  
19.  making you worry?                  0            1        2        3        4        5 
20.  making it difficult for you to concentrate 
        or remember things?                  0            1        2        3        4        5  
21.  making you feel depressed?                 0            1        2        3        4        5 
_________________________________________________________________________ 
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the past month (4 weeks) by -                          No      Little                 Much  
















